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Introduction
Worldwide cardiovascular disease (CVD) is a major 
cause of mortality and morbidity. An estimated 17.5 
million people died from CVD in 2005, representing 
30% of all global deaths (source: World Health 
Organization). In the United States1 and the 
Netherlands (source: Dutch Heart Foundation) CVD is 
the underlying cause of death in over a third of all 
occurring deaths. In the Netherlands, approximately 
one third of CVD deaths is related to ischemic heart 
disease such as  Acute Myocardial Infarction (AMI). 
AMI occurs when the supply of oxygen and metabolites 
to the myocardium is severely below its needs due to 
inadequate perfusion of the myocardium for an 
extended period of time (hours). In the majority of cases 
this results from severely reduced or inhibited blood 
flow through one or more of the coronary arteries, 
commonly through complications of atherosclerotic 
lesions. As a consequence of the ischemic period 
cardiomyocytes in the most severely deprived areas of 
the heart undergo cell death. Restoration of blood flow 
in the heart on the one hand initially salvages reversibly 
damaged cardiomyocytes in the surrounding less 
deprived areas, i.e. the border zones of infarction. In 
these border zones however a subset of cardiomyocytes 
was found to deteriorate from a viable state at the 
beginning of reperfusion to an irreversibly damaged 
state later 2. Indeed, accumulating evidence has shown 
that reperfusion of the infarcted myocardium 
contributes considerably to the extent of myocardial 
injury following AMI 3-5. This process is called 
(ischemia-) reperfusion injury. Evidence now suggests 
that it is inflammation that plays a substantial role in 
both the development of AMI, i.e. atherosclerosis 6 and 
outcome of AMI, especially reperfusion injury 7. 
 
Inflammation and atherosclerosis 
Lipid abnormalities (high cholesterol), hypertension, 
smoking and metabolic disorders such as 
hypercholesterolemia, hyperhomocysteinemia and 
diabetes are risk factors held responsible for the 
development of cardiovascular disease 8. In addition to 
these ‘traditional’ risk factors, inflammatory reactions 
considerably take part in both development and 
outcome of atherosclerosis and AMI 6. The combined 
observations of many studies on the development of 
atherosclerotic lesions in both animals and humans 
have led to the response-to-injury hypothesis of 
atherosclerosis 6, stating that each atherosclerotic lesion 
starts of as an injury or dysfunction of the vascular 
endothelium. The progress of an atherosclerotic lesion 
then represents a chronic inflammatory process within 
the artery. Notably, many processes that contribute to 
the development of the lesions are remarkably similar 
to those occurring in established immune or 
inflammatory diseases 6. 
Type IIA secretory phospholipase A2 (sPLA2-IIA), just 
as C-reactive protein (CRP) and complement, is an 
inflammatory mediator and possible cardiovascular risk 
factor that may contribute to the pathogenesis of 
atherosclerosis 8, 9. sPLA2-IIA is said to play a role in this 
cardiovascular event, as plasma levels of the enzyme 
are increased in response to atherosclerosis and 
depositions of the enzyme are found in atherosclerotic 
lesions 10, 11. sPLA2-IIA catalyzes the hydrolysis of the 
sn-2 ester bond in the glyceroacyl phospholipids 
present in lipoproteins and cell membranes, generating 
non-esterified fatty acids and lysophospholipids 12. 
Functional coupling of particularly two sPLA2 isozymes 
(sPLA2-IIA and sPLA2-V) with cyclooxygenase 
pathways may represent a key mechanism in the 
propagation of inflammation in inflammatory disease 13. 
The possible pathophysiological roles of sPLA2-IIA in 
the process of atherosclerosis are outlined in Figure 1 
and in chapter 2 14. An early event in the process of 
atherosclerosis is the modification of low density 
lipoproteins (LDL) that are entrapped in the intima 
extracellular matrix. A plasma lipoprotein profile with 
abundance of LDL and low levels of high density 
lipoprotein (HDL) constitutes a cardiovascular risk 15, 16, 
presumably because this predisposes to higher LDL 
concentrations in the vessel wall. A low phospholipid 
(PL) content and less non-esterified cholesterol renders 
these small, dense LDL particles more atherogenic than 
large buoyant LDL. Oxidation of LDL is another 
modification that may contribute to the atherogenic 
effect of LDL. Indeed, mildly modified (or mildly 
oxidized) malondialdehyde-modified LDL was shown 
to increase monocyte binding and transmigration in co-
cultures of endothelial cells and smooth muscle cells 17. 
Through its hydrolizing activity, sPLA2-IIA is thought 
to contribute to the reduction of PL content of LDL 18 
and has been shown to greatly enhance 15-lipoxygenase 
(15-LO) induced hydro(pero)xidation of LDL 19, and 
thus is acting as a pro-atherogenic factor. Another event 
in the process of atherosclerosis is the influx of 
inflammatory cells such as macrophages. sPLA2-IIA, but 
also types V and X sPLA2, have an effect on the 
development of these macrophages into foam cells 10, 20, 
21. It is well accepted that LDL in their modified (i.e. 
oxidized; oxLDL) form are no longer recognized by the 
LDL-receptor, but are taken up by especially 
macrophages in the arterial wall, in a non-regulated 
manner through the so-called scavenger-receptor 
pathway (Type A scavenger receptor and Type B 
scavenger receptor (CD36)) 22-24. Interestingly, free 
oxidized polyunsaturated fatty acids are peroxisome 
proliferator-activated receptor (PPARγ) ligands and 
activators, which in turn can up regulate CD36 24, 25. It 
therefore seems that oxidation of LDL by sPLA2-IIA and 
15-LO leads to binding of oxLDL to CD36, which 
internalizes PPARγ ligands which in turn leads to CD36 
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Figure 1: Atherosclerotic plaque formation and the possible roles of sPLA2‐IIA herein.
1. sPLA2‐IIA  induces higher affinity of  these small, dense LDL  for proteoglycans in  the arterial wall. 2. sPLA2‐IIA greatly 
enhances  15‐lipoxygenase  induced hydro(pero)xidation of LDL.  3.  sPLA2‐IIA  assists  in LDL  particle modification which 
results  in  the  formation  of  aggregated  and  fused  lipid droplets. 4.  sPLA2‐IIA  induces oxidation  of LDL  resulting  in  the 
uptake of oxLDL by macrophages through scavenger receptor CD36.  this results  in internalization of PPARγ ligands and 
activators,  leading  to  CD36  up‐regulation  through  PPARγ.  5.  Through  the  actions  of  sPLA2‐IIA,  oxLDL uptake  by 
macrophages spins out of control and leads to foam cell formation. 6. sPLA‐IIA may inhibit blood coagulation through the 
inhibition of prothrombinase, although this mechanism  is questioned by others. 7. sPLA‐IIA may  induce death of smooth 
muscle cells, which  in turn may  lead to plaque  instabillity. The picture was  inspired by Libby, P. The vascular biology of 
atherosclerosis. Heart Disease (Braunwald, Zipes and Libby Eds) 2001.
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up-regulation 24. This positive feedback loop of oxLDL 
is a possible explanation as to how oxLDL uptake by 
macrophages spins out of control and leads to foam cell 
formation.  
In addition to its association with LDL and 
inflammatory cells, sPLA2-IIA has also been found in 
vascular endothelial cells, vascular smooth muscle cells 
(SMCs) and the extracellular matrix of atherosclerotic 
lesions 11, 26-28. However, the putative role of sPLA2-IIA 
produced in these vascular cells is as yet not clear. In 
chapter 3 we have analyzed the role of extracellular 
matrix sPLA2-IIA in atherosclerotic plaque 
complication. 
Another inflammatory mediator related to the 
formation and acceleration of atherosclerotic lesions is 
the advanced glycation endproduct (AGE) Nε-
(carboxymethyl)lysine (CML), which accumulates during 
aging 29, 30 and at an accelerated rate in diabetes 31, 32. CML, 
a biomarker for oxidative stress and major product of 
oxidative degradation of glycated proteins and 
unsaturated fatty acids, was shown to be enhanced in 
vascular tissue of diabetic patients and in human 
atherosclerotic lesions 33, 34. CML was found in the aortic 
wall and coronary artery wall 33-35. Interestingly, recently 
an increased deposition of CML was found in small 
intramyocardial blood vessels of the heart that were 
without morphological changes in diabetic patients 
without AMI or any form of cardiomyopathy 36. 
Therefore, in Chapter 4 we studied a putative role for 
CML in these small intramyocardial arteries in non-
diabetic patients in the pathophysiological condition of 
AMI. 
 
Inflammation and AMI: induction of 
inflammation 
Also after AMI, inflammation appears to play a 
significant part. There is accumulating evidence that 
inflammation contributes considerably to the extent of 
myocardial injury following AMI. For instance, many 
animal studies and initial clinical studies show that 
inhibiting inflammation by anti-inflammatory agents 
can markedly reduce infarct size in AMI 3-5, 37. 
As stated earlier, during the ischemic period 
cardiomyocytes in the most severely deprived areas of 
the heart undergo cell death. In the less severely 
deprived areas cardiomyocytes are damaged but still 
viable. The common view on the mechanism of 
cardiomyocyte death induced by this ischemia has 
altered in recent years. Necrosis long time was regarded 
as the sole cause of cell death in myocardial infarction. 
Now, studies indicate that apoptosis also plays a role in 
the process of tissue damage subsequent to myocardial 
infarction as outlined in chapter 5. Although both 
necrosis and apoptosis result in the death of the cell, 
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they differ on several morphologic and cellular 
regulatory features. Necrosis is characterized by rapid 
loss of cellular homeostasis, rapid swelling due to 
accumulation of water and electrolytes, early plasma 
membrane rupture and disruption of cellular 
organelles. Apoptosis or programmed cell death is, 
unlike necrosis, a highly regulated and energy requiring 
process. Apoptosis is characterized by shrinkage of cell 
and nucleus and the nuclear chromatin is condensed 
and eventually breaks up. The cell detaches from the 
surrounding tissue after which it disintegrates into 
membrane-enclosed vesicles, called apoptotic bodies 38, 
39. Within the ischemic myocardium however, 
ischemia/reperfusion induced cardiomyocyte apoptosis 
does not share all the classic hallmarks of apoptosis 
originally described for other cells 38. For instance, 
electron microscopic analysis and histological studies of 
the ischemic rabbit myocardium revealed very 
sporadically cardiomyocytes, with the classic late 
apoptotic morphology like apoptotic bodies 40. It is 
suggested that the mechanism of ischemia/reperfusion 
induced cardiomyocyte cell death is largely dependent 
on the availability of intracellular ATP. Indeed, ATP 
was shown to be the critical determinant of the form of 
cell death in hypoxic cardiomyocytes. In the absence of 
ATP, necrosis prevailed, whereas presence of ATP 
favored and promoted apoptosis 41-43. It is known that 
apoptosis can convert to necrosis, for instance as a result 
of an ATP deficit or as a result of inflammation, 
whereby inflammatory cells such as neutrophil 
granulocytes or macrophages target apoptotic cells 44-47. 
Both these conditions occur in the ischemic heart. 
As a result of the membrane rupture and subsequent 
leakage of a broad array of cellular material, necrosis 
induces an inflammatory response 48. Classic unicellular 
apoptosis is generally considered not to trigger an 
inflammatory response 49. In AMI however 
cardiomyocytes undergo apoptosis on a massive scale, 
many of which will convert to (secondary) necrosis for 
reasons mentioned earlier. Upon reperfusion, all these 
apoptotic and (secondary) necrotic cells trigger an 
extensive inflammatory response whereby 
inflammatory mediators and inflammatory cells flood 
the jeopardized myocardium. Ischemia induced 
changes in the plasma membrane of dying, but also of 
reversibly damaged and thus still viable 
cardiomyocytes, are important in targeting the 
inflammatory response to these cells. As a result of this 
inflammatory response, the reversibly damaged 
cardiomyocytes will transfer to an irreversibly damaged 
state, thereby causing more extensive myocardial 
damage. 
An important change in the plasma membrane of 
cardiomyocytes in the ischemic myocardium is the 
exposure of phosphatidylserine (PS) in the outer 
membrane leaflet, a process called membrane flip-flop. 
In the cardiomyocyte plasma membrane just as in most 
if not all eukaryotic cells, under normal conditions, the 
phospholipids are asymmetrically distributed among 
the inner and outer leaflet. The outer leaflet 
Figure 2: Ischemia induced PS exposure
In the left tableau a schematic overview of the normal plasma membrane and the various presumed mechanisms involved 
in regulating the asymmetrical distribution of membrane phospholipids (floppase is left out). The ATP dependent flippase 
translocates preferably PS from outer to inner membrane layer, whereas the ATP independent but Ca2+ dependent 
scramblase translocated PS from inner to outer membrane layer.the high flippase and low scramblase activity result in a 
higher inward than outward translocation of PS. The ATP- and Ca2+ dependent annexins are believed to function as a link 
between the cytoskeleton and PS as they bind to both with high affinity, fixing PS in the inner membrane layer. In the right 
tableau a schematic overview of presumed ischemia induced regulatory system failure leading to PS exposure (flip-flop). 
Ischemia leads to ATP depletion and a raise in intracellular Ca2+, whereby flippase and annexin activity decrease and 
scramblase activity increases, resulting in a higher outward than inward translocation of PS.
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predominantly contains hydrophobic phospholipids 
such as phosphatidylcholine (PC), whereas anionic 
phospholipids such as PS and, to a lesser extent, 
phosphadidylethanolamine (PE) are actively kept 
within the inner leaflet. In response to certain 
conditions, including ischemia, this asymmetrical 
distribution is lost as the anionic phospholipids 
translocate from inner to outer leaflet. PS exposure can 
be visualized with fluorescent labeled annexin V as this 
binds with high affinity to PS. Indeed, Dumont et al. 
showed this PS exposure on cardiomyocytes in vivo in a 
mouse model of ischemia reperfusion 50. The exposure 
of PS in the outer plasma membrane leaflet has since 
long been considered as a hallmark of apoptosis. 
However, in various cell types including 
cardiomyoblasts, the loss of membrane asymmetry 
resulting in PS exposure and annexin V positivity may 
to a certain level be reversible or precede commitment 
to apoptotic cell death 51-54.  
Several mechanisms are believed to be involved in 
regulating the asymmetrical distribution of membrane 
phospholipids (Figure 2). Three classes of membrane 
proteins, i.e. two ATP-dependent (flippases and 
floppases) and an ATP-independent (scramblases), have 
been found to regulate transbilayer phospholipid 
asymmetry 55, 56. The flippase prefers PS over other 
lipids 57, 58. In addition, there is evidence supporting a 
role for phospholipid binding proteins such as 
membrane associated cytoskeleton elements 59-61 or 
annexin V 62-64 in maintaining phospholipid asymmetry. 
However, the majority of studies into the mechanisms 
maintaining asymmetrical phospholipid distribution in 
plasma membranes have been done in erythrocytes and 
platelets and little is known about the regulation of 
transbilayer phospholipid asymmetry in 
cardiomyocytes. Recently the low molecular weight 
GTP-binding protein RhoA was shown to participate in 
PS exposure on megakaryocytic cells 65.  This pointed to 
a role for RhoA in regulating transbilayer phospholipid 
asymmetry.  In Chapter 6 therefore a putative role for 
RhoA and its downstream effector Rho-associated 
kinase (ROCK) in regulating transbilayer phospholipid 
asymmetry in cardiomyocytes was investigated. 
Another ischemia induced event in cardiomyocytes is 
the production of reactive oxygen species (ROS). It was 
shown that mitochondria respond to graded hypoxia by 
increasing the generation of ROS 66. However, it is more 
and more understood that ROS produced in cells is not 
merely a by-product of cellular stress but may play vital 
roles in various signal transduction pathways, including 
proliferation and apoptosis 67-70. Indeed, in rat hearts 
both in vivo as in isolated perfused hearts, ischemia and 
oxidative stress induced apoptosis whereas treatment 
with antioxidants attenuated oxidative stress, myocyte 
apoptosis, caspase-3 activity and the expression of p53, 
Bax and caspase-3 protein 71, 72. Recently homologues of 
Nox2, the catalytic core of the ROS producing 
phagocyte NADPH oxidase, were found in various 
human non-cardiomyocyte cell types 73-76. In Chapters 7 
and 8 we studied the putative expression of Nox2 (or 
homologue) in human cardiomyocytes in control 
patients and in patients who suffered from AMI. In 
addition, in rat cardiomyoblast cells subjected to 
ischemia, putative roles for Nox2 and Nox2 related 
production of ROS were investigated in chapter 9. 
 
Inflammation and AMI: inflammation and 
its consequence 
The myocardial infarction area can be determined 
macroscopically using a lactate dehydrogenase staining, 
whereby the infarction area is characterized by loss of 
LDH activity (Figure 3). However, it is important to 
realize that not all cardiomyocytes within this 
macroscopical infarction area are dead. Microscopical 
analysis of tissue, taken from the macroscopical (LDH 
discolored) infarction area, shows multiple (secondary) 
necrotic areas (microscopical infarction areas) which 
presumably were most severely deprived of oxygen and 
metabolites during the ischemic period. These areas are 
surrounded by morphologically normal cardiomyocytes 
(border zones). During the ischemic period these border 
zones presumably were less deprived of oxygen and 
metabolites. 
Intensive study into the processes that occur in the heart 
after AMI has produced insight into the mechanisms 
involved in the development of myocardial damage and 
the contribution to this damage of the ischemia on the 
one hand and the inflammation on the other hand. 
Several mediators of inflammation deposit in the 
jeopardized areas of the heart after AMI. Three of these 
have been studied extensively: the acute phase proteins 
sPLA2-IIA and CRP and the complement system (see 
also chapter 10 77). As early as 1971 complement 
activation was demonstrated to be a part of the 
inflammatory response in the ischemic myocardium 78. 
Since then local activation of the classical pathway of 
complement was shown in various animal AMI models 
79-81. Moreover, the presence of the membrane attack 
complex (MAC) of complement on cardiomyocytes and 
endothelial cells within the microscopical infarction 
areas was shown in rabbits 82. Indeed also in humans 
activation of the classical pathway of complement and 
MAC assembly have been shown in the microscopical 
infarction areas of the heart 83, 84. Activation of 
complement and MAC assembly are detrimental to 
cardiomyocyte survival. Experiments in AMI models in 
which the complement system is inhibited or with 
deficient MAC assembly showed reduced infarct sizes 
37, 85-87. Complement may contribute to myocardial 
damage by attracting leukocytes such as 
polymorphoneutrophils (PMN) to cardiomyocytes and 
by inducing aggregation and degranulation of PMN 
thereby unleashing their toxic cocktail of ROS and 
tissue-damaging enzymes 88-90. 
Just as sPLA2-IIA, CRP is a cardiovascular risk marker. 
Elevated blood CRP levels were found to be a 
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diagnostic and prognostic marker in patients with AMI 
91. In the infracted heart, CRP was found to localize on 
cardiomyocytes within the microscopical infarction area 
in rabbits 92, 93 and in humans 83. Indeed, CRP was found 
not only to colocalize with complement in these 
microscopical infarction areas, but to facilitate 
complement binding and activation on cardiomyocytes 
94. As such CRP is also an inflammatory contributor to 
myocardial damage after AMI as was shown in a in vivo 
model in the rat where injection of human CRP 
significantly enlarged infarct size 95. In chapter 11 a 
putative effect of a reinfarction and of reperfusion 
therapy on the levels of CRP depositions and 
complement activation was investigated in patients who 
died within 14 days after AMI. 
Just as CRP and complement, sPLA2-IIA was found to 
be deposited in the heart after AMI 96. However, unlike 
CRP and complement depositions of sPLA2-IIA were 
not limited to the microscopical infarction areas but 
were also found in the border zones 96. Plasma levels of 
sPLA2-IIA were found to significantly increase 6 hours 
after onset of AMI as a result of the ensuing acute phase 
response and sPLA2-IIA starts to deposit approximately 
at this time suggesting that binding of sPLA2-IIA to 
cardiomyocytes may be among the first events during 
ischemia 96. sPLA2-IIA displays only low affinity for PC, 
the phospholipid most abundant in the outer membrane 
leaflet of normal cells 97. However, the enzyme displays 
high affinity for disarranged or flip-flopped membranes 
of damaged cells 98. Indeed, sPLA2-IIA only bound to 
flip-flopped membranes in neonatal rat cardiomyoblasts 
and adult cardiomyocytes of the rabbit 54. Thus the 
morphologically normal cardiomyocytes of the border 
zones are still viable but are presumably jeopardized 
and as a result have a flip-flop of the plasma membrane. 
The binding of sPLA2-IIA to reversibly damaged rat 
cardiomyoblasts induced cell death 54. This thus 
suggests that sPLA2-IIA is cytotoxic and may kill 
human cardiomyocytes upon myocardial infarction. In 
addition, sPLA2-IIA through its lipolytic action 
facilitates the binding of CRP to these reversibly 
damaged rat cardiomyoblasts indicating that sPLA2-IIA 
can also indirectly induce cell death through the actions 
of CRP and the complement system 54. Albeit, CRP can 
also bind independently of sPLA2-II to ischemic 
jeopardized cardiomyocytes, but only if these cells are 
necrotic.  
CRP is not the only protein that is able to target and 
activate complement. In mice, immunoglobulin M (IgM) 
was found to be an alternative molecular mechanism for 
complement activation during ischemia/reperfusion 
injury in the intestine and sketetal muscle 99, 100. The 
specificity of the ischemia/reperfusion injury mediating 
IgM is not known. Also, it is unknown whether a 
similar IgM-dependent mechanism occurs in the human 
heart during ischemia/reperfusion injury. In Chapter 12 
a putative role for IgM in the human heart after AMI 
was investigated. 
These data point to a mechanism whereby inflammation 
contributes to myocardial damage in AMI. As a result of 
the ischemia cardiomyocytes become irreversibly 
damaged i.e. apoptotic / (secondary) necrotic or 
reversibly damaged with changes in the plasma 
membrane, depending on the local severity of the 
ischemia. Upon reperfusion, sPLA2-IIA targets and 
binds to these flip-flopped irreversibly and reversibly 
damaged cells facilitating the binding of CRP or, 
particularly in the reversibly damaged cells, induces 
death itself. CRP then activates complement. It is of 
course the reversibly damaged cardiomyocytes which 
fall victim to the inflammation that provide for the extra 
reperfusion injury.  
What follows from this, and this is further hypothesized 
in chapter 10, is that the inflammatory mediator sPLA2-
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Figure 3: infarction area
Left  tableau: LDH  stained  heart  slice. 
The  light  colored  area  (LDH 
discolored)  is  the  macroscopical 
infarction area (I), in this case located 
mostly  in  the  septum.  Right  tableau: 
microscopcal analysis  of  the 
macroscopical  infarction  area.  The 
dark colored myocardium  is necrotic 
and  are  called  the  microscopical 
infarction  areas  (I)  (stained  with 
complement factor C3d). The areas of 
morphologically  normal  car‐
diomyocytes surrounding  the 
microscopical  infarction areas are  the 
border zones of infarction (BZ).
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IIA is a likely therapeutic target to inhibit reperfusion 
injury in the heart, without disrupting the (necessary) 
wound healing. In chapter 13 we tested this hypothesis 
in vivo using PX-18, a specific inhibitor of sPLA2-IIA, in 
an AMI model in the rat. In addition we analyzed the 
effects of PX-18 on cardiomyocyte membrane flip-flop 
and apoptosis in vitro. 
Another inflammatory mediator that is deposited in the 
infracted heart is clusterin (apolipoprotein J). Clusterin 
is constitutively expressed in almost all mammalian 
tissues by different cell-types 101, 102, and the expression 
of clusterin is up-regulated in acute myocardial 
infarction 103, atherosclerosis 103, 104, myocarditis 105, upon 
injury in general 102. Furthermore, clusterin was found 
to inhibit complement by binding to several 
components of MAC 106-111. Clusterin was found to 
colocalize on cardiomyocytes with activated 
complement within the microscopical infarction areas in 
humans 112. In contrast, in an in vivo model of AMI in 
the rat clusterin was found to deposit only on 
complement negative cardiomyocytes in the border 
zones 113. There thus exists conflicting data on the 
distribution of clusterin in rat versus human myocardial 
infarction. In Chapter 13 , the functional role of clusterin 
in the human heart is examined in more detail. 
 
References 
 
(1)   Rosamond W, Flegal K, Friday G et al. Heart disease and 
stroke statistics‐‐2007 update: a report from the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. 
Circulation 2007 February 6;115(5):e69‐171. 
(2)   Farb A, Kolodgie FD, Jenkins M, Virmani R. Myocardial 
infarct extension during reperfusion after coronary artery occlusion: 
pathologic evidence. J Am Coll Cardiol 1993 April;21(5):1245‐53. 
(3)   Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. 
Reduction of experimental myocardial infarct size by corticosteroid 
administration. J Clin Invest 1973 March;52(3):599‐607. 
(4)   Maroko PR, Carpenter CB, Chiariello M et al. Reduction by 
cobra venom factor of myocardial necrosis after coronary artery 
occlusion. J Clin Invest 1978 March;61(3):661‐70. 
(5)   Spath JA, Jr., Lane DL, Lefer AM. Protective action of 
methylprednisolone on the myocardium during experimental 
myocardial ischemia in the cat. Circ Res 1974 July;35(1):44‐51. 
(6)   Ross R. Atherosclerosis‐‐an inflammatory disease. N Engl J 
Med 1999 January 14;340(2):115‐26. 
(7)   Frangogiannis NG, Smith CW, Entman ML. The 
inflammatory response in myocardial infarction. Cardiovasc Res 2002 
January;53(1):31‐47. 
(8)   Niessen HW, Krijnen PA, Visser CA, Meijer CJ, Erik HC. 
Type II secretory phospholipase A2 in cardiovascular disease: a 
mediator in atherosclerosis and ischemic damage to cardiomyocytes? 
Cardiovasc Res 2003 October 15;60(1):68‐77. 
(9)   Krijnen PA, Nijmeijer R, Hack CE, Niessen HW. Group II 
Secretory PLA2: A new cardiovascular risk factor. Anti‐Inflammatory & 
Anti‐Allergy Agents in Medicinal Chemistry 2006;5:163‐73. 
(10)   Jaross W, Eckey R, Menschikowski M. Biological effects of 
secretory phospholipase A(2) group IIA on lipoproteins and in 
atherogenesis. Eur J Clin Invest 2002 June;32(6):383‐93. 
(11)   Schiering A, Menschikowski M, Mueller E, Jaross W. 
Analysis of secretory group II phospholipase A2 expression in human 
aortic tissue in dependence on the degree of atherosclerosis. 
Atherosclerosis 1999 May;144(1):73‐8. 
(12)   Davidson FF, Dennis EA. Evolutionary relationships and 
implications for the regulation of phospholipase A2 from snake 
venom to human secreted forms. J Mol Evol 1990 September;31(3):228‐
38. 
(13)   Touqui L, aoui‐El‐Azher M. Mammalian secreted 
phospholipases A2 and their pathophysiological significance in 
inflammatory diseases. Curr Mol Med 2001 December;1(6):739‐54. 
(14)   Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE, 
Niessen HW. Apoptosis in myocardial ischaemia and infarction. J Clin 
Pathol 2002 November;55(11):801‐11. 
(15)   Hakala JK, Oorni K, la‐Korpela M, Kovanen PT. Lipolytic 
modification of LDL by phospholipase A2 induces particle 
aggregation in the absence and fusion in the presence of heparin. 
Arterioscler Thromb Vasc Biol 1999 May;19(5):1276‐83. 
(16)   Sartipy P, Camejo G, Svensson L, Hurt‐Camejo E. 
Phospholipase A(2) modification of low density lipoproteins forms 
small high density particles with increased affinity for proteoglycans 
and glycosaminoglycans. J Biol Chem 1999 September 3;274(36):25913‐
20. 
(17)   Berliner JA, Territo MC, Sevanian A et al. Minimally 
modified low density lipoprotein stimulates monocyte endothelial 
interactions. J Clin Invest 1990 April;85(4):1260‐6. 
(18)   Hurt‐Camejo E, Camejo G, Sartipy P. Phospholipase A2 and 
small, dense low‐density lipoprotein. Curr Opin Lipidol 2000 
October;11(5):465‐71. 
(19)   Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. 
Secretory phospholipase A2 and lipoprotein lipase enhance 15‐
lipoxygenase‐induced enzymic and nonenzymic lipid peroxidation in 
low‐density lipoproteins. Biochemistry 1998 June 23;37(25):9203‐10. 
(20)   Hanasaki K, Yamada K, Yamamoto S et al. Potent 
modification of low density lipoprotein by group X secretory 
phospholipase A2 is linked to macrophage foam cell formation. J Biol 
Chem 2002 August 9;277(32):29116‐24. 
(21)   Wooton‐Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, 
Webb NR. Group V sPLA2 hydrolysis of low‐density lipoprotein 
results in spontaneous particle aggregation and promotes macrophage 
foam cell formation. Arterioscler Thromb Vasc Biol 2004 April;24(4):762‐
7. 
(22)   Leitinger N, Oguogho A, Rodrigues M, Sinzinger H. The 
effect of NO/EDRF and monocytes/macrophages on LDL‐oxidation. J 
Physiol Pharmacol 1995 December;46(4):385‐408. 
(23)   Kunjathoor VV, Febbraio M, Podrez EA et al. Scavenger 
receptors class A‐I/II and CD36 are the principal receptors responsible 
for the uptake of modified low density lipoprotein leading to lipid 
loading in macrophages. J Biol Chem 2002 December 20;277(51):49982‐
8. 
(24)   Nicholson AC. Expression of CD36 in macrophages and 
atherosclerosis: the role of lipid regulation of PPARgamma signaling. 
Trends Cardiovasc Med 2004 January;14(1):8‐12. 
(25)   Jostarndt K, Rubic T, Kuhn H et al. Enzymatically modified 
low‐density lipoprotein upregulates CD36 in low‐differentiated 
15
monocytic cells in a peroxisome proliferator‐activated receptor‐
gamma‐dependent way. Biochem Pharmacol 2004 March 1;67(5):841‐54. 
(26)   Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, 
Claesson HE. Expression of phospholipase A2 isoforms in human 
normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 
1997 October;17(10):2257‐63. 
(27)   Hurt‐Camejo E, Andersen S, Standal R et al. Localization of 
nonpancreatic secretory phospholipase A2 in normal and 
atherosclerotic arteries. Activity of the isolated enzyme on low‐
density lipoproteins. Arterioscler Thromb Vasc Biol 1997 
February;17(2):300‐9. 
(28)   Romano M, Romano E, Bjorkerud S, Hurt‐Camejo E. 
Ultrastructural localization of secretory type II phospholipase A2 in 
atherosclerotic and nonatherosclerotic regions of human arteries. 
Arterioscler Thromb Vasc Biol 1998 April;18(4):519‐25. 
(29)   Mitsuhashi T, Nakayama H, Itoh T et al. Immunochemical 
detection of advanced glycation end products in renal cortex from 
STZ‐induced diabetic rat. Diabetes 1993 June;42(6):826‐32. 
(30)   Nakayama H, Mitsuhashi T, Kuwajima S et al. 
Immunochemical detection of advanced glycation end products in 
lens crystallins from streptozocin‐induced diabetic rat. Diabetes 1993 
February;42(2):345‐50. 
(31)   Brownlee M. Advanced protein glycosylation in diabetes 
and aging. Annu Rev Med 1995;46:223‐34. 
(32)   Vlassara H, Bucala R, Striker L. Pathogenic effects of 
advanced glycosylation: biochemical, biologic, and clinical 
implications for diabetes and aging. Lab Invest 1994 
February;70(2):138‐51. 
(33)   Nerlich AG, Schleicher ED. N(epsilon)‐
(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker 
for local oxidative stress. Atherosclerosis 1999 May;144(1):41‐7. 
(34)   Schleicher ED, Wagner E, Nerlich AG. Increased 
accumulation of the glycoxidation product N(epsilon)‐
(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin 
Invest 1997 February 1;99(3):457‐68. 
(35)   Yoshida S, Yamada K, Hamaguchi K et al. 
Immunohistochemical study of human advanced glycation end‐
products (AGE) and growth factors in cardiac tissues of patients on 
maintenance dialysis and with kidney transplantation. Clin Nephrol 
1998 May;49(5):273‐80. 
(36)   Schalkwijk CG, Baidoshvili A, Stehouwer CD, van H, V, 
Niessen HW. Increased accumulation of the glycoxidation product 
Nepsilon‐(carboxymethyl)lysine in hearts of diabetic patients: 
generation and characterisation of a monoclonal anti‐CML antibody. 
Biochim Biophys Acta 2004 March 22;1636(2‐3):82‐9. 
(37)   de Zwaan C, Kleine AH, Diris JH et al. Continuous 48‐h C1‐
inhibitor treatment, following reperfusion therapy, in patients with 
acute myocardial infarction. Eur Heart J 2002 November;23(21):1670‐7. 
(38)   Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological 
phenomenon with wide‐ranging implications in tissue kinetics. Br J 
Cancer 1972 August;26(4):239‐57. 
(39)   Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its 
significance in cancer and cancer therapy. Cancer 1994 April 
15;73(8):2013‐26. 
(40)   Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler 
RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J 
Clin Invest 1994 October;94(4):1621‐8. 
(41)   Tatsumi T, Shiraishi J, Keira N et al. Intracellular ATP is 
required for mitochondrial apoptotic pathways in isolated hypoxic rat 
cardiac myocytes. Cardiovasc Res 2003 August 1;59(2):428‐40. 
(42)   Lieberthal W, Menza SA, Levine JS. Graded ATP depletion 
can cause necrosis or apoptosis of cultured mouse proximal tubular 
cells. Am J Physiol 1998 February;274(2 Pt 2):F315‐F327. 
(43)   Shiraishi J, Tatsumi T, Keira N et al. Important role of 
energy‐dependent mitochondrial pathways in cultured rat cardiac 
myocyte apoptosis. Am J Physiol Heart Circ Physiol 2001 
October;281(4):H1637‐H1647. 
(44)   Entman ML, Michael L, Rossen RD et al. Inflammation in 
the course of early myocardial ischemia. FASEB J 1991 
August;5(11):2529‐37. 
(45)   Smith CW, Entman ML, Lane CL et al. Adherence of 
neutrophils to canine cardiac myocytes in vitro is dependent on 
intercellular adhesion molecule‐1. J Clin Invest 1991 
October;88(4):1216‐23. 
(46)   Kukielka GL, Hawkins HK, Michael L et al. Regulation of 
intercellular adhesion molecule‐1 (ICAM‐1) in ischemic and 
reperfused canine myocardium. J Clin Invest 1993 
September;92(3):1504‐16. 
(47)   Niessen HW, Krijnen PA, Visser CA, Meijer CJ, Hack CE. 
Intercellular adhesion molecule‐1 in the heart. Ann N Y Acad Sci 2002 
November;973:573‐85. 
(48)   Majno G, Joris I. Apoptosis, oncosis, and necrosis. An 
overview of cell death. Am J Pathol 1995 January;146(1):3‐15. 
(49)   Saraste A, Pulkki K. Morphologic and biochemical 
hallmarks of apoptosis. Cardiovasc Res 2000 February;45(3):528‐37. 
(50)   Dumont EA, Reutelingsperger CP, Smits JF et al. Real‐time 
imaging of apoptotic cell‐membrane changes at the single‐cell level in 
the beating murine heart. Nat Med 2001 December;7(12):1352‐5. 
(51)   Geske FJ, Lieberman R, Strange R, Gerschenson LE. Early 
stages of p53‐induced apoptosis are reversible. Cell Death Differ 2001 
February;8(2):182‐91. 
(52)   Hammill AK, Uhr JW, Scheuermann RH. Annexin V 
staining due to loss of membrane asymmetry can be reversible and 
precede commitment to apoptotic death. Exp Cell Res 1999 August 
25;251(1):16‐21. 
(53)   Musters RJ, Probstl‐Biegelmann E, van Veen TA et al. 
Sarcolemmal phosphatidylethanolamine reorganization during 
simulated ischaemia and reperfusion: reversibility and ATP 
dependency. Mol Membr Biol 1996 July;13(3):159‐64. 
(54)   Nijmeijer R, Willemsen M, Meijer CJ et al. Type II secretory 
phospholipase A2 binds to ischemic flip‐flopped cardiomyocytes and 
subsequently induces cell death. Am J Physiol Heart Circ Physiol 2003 
November;285(5):H2218‐H2224. 
(55)   Bevers EM, Comfurius P, Dekkers DW, Zwaal RF. Lipid 
translocation across the plasma membrane of mammalian cells. 
Biochim Biophys Acta 1999 August 18;1439(3):317‐30. 
(56)   Daleke DL. Regulation of transbilayer plasma membrane 
phospholipid asymmetry. J Lipid Res 2003 February;44(2):233‐42. 
(57)   Daleke DL, Huestis WH. Incorporation and translocation of 
aminophospholipids in human erythrocytes. Biochemistry 1985 
September 24;24(20):5406‐16. 
(58)   Seigneuret M, Devaux PF. ATP‐dependent asymmetric 
distribution of spin‐labeled phospholipids in the erythrocyte 
membrane: relation to shape changes. Proc Natl Acad Sci U S A 1984 
June;81(12):3751‐5. 
16
(59)   Gupta CM. Membrane‐associated cytoskeleton and 
transbilayer phospholipid asymmetry. Indian J Biochem Biophys 1990 
December;27(6):365‐7. 
(60)   Manno S, Takakuwa Y, Mohandas N. Identification of a 
functional role for lipid asymmetry in biological membranes: 
Phosphatidylserine‐skeletal protein interactions modulate membrane 
stability. Proc Natl Acad Sci U S A 2002 February 19;99(4):1943‐8. 
(61)   Williamson P, Antia R, Schlegel RA. Maintenance of 
membrane phospholipid asymmetry. Lipid‐cytoskeletal interactions 
or lipid pump? FEBS Lett 1987 July 27;219(2):316‐20. 
(62)   Goossens EL, Reutelingsperger CP, Jongsma FH, 
Kraayenhof R, Hermens WT. Annexin V perturbs or stabilises 
phospholipid membranes in a calcium‐dependent manner. FEBS Lett 
1995 February 13;359(2‐3):155‐8. 
(63)   Meers P, Mealy T. Relationship between annexin V 
tryptophan exposure, calcium, and phospholipid binding. Biochemistry 
1993 May 25;32(20):5411‐8. 
(64)   Saurel O, Cezanne L, Milon A, Tocanne JF, Demange P. 
Influence of annexin V on the structure and dynamics of 
phosphatidylcholine/phosphatidylserine bilayers: a fluorescence and 
NMR study. Biochemistry 1998 February 3;37(5):1403‐10. 
(65)   Kunzelmann C, Freyssinet JM, Martinez MC. Rho A 
participates in the regulation of phosphatidylserine‐dependent 
procoagulant activity at the surface of megakaryocytic cells. J Thromb 
Haemost 2004 April;2(4):644‐50. 
(66)   Duranteau J, Chandel NS, Kulisz A, Shao Z, Schumacker 
PT. Intracellular signaling by reactive oxygen species during hypoxia 
in cardiomyocytes. J Biol Chem 1998 May 8;273(19):11619‐24. 
(67)   Abe J, Berk BC. Reactive oxygen species as mediators of 
signal transduction in cardiovascular disease. Trends in Cardiovascular 
Medicine 2002;8:59‐64. 
(68)   Lander HM. An essential role for free radicals and derived 
species in signal transduction. FASEB J 1997 February;11(2):118‐24. 
(69)   von Harsdorf R, Li PF, Dietz R. Signaling pathways in 
reactive oxygen species‐induced cardiomyocyte apoptosis. Circulation 
1999 June 8;99(22):2934‐41. 
(70)   Rao GN, Berk BC. Active oxygen species stimulate vascular 
smooth muscle cell growth and proto‐oncogene expression. Circ Res 
1992 March;70(3):593‐9. 
(71)   Galang N, Sasaki H, Maulik N. Apoptotic cell death during 
ischemia/reperfusion and its attenuation by antioxidant therapy. 
Toxicology 2000 August 7;148(2‐3):111‐8. 
(72)   Oskarsson HJ, Coppey L, Weiss RM, Li WG. Antioxidants 
attenuate myocyte apoptosis in the remote non‐infarcted myocardium 
following large myocardial infarction. Cardiovasc Res 2000 
February;45(3):679‐87. 
(73)   De D, X, Wang D, Many MC et al. Cloning of two human 
thyroid cDNAs encoding new members of the NADPH oxidase 
family. J Biol Chem 2000 July 28;275(30):23227‐33. 
(74)   Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, 
Busse R. A gp91phox containing NADPH oxidase selectively 
expressed in endothelial cells is a major source of oxygen radical 
generation in the arterial wall. Circ Res 2000 July 7;87(1):26‐32. 
(75)   Lassegue B, Sorescu D, Szocs K et al. Novel gp91(phox) 
homologues in vascular smooth muscle cells : nox1 mediates 
angiotensin II‐induced superoxide formation and redox‐ sensitive 
signaling pathways. Circ Res 2001 May 11;88(9):888‐94. 
(76)   Shiose A, Kuroda J, Tsuruya K et al. A novel superoxide‐
producing NAD(P)H oxidase in kidney. J Biol Chem 2001 January 
12;276(2):1417‐23. 
(77)   Krijnen PA, Meischl C, Nijmeijer R, Visser CA, Hack CE, 
Niessen HW. Inhibition of sPLA2‐IIA, C‐reactive protein or 
complement: new therapy for patients with acute myocardial 
infarction? Cardiovasc Hematol Disord Drug Targets 2006 June;6(2):113‐
23. 
(78)   Hill JH, Ward PA. The phlogistic role of C3 leukotactic 
fragments in myocardial infarcts of rats. J Exp Med 1971 April 
1;133(4):885‐900. 
(79)   Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The 
complement system in myocardial ischaemia/reperfusion injury. 
Cardiovasc Res 1994 April;28(4):437‐44. 
(80)   McManus LM, Kolb WP, Crawford MH, OʹRourke RA, 
Grover FL, Pinckard RN. Complement localization in ischemic baboon 
myocardium. Lab Invest 1983 April;48(4):436‐47. 
(81)   Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, 
Entman ML. Selective accumulation of the first component of 
complement and leukocytes in ischemic canine heart muscle. A 
possible initiator of an extra myocardial mechanism of ischemic 
injury. Circ Res 1985 July;57(1):119‐30. 
(82)   Mathey D, Schofer J, Schafer HJ et al. Early accumulation of 
the terminal complement‐complex in the ischaemic myocardium after 
reperfusion. Eur Heart J 1994 March;15(3):418‐23. 
(83)   Lagrand WK, Niessen HW, Wolbink GJ et al. C‐reactive 
protein colocalizes with complement in human hearts during acute 
myocardial infarction. Circulation 1997 January 7;95(1):97‐103. 
(84)   Niessen HW, Lagrand WK, Visser CA, Meijer CJ, Hack CE. 
Upregulation of ICAM‐1 on cardiomyocytes in jeopardized human 
myocardium during infarction. Cardiovasc Res 1999 March;41(3):603‐
10. 
(85)   Ito W, Schafer HJ, Bhakdi S et al. Influence of the terminal 
complement‐complex on reperfusion injury, no‐reflow and 
arrhythmias: a comparison between C6‐competent and C6‐deficient 
rabbits. Cardiovasc Res 1996 August;32(2):294‐305. 
(86)   Weisman HF, Bartow T, Leppo MK et al. Soluble human 
complement receptor type 1: in vivo inhibitor of complement 
suppressing post‐ischemic myocardial inflammation and necrosis. 
Science 1990 July 13;249(4965):146‐51. 
(87)   Weisman HF, Bartow T, Leppo MK et al. Recombinant 
soluble CR1 suppressed complement activation, inflammation, and 
necrosis associated with reperfusion of ischemic myocardium. Trans 
Assoc Am Physicians 1990;103:64‐72. 
(88)   Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, 
Lucchesi BR. Reduction of the extent of ischemic myocardial injury by 
neutrophil depletion in the dog. Circulation 1983 May;67(5):1016‐23. 
(89)   Simpson PJ, Todd RF, III, Fantone JC, Mickelson JK, Griffin 
JD, Lucchesi BR. Reduction of experimental canine myocardial 
reperfusion injury by a monoclonal antibody (anti‐Mo1, anti‐CD11b) 
that inhibits leukocyte adhesion. J Clin Invest 1988 February;81(2):624‐
9. 
(90)   Nijmeijer R, Lagrand WK, Visser CA, Meijer CJ, Niessen 
HW, Hack CE. CRP, a major culprit in complement‐mediated tissue 
damage in acute myocardial infarction? Int Immunopharmacol 2001 
March;1(3):403‐14. 
(91)   Sellmayer A, Limmert T, Hoffmann U. High sensitivity C‐
reactive protein in cardiovascular risk assessment. CRP mania or 
useful screening? Int Angiol 2003 March;22(1):15‐23. 
17
(92)   Kushner I, Kaplan MH. Studies of acute phase protein. I. An 
immunohistochemical method for the localization of Cx‐reactive 
protein in rabbits. Association with necrosis in local inflammatory 
lesions. J Exp Med 1961 December 1;114:961‐74. 
(93)   Kushner I, Rakita L, Kaplan MH. Studies of acute‐phase 
protein. II. Localization of Cx‐reactive protein in heart in induced 
myocardial infarction in rabbits. J Clin Invest 1963 February;42:286‐92. 
(94)   Nijmeijer R, Lagrand WK, Lubbers YT et al. C‐reactive 
protein activates complement in infarcted human myocardium. Am J 
Pathol 2003 July;163(1):269‐75. 
(95)   Griselli M, Herbert J, Hutchinson WL et al. C‐reactive 
protein and complement are important mediators of tissue damage in 
acute myocardial infarction. J Exp Med 1999 December 20;190(12):1733‐
40. 
(96)   Nijmeijer R, Lagrand WK, Baidoshvili A et al. Secretory type 
II phospholipase A(2) binds to ischemic myocardium during 
myocardial infarction in humans. Cardiovasc Res 2002 
January;53(1):138‐46. 
(97)   Snitko Y, Yoon ET, Cho W. High specificity of human 
secretory class II phospholipase A2 for phosphatidic acid. Biochem J 
1997 February 1;321 ( Pt 3):737‐41. 
(98)   Fourcade O, Le Balle F, Fauvel J, Simon MF, Chap H. 
Regulation of secretory type‐II phospholipase A2 and of 
lysophosphatidic acid synthesis. Adv Enzyme Regul 1998;38:99‐107. 
(99)   Weiser MR, Williams JP, Moore FD, Jr. et al. Reperfusion 
injury of ischemic skeletal muscle is mediated by natural antibody 
and complement. J Exp Med 1996 May 1;183(5):2343‐8. 
(100)   Williams JP, Pechet TT, Weiser MR et al. Intestinal 
reperfusion injury is mediated by IgM and complement. J Appl Physiol 
1999 March;86(3):938‐42. 
(101)   Aronow BJ, Lund SD, Brown TL, Harmony JA, Witte DP. 
Apolipoprotein J expression at fluid‐tissue interfaces: potential role in 
barrier cytoprotection. Proc Natl Acad Sci U S A 1993 January 
15;90(2):725‐9. 
(102)   Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002 
May;34(5):427‐31. 
(103)   Trougakos IP, Poulakou M, Stathatos M, Chalikia A, 
Melidonis A, Gonos ES. Serum levels of the senescence biomarker 
clusterin/apolipoprotein J increase significantly in diabetes type II and 
during development of coronary heart disease or at myocardial 
infarction. Exp Gerontol 2002 October;37(10‐11):1175‐87. 
(104)   Ishikawa Y, Akasaka Y, Ishii T et al. Distribution and 
synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler 
Thromb Vasc Biol 1998 April;18(4):665‐72. 
(105)   Swertfeger DK, Witte DP, Stuart WD, Rockman HA, 
Harmony JA. Apolipoprotein J/clusterin induction in myocarditis: A 
localized response gene to myocardial injury. Am J Pathol 1996 
June;148(6):1971‐83. 
(106)   Choi‐Miura NH, Sakamoto T, Tobe T, Nakano Y, Tomita M. 
The role of HDL consisting of SP‐40,40, apo A‐I, and lipids in the 
formation of SMAC of complement. J Biochem (Tokyo) 1993 
April;113(4):484‐7. 
(107)   Kirszbaum L, Bozas SE, Walker ID. SP‐40,40, a protein 
involved in the control of the complement pathway, possesses a 
unique array of disulphide bridges. FEBS Lett 1992 February 3;297(1‐
2):70‐6. 
(108)   McDonald JF, Nelsestuen GL. Potent inhibition of terminal 
complement assembly by clusterin: characterization of its impact on 
C9 polymerization. Biochemistry 1997 June 17;36(24):7464‐73. 
(109)   Partridge SR, Baker MS, Walker MJ, Wilson MR. Clusterin, a 
putative complement regulator, binds to the cell surface of 
Staphylococcus aureus clinical isolates. Infect Immun 1996 
October;64(10):4324‐9. 
(110)   Tschopp J, Chonn A, Hertig S, French LE. Clusterin, the 
human apolipoprotein and complement inhibitor, binds to 
complement C7, C8 beta, and the b domain of C9. J Immunol 1993 
August 15;151(4):2159‐65. 
(111)   Yamada K, Hori Y, Hanafusa N et al. Clusterin is up‐
regulated in glomerular mesangial cells in complement‐mediated 
injury. Kidney Int 2001 January;59(1):137‐46. 
(112)   Vakeva A, Laurila P, Meri S. Co‐deposition of clusterin with 
the complement membrane attack complex in myocardial infarction. 
Immunology 1993 October;80(2):177‐82. 
(113)   Silkensen JR, Hirsch AT, Lunzer MM et al. Temporal 
induction of clusterin in the peri‐infarct zone after experimental 
myocardial infarction in the rat. J Lab Clin Med 1998 January;131(1):28‐
35. 
 
 
 
18
 
 
Part I: 
 
Role of inflammation in the induction of AMI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19
 20
Chapter 2 
 
Type II secretory phospholipase A2 in 
cardiovascular disease: a mediator in 
atherosclerosis and ischemic damage to 
cardiomyocytes? 
 
Niessen HWM, Krijnen PAJ, Visser CA, Meijer CJLM, Hack CE. 
 
Cardiovascular Research 2003 Oct 15;60(1):68-77. 
 
21
Cardiovascular Research 60 (2003) 68–77
www.elsevier.com/ locate /cardiores
T ype II secretory phospholipase A2 in cardiovascular disease: a
mediator in atherosclerosis and ischemic damage to cardiomyocytes?
a,b , ,1 a,b ,1 a,c b*Hans W.M. Niessen , Paul A.J. Krijnen , Cees A. Visser , Chris J.L.M. Meijer ,
a,d,eC. Erik Hack
aICaR-VU, VU Medical Center, Amsterdam, The Netherlands
bDepartment of Pathology, VU Medical Center, Amsterdam, The Netherlands
cDepartment of Cardiology, VU Medical Center, Amsterdam, The Netherlands
dDepartment of Clinical Chemistry, VU Medical Center, Amsterdam, The Netherlands
eDepartment of Immunopathology, Sanquin Research at CLB, Amsterdam, The Netherlands
Received 5 November 2002; accepted 14 February 2003
Abstract
Inflammatory reactions contribute to the pathogenesis of cardiovascular conditions such as atherosclerosis and ischemic damage in
acute myocardial infarction (AMI). Among the mediators involved in inflammation are secretory phospholipase A2 group II (sPLA2-II)
enzymes. Though some cells constitutively express sPLA2-II, the synthesis by cells such as hepatocytes is typical for an acute-phase
reactant. Recent literature suggests multiple roles for sPLA2-II in cardiovascular disease. In this review we discuss the role of sPLA2-II in
various in vivo and in vitro models of atherosclerosis or AMI, including the therapeutic perspective of sPLA2-II inhibitors. It was
concluded that sPLA2-II appears to be an important inflammatory mediator of cardiovascular disease.
  2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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1 . Introduction typical inflammation marker in humans, constitute an
independent risk marker for cardiovascular events both in
Atherosclerosis and one its major consequences, acute apparently healthy individuals as well as in patients with
myocardial infarction (AMI), are major cardiovascular established cardiovascular disease such as stable angina
conditions in the Western World. Traditionally, these pectoris [1]. The beneficial effects of statins, originally
conditions are considered to result from lipid abnor- developed because of their cholesterol-lowering properties,
malities, and other risk factors such as hypertension, may at least in part be related to their anti-inflammatory
smoking, hyperhomocysteinemia and diabetes. However, properties [2]. Also, many of the processes ensuing in
evidence is now accumulating that in addition to these, atherosclerotic vessels during the various stages of the
inflammatory reactions in the atherosclerotic lesions as lesions, such as the influx and activation patterns of blood
well as in the infarcted myocardium have a major impact mononuclear cells, show remarkable similarities to pro-
on incidence and outcome of atherosclerosis and AMI. For cesses occurring in established immune or inflammatory
example, a number of studies during the last decade have diseases [3]. This growing appreciation of a role for
shown that plasma levels of C-reactive protein (CRP), a inflammation in atherosclerosis has even led some to
speculate that this condition may result from or be
enhanced by microbial infections in the vessel wall,
*Corresponding author. VU Medical Center, Department of Pathology, involving organisms such as Chlamydiae pneumoniae or
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viruses [4]. Pathological studies of the hearts of personsNetherlands. Tel.: 131-20-444-4003; fax: 131-20-444-2964.
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dying from AMI have provided compelling evidence that explains why inhibitors of PLA2 enzymes have received
inflammatory reactions ensue in the ischemic myocardium considerable attention by pharmaceutical companies as
starting hours after the onset of complaints. Numerous drug targets. Hydrolysis of phospholipids in membranes by
studies in animals have shown that anti-inflammatory PLA2 requires binding of the enzyme to the membrane, the
agents under some conditions can reduce infarction size binding of which is dependent on electrostatic (charge–
substantially in AMI [5–7]. Initial clinical studies with a charge) interactions amongst others [12].
naturally occurring complement inhibitor, C1-inhibitor,
have yielded promising results [8].
Inflammatory reactions are mediated by an array of
so-called inflammatory mediators which amongst others 3 . Secretory PLA2-II (sPLA2-II)
include cytokines, complement and many more. Type II
secretory phospholipase A2 (sPLA2-II) constitutes one of sPLA2-II accumulates in inflammatory fluids [13].
the inflammatory mediators possibly involved in the Being an acute phase protein, plasma levels strongly
pathogenesis of atherosclerosis and of AMI. A role for this increase during inflammatory diseases such as infections,
enzyme in either disease is suggested by observations that septic shock and RA. However, processes such as carcino-
its circulating levels are high in atherosclerosis and AMI. genesis and atherosclerosis may also be accompanied by
In addition, sPLA2-II has been shown to be deposited in increased circulating levels [14]. sPLA2-II is constitutively
atherosclerotic arteries as well as on ischemic car- expressed in organs dealing with inflammatory response,
diomyocytes. Here we discuss the idea that sPLA2-II such as spleen, thymus, intestines, liver and bone marrow,
enhances atherosclerosis and exerts detrimental effects on but also in lung, kidney and ovary. Furthermore, many cell
ischemic cardiomyocytes in infarcted myocardium, and types are able to secrete sPLA2-II such as endothelial cells,
that the enzyme should be considered as an inflammatory smooth muscle cells, platelets, mast cells, neutrophils,
mediator in cardiovascular disease rather than being an macrophages and hepatic cells. All these cells may contrib-
epiphenomenon. ute to the elevation of circulating levels during acute phase
responses, as the synthesis of sPLA2-II by these cells is
stimulated by proinflammatory cytokines [15,16]. The
2 . Phospholipase A2 (PLA2) enzymes expression of the sPLA2-II gene is stimulated by factors as
diverse as hypoxia, cytokines and phorbol esters [17], and
PLA2 are widely distributed enzymes that exist in many is amongst others regulated by transcription factors includ-
isoforms, including the 14-kDa secretory phospholipase ing NF-kB, PPAR and C/EBP [18]. NF-kB is an essential
A2 (sPLA2) and the 85-kDa cytosolic phospholipase A2 component of the cytokine signaling pathways inducing
(cPLA2) [9]. sPLA2 comprises a small group of homolo- sPLA2-II expression. PPARs control the regulation of
gous proteins with five to eight disulfide bridges. The genes involved in lipid metabolism in general. While the
location of these disulfide bonds in the protein backbone human sPLA2-II promoter is controlled by C/EBP factors
provides the basis for a classification into several sub- [18]. The activation of these transcription factors is under
groups [10]. the control of distinct signaling pathways, like PKC and
sPLA2-I is known as pancreatic PLA2, since it is cAMP [18].
expressed at high levels in the pancreas, to be secreted into Interaction of sPLA2-II with cellular phospholipids
the intestine where it hydrolyzes food-derived phos- depends in part on the nature of these phospholipids [16].
pholipids. The enzyme binds with a higher affinity to phosphatatic
Significant levels of sPLA2-I mRNA are also found in acid (PA) than to phosphatidylethanolamine (PE), phos-
spleen, lung and prostate. sPLA2-II was initially discov- phatidylserine (PS) and phosphatidylcholine (PC) [15,19].
ered in synovial fluid of patients with rheumatoid arthritis This binding specificity results from non-covalent interac-
(RA) [11], and subsequently found to be an acute phase tions of the amino acid backbone of the protein with the
protein, of which circulating levels may increase more then phospholipids, interactions of which are apparently
100-fold during acute phase reaction. Whereas sPLA2-I stronger in the case of PA as compared to PE, PS and PC
and -II are extracellular proteins that are secreted by cells, [19]. sPLA2-II has only a low affinity for PC as a
cPLA2 is an intracellular cytoplasmic protein, of which substrate, which in part is explained by the presence of a
mRNA has been found in many tissues including heart, critical valine residue, rather than a tryptophan residue,
spleen, lung and kidney [10]. which is found in PLA2 enzymes with a higher affinity for
PLA2 enzymes hydrolyze phospholipids at the sn-2 PC [20]. The presence of the amphiphilic indole side chain
position to generate free fatty acids and lysolipids, which is in tryptophan allows a better penetration of PLA-2 into the
the rate-limiting step in the biosynthesis of eicosanoids and lipid interface of membranes [20]. A V3W mutant of
platelet-activating factor (PAF) (Fig. 1) [12]. These sub- human sPLA2-II, in which this critical valine residue was
stances are potent mediators of inflammation, apoptosis replaced by tryptophan, showed strong (250-fold) en-
and tumorigenesis [12]. This important biological activity hanced enzymatic activity for small unilamellar vesicles of
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 505Fig. 1. Schematic presentation of the activation mechanisms and localization of activity of sPLA -II and cPLA . Phosphorylation of Serine by a kinase2 2
21leads to catalytic activity of cPLA . Ca (+) binds to the N-terminal calcium-dependent phospholipid-binding domain (CaLB) of cPLA and thereby2 2
21promotes translocation to membranes. sPLA is also dependent upon Ca , which binds to sPLA -IIvia, a specific calcium-loop. Also, sPLA -II can only2 2 2
bind flip-flopped membranes, i.e. when negatively loaded phospholipids PE and PS (depicted as += or ?=) are present in the outer membrane leaflet.
PC, whereas wild-type human sPLA2-II hardly hydrolyzed vital cells are tightly packed together, and are not hydro-
this substrate [20]. lyzed by sPLA2-II. Under some conditions, the phos-
Notably, some biological effects of sPLA2-II are in- pholipids of the inner and outer leaflet become rearranged
dependent of its catalytic function [21], suggesting it may leading to the presence of PS in the outer leaflet. This
interact with specific receptors. Indeed the enzyme has process is known as membrane ‘flip-flop’. Thus, a translo-
been shown to bind to a high affinity receptor (K 57.5 cation of negatively charged phospholipids (PS, and to ad
pM) of 180 kDa, present on rabbit skeletal muscle [22]. lesser extent PE) from the inner layer of the membrane to
This so-called M-type receptor mediates some of the the outer layer occurs during a membrane flip-flop [25]. In
physiological effects of mammalian sPLA2-II, including contrast to that of normal membranes, the outer leaflet of
vascular smooth muscle cell (SMC) contraction and cell flip-flopped membranes is easily hydrolyzed by sPLA2-II.
proliferation. In addition, binding of sPLA2-II to this This affinity of sPLA2-II for flip-flopped membranes is
receptor may induce internalization of sPLA2-II [23]. explained by the presence of a number of cationic residues
Also, murine sPLA2-II is a high affinity ligand for murine forming patches on the putative interfacial binding surface
M-type receptor [24]. However, human sPLA2-II does not of the enzyme [26].
seem to be a physiological ligand for the human M-type sPLA2-II generates various lysophospholipids, such as
receptor [24]. Thus, the function of this putative high lysoPC, lysoPE, lysoPS and lysoPA [13]. Interestingly,
affinity sPLA2-II receptor is likely to be species-depen- lyso-PA is a messenger acting through G protein-coupled
dent. receptors [27], and can stimulate platelet aggregation, cell
proliferation and SMC contraction [19]. sPLA2-II indeed
has been described to induce signal-transduction in in-
4 . Effector functions of sPLA2-II flammatory cells. For example, in combination with PAF,
the enzyme induces exocytosis of human neutrophils [28].
Under normal conditions, the composition of phos- Notably, the biological function of sPLA2-II in some cell
pholipids in inner and outer leaflet is not similar. The outer types is independent of its catalytic function [22].
leaflet of the membrane contains mainly hydrophobic sPLA2-II not only hydrolyzes phospholipids in the cell
phospholipids, whereas the inner contains anionic phos- membrane of cells, but also those in bacterial cell walls,
pholipids such as PS, as well. Due to their hydrophobic leading to impaired integrity of the membranes [15], and
nature, the phospholipids in the outer leaflet of normal, providing the enzyme with bactericidal properties [29]. It
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has been shown that the assembly of the membrane-attack However, native LDL proved to be a poor substrate for
complex of complement increases the susceptibility of the sPLA2-II, whereas after mild oxidation, which occurs in
cell membrane of Gram-negative bacteria for sPLA2-II by atherosclerosis, the susceptibility of LDL to phospholipid
producing sublethal alterations of the outer envelope of the hydrolysis is increased [42]. In another study it was shown
bacteria [29]. sPLA2-II is also a primary bactericidal agent that sPLA2-II induced only little lipolytic modification of
for Gram-positive bacteria [29]. LDL, while a strong lipolytic activity was found for the
subtype sPLA2-X [43]. Hence, likely subtle differences in
composition, oxidation, and possibly other aspects, may
5 . Crosstalk between cPLA2 and sPLA2-II alter the susceptibility of LDL for sPLA2-II and other
PLA2 enzymes.
In mast cells sPLA2-II was found to mediate the Normal high density lipoprotein (HDL) reduces activity
selective release of arachidonic acid (AA) by binding to of sPLA2-II [44]. However, in a co-culture system of
cell surface receptors, followed by induction of signal human endothelial cells and SMCs, HDL from sPLA2-II-
transduction events that lead to cPLA2 activation [30]. transgenic mice or human HDL treated with recombinant
This possibly involves the activation of the PKC/Raf-1 / sPLA2-II, failed to protect against the formation of bio-
MAPK signalling pathway [31]. Furthermore, in rat fi- logically active phospholipids in LDL [41]. Furthermore, it
broblastic 3Y1 cells cPLA2 and its downstream 12- or has been shown that acute phase HDL containing 27%
15-lipoxygenase pathway were shown to enhance sPLA2- serum amyloid A (SAA), an acute phase protein, enhanced
II gene expression. cPLA2 may also alter membrane sPLA2-II activity [44]. This interaction between HDL,
susceptibility for sPLA2-II [32]. For example, in human SAA and sPLA2-II may explain the alterations in lipopro-
embryonic kidney cells, prior production of AA by cPLA2 tein metabolism during acute phase reactions [44]. sPLA2-
in cytokine-stimulated cells destabilized the cellular mem- II may even hydrolyze the phospholipid monolayers of
branes, and rendered them more susceptible to subsequent HDL [15]. Therefore, transgenic mice overexpressing
hydrolysis by sPLA2-II [33]. In contrast, from a study in sPLA2-II have lower HDL levels, whereas levels of LDL
S49 cells, it was concluded that cPLA2 reduces suscep- are increased [45]. Furthermore, sPLA2-II caused a de-
tibility of membranes to sPLA2 during apoptosis [34]. crease in plasma HDL cholesterol in response to inflamma-
cPLA2 as well as sPLA2-II have partially overlapping tory stimuli in mice, via a direct interaction on HDL
functions. For example, in neutrophils stimulated with particle size and composition [46].
fMLP both cPLA2 and sPLA2-II were found to contribute
to AA release [35]. Moreover, in the human keratinocyte
cell line HaCaT, inhibition of both cPLA2 and sPLA2-II 7 . sPLA2-II interactions with cells of the vessel wall
blocked TNF-induced activation of NF-kB and subsequent
expression of ICAM-1 [36]. cPLA2 and sPLA2-II may be Incubation of macrophages with sPLA2-II-treated LDL
activated by similar stimuli, as has been shown in human and HDL results in increased intracellular lipid accumula-
natural killer cells, in which both sPLA2-II and cPLA2 tion, and triggers the formation of foam cells [15]. sPLA2-
were rapidly activated upon CD16 cross-linking [37]. II itself also activates macrophages via induction of the
secretion of enzymes and cytokines [47], while in the
presence of LPS, sPLA2-II stimulates iNOS expression
6 . Interactions of sPLA2-II with lipoproteins and nitrite production in macrophages [48]. In primary
cultures of rat endothelial cells and in two different rat
Among the first events in atherogenesis is modification endothelial cell lines (SVAREC and RBE4), IL-1b-induced
of low density lipoprotein (LDL) particles in the arterial sPLA2-II gene expression and secretion of the enzyme in a
wall, and subsequent formation of aggregated and fused dose- and time-dependent manner [49]. In contrast, LPS
lipid droplets that are relatively depleted in PC [38]. High treatment of cultured primary endothelial cells caused an
levels of small dense LDL in plasma are associated with an increase of cPLA2 mRNA, but not of sPLA2-II mRNA
increased risk for cardiovascular disease [39]. Small dense [50]. Whether sPLA2 contributes to AA release by endo-
LDL particles are formed by reduction of the phospholipid thelial cells is not clear. At least in bovine aortic endotheli-
content in the surface monolayer LDL, which causes an al cells, an inhibitor of sPLA2-II (CGP-43187) did not
enhanced interaction with proteoglycans [39]. sPLA2-II affect AA release induced by the non-selective activator of
may help to reduce the phospholipid content of LDL [39]. heterotrimeric guanine nucleotide-binding proteins, NaF
Also, 15-lipoxygenase-induced LDL oxidation was en- [51]. Furthermore, VEGF-enhanced PAF synthesis in
hanced by sPLA2-II [40]. In vitro it was shown that HUVEC was mediated by sPLA2-V, but not by sPLA2-II
sPLA2-II liberated polyunsaturated free fatty acids from [52].
phospholipids. These fatty acids increase the formation of In human vascular SMC, IL-1 did not affect sPLA2-II
bioactive phospholipids in LDL, resulting in an enhanced mRNA levels, while it increased cPLA2-mRNA [53]. In
ability to stimulate monocyte-endothelial interactions [41]. rabbit aortic vascular SMC, norepinephrine enhanced
25
release of AA via activation of cPLA2 but not sPLA2-II Chlamydia pneumonia, HSV-1 and CMV was found to be
[54]. associated with sPLA2-II expression and other signs of
A main process induced by activated endothelial cells or local inflammation in human atherosclerosis [15].
macrophages is coagulation. sPLA2-II inhibits blood
coagulation independent of its lipolytic action [55]. The
enzyme inhibits prothrombinase, which is the enzyme
complex that catalyzes the formation of thrombin from 9 . sPLA2-II in the heart
prothrombin, and which consists of activated factors Xa
and Va assembled onto a membrane surface in the presence We have described the presence of sPLA2-II in infarcted
of calcium [56,57]. Whether this anti-coagulant effect is myocardium [65] suggesting the enzyme to be involved in
relevant for the in vivo situation is not clear. From the inflammatory reactions ensuing in heart infarcts. This
ellipsometric studies (an optical technique measuring the sPLA2-II may originate from the blood or be produced
changes in surface-bound mass), it was concluded that locally by cardiomyocytes. Indeed, Northern blotting re-
plasma sPLA2-II concentrations in inflammatory disease vealed the presence of mRNA of sPLA2-II in the rat heart
will not be sufficiently elevated to inhibit coagulation [66]. Cytokines such as TNF-a stimulate transcription
efficiently [58]. levels of sPLA2-II in isolated neonatal rat cardiomyocytes
[67]. Interestingly, the borderzone of the infarcts in
humans contained cells that had bound sPLA2-II in spite
of normal morphology [65]. In contrast, normal car-
8 . Relation between sPLA2-II and atherosclerosis in diomyocytes in non-ischemic sites did not bind sPLA2-II.
vivo Thus, binding of sPLA2-II may be one of the earliest
phenomena on the outside of cells during ischemia. In
Rheumatoid arthritis (RA) patients have an increased vitro, we have identified a flip-flopped, but caspase-3-
risk for cardiovascular events. sPLA2-II in RA patients negative population of H9c2 cells, and a rat cardiomyocyte
significantly correlates with CRP, soluble ICAM and LDL- cell line, upon exposure to metabolic inhibitors. These
1, while it inversely correlates with HDL [59]. This would cells were killed upon subsequent incubation with sPLA2-
¨ ¨suggest that sPLA-II is a cardiovascular risk marker. II (manuscript submitted by Nymeyer et al.). Similar
Indeed, circulating levels of sPLA2-II constitute an in- results were obtained with adult rabbit cardiomyocytes.
dependent risk marker for coronary artery disease and These findings together suggest that sPLA2-II may induce
predict cardiovascular events [60]. An increase in circulat- cardiomyocyte cell death in human infarction. Previously,
ing levels of sPLA2-II also predicted clinical coronary we have hypothesized that sPLA2-II may also indirectly
events independently of other risk factors in patients with damage reversibly injured cardiomyocytes by generating
unstable angina [60]. Finally, elevated blood levels of binding sites for CRP [68], which upon binding may
sPLA2-II predict restenosis in patients undergoing cor- activate complement. Indeed, in human myocardial infarc-
onary angioplasty [61]. tion, sPLA2-II depositions precede those of CRP [65].
Atherosclerotic plaques exhibit a series of features that Interestingly, there is evidence that CRP can regulate
are similar to those of chronic inflammation [62]. In sPLA2-II activity in a substrate-concentration dependent
humans sPLA2-II is present in the intima, media and fashion [69].
adventitia of the atherosclerotic wall, not only in mature The studies discussed above suggest a role for sPLA2-II
lesions but also at a very early stage of atherosclerosis in the inflammatory damage ensuing in infarcted myocar-
[15]. sPLA2-II was found in foam cells, calcifications dium. However, from a study in hearts from wild-type and
sites, areas of cell necrosis and in the extracellular matrix sPLA2-II deficient mice it was concluded that sPLA2-II
[62]. In the abdominal human aorta, sPLA2-II was present does not play a prominent role in the development of
in all advanced atherosclerotic lesions, but only in some irreversible cell damage in the ischemic-reperfused murine
preatheromas and early lesions of atherosclerosis [63]. In myocardium [70]. Notably, in this study the role of
contrast, in the thoracic aorta, sPLA2-II was found at a sPLA2-II was not analyzed during acute phase reactions,
similar frequency in all stages of atherosclerotic lesions, in since Langendorf perfusion of isolated hearts was used. As
all three layers of the vessel wall [63]. In another study of we did not find sPLA2-II depositions in human myocardial
human carotid arteries, sPLA2-II was found throughout the infarction until at least 6–12 h after the onset of symptoms,
media in atherosclerotic but also in normal artery speci- i.e. at which time blood levels of sPLA2-II in patients with
mens [64]. In contrast, in another study, sPLA2-II did not AMI start to increase [65], acute phase concentrations of
stain normal human arteries without thickened intima [62]. sPLA2-II are likely to be required to mediate inflammatory
The presence of sPLA2-II in atherosclerotic lesions is not damage in the heart. Moreover, mouse blood hardly
unique for humans. The enzyme was also present in contains CRP, and hence CRP-dependent damage induced
atherosclerotic lesions of transgenic mice overexpressing by sPLA2-II may have been missed in the Langendorf
sPLA2-II [45]. Interestingly, the presence of DNA of perfusion model.
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1 0. Studies with sPLA2-II inhibitors suggests a role for sPLA2-II in cardiovascular pathology.
In atherosclerosis, sPLA2-II not only plays a role in
In the placenta, sPLA2-II specific antisense oligonucleo- macrophage activation and foam cell formation [15,47],
tides A and B inhibited the expression and activity of but it also hydrolyzes LDL [39] and HDL [15], resulting in
sPLA2-II [71]. Another potent inhibitor is LY315920 ([[3- increase numbers of pro-atherogenic small LDL particles,
(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4- and an impaired function of anti-atherogenic HDL. Al-
yl]oxy]acetate), a pharmacological drug that functions as a though sPLA2-II depositions have been found locally in
selective, stoichiometric inhibitor of the catalytic activity atherosclerotic lesions [62,63], and clinical studies have
of sPLA2-II. LY315920 inhibited sPLA2-II serum activity revealed a correlation between sPLA2-II and vascular
after intravenous or oral administration to transgenic mice complications [39,60], until now the role of sPLA2-II in
expressing the human sPLA2-II [72]. Other novel sPLA2- the induction of local complications of atherosclerotic
II inhibitors, petrosaspongiolide M (isolated from the plaques themselves or subsequent vascular complications
Caledonian marine sponge Petrosaspongia nigra), and has not been clarified. Also, the relevance of the anti-
cacospongionolide B (isolated from the sponge Fascios- coagulant function of sPLA2-II remains to be established
pongia cavernosa), had anti-inflammatory properties in [56]. With regard to the latter, one may speculate that the
mice and rats with respect to arthritis and post-inflamma- enzyme induces prolonged bleeding in a complicated
tory edema [73,74]. Unfortunately, no studies with these atherosclerotic plaque, which can result in vascular com-
inhibitors have been performed in animal models for plications. Also, the potential antibactericidal effects of
myocardial infarction. So it remains to be established sPLA2-II within atherosclerotic plaques, is not well estab-
whether sPLA2-II inhibitors are useful in the treatment of lished [15,29].
AMI. With respect to putative therapeutical options in athero-
Some drugs developed because of other biological sclerosis, it has been shown that sPLA2-II activity in
properties, also appeared to inhibit sPLA2-II activity or patients with hypercholesterolemia who receive statins, is
sPLA2-II-induced phenomena. Alminoprofen, a NSAID (a inhibited [2]. Also, aspirin is able to reduce sPLA2-II
member of the phenylpropionic acid class of drugs), and levels [75,76]. Yet, at the moment it can only be speculated
aspirin inhibit sPLA2-II activity [75,76], as does heparin that the beneficial effects of either drug is due to their
[77]. Another NSAID, indomethacin, inhibits sPLA2-in- effect on circulating sPLA2-II. Yet, except for a potential
duced aggregation of platelets [75]. Chemically modified anti-coagulant effect, all the evidence to date points to a
tetracyclines, devoid of antimicrobial properties, not only detrimental role for sPLA2-II in the development of
inhibit sPLA2-II but also some matrix metalloproteinases, atherosclerotic lesions. Thus, although the role of sPLA2-II
that play an important role in the process of atherosclerosis in atherosclerosis remains a matter of speculation, studies
[78]. Furthermore, in patients with hypercholesterolemia, with specific sPLA2-II inhibitors in animal models for
both simvastatin and atorvastatin caused a reduction in atherosclerosis seem to be warranted. Also, in AMI the
sPLA2-II [2]. Whether the beneficial effects on car- function of sPLA2-II seems to be detrimental in that it
diovascular disease of the drugs discussed in this section promotes inflammation. Hence, for the treatment of AMI,
are due to their effects on sPLA2-II remains to be specific inhibitors of the enzyme also constitute an attrac-
established yet. tive option. The time-window for the start of therapy with
sPLA2-II inhibitors in patients is likely to be 6–24 h after
the onset of complaints, as blood levels start to increase in
1 1. Discussion this period, which is accompanied with deposition of the
enzyme in the ischemic myocardium. To our knowledge,
Inflammation plays an important role in both athero- binding of sPLA2-II to jeopardized cardiomyocytes seems
sclerosis and acute myocardial infarction (AMI), although to be among the first events in the processes that ultimately
via different mechanisms. Inflammation in atherosclerosis lead to the death of these cells [65]. We speculate that a
likely contributes to recruitment of inflammatory cells in major event in these processes is the binding of CRP,
the lesions and the formation of foam cells, and also to the which is facilitated by the effects of sPLA2-II on mem-
formation of unstable plaques or plaque ruptures, which brane phospholipids in the outer leaflet of injured cells.
are the main processes that elicit (cardio)vascular events. Complement and neutrophils are also among the inflamma-
In AMI, local inflammatory reactions in the ischemic tory mediators triggered by sPLA2-II and CRP in the
myocardium contribute to myocardial damage and infarc- ischemic myocardium [1,65]. To what extent sPLA2-II
tion size and play a role in tissue remodelling [65]. locally produced by cardiomyocytes contribute to the
Various inflammatory mediators have been identified to inflammation in the heart is not yet clear, although the
play a role in both atherosclerosis and AMI, including time-relationship between increasing plasma levels and the
cytokines, adhesion molecules, complement and acute deposition in the heart suggest most of the enzyme is
phase proteins. Among the latter is type-II secretory derived from the blood [70]. Nevertheless, current under-
phospholipase A2 (sPLA2-II) [1]. All current evidence standing of the role of sPLA2-II in patients with AMI thus
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far supports the use of specific sPLA2-II inhibitors in these (Fig. 2). Although the local effect of sPLA2-II in athero-
patients. sclerosis has to be studied in more detail, the results of the
In conclusion sPLA2-II plays an important studies discussed above make it worthwhile to start in vivo
pathophysiological role in both atherosclerosis and AMI animal studies with sPLA2-II inhibitors with respect to
 
Fig. 2. Overview of the role of sPLA -II in atherosclerosis and in post-AMI damage to cardiomyocytes. In blood vessels sPLA -II promotes2 2
atherosclerosis. sPLA has been found in atherosclerotic plaques where it induces (small dense) LDL increase, HDL decrease and it triggers macrophages2
to express certain enzymes and to transform into foam cells. Atherosclerosis may lead to AMI. sPLA -II induces damage to cardiomyocytes during the2
inflammatory reactions ensuing in the ischemic myocardium. It can bind to flip-flopped membranes [PE and PS (+= / ?=) in outer leaflet] promoting cell
death through the activation of caspase 3, which ultimately leads to secondary necrosis. sPLA -II also promotes the binding of CRP and the subsequent2
activation of the complement system, leading to secondary necrosis.
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ABSTRACT
Background Secretory type-II phospholipase A2 (sPLA2-II) is a cardiovascular risk marker since higher levels of 
this acute phase protein imply an increased risk for coronary artery disease. Moreover, it is hypothesized that 
local activity of sPLA2-II in the atherosclerotic plaque facilitates an inflammatory response to induce plaque 
instability or rupture. We have studied the presence of sPLA2-II in culprit lesions in the coronary arteries of patients 
with acute myocardial infarction (AMI) or angina pectoris.
Materials and methods We performed a histological examination of culprit lesions in 41 patients with stable 
(SAP) or unstable angina pectoris (UAP), or AMI using directed coronary atherectomy (DCA). Frozen slides were 
analysed immuno-histochemically for the presence of sPLA2-II, macrophages and smooth muscle cells. 
Immunopositive areas were calculated as a percentage of the total tissue area using image analysis software.
Results Intracellular sPLA2-II was found in atherosclerotic lesions in the macrophages of the intima 
as well as in vascular smooth muscle cells. Next to this, extracellular sPLA2-II depositions were also found. 
These depositions were significantly more extensive in patients with AMI, 
i.e. 26%median [6%25th(percentile)–44%75th(percentile)] of the intima area, than in patients with 
SAP 0%median (0%25th–10%75th; P = 0·013) or UAP 0%median (0%25th–0%75th; P = 0·04).
Conclusions Extracellular sPLA2-II is more abundantly present in atherosclerotic culprit lesions that have led to 
myocardial infarction. This suggests a role for extracellular sPLA2-II in the development of complications of 
atherosclerotic lesions in coronary arteries.
Keywords Acute myocardial infarction, coronary arteries, culprit lesions, sPLA2-II.
Eur J Clin Invest 2008; 38 (4): 205–210
Introduction
Inflammatory reactions contribute to the pathogenesis of 
cardiovascular conditions such as atherosclerosis and ischaemic 
damage to the heart during acute myocardial infarction (AMI). 
Secretory type-II phospholipase A2 (sPLA2-II), an acute phase 
reactant, has been postulated to be a key factor mediating tissue 
damage in human acute and chronic inflammatory diseases  such 
as rheumatoid arthritis and sepsis [1]. Increased levels of this 
mediator in the blood indeed are a risk marker for the 
development of complications of coronary artery disease [2]. 
Blood levels of sPLA2-II are independent predictors of long term 
atherosclerotic mortality in patients with suspected AMI [3]. 
A subsequent decrease of these levels, for example due to effective 
medication, is associated with a lower risk for these complications 
[4]. The molecular link between sPLA2-II and cardiovascular 
disease is not clear. Variable amounts of sPLA2-II depositions 
may occur in atherosclerotic plaques [5] suggesting an active 
role for the enzyme in the atherosclerotic process. Indeed, some 
evidence suggests that sPLA2-II may modulate plaque formation 
and rupture [5], for example by increasing the accumulation of 
intracellular lipids in macrophages and stimulating the formation 
of foam cells.
To obtain more insight into a possible role for sPLA2-II in 
atherosclerosis and its sequela, we performed a study on the 
presence of this enzyme in samples of atherosclerotic lesions 
obtained via directed coronary atherectomy (DCA). Culprit 
lesions of 41 patients with stable (SAP) or unstable angina 
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pectoris (UAP), or AMI were examined for the presence of 
sPLA2-II in the intima of the specimens.
Materials and methods
Patients
A total of 41 patients with culprit lesions suitable for DCA 
were included. The patient cohort consisted of 20 patients with 
chronic stable angina (SAP), classes I-III according to the 
Canadian Cardiovascular Society classification [6], 11 patients 
with unstable angina pectoris (UAP), classes II-III according to 
Braunwald’s classification [7], and 10 patients with AMI 
(defined by 30 min rest angina with a large transmural 
anteroseptal infarction and/or a transmural inferior infarction 
with involvement of the right ventricle or the posterolateral wall 
of the left ventricle). Tissue was obtained from the AMI patients 
on average 3·2median (225th–3·575th) hours after onset of complaints. 
The coronary lesion was identified as the ‘culprit lesion’ in UAP 
based on clinical, electrocardiographic and angiographic findings. 
In addition, the identification of the culprit lesion in patients 
with SAP included the results of exercise testing.
The study protocol was approved by the medical-ethical 
Committee of the hospital and all patients  gave informed 
consent.
Immunohistochemistry
The obtained coronary plaque specimens were directly frozen 
in liquid nitrogen and stored at –80 °C until further analyzed. 
All specimens were serially sectioned at 5 μm thickness and 
prepared for immunohistochemistry. The primary monoclonal 
antibodies used were anti-CD68 against macrophages (Dakopatts, 
Glostrup, Denmark), mAb 4A1 against sPLA2-II (kindly provided 
by Dr F.B. Taylor Jr, Oklahoma Medical Research Foundation, 
Oklahoma City, OK, USA), and anti-alpha smooth muscle actin 
(SMA-1: Dakopatts) for vascular smooth muscle cells (VSMCs). 
In all cases a three step indirect peroxidase method was used as 
previously described [8]. Antibody complexes were visualized 
with 3-amino-ethylcarbazole. Control experiments were 
performed by substituting the primary antibody with an 
irrelevant antibody of similar isotype.
Morphometric analysis
Serial slides were used for morphometric analysis of the 
various parameters. The results of immunostaining of sPLA2-II, 
macrophages and VSMCs were planimetrically quantified with the 
use of image analysis software on a personal computer connected 
to a video-mounted microscope. The total tissue area of each 
atherectomy section was outlined manually on the video 
screen and measured. Immunopositive areas (SMA-1, sPLA2-II, 
CD68) were calculated as a percentage of the total tissue area 
present.
Statistical analysis
Data was expressed as median and 25th and 75th percentiles. 
For comparison of continuous data, that is the percentages of 
surface area in which sPLA2-II, SMA (for VSMCs) and CD68 
(for macrophages) were deposited, within the three patient 
subgroups (SAP, UAP and AMI), unpaired t-tests for equality of 
means were performed. Chi-square tests were performed for 
categorical data, which are patient and lesion characteristics 
depicted in Tables 1 and 2. Both tests were performed using 
statistical analysis software (SPSS for windows, vs. 9·0 Arlington, 
VA, USA). Values of P < 0·05 were considered significant.
Results
Patients and lesions
Clinical data of the patients are given in Table 1. The median 
age of each group was not different, being 60median (5125th–6975th) 
years for SAP, 59median (5425th–6875th) years for UAP, and 65median 
(5825th–7275th) years for the AMI patients. In the AMI group 
fewer patients had a family history of myocardial infarction 
(P = 0·05) or smoking (P < 0·05). Furthermore, the use of beta 
blockers, calcium-antagonists or nitrate was significantly less in 
the AMI group when compared to the SAP or UAP groups 
(P = 0·002, P = 0·001 and P = 0·01, respectively).
Angiographic data of the patients are described in Table 2. 
As can be seen, there were significant differences regarding the 
lesions among the groups. Patients of the AMI group had 
significantly more often a stenosis of the culprit lesions of 
over 70% of the diameter of the affected vessel (P = 0·009). 
Similarly, AMI patients had significantly more reduced flow 
(P = 0·001) as quantified according to the TIMI (Thrombolysis In 
Myocardial Infarction) flow grades (Meuwissen et al. submitted). 
The lesion length though did not differ significantly among 
groups.
Quantitative immunohistochemistry
Intracellular sPLA2-II was found in the atherosclerotic intima 
within VSMCs and macrophages, but also extracellular (Fig. 1). 
In a minority of the tissue fragments (n = 11), part of the arterial 
media was available for analysis as well. The VSMCs of these 
media fragments stained positive for sPLA2-II in all cases 
(not shown).
The area of sPLA2-II positivity of the intima, thus excluding 
the media, varied strongly among individual patients (Fig. 2a). 
The extent of sPLA2-II deposition, quantified as a percentage 
of intimal containing detectable sPLA2-II, did not differ 
significantly among the SAP, UAP and AMI groups, 
although the area of sPLA2-II was somewhat smaller in the 
unstable group 22%median (15%25th–41%75th) as compared to SAP 
44%median (24%25th–66%75th) and AMI 48%median (24%25th–59%75th) 
(Fig. 2a).
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The number of macrophages in the lesions increased from SAP 
(20%median) of the intima area, to UAP (30%median) and AMI 
(45%median). However, the contribution of macrophages to the 
sPLA2-II positivity was limited (Fig. 2b). sPLA2-II-positive 
macrophages occupied 6%median (1%25th–27%75th) of the 
intima area in the SAP group versus 6%median (0%25th–9%75th) 
in the UAP group. The area containing sPLA2-II-positive 
macrophages was lower in the AMI patients 0%median 
(0%25th–5%75th). The difference between SAP and AMI 
was significant (P = 0·019).
The number of smooth muscle actin (SMA)-positive cells also 
varied among the groups. SMA-positive cells occupied 66%median 
(47%25th–79%75th) of the intima in the SAP group which tended to 
be higher  than the area of the intima occupied by SMA-positive 
cells in the UAP group 45%median (31%25th–74%75th), and which 
was significantly higher than that in the AMI group 28%median 
(20%25th–57%75th; P = 0·01; data not shown). The number of 
sPLA2-II-postitive SMA cells, however, did not differ significantly 
between the three groups, being 22%median (12%25th–45%75th) in 
the patients with SAP, 14%median (10%25th–26%75th) in the patients 
with UAP, and 16%median (0%25th–30%75th) in the patients with AMI 
(Fig. 2c).
By subtracting the amount of sPLA2-II-positive macrophages 
and VSMCs from the total amount of sPLA2-II present in the 
lesions, the amount of extracellular sPLA2-II in the intima was 
assessed (Fig. 2d). Interestingly, it was found that this amount 
was significantly higher in the AMI group 26%median 
(6%25th–44%75th) than in the SAP 0%median (0%25th–10%75th; 
P = 0·013) or UAP group 0%median (0%25th–0%75th; P = 0·04).
The different groups of patients had significant differences 
regarding smoking or a history of previous AMI. Therefore, 
we analysed whether these parameters were associated with 
the presence of sPLA2-II in the culprit lesions. However, no 
significant effect of clinical history, risk factors or medication 
was found with respect to the sPLA2-II findings.
Discussion
In this study, we found that the intima of culprit coronary 
atherosclerotic lesions of patients with stable or unstable angina 
pectoris had comparable amounts of sPLA2-II as those of patients 
with acute myocardial infarction. Interestingly, however, there was 
a marked difference in the amount of sPLA2-II in the extracellular 
matrix of culprit lesions between patients with AMI versus that 
in patients with angina pectoris: the amount of sPLA2-II in the 
Table 1 Patient characteristics
Characteristics
Number (%)
P-value†
Category* (total n = 41)
SAP (n = 20) UAP (n = 11) AMI (n = 10)
Male 16 (39) 10 (24) 7 (17) NS
Female 4 (10) 1 (2) 3 (7) NS
Prior myocardial infarction 10 (24) 8 (19) 2 (5) 0·05
Risk factors
Family history of AMI 7 (17) 8 (19) 2 (5) NS
Hypertension 3 (7) 3 (7) 4 (10) NS
Diabetes 2 (5) 1 (2) – NS
Hyperlipidaemia 6 (15) 2 (5) 3 (7) NS
Smoking 7 (17) 8 (19) 2 (5) 0·048
Use of
Beta blockers 16 (39) 9 (22) 2 (5) 0·002
Ace inhibitors 3 (7) 2 (5) 2 (5) NS
Calcium antagonists 18 (44) 10 (24) 1 (2) 0·001
Nitrates 18 (44) 7 (17) 2 (5) 0·01
Aspirin 18 (44) 10 (24) 6 (15) NS
Statins 1 (2) 1 (2) 1 (2) NS
*SAP, stable angina pectoris; UAP, unstable angina pectoris; AMI, acute myocardial infarction.
†P-value according to Chi-square test, NS, not significant.
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Table 2 Lesion characteristics
Characteristics
Number (%)
Category* Total number 
of patients P-value†SAP (n = 20) UAP (n = 11) AMI (n = 10)
Vessel location‡ 41 NS
LAD 15 (37) 8 (19) 7 (17)
LCX 1 (2) 1 (2) –
RCA 4 (10) 2 (5) 3 (7)
Diameter of stenosis 41 0·009
> 70% 8 (19) 4 (10) 10 (24)
Length of stenosis 37 NS
> 10 mm 9 (24) 6 (16) 3 (8)
TIMI§ flow grade 38 0·001
0 – – 10 (26)
1 – 1 (3) –
2 2 (5) 2 (5) –
3 16 (42) 7 (18) –
Multi vessel disease 5 (12) 1 (2) 1 (2) 41 NS
*SAP, stable angina pectoris; UAP, unstable angina pectoris; AMI, acute myocardial infarction.
†P-value according to Chi-square test, NS, not significant.
‡LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; RCA, right coronary artery.
§TIMI, thrombolysis in myocardial infarction.
Figure 1 Presence of secretory type II 
phospholipase A2, vascular smooth 
muscle cells and macrophages in 
culprit atherosclerotic lesions. Frozen 
serial slides of a coronary culprit lesion of 
an AMI patient, stained for sPLA2-II (top 
left), smooth muscle actin (SMA, lower 
left), HE (top right) and macrophages 
(CD68, lower right). The dotted lines 
highlight the positivity of sPLA2-II, 
SMA and CD68. Pictures were taken 
at 400× magnification.
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extracellular matrix in patients that developed AMI was 
significantly higher than that in the AP groups.
Circulating levels of sPLA2-II predict cardiovascular events 
and increased circulating levels of sPLA2-II predict clinical 
coronary events, independently of other risk factors, in patients 
with unstable angina [2]. However, the association between 
sPLA2-II and complications of atherosclerosis is not clear. 
sPLA2-II was found in advanced atherosclerotic lesions of the 
aorta but also in some early lesions of atherosclerosis [9].
With regard to extracellular sPLA2-II in atherosclerotic lesions, 
several studies have shown localization of sPLA2-II in cholesterol 
crystals in the  centre of necrosis [9,10], in the lipid core of the 
plaque [11], as well as on collagen fibres and in extracellular 
lipid droplets [12]. To the best of our knowledge, however, this 
was never analysed for coronary arteries.
sPLA2-II found in the extracellular matrix of the atherosclerotic 
plaque can originate from different sources, i.e. locally from cells 
that produce the enzyme, or from the blood via diffusion. VSMCs, 
macrophage and endothelial cells, all present in atherosclerotic 
plaque, have the ability to synthesize sPLA2-II [13,14]. Indeed we 
found detectable amounts of sPLA2-II in macrophages and VSMCs 
in the lesions. However, extracellular sPLA2-II was more 
abundantly present in lesions from the AMI patients, who had 
lower numbers of sPLA2-II-positive cells in the lesions. Therefore, 
diffusion from blood seems a more likely source of the enzyme, at 
least in the AMI patients. As a consequence of the acute phase 
reaction triggered by the infarcted myocardium, blood levels of 
sPLA2-II may increase in patients with AMI [15], which would 
favour better diffusion from the blood compartment into the 
lesions. However, we don’t think that this explains the more 
abundant presence of extracellular sPLA2-II in the atherosclerotic 
lesions in the AMI group. The culprit lesions were taken from the 
patients on average 3·18 h after onset of complaints, whereas 
sPLA2-II plasma levels do not increase in AMI patients  until 6 h 
after the onset of complaints [15].
Our finding of significantly more extracellular sPLA2-II in the 
intima of culprit coronary atherosclerotic lesions of patients with 
AMI, suggested a role for extracellular intimal sPLA2-II in the 
induction of AMI. What could that role be? The presence of 
more extracellular sPLA2-II in the lesions of the AMI patients 
coincided with the presence of significantly less VSMCs. A low 
content of these cells  favours plaque instability [16]. To some 
extent, sPLA2-II is cytotoxic and the enzyme can induce death in 
several cell types [17,18]. The increased content of extracellular 
sPLA2-II in the lesions from AMI patients could therefore have 
resulted in decreased numbers of VSMCs through a toxic effect 
of the enzyme. Alternatively, we recently  observed that coronary 
culprit lesions of AMI patients contain significantly more CRP, 
complement and oxLDL [19]. sPLA2-II may initiate and enhance 
CRP-mediated complement activation in the infarcted heart 
[18,20]. Thus, the presence of more extracellular sPLA2-II may 
intensify an inflammatory response within the atherosclerotic 
plaque, initiating plaque complication, and clinically resulting 
in AMI. Indeed, recent studies show that acute ischaemic events 
are more closely related to the histopathological characteristics 
of atherosclerotic plaque than to the number of plaques or the 
Figure 2 Box plots of the presence of 
secretory type II phospholipase A2 in 
culprit lesions of the coronary artery. 
(a) extent of area in the intima positive for 
sPLA2-II; (b) number of sPLA2-II-positive 
macrophages in the intima, expressed as 
a percentage of total number of 
macrophages in the intima; (c) number of 
sPLA2-II-positive vascular smooth muscle 
cells (VSMCs) in the intima expressed as a 
percentage of total number of VSMCs; and 
(d) presence of extracellular sPLA2-II in the 
intima, expressed as a percentage of the 
total area. The error bars represent 
minimum and maximum values, while the 
boxes represent the lower and upper 
quartiles. Medians are indicated with black 
lines within the boxes. N = the number of 
patients examined. An unpaired t-test was 
used for equality of means. SAP = stable 
angina pectoris; UAP = unstable angina 
pectoris; AMI = acute myocardial 
infarction.
38
degree of stenosis [21]. The mechanisms of acute coronary 
events are believed to involve unstable atherosclerotic plaque, 
which activates subsequent platelet aggregation and vessel 
thrombosis. Therefore, it is of clinical importance to understand 
the phenomena that lead to atherosclerotic plaque instability.
In conclusion, we found an increased content of sPLA2-II in 
atherosclerotic lesions associated with clinical complications, 
as compared to that of lesions that has not led to clinical 
complications. We suggest that inhibition of sPLA2-II in patients 
with atherosclerotic lesions may help to reduce the risk of plaque 
complications.
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N-(Carboxymethyl)lysine Depositions in Intramyocardial
Blood Vessels in Human and Rat Acute
Myocardial Infarction
A Predictor or Reflection of Infarction?
A. Baidoshvili, P.A.J. Krijnen, K. Kupreishvili, C. Ciurana, W. Bleeker, R. Nijmeijer, C.A. Visser,
F.C. Visser, C.J.L.M. Meijer, W. Stooker, L. Eijsman, V.W.M. van Hinsbergh, C.E. Hack,
H.W.M. Niessen, C.G. Schalkwijk
Objective—Advanced glycation end products (AGEs), such as N-(carboxymethyl)lysine (CML), are implicated in vascular
disease. We previously reported increased CML accumulation in small intramyocardial blood vessels in diabetes
patients. Diabetes patients have an increased risk for acute myocardial infarction (AMI). Here, we examined a putative
relationship between CML and AMI.
Methods and Results—Heart tissue was stained for CML, myeloperoxidase, and E-selectin in AMI patients (n26),
myocarditis patients (n17), and control patients (n15). In AMI patients, CML depositions were 3-fold increased
compared with controls in the small intramyocardial blood vessels and predominantly colocalized with activated
endothelium (E-selectin–positive) both in infarction and noninfarction areas. A trend of increased CML positivity of the
intima of epicardial coronary arteries did not reach significance in AMI patients. In the rat heart AMI model, CML
depositions were undetectable after 24 hours of reperfusion, but became clearly visible after 5 days of reperfusion. In
line with an inflammatory contribution, human myocarditis was also accompanied by accumulation of CML on the
endothelium of intramyocardial blood vessels.
Conclusions—CML, present predominantly on activated endothelium in small intramyocardial blood vessels in patients
with AMI, might reflect an increased risk for AMI rather than being a result of AMI. (Arterioscler Thromb Vasc Biol.
2006;26:2497-2503.)
Key Words: acute myocardial infarction  AGEs  CML  endothelium  myocarditis  vascular disease
Advanced glycation end products (AGEs) are advancedproducts of the Maillard reaction, including pentosidine,
N-(carboxyethyl)lysine, and N-(carboxymethyl)lysine
(CML). AGEs also accumulate during aging1,2 and at an
accelerated rate in diabetes.3,4 In diabetes patients, the accu-
mulation of AGEs has been associated with vascular compli-
cations.5,6 AGEs are also found in human atherosclerotic
lesions in blood vessels, raising a potential link between
deposition of AGEs and atherogenesis.7
The major AGE CML has received considerable interest,
because it can act as a ligand for the receptor of AGE (RAGE)
and it has been associated with increased oxidative stress.8 CML
can be formed on proteins by an oxidative cleavage of the
Amadori product fructose-lysine,9,10 and by a reaction of pro-
teins with the peroxidation products of polyunsaturated fatty
acids11 or the dicarbonyl compound glyoxal.12,13 Recent data
indicated that myeloperoxidase activity and NADPH oxidase
can also represent an important source of CML in tissue
proteins.14 It has been demonstrated that CML is enhanced in
vascular tissue of diabetic patients and in human atherosclerotic
lesions.15,16 We recently demonstrated in diabetic patients with-
out AMI or any form of cardiomyopathy an increased deposition
of CML in small intramyocardial blood vessels of the heart that
were without morphological changes.17
While studying the pathophysiological role of CML deposi-
tions in the heart in more detail, we analyzed CML depositions
in heart tissue of AMI patients and observed clear CML
deposition in the intramyocardial blood vessels of these patients.
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Subsequently, the role and mechanism of generation of these
CML depositions were further analyzed in an in vivo model of
AMI in rats, at a cellular level in endothelial cells, and in human
heart tissue of patients with myocarditis.
Methods
Patients
Patients included in this study underwent autopsy within 24 hours
after death. We included heart tissue from 15 control patients and 26
patients with AMI (Table). The AMI patients had infarcts of variable
duration. From these AMI patients, tissue was taken from the
infarcted as well as the noninfarcted areas of the heart. In addition,
epicardial coronary artery sections were taken. Patients with diabetes
were excluded because theoretically this condition can also cause
increased CML depositions. Control patients died because of a cause
not related to any form of heart disease and did not have inflamma-
tion of the heart. In addition, we included heart tissue from 17
patients with myocarditis (bacterial myocarditis n4; viral myocar-
ditis n13) without signs of other forms of heart disease. Age and
sex distribution did not differ significantly between the control or
AMI group. From all patients included in this study, tissue from lung
and kidney also were obtained for immunohistochemical analysis.
This study was approved by and performed according to the guide-
lines of the ethics committee of the VU University Medical Center,
Amsterdam. Use of leftover material after the pathological examination
has been completed is part of the patient contract in our hospital.
mAb Against CML
In a recent study we described the development and characterization
of a specific CML monoclonal antibody (mAb).18 Briefly, antisera
against CML-modified keyhole limpet hemocyanin were raised in
mice (Harlan, Horst, the Netherlands), and the mouse with the
highest titer for CML-human serum albumin (HSA) was used for the
production of mAbs. One of these, of the IgG1 class, was used in this
study. The antibody immunoreactivity for CML-HSA, as determined
in enzyme-linked immunosorbent assay (ELISA), appeared to be
proportional to the yield of CML as determined using stable-isotope
dilution tandem mass spectrometry (LC-MSMS), as recently de-
scribed in detail.19 The antibody did not cross-react with
N-(carboxyethyl)lysine.
Immunohistochemistry
For immunohistochemistry paraffin-embedded tissue sections
(4 m) were used. After deparaffinization and dehydration, sections
were stained with hematoxylin-eosin and subsequently incubated
with 0.3% H2O2 in methanol for 30 minutes. Sections were not
heated to prevent artificial induction of CML by this procedure.9
After incubation with normal rabbit serum (1:50; Dako, Glostrup,
Denmark) for 10 minutes, sections were incubated for 60 minutes
with anti-CML (1:500) or anti- myeloperoxidase (MPO) (1:500;
mAb, Dako). After washing in phosphate-buffered saline (PBS), pH
7.4, sections were incubated for 30 minutes with rabbit anti-mouse
biotin-labeled antibody (1:500; Dako) , washed in PBS, incubated
with streptavidin-horseradish peroxidase (HRP) (1:200; Dako) for 60
minutes, and visualized with 3,3-diamino-benzidine-tetrahydrochlo-
ride/H2O2 (DAB) (Sigma Chemical Company, St. Louis, Mo) for 3 to
5 minutes. For E-selectin, sections were incubated for 30 minutes in
pepsin and stained with anti-E-selectin (1:50; mAb, Monosan, Uden,
The Netherlands). After washing in PBS, sections were incubated for
60 minutes with rabbit-anti-mouse-HRP (1:1000; Dako), subse-
quently washed in PBS, and then visualized with DAB for En Vision
(Dako) (3 to 5 minutes).
Microscopic criteria20–22 were used to estimate infarct duration in
all myocardial tissue specimens.
Immunoscoring was performed by 3 independent investigators (A.B.,
P.A.J.K., and H.W.M.N.). CML, MPO, and E-selectin positivity were
scored for anatomic localization and intensity. For the intensity scoring
each positive vessel was given a score of: 1weak positivity; 2mod-
erate positivity; or 3strong positivity. CML positivity in coronary
arteries was measured as the area of CML positivity/ mm2 intima using
Q-prodit.23 Subsequently, the area of the slide was measured. Each
intensity score was multiplied by the amount of vessels positive for this
score. Each multiplication score (for 1, 2, and 3) was then added and the
sum subsequently was divided by the slide area resulting in a immuno-
histochemical score per cm2.
Cell Culture
The HUVEC-derived immortalized EC-RF24 endothelial cells24
were cultured on fibronectin-coated, tissue-culture plates in “growth
medium” containing medium-199 (Gibco-BRL, Gaithersburg, Md)
supplemented with 20% (v/v) fetal bovine serum, 2 mmol/L
L-glutamine, 50 g/mL heparin (Sigma), 12.5 g/mL EC growth
supplement (Sigma), and 100 U/mL penicillin/streptomycin (Gibco-
Patient Characteristics
Control AMI Statistics
n 15 26 NA
Sex (male/female) 7/8 18/8 NS*
Mean ageSE 66.06.12 63.52.96 NS†
Infarct age NA NA
0–24 h n7
1–5 days n11
5–14 days n8
Maximal lumen obstruction of the coronary arteries P0.001*
0–25% n4 0–25% n1
25–50% n10 25–50% n6
50–75% n1 50–75% n16
75% n0 75% n3
Angina pectoris (yes/no) 0/15 11/15 P0.04*
Smoker (yes/no) 2/13 4/22 NS*
nnumber of patients.
AMI indicates acute myocardial infarction; NA, not applicable; NS, not significant.
*The distribution of patients among the different categories 2 test.
†Age distribution was analyzed by independent t test.
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BRL) under a 5% CO2 atmosphere at 37°C. Metabolic inhibition was
induced by incubating the cells in 20 mmol/L 2-deoxy-D-glucose
(Sigma, St. Louis, Mo) in PBS for 2 hours under a 5% CO2
atmosphere at 37°C. Oxidative stress was induced by incubation in
0.03% H2O2 in PBS for 2 hours under a 5% CO2 atmosphere at 37°C.
Cells were then reperfused for 24 hours with normal culture medium.
Western Blot
EC-RF24 cells were dissolved in sodium dodecyl sulfate sample
buffer, stirred, and heated for 10 minutes at 95°C. The samples were
subjected to sodium dodecyl sulfate polyacrylamide gel electro-
phoresis, transferred to nitrocellulose membranes, and immuno-
blotted with CML antibody (1/1000 dilution) and subsequently with
horseradish peroxidase conjugated rabbit-anti-mouse immunoglobu-
lins (RaM-HRP; Dakopatts, Glostrup, Denmark; 1/1000 dilution).
The blots were then visualized by enhanced chemiluminescence
(ECL) (Amersham, Buckinghamshire, UK). As a positive control
CML-modified albumin was used.
AMI in the Rat
Female Wistar rats (7 to 8 weeks of age, Harlan CPB, Zeist, The
Netherlands) were acclimated to the facility for at least 2 weeks
before surgery. Rats were anesthetized with halothane (with O2 and
N2O in a 2:1 ratio), endotracheally intubated, and ventilated by a
respirator. After a left-sided thoracotomy, the left coronary artery
was occluded 2 mm from the origin with a 7-0 silk suture. Thirty
minutes after ligation, the ligature was released for reperfusion for
different periods of time, varying from 2 up to 24 hours, and 5 days.
Infarct areas were determined using Nitro Blue Tetrazolium.
Subsequently, sections were made for immunohistochemical detec-
tion of CML.
All animals were treated in compliance with the Dutch guidelines
for the care and use of laboratory animals and the experiments were
approved by the institutional ethical committee for animal
experimentation.
Peritoneal Dialysis of the Rat
Rats (n5) received 10 mL lactate buffered 3.86% glucose-
containing peritoneal dialysis fluid during a 5-week period via a
subcutaneously implanted mini access port that was connected via a
catheter to the peritoneal cavity. Subsequent to euthanizing the rats,
peritoneal tissue was isolated and CML on this tissue was determined
by immunohistochemistry.
Data Analysis
Data were analyzed with SPSS for windows version 9.0. To evaluate
whether observed differences were significant, Mann-Whitney anal-
ysis, independent t tests or 2 tests were used when appropriate. In
the text and relevant figure, values are given as meansstandard
error (SE). A 2-sided P0.05 was considered to represent a
significant difference.
Results
CML Accumulates in Intramyocardial Blood
Vessels of AMI Patients
The presence of CML in human heart tissue was investigated
in tissue specimens of AMI patients and in control patients.
Immunohistochemical analysis revealed no or only focal
weak staining of CML in especially endothelial cells of
intramyocardial blood vessels in control patients (Figure 1A).
Notably, these control patients had different degrees of
atherosclerotic lesions, varying from no to severe atheroscle-
rosis of the epicardial coronary arteries (Table). Within the
AMI group and control group, the degree of atherosclerosis of
epicardial coronary arteries did not correlate significantly
with the CML immunohistochemical score (not shown).
In AMI patients, CML depositions were clearly present in the
small intramyocardial blood vessels (Figure 1B). In these blood
vessels, CML adducts were localized in endothelial cells as well
as smooth muscle cells. It is noteworthy that these small
intramyocardial blood vessels did not show obvious atheroscle-
rotic changes whereas atherosclerosis of epicardial coronary
arteries did occur, with lumen obstruction in majority of 50% to
75% (Table). In controls, lumen obstruction of coronary arteries
Figure 1. Immunohistochemical analysis of CML in in heart tis-
sue of control patients, patients with AMI and patients with
myocarditis. Heart tissue specimens were from a control patient
(A) and a patient without diabetes but with AMI (B) (original
magnification: 400). Arrows: blood vessels. C, Quantitative
evaluation of CML. Bars represent meanSE immunohisto-
chemical score per cm2 (defined in Methods) for CML in control
patients (white bars), AMI patients (gray bars), and myocarditis
patients (black bars). nnumber of patients.
44
in the majority was 25% to 50%. As to be expected, angina
pectoris was significantly more present in AMI patients, com-
pared with controls (Table). In the epicardial coronary arteries,
the area of CML positivity of the intima showed a trend to an
enhanced CML content in AMI patients (as compared with
controls, but the difference was not statistically significant
(43.47.9 versus 25.66.6 AU/mm2; P0.17).
In contrast, in the intramyocardial blood vessels, the immu-
nohistochemical score per cm2 (defined in Methods) of CML
was significantly higher (P0.002) in AMI patients than in
control patients (Figure 1C). We found no significant differences
in immunohistochemical score per cm2 for CML between the
different infarct durations (Figure 2A). However, the immuno-
histochemical score per cm2 for CML was significantly higher in
all groups of different infarct duration than in control patients
(P0.02 for 0 to 1 day; P0.01 for 1 to 5 days; P0.02 for 5
to 14 days). The majority of CML-positive vessels in all groups
of different infarct duration were intensely positive and received
a maximal “3-score” (Figure 2B). The immunohistochemical
score per cm2 for strong CML-positive “3-score” vessels was
significantly higher in all groups of different infarct duration
than in control patients (P0.005 for 0 to 1 day; P0.005 for 1
to 5 days; P0.04 for 5 to 14 days).
To study if CML was limited to the infarcted area of the heart
of patients with AMI, we also stained noninfarcted parts of the
heart. Remarkably, no differences in the intensity of CML
staining of the small intramyocardial blood vessels were found
between infarcted and noninfarcted areas (not shown).
To analyze if the CML adducts were specific for the heart, or
were also present in other organs of the same patient, we
analyzed CML depositions in small arteries of kidney and lungs
of all patients included in this study. In contrast to the heart, no
significant difference in CML adducts in small arteries in the
lungs and kidneys were found between patients with or without
AMI (not shown).
Age, male/female distribution, or smoking did not signifi-
cantly differ between the control group and AMI group (Table).
Accumulation of CML Is Not Accompanied by the
Presence of Myeloperoxidase
MPO can play a role in the formation of CML.14 MPO can be
derived from neutrophils but can also be produced by blood
vessels themselves. MPO positivity was therefore evaluated
in the hearts of AMI patients and healthy controls and
compared with CML accumulation. The presence of MPO
was limited to a small part within the vessel wall, especially
endothelial cells, and was found only in a minority (5%) of
the blood vessels that stained positive for CML (not shown).
Accumulation of CML Is Accompanied by the
Presence of E-selectin
To assess whether CML was predominantly associated with
activated endothelium we analyzed E-selectin expression in
the hearts of AMI patients and healthy controls and compared
it with CML accumulation. Within the infarcted myocardium,
we found a significant increase (P0.001) of E-selectin
positivity in intramyocardial blood vessels compared with
controls (Figure 3C). E-selectin was present in the vessel
wall, predominantly on endothelial cells, and was found in
almost all of the blood vessels that stained positive for CML
(Figure 3A, 3B), demonstrating colocalization of CML and
E-selectin.
AMI in Rats Does Not Cause CML Generation
Within 24 Hours of Reperfusion
To investigate whether the formation of CML in the heart was
directly related to the occurrence of AMI, we used a rat model
of AMI. Heart tissues of these rats were evaluated at different
time points after 30 minutes of acute ischemia and subsequent
perfusion, which varied from 2 to 24 hours. No CML was
detectable in these hearts (Figure 4A), although neutrophils
were present, indicative for AMI.
Subsequently, we verified whether the CML antibody used
did recognize CML in rats. To that end, we studied peritoneal
biopsies of rats that had undergone peritoneal dialysis for 5
Figure 2. Quantitative evaluation of CML in heart tissue, distinc-
tion between the different infarct ages. A, Bars represent
meanSE immunohistochemical score per cm2 for CML
(defined in Methods) in the infarcts of different infarct duration
and in control patients. B, Bars represent meanSE immunohis-
tochemical score per cm2 for the 3 different intensity scores for
CML (1minor; 2moderate; 3strong; defined in detail in
Methods) in the infarcts of different infarct duration and in con-
trol patients. nnumber of patients.
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weeks. Significant amounts of CML were detected in the
peritoneum of these rats (Figure 4B). These data thus dem-
onstrate that CML can be formed in the rat and that the CML
antibody is suitable for studies in rats.
Together these findings strongly suggest that the CML ad-
ducts as found in small intramyocardial blood vessels in the
hearts of patients that have died of AMI were present in advance
of the AMI.
Oxidative Stress but not Metabolic Inhibition
Causes CML Generation by Endothelial Cells
The CML staining was most striking in the endothelium of
the intramyocardial blood vessels of AMI patients. To eval-
uate whether ischemia by itself can cause CML formation in
endothelial cells, we treated human endothelial cells (EC-
RF24) with conditions of either ischemia (metabolic inhibi-
tion) or oxidative stress (H2O2), followed by reperfusion.
Western blot analysis showed no detectable production of
CML residues as a result of ischemia. However, in cells
incubated with H2O2, minor accumulations of CML adducts
were found (Figure 5). Similar results were obtained with
quantification of CML in EC-RF24 lysates using LC-MSMS. In
control cells 65 nmol CML/mmol lysine was found, whereas in
metabolically inhibited/reperfused cells 78 nmol CML/mmol
lysine was found and in cells incubated with H2O2 313 nmol
CML/mmol lysine was found.
CML Accumulates in Intramyocardial Blood
Vessels of Myocarditis Patients
To investigate whether inflammation in the heart in general
induces CML upregulation in intramyocardial blood vessels,
we investigated the presence of CML in patients with
myocarditis. In these patients, CML depositions were present
in the small intramyocardial blood vessels, in particular on
the endothelium. CML depositions were significantly in-
creased (P0.0001) compared with control hearts (Figure
1C). The immunohistochemical score of CML in myocarditis
patients in fact was significantly higher than in AMI patients
(240.552.4 and 49.67.3, respectively; P0.0001).
AMI Followed by 5 Days of Reperfusion in Rats
Does Cause CML Generation in Intramyocardial
Blood Vessels.
Because myocarditis in humans is accompanied by CML
depositions in intramyocardial blood vessels, indicating that
chronic inflammation cause CML depositions, we next stud-
ied in our rat AMI model whether AMI in the chronic state
was capable of inducing CML depositions. Therefore, rats
were subjected to acute myocardial ischemia and subsequent
perfusion for 5 days. At 5 days of infarction, granulation
tissue including lymphocytes and macrophages were detected
in the heart indicative for chronic inflammation (not shown).
Although minor background staining was found in cardio-
myocytes, a clear positive CML signal was found especially in
endothelial cells, but also in smooth muscle cells of intramyo-
cardial blood vessels in infarction and noninfarction areas
(Figure 4C). Therefore, in rat hearts after AMI, CML deposi-
tions can be found in blood vessels, but only in the chronic
phase.
Discussion
In the present study we found CML depositions in small
intramyocardial blood vessels in the heart of patients with
Figure 3. Immunohistochemical analysis of CML and E-selectin in
heart tissue of control patients and patients with AMI. Immunohis-
tochemical detection on serial slides of E-selectin (A) and CML (B)
in a patient without diabetes but with AMI (original magnification:
400). Arrows: blood vessels. C, Quantitative analysis. Bars repre-
sent meanSE immunohistochemical score per cm2 (defined in
Methods) for CML (white bars) and E-selectin (black bars).
*P0.001 (CML) and †P0.001 (E-selectin) in control patients vs
AMI patients. nnumber of patients.
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AMI, irrespective of the age of infarction and the degree of
atherosclerosis of epicardial coronary arteries. CML was
found in infarcted and noninfarcted areas of the heart.
AMI in general is related to the process of atherosclerosis of
epicardial coronary arteries and its complications, such as
thrombosis, bleeding within atherosclerotic plaques, and partic-
ularly plaque rupture. The questions then raised are how CML is
formed, and what is the function of these depositions? It is
known that formation of CML may proceed by multiple routes,
namely glycation followed by an oxidative cleavage of Amadori
adducts,12,25 auto-oxidative glycosylation,13,26 reaction of pro-
teins with nonglucose carbohydrates11 and/or via lipoxidation.14
Next, CML can be formed via the reaction of proteins with
products of MPO.14 However, in the small nonatherosclerotic
intramyocardial blood vessels, the number of vessels positive for
CML, and the intensity of this staining were considerably higher
than for MPO. We cannot exclude that MPO activity in these
intramyocardial blood vessels has been transient and disap-
peared again, but the fact that in all cases only a minority of the
vessels was positive for MPO makes it unlikely that MPO is
playing a major role in CML formation.
CML also has been hypothesized to represent a marker for
chronic hypoxic stress.16 In patients with AMI, a phase of (acute)
hypoxia is induced. However, we found no differences in CML
accumulation in the infarcted area of the heart, and control
noninfarcted areas in the heart of the same patient. Although an
episode of global ischemia of the whole heart in patients with
AMI is supposed, it is difficult to explain CML positivity as a
result of ischemia alone. Furthermore, we could not detect CML
depositions in intramyocardial blood vessels in rats with AMI,
including episodes of reperfusion up to 24 hours. This indicated
that CML is not induced in the heart by ischemia/reperfusion in
the acute phase. In line with this, also in isolated endothelial
cells, ischemia and/or reperfusion did not result in CML forma-
tion. This makes it unlikely that in patients with AMI, CML is
formed as a direct result of AMI.
Another explanation for the formation of CML might be
chronic inflammation. However, it is unlikely that chronic
inflammation of the epicardial coronary arteries is playing a role
herein, as we did not find a correlation between the degree of
atherosclerosis and CML depositions in control nor in AMI
patients. We did not find a significant difference in the CML
positivity of these epicardial coronary arteries between AMI
patients and controls.
It is known that inflammation plays a role in the formation of
CML.27 In line with this, in the present study we found that CML
positivity colocalized with E-selectin–positive endothelial cells. In
addition we have shown that in non-AMI, nondiabetes patients
having myocarditis, CML depositions are present on intramyocar-
dial blood vessels, with even a 5-fold increase compared with AMI
patients. In line with this, in the rat, AMI-induced inflammation in
the chronic phase induced CML on intramyocardial blood vessels in
infarction and noninfarction areas. Remarkably, also in humans we
found CML in the noninfarction areas. This therefore may suggest
that any local inflammatory response on endothelium is capable of
inducing CML depositions on intramyocardial blood vessels. Such
an inflammatory response may lead to AMI, because it is known
Figure 4. Immunohistochemical detection of CML in the rat. A, Immunohistochemical detection of CML in heart tissue of the rat after
acute myocardial infarction (original magnification: 400). Tissue was taken from the infarcted heart 24 hours after onset of infarction.
Arrows: neutrophils present in the heart. There is no CML positivity in the blood vessels. B, Immunohistochemical detection of CML in
the peritoneum of rats undergoing peritoneal dialysis (original magnification: 400). Arrows: blood vessels. C, Immunohistochemical
detection of CML in heart tissue of the rat after AMI (original magnification: 400). Tissue was taken from the noninfacrtion area of the
heart 5 days after onset of infarction. Arrows: CML depositions on endothelial cells in intramyocardial blood vessel.
Figure 5. Western blot analysis of CML in lysates of the endo-
thelial cell line EC-RF24. Lanes 1 and 2 contained purified CML
(0.1 and 0.01 g) as a positive control. Lane 3 contained control
EC-RF24 cells. Lane 4 contained EC-RF24 cells treated with
metabolic inhibition (2 hours) and reperfusion (24 hours). Lane 5
contained EC-RF24 cells treated with 0.03% H2O2 (2 hours) and
reperfusion (24 hours).
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that in patients with fulminant myocarditis, secondary AMI can
occur.28
Therefore, the combination of the human and animal studies
suggests that CML already is present in intramyocardial blood
vessels of the hearts of patients that develop AMI. At this moment,
however, we do not know the time frame during which this CML
positivity is formed. Nevertheless, this finding may be important, as
it has been reported that especially in endothelial cells CML-
modified proteins can act as a ligand for RAGE (receptor of AGE),8
thereby causing processes linked to inflammatory complications.29
Furthermore, it is known that patients with diabetes have a higher
risk of AMI.30,31 We have shown that the CML accumulates in
heart tissue in patients with diabetes.17
Whether the accumulation of CML in small intramyocar-
dial blood vessels of the heart indeed does contribute to the
induction of AMI or merely reflects the occurrence of an
AMI-inducing process remains uncertain. Validation of CML
as a risk indicator for AMI will be the subject of a further
prospective study, in which CML levels in the blood will be
analyzed in patients with stable AP, unstable AP, and AMI.
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Recent studies indicate that, in addition to necrosis,
apoptosis also plays a role in the process of tissue
damage after myocardial infarction, which has
pathological and therapeutic implications. This review
article will discuss studies in which the role and
mechanisms of apoptosis in myocardial infarction were
analysed in vivo and in vitro in humans and in animals.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The common view on how cardiomyocytes dieduring or after myocardial infarction hasaltered in recent years. For a long time necro-
sis was regarded as the sole cause of cell death in
myocardial infarction. Now, recent studies indi-
cate that apoptosis also plays a role in the process
of tissue damage subsequent to myocardial
infarction. Although both necrosis and apoptosis
result in the death of the cell, they differ in several
morphological and cellular regulatory features.
Necrosis is characterised by the rapid loss of
cellular homeostasis, rapid swelling as a result of
the accumulation of water and electrolytes, early
plasma membrane rupture, and the disruption of
cellular organelles. As a result of the membrane
rupture and subsequent leakage of a broad array
of cellular material, necrosis induces an inflam-
matory response.1–3
Apoptosis or programmed cell death is, unlike
necrosis, a highly regulated and energy requiring
process. Apoptosis is characterised by shrinkage
of the cell and the nucleus. The nuclear chromatin
is condensed into sharply delineated masses, and
eventually breaks up. The cell then detaches from
the surrounding tissue. At this stage, extensions
bud out from its membrane, which eventually
seal off to form membrane enclosed vesicles,
called apoptotic bodies, containing condensed
cellular organelles and nuclear fragments. These
apoptotic bodies are either rapidly phagocytosed
by neighbouring cells or undergo degradation,
which resembles necrosis in a process called sec-
ondary necrosis. However, apoptosis is generally
considered not to trigger an inflammatory
response.4
“Although both necrosis and apoptosis
result in the death of the cell, they differ in
several morphological and cellular
regulatory features”
However, recently there has been much debate
concerning which morphological features accu-
rately reflect apoptosis. Furthermore, it has been
suggested that the process of apoptosis is
regulated by a large variety of different cellular
mechanisms. Therefore, Sloviter suggested that
perhaps the terms necrosis and apoptosis should
be redefined as “passive cell death” and “active
cell death”, respectively.5
The fact that apoptosis plays a role in the tissue
damage seen after myocardial infarction has
pathological and therapeutic implications. Be-
cause apoptosis is a highly regulated process, a
better understanding of the circumstances that
specifically trigger apoptosis during and after
myocardial infarction, and a better understanding
of the cellular mechanisms that control apoptosis,
could lead to therapeutic strategies to limit the
amount of tissue damage in patients with
myocardial infarction.
In this review article, we will discuss studies in
which the role of apoptosis in myocardial infarc-
tion was analysed in vivo and in vitro. In these
studies, apoptotic cells were detected using the
terminal deoxynucleotidyl transferase mediated
dUTP nick end labelling method (TUNEL) com-
bined with agarose gel DNA laddering, unless
stated otherwise.
STUDIES IN HUMANS
Apoptosis in human cardiomyocytes after
myocardial infarction
Studies in the ventricular myocytes of the hearts
of patients who died of acute myocardial infarc-
tion (AMI) have shown that apoptosis plays a role
in the process of cell death of cardiomyocytes.
Saraste et al showed, in myocardial samples
obtained from patients who died of acute AMI,
that in addition to overt necrosis, a subset of
myocytes undergoes apoptosis during ischaemia/
reperfusion injury6 (table 1). The apoptotic
myocytes were most prominent in the border
zones of recent infarction,6–9 whereas very few
apoptotic cells were present in the remote
non-infarcted myocardium.6 In line with this,
increased uptake of Tc-99m labelled annexin V in
the infarcted area, but not outside the infarcted
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area in patients with AMI, suggests the occurrence of apopto-
sis in this area,6 although it should be noted that annexin V
stains necrotic cells in addition to apoptotic cells. In contrast,
other studies have shown a substantial amount of apoptosis in
the “remote from ischaemia” areas also.8 10
Bcl-2 and Bax
As mentioned earlier, apoptosis is a highly regulated process in
which several regulatory proteins play a part, and in which the
balance between an array of regulatory proteins decides the
fate of the cell. The expression of two such regulatory proteins,
bcl-2 and Bax, has been studied in the hearts of patients who
died of AMI.37 Bcl-2, an apoptosis inhibitor, is not expressed in
non-infarcted myocardial tissue,38 but it is expressed in
cardiomyocytes surrounding infarcted areas soon after the
onset of infarction. However, no bcl-2 was found in the
infarcted area itself. Bax is a member of the bcl-2 family and,
when overexpressed, accelerates apoptosis. It also counters the
death repressor activity of bcl-2.39 In contrast to bcl-2, Bax has
a low basal expression in human hearts without cardiac
disease.37 The overexpression of Bax was found in two of 15
hearts at the acute stage of infarction (between six hours and
20 days after the onset of myocardial infarction (MI)). At the
old stage (more than a month after the onset of MI) Bax over-
expression was found in 10 of 12 hearts, predominantly in the
areas surrounding infarcted areas. In these areas the
expression of bcl-2, present in the acute stage, had disap-
peared. Therefore, the Bax to bcl-2 ratio is high and may be
related to apoptotic cell death in these areas in the old
infarction.37
Fas
In AMI, soluble Fas (sFas: an inhibitor of apoptosis) values
increase, whereas sFas ligand (an inducer of apoptosis) values
do not change.40 Circulating sFas values are significantly
higher in acute MI than in old MI. Remarkably, sFas values
increase in AMI independent of infarct size.
IN VIVO ANIMAL MODELS
Apoptosis triggered by ischaemia and/or reperfusion?
Cell death resulting from MI has been extensively investigated
in vivo in various animal models. Usually, MI was induced by
the occlusion of a major coronary artery.
Upon permanent occlusion of a coronary vessel in rats,
apoptosis occurred in the ischaemic region, the area immedi-
ately bordering the ischaemic region and in the remote from
ischaemia region. Therefore, it was suggested that apoptosis is
the major determinant of infarct size. Necrosis occurred less
often and was seen only in the ischaemic region.12 In a similar
experiment in rats, Fliss and Gattinger also showed that
apoptosis occurred after constant ischaemia.13 However, they
found that apoptosis appeared solely in the ischaemic
myocardium, not in the bordering or remote from ischaemia
regions. Although reperfusion after 45 minutes of ischaemia
appeared to attenuate apoptosis in the infarcted area, it
enhanced apoptosis in the bordering zones and the remote
from ischaemic regions. In a similar study in rats by Palojoki et
al,14 enhanced apoptosis was seen from 24 hours up to 12
weeks after experimental MI in the ischaemic area and in its
Table 1 Overview of the prevalence and timing of apoptosis in the different models of investigation
Model
Prevalence of
apoptosis Source Timing of apoptosis Marker of apoptosis used
Human Yes Human 6–120 h after AMI TUNEL + DNA laddering6
Yes Human 3–14 h after AMI TUNEL + DNA laddering8
Yes Human 3.5–22 h after AMI Annexin V11
In vivo animal Yes Rat 2 h to 7 d TUNEL + Ab myosin heavy chain12
Yes Rat 2.25 h I TUNEL ISEL + DNA laddering13
Yes Rat 45 min I and 1 h R TUNEL ISEL + DNA laddering14
Yes Rat 24 h to 12 w TUNEL14
No Dog 7 h I TUNEL + DNA laddering15
Yes Dog 6 h I and 6 h R TUNEL + DNA laddering15
Yes Rat 3 h I TUNEL + DNA laddering16
Yes Rabbit 30 min and 4 h R TUNEL + DNA laddering17
No Rat 10 min I and 3 h R TUNEL + sandwich enzyme assay18
Yes Rat 20 min I and 3 h R TUNEL + sandwich enzyme assay18
Yes Dog 30 min I and 3 h R DNA laddering19
Yes Rat 30 min I and 3 h R TUNEL + DNA laddering20
Yes Rat 30 min I and 3 h R Elisa and westernblot21
Yes Rat 30 min I and 6 h R TUNEL + DNA laddering22
Yes Mouse 1 h – 72 h TUNEL + DNA laddering23
Yes Rat until 24 h TUNEL + DNA laddering24
No Rabbit 4,5 h I TUNEL + DNA laddering25
Yes Rabbit 30 min I and 4 h R TUNEL + DNA laddering25
Yes Mouse 15 min I and 30 min R Annexin V and DNA laddering26
Isolated animal hearts Yes Rat/Mouse 25 min I and 4 h R TUNEL27
Yes Rat 30 min I and 2 h R TUNEL + DNA laddering28
Yes Rat 30 min I and 2 h R TUNEL + DNA laddering29
No Rat 60 min I TUNEL + Ab myosin heavy chain30
Yes Rat 15 min I and 2 h R TUNEL + Ab myosin heavy chain30
Yes Rabbit 30 min I and 1 h R TUNEL + DNA laddering31
Isolated cardiomyocytes Yes Rat 48 h I TUNEL + DNA laddering32
Yes Rat 48 h I and 3 h R TUNEL + DNA laddering32
No Rat 18 h I and 12 h R Annexin V/PI + TUNEL + DNA laddering33
Yes Rabbit 30 min I and 24 h R TUNEL34
No Rat 3 h I and 2 h R Annexin V/PI35
No Mouse 24 h I DNA laddering36
Yes Mouse 24 h I and 8 h R DNA laddering36
AMI, acute myocardial infarction; d, days; h, hours; I, ischaemia; min, minutes; PI, propidium iodide; R, reperfusion; TUNEL, terminal deoxynucleotidyl
transferase mediated dUTP nick end labelling; w, weeks.
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border zone. Apoptosis was also increased in the remote non-
infarcted tissue up to four weeks after infarction.14 However, in
this study apoptosis was measured by the TUNEL method
only.
“A better understanding of the cellular mechanisms that
control apoptosis could lead to therapeutic strategies to
limit the amount of tissue damage in patients with
myocardial infarction”
Apoptosis after ischaemia/reperfusion was also shown in an
in vivo dog model in the ischaemic area.15 However, apoptosis
was not found in this area in dogs subjected to ischaemia
alone.
Bcl-2 and Bax
In an in vivo experiment in rats, DNA strand breaks were seen
as early as three hours after coronary artery occlusion.41 Apop-
tosis was accompanied by a decrease in bcl-2 protein values
and an increase in the expression of Bax, indicating a role for
these proteins in the regulation of ischaemia induced apopto-
sis in rats. In another in vivo rat model it was found that EAT/
mcl-1, a bcl-2 related immediate early gene, is strongly
upregulated as early as 30 minutes after coronary artery
occlusion.16 In line with this, in transgenic mice overexpress-
ing human bcl-2, myocardial reperfusion injury was
reduced.42 This reduction of reperfusion injury correlated with
a significant reduction in apoptosis, as measured by means of
the TUNEL staining method only. In dogs, reperfusion resulted
in reduced bcl-2 expression and increased Bax expression in
the ischaemic area, whereas after permanent ischaemia, bcl-2
and Bax values did not change.15
Fas
In an in vivo rabbit model it was shown that Fas receptor
expression was dramatically upregulated in the border zone of
histologically infarcted myocardium after ischaemia/
reperfusion.17 In line with this, carvedilol, a vasodilating β
adrenoceptor antagonist and a potent antioxidant, caused a
77% reduction of apoptotic cells in the border zone and at the
same time significantly reduced Fas receptor expression after
ischaemia/reperfusion.17 In addition, in an in vivo rat model it
was found that Fas receptor expression increased 131 fold in
cardiomyocytes after coronary artery occlusion.43 These results
indicate that the Fas receptor is involved in ischaemia/
reperfusion induced apoptosis in rabbit and rat hearts.
Preconditioning
Ischaemic preconditioning is a phenomenon whereby a series
of brief periods of alternating ischaemia and reperfusion
increase myocardial tolerance to the subsequent prolonged
ischaemia. This phenomenon was first described by Murry et
al.44 Since then, numerous studies have shown the cardiopro-
tective effect of preconditioning in different animal species
and in humans.45–57
Piot et al showed that ischaemic preconditioning in rats
caused a significant reduction in the amount of apoptosis and
infarct size.18 However, the exact mechanisms by which
ischaemic preconditioning causes this cardioprotective effect
are still unclear. A correlative effect of reduced myocardial
apoptosis, reduced Bax expression, increased bcl-2 expression,
and reduced neutrophil accumulation in ischaemic precondi-
tioning experiments in rats and dogs has been suggested.19 20
Ischaemic preconditioning also seems to attenuate the
ischaemia/reperfusion induced activity of caspase 1 and
caspase 3 in rats21.
Accumulative evidence points to a role for protein kinase C
(PKC) as a final common pathway in the cardioprotective
effect of ischaemic preconditioning in rats. It was shown that
pretreatment with calphostin C, an inhibitor of PKC,
completely aborted the protective effect of ischaemic precon-
ditioning on infarct size58 and most apoptosis22 caused by
ischaemia/reperfusion. Piot et al suggest that in ischaemic pre-
conditioning possible end effectors of PKC are ATP sensitive
potassium channels, because it was shown that the activation
of mitochondrial KATP channels induces preconditioning
against MI and reduces ischaemic/reperfusion induced apop-
tosis through the PKC signalling pathway.59
Reactive oxygen species
Increased oxidative stress was found to coexist with apoptosis
in the remote non-infarcted rat myocardium after myocardial
infarction.60 Longterm treatment with the antioxidants
probucal and pyrrolidine dithiocarbamate, starting three days
after MI in an in vivo rat ischaemia/reperfusion model,
attenuated oxidative stress, myocyte apoptosis, caspase 3
activity, and the expression of p53, Bax, and caspase 3 protein
in the remote non-infarcted myocardium.61 These findings
indicate a causal relation between oxidative stress and
apoptosis in the remote non-infarcted rat myocardium after
MI.
p53
One hypothesised general molecular mediator of hypoxia
induced apoptosis is the tumour suppressor transcription fac-
tor p53. It is suggested that p53 may induce apoptosis by
stimulating the expression of Bax and/or repression of bcl-2
expression.62 In contrast, in an in vivo model of apoptosis in
wild-type mice and homozygous p53 knockout mice, it was
found that ischaemia induced apoptosis occurred as readily in
the p53 knockout mice as in wild-type mice.23 This finding
indicates the existence in the heart of other, p53 independent,
mechanisms of postischaemic apoptosis.
JAK/STAT pathway
In general, the Janus kinase/signal transducer and activator of
transcription (JAK/STAT) pathway is reported to be involved
in the transduction of cytoprotective signals in stressful
conditions, such as hypoxia.63 64 In an in vivo rat experiment, it
was found that rats treated with a specific JAK-2 inhibitor
AG-490, subsequent to ischaemia, did show a significant
upregulation of caspase 3 activity and Bax expression, in
addition to a significant increase in the number of apoptotic
cells compared with control rats.65 These results indicate an
antiapoptotic role for the JAK/STAT signalling pathway in the
rat myocardium.
Stress activated protein kinases
The stress activated protein kinase (SAPK) signalling pathway
has recently been implicated as an important mediator of
apoptosis.66 SAPK activity is dramatically increased in rabbit
hearts after ischaemia/reperfusion.17 Carvedilol, a β adreno-
ceptor antagonist, when administered before reperfusion, sig-
nificantly reduces apoptosis and significantly attenuates
SAPK activity in rabbit hearts.17
Other stress activated mitogen activated protein kinases
(MAPKs) have also been implicated in ischaemia/reperfusion
induced apoptosis. p38 MAPK activity was induced in the rat
heart as early as 15 minutes after coronary artery occlusion
and also by reperfusion.67 Jun N-terminal kinase (JNK) activ-
ity was also induced after ischaemia followed by reperfusion
in the rat heart, although no JNK activity was seen as a result
of ischaemia alone. Both MAPK and JNK are suggested to play
a role in apoptosis because the time course of the activation
patterns of these kinases and the increase in DNA laddering
are highly correlated.67
Insulin-like growth factor I
Insulin-like growth factor I (IGF-I) appeared to be cardiopro-
tective in a rat in vivo ischaemia/reperfusion model.68 When
administered one hour before ischaemia, IGF-I attenuated
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polymorphonuclear neutrophil accumulation in the ischaemic
area. Furthermore, IGF-I significantly attenuated the inci-
dence of myocyte apoptosis after myocardial ischaemia and
reperfusion.68 In addition, in transgenic mice overexpressing
human IGF-I, it was found that both apoptosis and necrosis
were attenuated in the viable myocardium after infarction.69
“Insulin-like growth factor I appeared to be
cardioprotective in a rat in vivo ischaemia/reperfusion
model”
Interestingly, IGF-I also promotes the release of physiologi-
cal amounts of nitric oxide (NO).70 71 In an in vivo mouse
model it was shown that the inhibition of endogenous NO
synthesis increased apoptosis during ischaemia.72 It seems
that endogenous NO suppresses apoptosis by interfering with
the caspase cascade, because the inhibition of endogenous NO
correlated with increased caspase activity, whereas bcl-2 and
Bax protein values were unchanged.72 However, it cannot be
excluded that reduced apoptosis is a systemic effect rather
than an effect of endogenous NO on the caspase machinery
because NO, through an effect on microcirculation, influences
perfusion.
Heat shock protein
Heat shock protein 70 (HSP70) is a self preservation protein
that maintains cellular homeostasis under environmental
stress. HSP70 acts as a molecular chaperone and plays an
important role in protein folding, assembly, transport, and
degradation although it also helps to prevent protein
denaturation and aggregation.73 In an in vivo experiment in
rats it was shown that overexpression of HSP70, via gene
transfection, reduced apoptosis after ischaemia/reperfusion.74
Calcineurin
In rats adenovirally transfected with constitutively active cal-
cineurin cDNA, ischaemia/reperfusion induced apoptosis was
significantly attenuated, whereas the inhibition of endog-
enous calcineurin reversed the antiapoptotic effects.75 These
results indicate a calcineurin dependent protection from
apoptosis in cardiomyocytes.
Tumour necrosis factor
Recently it was found that tumour necrosis factor (TNF) is
expressed within the myocardium of rats76 and dogs77 in
response to ischaemic injury.78 TNF has dual effects with
regard to apoptosis. It provokes the expression of several
antiapoptotic factors in a variety of mammalian cell types,
although it can also induce apoptosis in mouse fibroblasts.79 In
an in vivo ischaemia model in mice lacking none, one, or both
types of TNF receptor, it was found that endogenous TNF pro-
tected cardiomyocytes against ischaemia induced apoptosis.80
Caspases
In general, caspases form a key step in the process of apopto-
sis. In a rat and rabbit in vivo ischaemia/reperfusion model,
the tripeptide inhibitor of the caspase interleukin 1β convert-
ing enzyme (ICE) family of cysteine proteases—ZVAD-fmk—
was able to reduce infarct size and attenuated the amount of
TUNEL positive cardiomyocytes.24 Remarkably, ZVAD-fmk
might also interfere with myocardial necrotic cell death
because it was found that ICE-like inhibitors attenuate both
apoptotic and necrotic cell death in an in vitro system of
chemical hypoxia.81 82 Therefore, the reduction in infarct size
might result from both reduced apoptosis and necrosis. In a
similar model, YVAD-aldehyde, a caspase 1-like protease
inhibitor and DEVD-aldehyde, a caspase 3-like protease
inhibitor, both attenuated the amount of myocardial
apoptosis.83 Remarkably however, these two inhibitors did not
reduce infarct size.
Overexpression of cardiac specific caspase 3 in transgenic
mice induced transient depression of cardiac function, caused
abnormal ultrastructural damage to the nucleus in addition to
the mitochondrial and myofibrillar content, and increased
infarct size. However, it did not induce an apoptotic response
that progressed through to the late apoptotic phases, such as
the production of apoptotic bodies.84
Kallikrein
The activity of kallikrein leads to the production of intact
kinins, which act through specific receptors to activate second
messengers to trigger biological effects such as vasodilation
and vasoconstriction.85 The tissue kallikrein–kinin system
components have been identified in the heart.86–88 In an in vivo
rat experiment it was found that, through the delivery of the
human tissue kallikrein gene, myocardial infarction and
apoptosis were significantly reduced after ischaemia/
reperfusion injury.85 This effect of kallikrein is probably medi-
ated through an NO–cGMP dependent signal transduction
pathway.85
Influence of age on apoptosis
In a mouse in vivo ischaemia/reperfusion model it was found
that there are age associated differences in reperfusion injury
between young (6–8 months) and old (22–24 months) mice.89
It was shown that mortality was higher and infarct size was
significantly larger in old animals, compared with young ani-
mals. Furthermore, the occurrence of DNA fragmentation was
significantly higher in old hearts, indicating that the amount
of apoptosis as a result of ischaemia/reperfusion is greater in
old hearts.89 A higher occurrence of DNA fragmentation was
also seen in an in vivo rat model.90 In this model, DNA
fragmentation began and peaked earlier after infarction in the
old heart than in the young heart, and bcl-2 and Bax showed
a heightened baseline expression in the old hearts, which
might indicate a higher degree of chronic stress in the old
hearts.90 The hearts of older animals might therefore be more
susceptible to ischaemia/reperfusion related apoptosis.
ISOLATED ANIMAL HEARTS
The studies described below with isolated hearts were carried
out in hearts that were perfused with a perfusion buffer (usu-
ally a Krebs Heinselheit buffer) in an atmosphere of 95% O2
and 5% CO2 at 37°C.
Fas
In isolated rat and mouse hearts subjected to ischaemia/
reperfusion, it was found that soluble Fas ligand was released
after the onset of reperfusion.27 Isolated mouse hearts lacking
functional Fas show a significant reduction in cell death after
ischaemia/reperfusion, compared with wild-type mice, sug-
gesting a proapoptotic role.27
Preconditioning
In isolated rat hearts, it has also been shown that
preconditioning reduces cardiomyocyte apoptosis and oxida-
tive stress.28 91 Preconditioning in this model induced tyrosine
kinase phosphorylation, leading to the activation of MAPKAP
kinase 2 and p38 MAPK, and was associated with induced
expression of bcl-2 mRNA and translocation and activation of
the nuclear transcription factor nuclear factor κB (NfκB).91
AP-1, another transcription factor, which is highly upregu-
lated by prolonged ischaemia followed by reperfusion, is unaf-
fected by preconditioning.28 Preincubation with DMTU, a
hydroxyl radical scavenger, or SN50, an NFκB blocker,
abolished the antiapoptotic effect of preconditioning, and this
is possibly related to the prevention of the preconditioning
induced upregulation of bcl-2.91 Indeed, in rat hearts treated
with antisense bcl-2 oligonucleotides, the antiapoptotic effects
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of preconditioning were abolished, as was the reduced oxida-
tive stress, suggesting an antioxidant role for bcl-2 in
preconditioning.92
Reactive oxygen species
In isolated perfused rat hearts it was shown that apoptosis
only occurred in reperfused hearts when oxidative stress was
induced.29 The reperfusion injury effects could be reversed by
epselen, which removed the oxidative stress from the heart,
indicating that oxidative stress in this model plays a role in the
development of ischaemia/reperfusion related apoptosis.29
p53
In contrast to animal in vivo studies, in isolated rat hearts,
mRNA encoding the proapoptotic oncogene p53 was highly
induced by reperfusion, whereas it was barely detected after
ischaemia alone.30 Ischaemic preconditioning prevented the
activation of p53 and inhibited apoptosis.30
JAK/STAT pathway
Isolated rat hearts subjected to ischaemia/reperfusion show
activation of STAT5A and STAT6. Treatment of these hearts
with tyrphostin AG490, which inhibits JAK2 phosphorylation,
resulted in reduced infarct size and apoptosis.93
Stress activated mitogen activated protein kinases
In isolated rat hearts, SAPK activity is raised as a result of
ischaemia/reperfusion.94 Treatment of these hearts with mag-
nesium tanshinoate B, a bioactive compound isolated from
Danshen, resulted in a reduction of apoptotic nuclei. Further-
more, it abolished the raised SAPK activity, suggesting a proa-
poptotic role for SAPK in ischaemia/reperfusion induced
apoptosis in rats.94
“In addition, p38 MAPK and JNK activities were
greatly increased after ischaemia/reperfusion in an
isolated rat heart model”
It has also been found that myocardial ischaemia/
reperfusion results in the activation of p38 MAPK, whereby
reperfusion has a more profound effect on p38 MAPK activity
than ischaemia alone.31 67 95 96 In line with this, in isolated rab-
bit hearts the p38 MAPK inhibitor SB 203580 greatly reduced
postischaemic myocardial apoptosis and significantly im-
proved cardiac function recovery after reperfusion.31 In
addition, p38 MAPK and JNK activities were greatly increased
after ischaemia/reperfusion in an isolated rat heart model.97
However, inhibition of the extracellular signal related kinase
(ERK) significantly increased the number of apoptotic cells,
suggesting that p38 MAPK and JNK mediate myocardial
apoptosis and that ERK plays a protective role.97
Heat shock protein
Recent reports indicate a role for the small HSP family in
ischaemic preconditioning.98 99 αB crystalline is a member of
the small HSP family and is the most abundantly expressed
stress protein in the heart.100 In transgenic mice overexpress-
ing αB crystalline, it was found that the overexpression of αB
crystalline results in attenuated apoptotic myocardial cell
death, decreased oxidative stress, and a decrease in the extent
of infarction, upon ischaemia/reperfusion.101
Caspases
In isolated rat hearts subjected to prolonged ischaemia, a sig-
nificant accumulation of cytochrome c occurred in the cytosol,
which was accompanied by activation of caspase 3-like
proteases.102 In contrast, caspase 1-like proteases were not
activated.
ISOLATED AND CULTURED CARDIOMYOCYTES
Apoptosis induced by hypoxia?
Exposure of cultured neonatal rat cardiomyocytes to chronic
hypoxia causes the activation of the terminal apoptotic
machinery, including cytochrome c release, effector caspase
activation, and cleavage of the death substrate poly(ADP-
ribose) polymerase (PARP).32 103 The same effects were seen
after exposure of neonatal rat cardiomyocytes to metabolic
inhibition using 2-deoxyglucose.104 These results indicate that
both hypoxia and metabolic inhibition induce apoptosis
through the mitochondrial pathway. Reoxygenation further
increased the number of apoptotic cells and resulted in a
decrease in bcl-2 and an increase in the Fas receptor.32
Interestingly, these effects could be countered by incubation
with either recombinant transforming growth factor β1
(TGF-β1) or aggregated platelet supernatant.32 Aggregated
platelet supernatant was found to protect the heart from
reperfusion induced apoptosis, partly because of platelet
released TGF-β1.32 In contrast, in isolated ventricular rat
cardiomyocytes, 60 minutes of anoxia alone did not increase
annexin V staining, but induced a significant increase in pro-
pidium iodide staining.105 An increase in annexin V staining
was seen only after a period of reperfusion. In contrast, in
another study with rat cardiomyocytes anoxia/reoxygenation
caused necrosis in isolated rat cardiomyocytes but failed to
induce apoptosis.33
Fas
In an in vitro study using neonatal rat cardiomyocytes it was
shown that the expression of mRNA for the Fas antigen was
upregulated twofold under hypoxic conditions, whereby Fas
receptor and Fas ligand induction correlated with induced
apoptosis.106 Recently, it was also shown that STAT1 induced
Fas receptor and Fas ligand expression after ischaemia/
reperfusion in neonatal rat cardiomyocytes.107 Furthermore, in
primary adult rat culture, ischaemia followed by reperfusion
caused a pronounced increase in sensitivity to the apoptotic
effects of soluble Fas ligand.27
Preconditioning
In isolated adult cardiomyocytes from rabbit hearts, ischaemic
preconditioning attenuated cardiomyocyte apoptosis, which
correlated with a diminution in the fall of intracellular pH.34
The antiapoptotic effects of ischaemic preconditioning could
be prevented by blocking the vacuolar proton ATPase, suggest-
ing that the maintenance of intracellular pH homeostasis
attenuates apoptosis in ischaemic preconditioning.34
Reactive oxygen species
Oxidative stress through H2O2 and the NO donor, N2-acetyl-S-
nitroso-DL-penicillinaminamide (SNAP), induced apoptosis
in ventricular cardiomyocytes isolated from a rat heart.35 In
isolated rat cardiomyocytes, a correlation between the
apoptotic effect of SNAP or YC-1 (a direct activator of soluble
guanylyl cyclase) and the increased activity of soluble guany-
lyl cyclase (that is, the intracellular cGMP content) was
seen.35 It has been suggested that NO induces apoptosis in a
cGMP dependent manner and necrosis in a cGMP independ-
ent manner.
Both reactive oxygen species H2O2 and O2
− induced apopto-
sis in neonatal rat cardiomyocytes, which was associated with
an increase in p53 protein content, whereas protein concentra-
tions of bcl-2 and Bax were unaltered.108 Interestingly, both
H2O2 and O2
− induced apoptosis through distinct pathways.
H2O2 induced the release of cytochrome c, activation of CPP32,
and cleavage of PARP, through Bax and Bad (another
proapoptotic bcl-2 family member). This can be suppressed by
the pharmacological opening of the mitochondrial ATP sensi-
tive K+ channels by diazoxide, which preserves mitochondrial
integrity.109 In contrast, O2
− promoted apoptosis through the
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activation of Mch2α (a caspase family member and the only
known laminase110), which cleaves its substrate lamin A (a
type of filament protein which, together with lamins B and C,
forms the nuclear lamina of eukaryotic cells).108
p53
Exposure of neonatal rat cardiomyocytes to 24 hours of
hypoxia resulted in an increase of apoptosis, as measured by
DNA laddering, detection of DNA fragmentation by enzyme
linked immunosorbent assay, and annexin V–FLUOS/
propidium iodide double staining.111 Reoxygenation further
increased the number of apoptotic cells. Hypoxia resulted in
the upregulated expression of the bcl-2 and p53 proteins,
whereas reoxygenation downregulated bcl-2 expression and
further upregulated p53.111 Chinonin, a natural antioxidant,
significantly attenuated hypoxia/reoxygenation induced apop-
tosis, downregulated p53 expression, and induced bcl-2
upregulation.111
“It has been suggested that p53 plays a crucial role in
the induction of apoptosis as a result of hypoxia in
cultured neonatal rat cardiomyocytes”
In another experiment in neonatal rat cardiomyocytes, 48
hours of hypoxia resulted in an increase of TUNEL positive
cells and an increase in p53 protein, which was not accompa-
nied by increased DNA laddering.112 This was also accompa-
nied by increased expression of p21/WAF-1/CIP-1, a well char-
acterised target of p53 transactivation.112 Because
overexpression of wild-type p53 by adenovirus mediated gene
transfer is sufficient to induce apoptosis in neonatal rat
cardiomyocytes under normoxic conditions,112 it has been sug-
gested that p53 plays a crucial role in the induction of apopto-
sis as a result of hypoxia in cultured neonatal rat cardiomyo-
cytes.
In contrast, equivalent apoptosis was measured in hypoxic/
acidotic cardiomyocytes isolated from the hearts of wild-type
or homozygous p53 knockout mice.36 However, in these mice
severe chronic hypoxia alone was not sufficient to induce
apoptosis, but had to be accompanied by a decrease in the
extracellular pH to induce apoptosis, whereas reoxygenation
resulted in increased apoptosis in a p53 independent manner.
These results indicate that the fall in extracellular pH or
reoxygenation, but not solely hypoxia, is responsible for the
induction of apoptosis in murine cardiomyocytes, and that the
process is a p53 independent one.
Figure 1 Overview of the signal transduction pathways related to ischaemia/reperfusion induced apoptosis in cardiomyocytes. In this figure,
inducing or activating effects are depicted by an arrow and inhibitory effects are depicted by a blocked line. Akt, protein kinase B; ERK,
extracellular signal related kinase; JAK, Janus kinase; JNK, Jun N-terminal kinase; MAPK, mitogen activated protein kinase; NFκB, nuclear
factor κB; PI3 kinase, phosphatidylinositol 3′-kinase; ROS, reactive oxygen species; SAPK, stress activated protein kinase; STAT, signal
transducer and activator of transcription; TNF, tumour necrosis factor.
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The role of kinases
In cultured neonatal rat cardiomyocytes, two distinct phases
of p38 MAPK activation are seen during hypoxia; a transient
activation that starts within 10 minutes of hypoxia and a sus-
tained activation that starts after two hours of hypoxia.113 In
this model, ERK2 and JNK are not activated. By using the
specific p38 MAPK inhibitor SB 203580, apoptosis was
attenuated, even when only the sustained activation of p38
MAPK was inhibited. This suggests that the sustained activa-
tion of p38 MAPK induces apoptosis in neonatal rat
cardiomyocytes after hypoxia.113 In this study, however, the
distinction between necrotic and apoptotic cells was made
solely by differences in the morphology of their nuclei.
In agreement with this study, embryonic stem cell derived
cardiomyocytes (ESCM) with targeted disruption of the
MEKK1 (a MAPK kinase kinase) gene were extremely sensi-
tive, compared with wild-type ESCM, to H2O2 induced apopto-
sis. p38 MAPK was suggested to play a proapoptotic role by
activating the production of TNF-α,114 whereas an antiapop-
totic role was suggested for MEKK1. MEKK1 inhibits the pro-
duction of TNF-α via the activation of JNK, suggesting an
antiapoptotic role for JNK. In contrast, in rat neonatal cardio-
myocytes transfected with antisense JNK DNA, condensation
of the nuclei was inhibited after H2O2 treatment, suggesting a
proapoptotic role for JNK.115
Treatment of both isolated adult rat cardiomyocytes and
cultured mouse cardiomyocytes with hepatocyte growth
factor (HGF), subsequent to oxidative stress, resulted in
attenuated apoptosis, partially through the MEK–p44/42
MAPK pathway,116 suggesting an antiapoptotic role for HGF.
In neonatal rat cardiomyocytes, it was suggested that ERKs
have an antiapoptotic role in response to raised H2O2 concen-
trations after oxidative stress, through the activation of
cyclooxygenase 2 expression and subsequent prostaglandin
production.117
Insulin-like growth factor I
In rat neonatal cardiomyocytes, treatment with IGF-I in-
creased the activity of phosphatidylinositol 3′-kinase (PI3
kinase) and Akt (protein kinase B).118 119 Interestingly, in
cardiomyocytes infected with an adenovirus carrying consti-
tutively active forms of PI3 kinase or Akt, apoptosis is signifi-
cantly inhibited after hypoxic treatment.118 Indeed, in another
study it was found that the inhibition of PI3 kinase or Akt
abolished the antiapoptotic effects of IGF-I.119 In neonatal rat
cardiomyocytes, IGF-I did prevent apoptosis after hypoxia,
which also could be suppressed with genistein, a tyrosine
kinase inhibitor, and PD-098059, a MAPK inhibitor.118 Subse-
quently, it was also found that IGF-I exerts its antiapoptotic
effect through ERK1 and ERK2, resulting in activation of the
transcription factor cAMP response element binding protein,
which induces bcl-2 expression.119
Heat shock protein
A significant reduction of stress induced apoptosis was found
in cardiomyocytes isolated from rat hearts overexpressing
HSP70.74 120–122
Calcineurin
In H2O2 treated neonatal rat cardiomyocytes, apoptosis was
almost completely abolished by endothelin 1, a growth
promoting peptide.123 In this study, apoptosis was measured by
TUNEL, DNA laddering, morphological features, cytofluoro-
metric analysis, and caspase 3 cleavage. Inhibition of
calcineurin countered the antiapoptotic effects of endothelin
1, indicating a role for calcineurin in the antiapoptotic
pathway of endothelin 1.
Tumour necrosis factor
In rat cardiomyocytes it was shown that physiologically
relevant concentrations of TNF-α induced apoptosis (as
measured by single cell microgel electrophoresis of nuclei and
Table 2 Overview of proapoptotic and antiapoptotic mediators in ischaemia/reperfusion induced apoptosis in
cardiomyocytes
Type of mediator Human In vivo animal
Isolated animal
hearts Isolated and cultured cardiomyocytes
Proapoptotic Bax37 39 Bax15 41 Fas27 Soluble Fas ligand27
Soluble Fas ligand40 Fas17 43 Bcl-292 ROS35 108
ROS60 61 ROS29 p53112
p5362 p5330 p38 MAPK113 114
SAPK17 66 JAK93 JNK115
JNK67 SAPK94 TNF-α124
p38 MAPK67 p38 MAPK31 97 Caspases32 103
TNF79 JNK97 Cytochrome c32 103
Caspase 121 24 81–83 Fas receptor32
Caspase 321 24 81–83 Vacualar proton ATPase34
Bad109
Bax109
Antiapoptotic Bcl-237–39 Bcl-215 17 41 ERK97 TGF-β132
Soluble Fas40 PKC22 58 59 αβ Crystalline101 Mitochondrial ATP sensitive K+ ch.109
JAK/STAT65 MEKK1114
IGF-I68 69 JNK114
NO70–72 HGF116
HSP7074 ERK117 119
Calcineurin75 PI3 kinase118 119
TNF80 Akt118 119
Kallikrein85 HSP7074 120–122
IGF-I119
CREB119
Bcl-232 119
Calcineurin123
TNF-α125
Akt, protein kinase B; CREB, cAMP response element binding protein; ERK, extracellular signal related kinase; HGF, hepatocyte growth factor; HSP, heat
shock protein; IGF, insulin-like growth factor; JAK/STAT, Janus kinase/signal transducer and activator of transcription; JNK, Jun N-terminal kinase; MAPK,
mitogen activated protein kinase; MEKK, MAPK kinase kinase; NO, nitric oxide; PKC, protein kinase C; ROS, reactive oxygen species; SAPK, stress
activated protein kinase; TGF, transforming growth factor; TNF, tumour necrosis factor.
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by morphological and biochemical criteria).124 The production
of the second messenger sphingosine was also upregulated by
TNF-α, indicating the possible involvement of sphingosine in
TNF-α mediated cardiomyocyte apoptosis, and it was shown
that treatment with sphingosine strongly induced apoptosis in
rat cardiomyocytes.124 However, in neonatal rat cardiomyocytes
and H9c2 cells it was also shown that TNF-α activates both
proapoptotic and antiapoptotic pathways.125 This antiapoptotic
signal was mediated via the translocation of NFκB.
DISCUSSION
In recent years much evidence has implicated apoptosis in
myocardial cell loss in ischaemia/reperfusion injury. In vivo
studies in humans and in animals, and in vitro studies in iso-
lated animal hearts and cultured cardiomyocytes, all indicate
that apoptosis contributes to the death of cardiomyocytes as a
result of ischaemia/reperfusion injury. Here, we present an
overview of recent studies into ischaemia/reperfusion induced
apoptosis in cardiomyocytes in various models and of the
molecular mechanisms underlying this process (fig 1; table 2).
One of the conflicting areas in the study of apoptosis in the
heart is the mechanism of induction. In some studies, apopto-
sis was found to be induced by ischaemia alone, and after
ischaemia followed by reperfusion,6–8 10 12–15 whereas in other
studies ischaemia alone was not sufficient to trigger
apoptosis.15 72 105 The absence of apoptosis during ischaemia
can be explained by the notion that during ischaemia
intracellular ATP stores are depleted. This absence of
intracellular ATP might prevent the occurrence of apoptosis
because apoptosis is an energy requiring process.
Studies are also conflicting with respect to the area of the
heart in which apoptosis is found. In humans, apoptosis seems
to occur primarily in the border zone of the ischaemic
region6–8 10 and, according to some studies, in the remote from
ischaemia regions.8 10 However, in vivo animal studies have
demonstrated apoptosis both in the ischaemic region and the
ischaemic border zone. In contrast, in some studies ischaemia
caused apoptosis in the ischaemic region alone, whereas
reperfusion caused a decrease in apoptotic cells in the ischae-
mic region and an increase in apoptotic cells in the ischaemic
border zone and the remote from ischaemia regions.13 14 These
differences, with respect to the mechanism of induction of
apoptosis and for the area in which apoptosis was found,
theoretically could be explained by the different methods of
measuring apoptosis that were used.
“One of the conflicting areas in the study of apoptosis
in the heart is the mechanism of induction”
The TUNEL staining method is now the most widely used
marker for apoptosis in cardiomyocytes. However, it has
become increasingly clear that the TUNEL assay is prone to
false positive and negative results.126 For instance, the staining
kinetics of TUNEL is dependent on the reagent concentration,
the extent of proteolysis, and fixation of the tissue.
Furthermore, non-specific staining may be caused by active
RNA synthesis and DNA damage in necrotic cells.126 It is
therefore important to standardise the TUNEL assay carefully
by using DNAse treated tissue sections. Furthermore, these
TUNEL positive cells must be characterised and a sufficient
number of microscopic fields must be analysed. Even then,
other methods of measuring apoptosis such as DNA laddering
on agarose gels or the evaluation of apoptotic morphology
should be combined with TUNEL to confirm the results.
The TUNEL method can also be used in electron microscopy
analysis. In this method, the fragmented DNA is labelled using
components of the ApopTag kit and subsequently with gold. In
this way, nuclei can be analysed for TUNEL positivity and
apoptotic morphology at an ultrastructural level at the same
time.105 127 However, a limitation of electron microscopic
techniques is the small number of cells that can be analysed.
The detection of DNA fragments (DNA laddering) of sizes
equivalent to mononucleosomes and oligonucleosomes is
considered a trademark for apoptosis.128–130 The analysis of
these fragments on agarose gel results in a “ladder” pattern. In
necrosis, DNA is cleaved at random, thus creating DNA
fragments that vary greatly in size. On agarose gels, these
fragments produce a smear. However, it is important to bear in
mind the fact that in the heart cardiomyocytes are not the only
cells that are prone to apoptosis. When DNA laddering is used
to analyse cardiac homogenates, apoptotic granulocytes or
endothelial cells may contribute to the laddering, making it
uncertain that it results from the apoptosis of cardiomyocytes
alone.25
Another often used marker for apoptosis is annexin V.
Annexin V binds with high affinity to phosphatidylserine
(after its translocation via the process of membrane flip flop)
and labelled annexin V has been used to detect apoptosis both
in vivo and in vitro.11 26 105 131 132 It has been suggested that
annexin V could have an immediate clinical use in patients for
live image apoptosis monitoring.11 131 An advantage of annexin
V staining over the TUNEL method is that it can detect early
apoptosis.105 Indeed, cardiomyocytes stained with annexin V
did not display late apoptotic morphology.26 However, like
TUNEL, annexin V might not be a totally specific marker for
apoptosis because it can also bind to membrane fragments of
late necrotic cells or flip flopped cells that have not undergone
apoptosis/necrosis. Therefore, conclusions based solely on
annexin V staining should be drawn with caution.
Thus, to date, there is no totally specific apoptotic marker
that solely detects apoptotic cells, so that a combination of
techniques should always be used to detect apoptosis.
Regardless of the limitations of the different methods for
determining apoptosis, it is suggested that cardiomyocyte
apoptosis as a result of ischaemia/reperfusion does not share
all the classic hallmarks of apoptosis originally described for
other cells.3 For instance, electron microscopic analysis and
histological studies have revealed only sporadic cardiomyo-
cytes with classic late apoptotic morphology, such as the pres-
ence of apoptotic bodies.25 This could be explained by the
involvement of common mediators in both apoptosis and
necrosis,82 or an interchange between apoptosis and necrosis.
It has been suggested that inflammatory cell activation could
alter the process of apoptosis. Entman et al showed in
reperfused canine myocardium that the presence of adhesion
molecules on myocytes may allow the attachment of
neutrophils and superoxide production, thereby converting
apoptosis to necrosis.133–136
In line with this, in a recent study we have shown that car-
diomyocytes that underwent flip flop of the plasma membrane
(and were therefore annexin V positive but caspase 3 negative)
bind secretory type II phospholipase A2 and subsequently
potentiate the binding of the acute phase protein, C reactive
protein (our unpublished data, 2002).
Another cause of the conversion of apoptosis to necrosis
might be the depletion of ATP. In an ischaemia/reperfusion
study, Lieberthal et al showed that the severity and duration of
ATP depletion determines the mechanism of death, at least in
proximal tubular cells: cells with an intracellular ATP concen-
tration below a certain threshold become necrotic, whereas an
ATP value above that threshold induces apoptosis.137 It is likely
that ATP plays a similar role in cardiomyocytes because
ischaemia results in ATP depletion. Indeed, neonatal rat
cardiomyocytes subjected to metabolic inhibition and subse-
quent ATP depletion favour necrotic cell death, whereas meta-
bolic inhibition under ATP replenishing conditions increased
the proportion of apoptotic cells, as determined by nuclear
morphology and DNA fragmentation.138 These authors sug-
gested a model in cardiomyocytes in which intracellular ATP
concentrations dictate the means of cell death—via necrosis
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when ATP is depleted and via caspase activated apoptosis
when ATP is present.
“There is no totally specific apoptotic marker that solely
detects apoptotic cells, so that a combination of
techniques should always be used to detect apoptosis”
In conclusion, numerous studies indicate that apoptosis can
cause cardiomyocyte cell death after myocardial infarction,
although the exact mechanisms of apoptosis within the heart
are not known and the interpretation of studies is somewhat
difficult because of the different methods used to determine
apoptosis. Nevertheless, the process of apoptosis in the heart
has a unique position within the field of apoptosis, analogous
to other ischaemically challenged processes: a lack of comple-
tion of the apoptotic process seems to be related to a lack of
ATP and/or a conversion of apoptosis to necrosis by a second-
ary inflammatory response.
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Summary 
Subsequent to myocardial infarction cardiomyocytes 
within the infarcted areas and morphologically 
normal cardiomyocytes in its border zones expose 
phosphatidylserine (PS) in the outer plasma 
membrane leaflet (flip-flop). We showed earlier that 
this flip-flop is partially reversible in cardiomyocytes. 
We now investigated a possible role for RhoA and its 
downstream effector Rho-associated kinase (ROCK) 
in the process of PS exposure and apoptosis in rat 
cardiomyoblasts (H9c2 cells). Clostridium difficile 
Toxin B (TcdB) (Rho family inhibitor), and the ROCK 
inhibitors Y27632 and H1152 significantly increased 
PS exposure, identified as mainly annexin V-FITC-
positive/PI-negative cells. TcdB, Y27632 and H1152 all 
significantly inhibited phosphorylation of the anti-
apoptotic protein Akt. However, only TcdB, but not 
ROCK inhibition led to caspase 3 activation and thus 
apoptosis. Notably, pancaspase inhibitor zVAD only 
partially inhibited TcdB induced PS exposure 
indicating the existence of apoptotic and non-
apoptotic PS exposure. The induced flip-flop 
coincided with decreased flippase activity as 
measured with NBD-labeled PS flip-flop. In this 
study we show a regulatory role for a novel signaling 
route, RhoA – ROCK – flippase signaling, in 
maintaining asymmetrical membrane phospholipid 
distribution in cardiomyocytes.   
 
Introduction 
In the plasma membrane of most if not all eukaryotic 
cells, the phospholipids are normally asymmetrically 
distributed among the inner and outer leaflet (1-3). The 
outer leaflet predominantly contains hydrophobic 
phospholipids such as phosphatidylcholine (PC), 
whereas anionic phospholipids such as 
phosphatidylserine (PS) and, to a lesser extent, 
phosphatidylethanolamine (PE) are kept within the 
inner leaflet. Loss of this phospholipid asymmetry 
occurs in some activated cells (4) and under 
pathological conditions. This process, called membrane 
flip-flop, involves the exposure of PS and PE in the 
outer plasma membrane leaflet. PS exposure at the cell 
surface was reported to occur in both apoptotic (5;6) as 
well as necrotic cells (7), presumably to potentiate 
recognition by phagocytic cells (5;8). However, we and 
others have observed that plasma membrane flip-flop in 
cardiomyocytes is not always a determinant of death 
but can in fact be reversible (9-15).  
After acute myocardial infarction (AMI) 
cardiomyocytes within the infarcted areas, as well as 
morphologically normal cardiomyocytes in the border 
zones of infarction, loose their membrane phospholipid 
asymmetry (16). We have observed in vivo as well as in 
vitro that the inflammatory mediator type IIA secretory 
phospholipase A2 (sPLA2-IIA) binds to and induces 
death in these flip-flopped cardiomyocytes, but not in 
cardiomyocytes that maintain their plasma membrane 
phospholipid asymmetry (17;18). Therefore, PS 
exposure is pro-inflammatory and targets the 
inflammatory response to cells that do so, including 
cells that reversibly expose PS. Through membrane flip-
flop these reversibly damaged cardiomyocytes fall 
victim to the inflammatory response leading to 
additional damage in the reperfused heart after AMI. 
Thus, insight into systems that regulate transbilayer 
phospholipid asymmetry may offer clues for preventing 
propagation of inflammation in the heart after AMI. 
Three classes of membrane proteins, i.e. two ATP-
dependent (flippases and floppases) and an ATP-
independent (scramblases), have been found to regulate 
transbilayer phospholipid asymmetry (19). The flippase 
prefers PS over other lipids (20). In addition, there is 
evidence supporting a role for phospholipid binding 
proteins such as membrane associated cytoskeleton 
elements (21) or annexin V (22;23) in maintaining 
phospholipid asymmetry. However, the majority of 
studies into the mechanisms maintaining asymmetrical 
phospholipid distribution in plasma membranes has 
been done in erythrocytes and platelets and little is 
known about the regulation of transbilayer 
phospholipid asymmetry in cardiomyocytes. Recently 
RhoA was shown to participate in PS exposure in 
megakaryocytes (24).  
Here we have investigated a putative regulatory role for 
RhoA, its downstream effector Rho associated kinase 
(ROCK) and flippase in regulating transbilayer 
phospholipid asymmetry in the rat neonatal 
cardiomyoblast line H9c2.  
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Experimental procedures 
Cell culture  
Neonatal rat cardiomyoblasts (H9c2 (2-1) cells; ATCC, 
Manassas, Virginia, USA) were cultured in culture 
medium, that is Dulbecco’s Modified Eagles Medium 
(DMEM; BioWhittaker, Verviers, Belgium) containing 
10% (v/v) heat-inactivated Fetal Calf Serum (FCS; 
BioWhittaker, Verviers, Belgium), 100 IU/mL penicillin 
(Yamanouchi Europe BV, Leiderdorp, Netherlands), 100 
µg/mL streptomycin (Radiopharma-Fisiopharma, 
Palomonte, Italy) and 2 mmol/L L-glutamine (Gibco, 
Paisly, England), under a 5% CO2 atmosphere at 37°C. 
For experiments, cells were used at 60 to 80% 
confluency. 
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Figure 1: Effects of TcdB, Y27632 and H1152 on PS exposure 
in H9c2  cells The  effects of  the Rho protein  inhibitor TcdB 
and Rho kinase  inhibitors Y27632 and H1152 on membrane 
flip‐flop  in H9c2 cells were determined via Flow cytometry
using  annexin  V‐FITC  and  propidium  iodide  (PI).  (a) 
(representative of two experiments) Cells were subjected for 
24  hours  to  either  100pg/mL,  1  ng/mL or  10  ng/mL TcdB. 
Percentage  of  single‐annexin V‐positive H9c2  cells  is  given 
for  1  ng/mL.  (b)  Percentages  (5  experiments)  of  single‐
annexin  V‐positive H9c2  cells.  Cells were  subjected  for  24 
hours  to  1  ng/mL TcdB.  ∗p<0.0001.  (c)  Percentages  (9 
experiments)  of  single‐annexin  V‐positive H9c2  cells.  Cells 
were  subjected  for  24 hours  to  10 μmol/L Y27632.  ∗p<0.001 
(d). Percentages (9 experiments) of single‐annexin V‐positive 
H9c2  cells.  Cells  were  subjected  for  4  hours  to  1  μmol/L 
H1152. ∗p<0.001
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Toxin B from Clostridium difficile (TcdB; List Biological 
Laboratories Inc, Campbell, CA, USA), Y27632 
(Calbiochem, Nottingham, UK) and zVAD-fmk (zVAD; 
Alexis Biochemicals, San Diego, CA, USA) were all 
incubated for 24 hours under a 5% CO2 atmosphere at 
37°C. H1152 (Calbiochem) was incubated for 4 hours 
under a 5% CO2 atmosphere at 37°C. Throughout the 
study final concentrations of 1 ng/mL for TcdB, 10 
μmol/L for Y27632, 1 μmol/L for H1152 and 25 μmol/L 
for zVAD were used.  
 
Membrane flip flop analysis by Flow Cytometry 
FITC-labeled human recombinant (hr) annexin V and 
RPE-labeled hr-annexin V (Bender Med Systems, 
Vienna, Austria) were used to assess flip-flop of the cell 
membrane. Propidium iodide (PI; Bender Med Systems) 
was used to assess membrane permeability, and thus 
cell death. A CaspatagTM caspase 3/7  in situ kit 
(Chemicon Int. Inc. Temecula, CA, USA), a green 
fluorescent probe that binds active caspase 3 (FAM-
DEVD-fmk), was used to stain for active caspase 3. 
H9c2 cells were incubated in culture medium. All cells 
(attached- as well as detached cells) were then collected 
and stained with either annexin V-FITC (1:40) or 
annexin V-PE (1:40) for 30 minutes at 37°C. Cells were 
stained for active caspase 3 according to the 
manufacturer’s protocol. Briefly, cells were stained with 
FAM-DEVD-fmk for one hour at 37°C in serum-free 
culture medium and subsequently washed twice with 
serum-free culture medium (the supplied wash buffer 
was not used since it interfered with the annexin V-PE 
staining). PI (1:40) was added only few minutes prior to 
measurement. The cells were then analyzed by flow 
cytometry (FACSCalibur; Becton Dickinson, Franklin 
Lakes, NJ, USA).  
  
Akt / phospho-Akt protein expression 
The expression of Akt and phosphorylated Akt was 
quantified using Western blot. H9c2 cells were lysed in 
a buffer containing 250 mmol/L NaCl, 0.1% Nonidet P-
40, 50 mmol/L HEPES pH 7.0, 5 mmol/L EDTA and 
0.5 mmol/L DTT in H2O, supplemented with protease 
inhibitor cocktail (1:40; Sigma, St. Louis, MO, USA). 
Protein concentrations in the samples were determined 
using the Bio-Rad protein assay kit (Bio-Rad, Hercules, 
CA, USA). After adding SDS sample loading buffer 
containing β-mercaptoethanol as a reducing agent, the 
samples were stirred, and heated for 10 min at 95°C. 36 
μg protein of each sample was subjected to SDS-PAGE, 
transferred to nitrocellulose membranes and 
immunoblotted using either a rabbit polyclonal Ab 
against Akt (1:1000, over-night 4°C; Cell Signaling, 
Danvers, MA, USA) or a rabbit polyclonal Ab against 
phospho-Akt (ser473) (1:1000, over-night 4°C; Cell 
Signaling) followed by horseradish-peroxidase-
conjugated swine-anti-rabbit immunoglobulins (1:1000, 
60 minutes; DakoCytomation, Glostrup, Denmark). The 
blots were visualized by enhanced chemiluminescence 
(ECL; Amersham Biosciences AB; Uppsala; Sweden). 
Staining was quantified with a charge-coupled device 
camera (Fuji Science Imaging Systems; Düsseldorf, 
Germany) in combination with AIDA Image Analyzer 
software (Isotopenmessgeräte; Staubenhardt, Germany). 
 
Caspase 3 measurements  
Caspase 3 activity was determined using a fluorimetric 
homogeneous caspase assay (Roche, Mannheim, 
Germany), according to the manufacturer’s instructions. 
Cells were lysed and incubated with DEVD-rhodamine 
110 substrate for one hour at 37 °C. Subsequently, the 
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amount of free rhodamine was determined at a 
microplate fluorescence reader (TECAN spectrafluor, 
Hombrektikon, Switzerland). The developed 
fluorochrome was proportional to the concentration of 
activated caspase 3 and could be quantified by a 
calibration curve of diluted free rhodamine [formula: 
caspase concentration (nmol/L) = 
(
11510
2273.4absorption −
)∗1000]. Active caspase 3 
concentration levels were indicated as the difference (Δ) 
in caspase 3 concentration levels relative to control cells.  
 
ATP measurements 
Samples for ATP measurements were prepared as 
follows. The described steps were all performed at 4°C. 
After treatment, the cells (∼6x106) were collected and 
counted and the cell concentrations were equalized 
accordingly. After centrifugation (400xg) the cells were 
incubated in 500 μL 0.4 mol/L Perchloric Acid (Sigma) 
for 30 minutes and subsequently centrifuged (1600xg). 
The supernatants were collected and the pH was 
restored to 7 by adding 25 μL 5 mol/L K2CO3 (Sigma, 
St. Louis, MO, USA). The samples were frozen (-80°C) 
until measurement. ATP levels were measured either in 
a bioluminescence assay, using a sensitive ATP 
determination kit following the manufacturers protocol 
(Biaffin GmbH & Co KG, Kassel, Germany), or using 
high pressure liquid chromatography (HPLC), which 
was also used to measure GTP levels. For the ATP 
assay, luminescence was measured using a Tecan 
GENios Plus reader (Tecan Benelux, Mechelen, 
Belgium). For HPLC, the columns used were prepacked 
Partisphere (partisil-5) SAX cartridges (4.6 x 125mm 
internal dimensions, Whatman International Ltd, 
Maidstone England. The concentration of the different 
substances were calculated by comparison with highly 
purified standards (Sigma). 
 
Analysis of flippase activity by Flow Cytometry 
For the PS-NBD staining, H9c2 cells were harvested and 
resuspended in serum-free culture medium. For 
measurement of flippase activity, cells were incubated 
with NBD labeled phosphatydylserine (25) (PS-NBD: (1-
palmitoyl-2-[6-[(7-nitro-2–1,3-benzoxadiazol-4-
yl)amino]caproyl]-sn-glycero-3-phosphoserine) (Avanti 
Polar Lipids, Alabaster, AL, USA) in a final 
concentration of 1 μmol/L at 37°C for 30 minutes. The 
cells were then transferred to ice and 5 mL ice-cold 1% 
(w/v) BSA/PBS solution was added to extract label 
present in the outer leaflet of the membrane. To 
measure total fluorescence, 5 ml ice-cold PBS without 
BSA was added. After 15 minutes the cells were 
pelleted and resuspended in serum-free culture 
medium and then analyzed by flow cytometry (FACS-
Calibur). With each experiment, part of the harvested 
cells were analyzed for membrane flip flop as described 
before. 
Statistics 
Statistics were performed with the SPSS statistical 
program (windows version 9.0). To evaluate whether 
observed differences were significant, One-way 
ANOVA analysis combined with Bonferroni’s multiple 
comparison test, Mann-Whitney analysis or 
independent T-test were used when appropriate. In the 
text and relevant figures values are given as means ± 
SE. A p-value (two-sided) of less than 0.05 was 
considered to represent a significant difference. 
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Figure  2: Quantitative western  blot  analysis  of Akt  and 
phosphorylated Akt  in  H9c2  cells  H9c2  cells  were 
subjected  to  for  24  hours  to  1  ng/mL TcdB,  10  μmol/L 
Y27632 or 1 μmol/L H1152. Sample  sizes were all equated 
according  to  total protein  content  and  the  loading  control 
for all  lanes was verified to be equal according  to ponceau
staining. (a) Akt was detected at approximately 60 kDa and 
is  depicted  as  as percentages  relative  to  control  cells.  (b) 
Phosphorylated Akt  (pAkt, phosphorylated on  serine  473) 
was detected at approximately 60 kDa and is depicted as as
percentages  relative  to  control  cells.  ∗p<0.01,  †p<0.05  (3 
experiments). 
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Inhibition o
exposure in H9c2 cells 
The effect of Rho prote
flip-flop in H9c2 cells was analyzed using flow 
cytometry. FITC–labeled human recombinant annexin V 
(annexin V; a marker for membrane flip-flop) and 
propidium iodide (PI; a marker for cell-death) to 
determine whether the cells were viable (negative for 
both annexin V and PI), damaged (single-annexin V-
positive) or dead (annexin V/PI-positive or single-PI-
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The H9c2 flip-flop inducing effect of TcdB was 
concentration dependent. The percentage of single-
annexin V-positive cells was increased relative to 
control cells by TcdB concentrations of 1 ng/mL after 24 
hours incubation, whereas a TcdB concentration of 10 
ng/mL resulted mainly in increased PI positive cells 
(figure 1a). Experiments were therefore performed with 
a TcdB concentration of 1 ng/mL. TcdB induced a 
significant increase in the percentage of single-annexin 
V-positive cells to 33±5 % compared to control cells (5±1 
%; p<0.0001; figure 1b). TcdB induced a significant 
decrease in the percentage of viable cells to 44±6 % 
compared to control cells (77±3 %; p<0.0001), but had 
no effect on the percentage of PI-positive cells (not 
shown). Thus, inhibition of the Rho proteins by TcdB 
induced PS exposure in H9c2 cells. We subsequently 
investigated whether inhibition of ROCK, a 
downstream effector of RhoA, also has an effect on PS 
exposure in H9c2 cells. a
 
Inhibition of ROCK by Y27632 and H1152 induces PS 
exposure in H9c2 cells 
The effect of inhibition of ROCK by the selective ROCK 
inhibitors Y27632 and H1152 on membrane flip-flop in 
H9c2 cells was analyzed via flow cytometry using 
annexin V and PI. 
Similar to TcdB, both Y27632 and H1152 induced a 
significant increase in the percentage of single-annexin 
V-positive cells compared to control cells (p<0.001). 
Y27632 increased the percentage of single-annexin V 
positive cells to 17±3 % (figure 1c) and H1152 increased 
the percentage of single-annexin V positive cells to 21±1 
% (figure 1d). Both Y27632 and H1152 did not have a 
significant effect on the percentages of viable or PI-
positive cells (not shown). These data suggest that 
interference with RhoA – ROCK activation leads to loss 
of transbilayer phospholipid asymmetry. 
 
Inhibition of RhoA – ROCK signaling leads to 
reduced Akt phosphorylation in H9c2 cells 
The PS exposure due to inhibition of RhoA – ROCK 
signaling is indicative of cell stress. In endothelial cells 
PS exposure and apoptosis was found to be inhibited 
through Akt activity (26). The effect of RhoA – ROCK 
inhibition on the expression of Akt and on Akt 
activation via the expression of phosphorylated Akt 
(pAkt) was therefore quantified in H9c2 cells using 
Western blot analysis. 
Total Akt protein migrated to approximately 60 kDa 
(figure 2a). Neither Rho protein inhibition by TcdB, nor 
ROCK inhibition by either Y27632 or H1152 altered Akt 
expression significantly compared to control cells. 
Maximal activation of Akt is achieved through 
phosphorylation on serine 473 (27). Quantification of 
pAkt levels revealed that Rho protein inhibition by 
TcdB significantly reduced the amount of pAkt to 3±1 %  
of control cells (p<0.001; figure 2b). Similarly, ROCK 
inhibition by both Y27632 and H1152 significantly 
reduced the amount of pAkt to respectively 9±7 % 
(p<0.001) or 41±20 % (p<0.05) of control cells. No 
significant difference in the amount of pAkt was found 
between TcdB, Y27632 or H1152 treated cells. Thus 
inhibition of RhoA – ROCK signaling does not affect 
Akt expression, but leads to inhibition of Akt activity. 
 
b
c
-200
0
200
400
600
control TcdB
zVAD
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
o ∗
∗ †
l/L
) †
control Y27632
-200
0
200
400
600
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
ol
/L
)
control H1152
-200
0
200
400
600
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
ol
/L
)
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
ol
/L
)
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
ol
/L
)
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
ol
/L
)
Δ c
as
pa
se
 3
 c
on
c.
 (n
m
ol
/L
)
Figure  3:  Effects  of  TcdB,  Y27632  and  H1152  on  active 
caspase 3  concentration  in H9c2 cells(a ‐ c) Concentrations 
(nmol/L) of active caspase 3 are depicted as the difference (Δ) 
in caspase 3 concentrations relative to control cells. (a) TcdB 1 
ng/mL 24  hours  +/‐ zVAD  25  μmol/L  24  hours  (4 
experiments);  ∗p<0.01,  †p<0.05.  (b)  Y27632  10  μmol/L  24 
hours  (4  experiments).  (c)  H1152  1μmol/L  4  hours  (4 
experiments).
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Figure 4: Effects of zVAD on TcdB and Y27632 induced PS 
exposure in H9c2 cells Flow cytometry analysis of H9c2 cells 
using  annexin  V‐FITC  and  propidium  iodide  (PI).  The 
percentages of single‐annexin V‐positive cells are shown. (a) 
TcdB  1  ng/mL 24  hours  +/‐ zVAD  25  μmol/L  24  hours  (4 
experiments);  ∗p<0.001,  †p<0.05,  ‡p<0.001.  (b)  Y27632  10 
μmol/L 24 hours (4 experiments); ∗p<0.001, †p<0.01. 
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TcdB but not Y27632 or H1152 induce caspase 3 
activation 
PS exposure is a hallmark of apoptosis and inhibition of 
Akt has been shown to lead to apoptosis (26;28). To 
assess whether the observed inhibition of RhoA – 
ROCK signaling-induced PS exposure and Akt 
inhibition is related to apoptosis we quantified putative 
caspase 3 activation in H9c2 cells.   
TcdB significantly increased the active caspase 3 
concentration to 386±92 nmol/L above that in control 
cells (p<0.01; figure 3a). In cells treated with TcdB in 
combination with pancaspase inhibitor zVAD, the 
active caspase 3 concentration was completely reduced 
to control level (p<0.05 compared to TcdB alone). In 
contrast to TcdB, Y27632 nor H1152 did significantly 
increase the active caspase 3 concentration (figure 3b 
and 3c).  
Thus, Rho protein inhibition by TcdB, but not ROCK 
inhibition by Y27632 or H1152, induced apoptosis in 
H9c2 cells. The PS exposure induced by ROCK 
inhibition therefore is not related to caspase 3 activity.  
The effect of caspase 3 inhibition on TcdB-induced PS 
exposure 
To assess whether the observed membrane flip-flop, as 
induced by impaired Rho protein signaling, is solely the 
result of concurrently induced apoptosis, we quantified 
the effects of zVAD on TcdB-induced membrane flip-
flop in H9c2 cells, using flow cytometry analysis with 
double staining of FITC–labeled human recombinant 
annexin V and PI.   
zVAD significantly reduced the percentage of single-
annexin V-positive cells induced by TcdB alone to 36±3 
% compared with 50±3 % of cells treated with TcdB 
alone (p<0.05; figure 4). Interestingly however, the 
percentages of single-annexin V positive cells after 
treatment with TcdB + zVAD, were still significantly 
higher than 5±1 % in control cells (p<0.001).  
In addition, we analyzed H9c2 cells treated with TcdB 
by flow cytometry, using a double labeling with RPE–
labeled human recombinant annexin V (annexin V-PE) 
and a green fluorescent probe that binds active caspase 
3 (FAM-DEVD-fmk). In line with the caspase 3 activity 
assay results, TcdB induced a population of cells 
positive for annexin V-PE and active caspase 3. In 
addition, TcdB induced a population of cells positive for 
annexin V-PE but negative for active caspase 3 (not 
shown).   
Thus, a significant part of the TcdB-induced plasma 
membrane flip-flop is not dependent upon activation of 
caspase 3.  
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Figure 5: The effect of TcdB, Y27632 and H1152 on cellular 
ATP content of H9c2 cells (a) ATP levels measured by ATP 
luminescence assay. Cellular ATP is depicted as percentages 
relative to control cells. Cells were subjected to TcdB 1 ng/mL
for 24 hours, or to Y27632 10 μmol/L for 24 hours, or to H1152 
1  μmol/L  for  4  hours.  (4  experiments)  ∗p<0.001.  (b)  ATP 
levels measured  by HPLC. Cells were  subjected  to  TcdB  1 
ng/mL for  24  hours. Cellular ATP  is depicted  as pmol per 
1E106 cells. (3 experiments) ∗p<0.005
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The effect of inhibition of RhoA – ROCK signaling on 
cellular ATP content 
ATP-dependent systems are involved in maintaining 
plasma membrane asymmetry and loss of cellular ATP 
content may result in PS exposure, while ATP is 
necessary for completing the process of apoptosis (29). 
We therefore measured the effects of RhoA – ROCK 
signaling inhibition on cellular ATP content in H9c2 
cells. 
TcdB almost completely depleted cellular ATP to 4±3 % 
of control cells. (p<0.001; figure 5a). In contrast to TcdB, 
both ROCK inhibitors Y27632 as well as H1152 did not 
significantly reduce the cellular ATP content in H9c2 
cells. The ATP depleting effect of TcdB was confirmed 
via nucleotide analysis using HPLC where TcdB 
induced a significant decrease in cellular ATP to 191±59 
pmol ATP/1E106 cells compared to the 1769±71 pmol 
ATP/1E106 cells in control cells  (p<0.005; figure 5b). 
 
The effect of inhibition of RhoA – ROCK signaling on 
flippase activity 
Flippase selectively transports PS from the outer to the 
inner plasma membrane layer and thereby maintains 
transbilayer phospholipid asymmetry (19;20). As 
flippase activity is ATP dependent and TcdB depletes 
cellular ATP, whereas the ROCK inhibitors had no 
effect on cellular ATP, the effect of ROCK inhibition on 
flippase activity was subsequently analyzed in H9c2 
cells, treated with either Y27632 or H1152. These cells 
were incubated with NBD-labeled PS and then analyzed 
by flow cytometry. Internalization of PS-NBD results in 
PS-NBD-positive cells and is a measure for flippase 
activity. PS-NBD-negative cells therefore are cells in 
which flippase activity is inhibited. 
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Y27632 significantly increased the percentage of PS-
NBD-negative cells to 18±3 % compared with 5±1 % in 
control cells (p<0.004; figure 6a). Similarly, H1152 
significantly increased the percentage of PS-NBD-
negative cells to (p<0.004; figure 6b). Figure 6c shows a 
typical example of how Y27632-induced flip-flop 
(panels I, II) coincides with increased PS-NBD 
negativity, i.e. flippase inhibition (panels III, IV). These 
results show that ROCK inhibition leads to inhibition of 
flippase activity. 
Discussion 
There is accumulating evidence that plasma membrane 
alterations such as the exposure of anionic 
phospholipids, for instance PS, in the outer leaflet (flip-
flop) of jeopardized cardiomyocytes target the 
inflammatory response to these cells in the reperfused 
myocardium (17;18;30). We and others however, have 
shown that this flip-flop can be a reversible 
phenomenon and may precede commitment to death (9-
11;14). Thus, (reversible) plasma membrane flip-flop 
may serve as a handle by which inflammatory 
mediators bind and induce additional damage in the 
reperfused heart after AMI. We now show evidence that 
RhoA – ROCK signaling is involved in the regulation of 
transbilayer phospholipid asymmetry in 
cardiomyocytes, which may involve regulation of 
flippase activity. 
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Figure  6:  The  effect  of  Y27632  and  H1152  on  flippase 
activity in H9c2 cells The effect of (a) Y27632 (10 μmol/L, 24 
hour  incubation)  on  the  percentage  of  cells  negative  for 
NBD‐labeled PS. (b) H1152 (1 μmol/L, 4 hour incubation) (a) 
6  experiments;  ∗p<0.004  (b)  4  experiments;  ∗p<0.004.  (c) 
Example of Y27632 (10 μmol/L, 24 hour incubation)‐induced 
PS  exposure  (panel  II)  versus  control  cells  (panel  I)  as 
determined via Flow cytometry using annexin V‐FITC and 
propidium  iodide  (PI). The PS exposure manifests  itself as 
increased  population  of  single‐annexin  V‐positive  cells 
(arrow, panel  II). This PS  exposure  coincides with Y27632 
(10  μmol/L,  24  hour  incubation)‐induced  increase  in  the 
percentage  of  PS‐NBD‐negative  cells  (arrow  panel  III) 
versus that in control cells (panel IV).
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Figure 7: RhoA – ROCK – flippase  signaling is involved in 
maintenance  of  membrane  phospholipid  asymmetry. 
Interference  leads  to  PS  exposure  and  apoptosis  Our  data 
point  to  a  role  for  RhoA  – ROCK  signaling  via  flippase 
activity  in  maintenance  of  phospholipid  transbilayer 
asymmetry  (a).  Impaired  Rho  protein  signaling  through 
TcdB  leads  to  PS  exposure,  in  part  through  induction  of 
apoptosis  (caspase 3 activation)  and  in part  through  a non‐
apoptotic  route probably via  impaired ROCK  signaling and 
impaired  flippase  activity  (b).  Impaired  ROCK  signaling 
through direct inhibition by Y27632 or H1152 indeed leads to 
non‐apoptotic PS exposure (c).
In the present study we namely show that Rho protein 
inhibitor TcdB and ROCK inhibitors Y27632 and H1152 
induced increased apoptotic and non-apoptotic plasma 
membrane flip-flop in cardiomyocytes. In addition, 
TcdB, Y27632 and H1152 also induced a significant 
decrease in the activity of the anti-apoptotic protein 
Akt, as shown by decreased phosphorylation on serine 
473. Studies have shown before that in various cells, i.e. 
rat mast cells, human vascular smooth muscle cells, HL-
60 cells and rat fibroblasts, Akt phosphorylation and 
translocation is inhibited by TcdB, perhaps through 
inhibition of Rac (31-34). In our study TcdB also led to 
ATP depletion, which may contribute to decreased 
phosphorylation of Akt, whereas in the mentioned 
69
studies the effect of TcdB on ATP levels was not 
investigated. The inhibition of ROCK appears to have 
different effects on Akt activity in different cells. For 
instance, ROCK inhibitor fasudil inhibited Akt 
phosphorylation in bovine retinal microvascular 
endothelial cells whereas in human endothelial cells 
fasudil activated Akt (34;35). In neonatal rat 
cardiomyocytes transfected with a constitutively active 
ROCK1 vector Akt phosphorylation was inhibited (36). 
Loss of Akt signaling has been shown to lead to 
apoptosis, also in cardiomyocytes (28). However, 
whereas TcdB also induced caspase 3 activation, 
indicative for increased apoptosis, Y27632 and H1152 
did not, indicating that decreased Akt activity through 
impaired RhoA – ROCK signaling leads to PS exposure, 
but need not necessarily to apoptosis. Indeed, 
Pancaspase inhibitor zVAD could only partially inhibit 
TcdB-induced PS exposure, again indicating that 
membrane flip-flop does not necessarily coincide with 
apoptosis. Recently we showed that ischemia induced 
PS exposure can be a non-apoptotic and reversible 
phenomenon in cardiomyocytes (9). Therefore in H9c2 
cells Rho protein inhibition by TcdB induced both 
apoptotic and non-apoptotic PS exposure.  
The apoptosis inducing properties of TcdB have been 
shown in several different cell types (37-40), indicating 
that inhibition of the Rho protein family can induce 
apoptosis. Although Y27632 has been reported to 
induce apoptosis in human airway epithelial cells and 
HUVECs (40;41), in our experiments neither Y27632 nor 
H1152 led to increased caspase 3 activation in 
cardiomyocytes. In a recent study by Huelsenbeck et al. 
inhibition of RhoA by TcdB was shown to upregulate 
and activate RhoB in murine NIH3T3 fibroblasts (42). 
They found that this activated RhoB was required for 
the TcdB-induced apoptosis in these cells. This data, 
combined with ours, may suggest a mechanism wherein 
impaired RhoA signaling by TcdB leads to non-
apoptotic PS exposure, probably through impaired 
ROCK signaling, as assessed by Y27632 and H1152, and 
impaired flippase activity and in addition leads to 
apoptosis and apoptotic PS exposure, perhaps through 
upregulation of RhoB (figure 7). 
TcdB, but not Y27632 or H1152, significantly lowered 
cellular ATP levels. Earlier studies have shown cellular 
ATP depletion induced by Clostridium difficile Toxin A 
(43;44). How these compounds interfere with cellular 
ATP levels we do as yet not know, however they both 
may interfere with mitochondrial respiratory function 
(39;43;45). This ATP depletion effect of TcdB possibly 
also down-regulates known ATP-dependent regulators 
of transbilayer phospholipid asymmetry such as 
flippases and floppases. This may therefore contribute 
to TcdB-induced membrane flip-flop. In contrast, the 
ROCK inhibitors Y27632 and H1152, which also 
induced membrane flip-flop, did not lower cellular 
ATP. This indicates involvement of RhoA – ROCK 
signaling independent of putative ATP lowering effects 
in maintaining membrane asymmetry.  
Flippase-catalyzed transport translocates preferably PS 
from the outer to the inner plasma membrane layer and 
this transport requires ATP (20). Both Y27632 and 
H1152, which as mentioned earlier did not deplete ATP, 
significantly increased the percentage of PS-NBD-
negative cells, i.e. cells that were incapable of 
internalizing PS-NBD, which is a measure for flippase 
inhibition (46).  
In conclusion, in recent years we have provided 
evidence for the importance of (reversible) plasma 
membrane flip-flop in jeopardized cardiomyocytes in 
the border zones of AMI for the propagation of 
inflammation and the additional damage this brings 
about (9;17;18). In this study we now provide evidence 
for a role for RhoA – ROCK signaling in maintaining the 
asymmetrical distribution of membrane phospholipids 
in cardiomyocytes, which directly involves flippase 
activity.  
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Increased Nox2 expression in human cardiomyocytes
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Background/Aims: Recent studies indicate the presence of reactive oxygen species (ROS) producing
homologues of the enzymatic subunit (Nox2) of phagocytic NADPH oxidase in non-phagocytic cells.
Interestingly, in these cells, ROS produced by the Nox2 homologue(s) was shown to play a role in vari-
ous regulatory processes, including cell death, proliferation, and aging. The purpose of this study was
to investigate whether human cardiomyocytes express Nox2.
Methods: The expression of Nox2 was studied in human cardiomyocytes using western blot and
immunohistochemical analysis. To analyse the putative expression of Nox2 in human heart disease,
cardiac samples from patients who had died subsequent to acute myocardial infarction (AMI) were
studied.
Results: Both in western blot and immunohistochemical studies, Nox2 expression was found in normal
human cardiomyocytes. In patients with AMI, a significant increase in Nox2 expression was found both
in viable and in jeopardised cardiomyocytes in the infarcted area. In addition, in the “remote from inf-
arction” area, Nox2 expression was present in cardiomyocytes, but was not increased.
Conclusions: Nox2 or its homologue(s) is expressed in normal and jeopardised human
cardiomyocytes. This expression is increased in patients with AMI, suggesting a role for this ROS pro-
ducing Nox2 homologue(s) in the human heart after AMI.
Cardiomyocytes produce reactive oxygen species (ROS)under different pathological conditions.1 From studiesin non-cardiomyocytes it is known that ROS do not only
induce cell damage, but also play a role in processes such as
cell proliferation, apoptosis, gene expression, and aging.2–6
Furthermore, recent studies also point to a new, more or less
cell specific source of ROS, namely homologues of the NADPH
oxidase of phagocytes.7
The catalytic core of the phagocytic NADPH oxidase is a
membrane integrated flavocytochrome b558, comprising the
p22phox and the enzymatic gp91phox (Nox2) subunits.
Recently, several Nox2 homologues have been identified in
various human cell types. For instance, in blood vessels Nox2
has been reported in endothelial cells,8 whereas the Nox2
homologues, Nox1 and Nox4, were found in vascular smooth
muscle cells.9 In addition, in thyroid, ThOX1 and ThOX2 were
identified,10 and in the kidney Nox4.11 In heart homogenates
from guinea pigs suffering from experimental hypertension,
Nox2 was also found to be expressed, although it was not
specified whether the enzyme was located in cardiomyocytes,
fibroblasts, or endothelial cells.12
“Reactive oxygen species do not only induce cell
damage, but also play a role in processes such as cell
proliferation, apoptosis, gene expression, and aging”
To date, there are no data available regarding the expression
of Nox2 or its homologues in human cardiomyocytes.
Therefore, we have analysed the expression of Nox2 by human
cardiomyocytes at the cellular level. Furthermore, we have
studied the putative expression of Nox2 in the hearts of 62
patients who died as a result of acute myocardial infarction
(AMI), to obtain some insight into the expression of the
enzyme in pathological conditions.
MATERIALS AND METHODS
Patients
Our study was carried out using tissue from patients referred
to the department of pathology for necropsy. Patients in the
AMI model showed signs of a recently developed AMI (table
1) at necropsy; that is, on histochemical examination they had
decreased lactate dehydrogenase (LD) staining (decoloura-
tion) of the affected myocardium. Clinical data with respect to
the time duration of AMI correspond to the time intervals of
the different morphological stages of AMI. Necropsies were
performed as soon as possible, within 24 hours of death. Our
study was approved by the ethics committee of the VU Medi-
cal Center, Amsterdam. The investigation conforms with the
principles of the Declaration of Helsinki. The use of left over
material after the pathological examination is part of the
standard patient contract in our hospital.
Processing of tissue specimens
Specimens from the left ventricle were used for isolation of
cardiomyocytes from patients who died from a cause not
related to heart disease. For the immunohistochemistry of
AMI samples, myocardial tissue specimens were obtained
from both the infarcted zone and from remote sites of the
healthy part of the heart. These remote sites showed normal
LD staining patterns and were studied as internal non-
infarcted controls. The internal controls were taken from all
different phases of infarction and reinfarction. None of these
patients had sepsis or malignancy. Before being prepared as
cryosections, tissue specimens were stored at −196°C (liquid
nitrogen). Frozen sections were mounted on to SuperFrost®
Plus glass slides (Menzel-Gläser, Braunschweig, Germany).
Isolation of human cardiomyocytes
Healthy heart tissue obtained during necropsy, approximately
5 cm3, was cut into small pieces, rinsed twice in phosphate
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buffered saline (PBS), and pelleted by centrifugation (six
minutes at 100 ×g on a low brake). The tissue was then incu-
bated at 37°C in a solution of collagenase type 2 (Worthington
Biochemical Corporation, Lakewood, New Jersey, USA) at
0.8 mg/ml in Ca2+ free Krebs Ringer buffer (pH 7.4). After
separation of cardiomyocytes, the solution was filtered
through a 100 µm filter and centrifuged (six minutes at
100 ×g on a low brake). The pellet contained morphologically
purified human cardiomyocytes.
Western blotting
Isolated human cardiomyocytes were dissolved in Laemmli
sodium dodecyl sulfate (SDS) sample buffer, stirred and
heated at 95°C for 10 minutes. The samples were subjected to
SDS polyacrylamide gel electrophoresis (10% gels), trans-
ferred to nitrocellulose membranes, and immunoblotted with
monoclonal antibody 48 (1/250 dilution) and subsequently
with horseradish peroxidase conjugated rabbit antimouse
immunoglobulins (RaM-HRP; Dakopatts, Glostrup, Denmark;
1/1000 dilution). The blots were then visualised by enhanced
chemiluminescence (ECL; Amersham, Buckinghamshire,
UK).
Antibodies
A monoclonal antibody (C3-15) against the complement fac-
tor C3d has been used previously for immunohistochemical
studies.13 Monoclonal antibodies against CD66b (previously
clustered as CD67 (B13.9))14 and against Nox2 (monoclonal
antibodies 48 and 7D5)15 16 were obtained from Sanquin
Research at CLB, Amsterdam, The Netherlands. Monoclonal
antibody KP1 against CD68 was obtained from Dakopatts,
Glostrup, Denmark. The monoclonal antibodies were stored at
1 mg/ml in PBS. For all monoclonal antibodies we included
controls. Healthy appearing parts of the heart did not stain
with C3-15. Irrelevant monoclonal antibodies (two IgG1 and
one IgG2a), tested at concentrations similar to those used for
the specific monoclonal antibodies, yielded negative results.
Immunohistochemistry
Frozen sections (5 µm thick) were mounted on to glass slides,
dried for one hour by exposure to air, and fixed in acetone
(“Baker analysed reagent”; Mallinckrodt Baker, Deventer,
Netherlands). After rinsing in PBS, the slides were incubated
at room temperature for 10 minutes with normal rabbit serum
(Dakopatts), diluted 1/50 in PBS containing 1% (wt/vol)
bovine serum albumin (PBS-BSA) (BSA from Boehringer,
Mannheim, Germany). Incubation of the slides with specific
antibody solutions (diluted in PBS-BSA) was performed for 60
minutes (monoclonal antibody 48 was diluted 1/150; CD66b
was diluted 1/750; C3–15 was diluted 1/1500; and KP1 was
diluted 1/400). The slides were washed for 30 minutes with
PBS and incubated with RaM-HRP, diluted 1/25 in PBS-BSA.
Thereafter, the slides were washed again in PBS and incubated
for three minutes in 0.5 mg/ml 3,3′-diaminobenzidine tet-
rahydrochloride (DAB; Sigma, St Louis, Missouri, USA) in
PBS, pH 7.4, containing 0.01% (vol/vol) H2O2, washed again,
counterstained with haematoxylin for one minute, dehy-
drated, cleared, and finally mounted.
Microscopic criteria17 18 were used to estimate infarct dura-
tion in all myocardial tissue specimens. Because morphologi-
cal assessment is more reliable in paraffin wax embedded sec-
tions, corresponding paraffin wax embedded slides were also
made. We characterised jeopardised myocardium by the
intensity of eosinophilic staining of involved myofibres, loss of
nuclei, and cross striation. We classified the infarction age as
follows: no microscopical changes but macroscopically LD-
decolouration (early phase (phase 1)), infiltration of polymor-
phonuclear leucocytes (PMNs) (PMN phase (phase 2)), infil-
tration of lymphocytes and macrophages and fibrosis (chronic
phase (phase 3)). Furthermore, patients with phase 3
morphology and phase 1 morphology were classified as reinf-
arction early phase (phase 4). Patients with phase 3 morphol-
ogy and phase 2 morphology were classified as reinfarction
PMN phase (phase 5). In all cases, the histologically assessed
infarct age corresponded with the clinical course.
Two investigators (PAJK and HWMN) each judged and
scored independently all slides for infarct age and anatomical
localisation of the specific antibodies, as visualised by
immunohistochemical staining. Scoring of the slides was per-
formed by first determining complement positive (represent-
ing jeopardised cardiomyocytes) and complement negative
regions (representing morphologically viable cardiomyocytes)
in slides of the macroscopic infarcted area and control area.
Thereafter, the number of CD66b and Nox2 positive cardio-
myocytes was counted in 25 high power fields (HPF; 400×
magnification), both in the complement positive and in the
complement negative areas. The slides stained with C3-15,
CD66b, monoclonal antibody 48, and KP1 were serial slides.
For the final scoring results, consensus was achieved by the
two investigators. The average number of positive cardiomyo-
cytes in each HPF was used in the calculations.
Statistics
Statistics were performed with the SPSS statistics program
(windows version 9.0). To evaluate whether observed differ-
ences were significant, paired or non-paired t tests were used
when appropriate. A p value (two sided) of less than 0.05 was
considered to be significant.
RESULTS
Nox2 in isolated human cardiomyocytes
Human cardiomyocytes were isolated from the heart of two
patients who had died as a result of a condition not related to
AMI, and who had suffered from no other forms of heart dis-
ease. When analysing the protein expression of Nox2 by
human cardiomyocytes with immunoblotting using mono-
clonal antibody 48 (fig 1), a strong protein band was detected
that migrated at a position of approximately 55–65 kDa,
presumably representing unglycosylated Nox2. Furthermore,
two thinner bands migrating at about 80 kDa were detected,
probably representing various degrees of glycosylation of
Nox2. These results suggest the presence of Nox2 within
human cardiomyocytes.
Nox2 in the human heart
Heart tissue slides, prepared from the hearts of three patients
who had died from a cause other than AMI, and did not suffer
Table 1 Patient characteristics
AMI phase Infarct age
Number of
patients Male/Female Age range
Early phase 0–12 h 20 11/9 36–88
PMN phase 12 h to 5 days 19 14/5 47–85
Chronic phase 5–14 days 6 5/1 62–75
Reinfarction early phase 0–12 h 9 6/3 45–85
Reinfarction PMN phase 12 h to 5 days 8 7/1 50–83
AMI, acute myocardial infarction; h, hours; PMN, polymorphonuclear leucocytes.
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from any other form of heart disease, were stained with
monoclonal antibody 48 to localise Nox2. In agreement with
the results obtained by western blotting, Nox2 was detected
within human cardiomyocytes (fig 2A), although only limited
numbers of cardiomyocytes were positive. Nox2 expression
was localised both on the plasma membrane and in the cytosol
of cardiomyocytes, including the perinuclear region. Some
Nox2 antigen was also found on cross striations.
In addition to monoclonal antibody 48, we also used mono-
clonal antibody 7D5, which detects the extracellular domain
of Nox2.16 A positive signal was also seen in cardiomyocytes
with monoclonal antibody 7D5, although this signal was less
intense than that obtained with monoclonal antibody 48 (not
shown). This was probably because monoclonal antibody 7D5
only stained Nox 2 at the plasma membrane of cardiomyo-
cytes.
Therefore, using western blotting and immunohistochemis-
try with two different antibodies, we have shown (to our
knowledge, for the first time) the presence of Nox2 within
human cardiomyocytes.
Expression of Nox2 in infracted myocardium
To characterise the expression pattern of Nox2 in more detail,
we subsequently analysed in more detail the expression
pattern of Nox2 in heart tissue from patients with AMI by
immunohistochemistry, particularly because in these patients
there is a dramatic ROS increase within cardiomyocytes after
AMI. Myocardial tissue specimens were obtained from 62
patients who died of AMI (table 1), as confirmed by necropsy.
Specimens were obtained from the infarcted myocardium as
determined macroscopically with LD staining (see “Materials
and methods” and fig 3). Infarct age, determined by
microscopical criteria,17 18 varied from less than 12 hours up to
two weeks. Patients were divided into different groups accord-
ing to infarct age, notably the early phase (less than 12 hours),
PMN phase (12 hours to five days), and the chronic phase (five
days to 14 days) (table 1). In addition, patients suffering from
reinfarction were divided into separate groups, namely reinf-
arction in the early phase (12 hours) and reinfarction in the
PMN phase (12 hours to five days) (table 1). Tissue specimens
from sites distant from the infarct were taken from nine
patients who had died after AMI. The infarcts in these patients
were at different AMI phases. These specimens were used as
an internal negative control.
Because macrophages also express Nox2, we stained serial
heart tissue slides from all phases of infarction with the
monoclonal antibody KP1 (directed against CD68, a marker
for macrophages). Macrophages were indeed positive for
Nox2. Nevertheless, there were large areas in which cardio-
myocytes were positive for Nox2, whereas only limited
numbers of macrophages were found in the interstitium that
did not adher to cardiomyocytes. In addition, in the areas in
which more macrophages were present, they were almost all
localised to the interstitium. Therefore, it is unlikely that mac-
rophages interfered with the Nox2 positivity of cardiomyo-
cytes.
In previous studies we have shown that in the macroscopi-
cal infarction area viable cardiomyocytes are still present.13 To
differentiate within this microscopical infarction area be-
tween the expression of Nox2 in non-jeopardised (comple-
ment negative) and jeopardised (complement positive)
cardiomyocytes, we stained the slides with an antibody
against activated complement (C3d) (fig 3).
Specimens obtained from the non-infarcted control areas
showed no C3d deposition (data not shown). In the infarction
site, extensive complement deposition was found in the PMN
phase and PMN reinfarction phase, whereas in the early phase
no complement deposition, and in the chronic or early
reinfarction phase, only limited areas containing complement,
were found (data not shown, also see Lagrand and col-
leagues13).
Figure 1 Western blot analysis
of Nox2 expression by isolated
human cardiomyocytes. Isolated
human cardiomyocytes were
subjected to sodium dodecyl
sulfate polyacrylamide gel
electrophoresis. Proteins were
transferred on to nitrocellulose
sheets. Nox2 was visualised with
monoclonal antibody 48 (1/250
dilution).
Figure 2 Immunohistochemical analysis of human heart tissue. (A)
Localisation of Nox2 in the heart of a patient who had died in the
absence of heart disease (original magnification, ×630). (B, C)
Localisation of Nox2 in a myocardial infarct area in a patient who
had died after acute myocardial infarction (original magnification,
×400). Slides were stained with monoclonal antibody 48 (1/150
dilution). (C) The arrow indicates the perinuclear localisation of
Nox2.
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Expression of Nox2 in complement negative (viable)
areas of the macroscopical infarct
Nox2 was present in cardiomyocytes within the macroscopi-
cally determined infarction area of the heart of patients who
had died after AMI (fig 2B,C). Similarly, as in normal cardio-
myocytes (see above), Nox2 was localised to the plasma mem-
brane and the cytosol of cardiomyocytes, including the
perinuclear region (arrow, fig 2C). Some Nox2 was also found
on cross striations.
Because PMNs strongly express Nox2 and adhere to cardio-
myocytes, possibly resulting in false positive Nox2 staining of
cardiomyocytes, especially in the complement positive infarc-
tion area,13 we had to correct for their contribution. Therefore,
we analysed the presence of CD66b (an immunohistochemical
marker for PMNs) on cardiomyocytes. As expected, myofibres
did not stain with CD66b in the non-infarcted control areas
(fig 4A). However, in these control areas, small numbers of
Nox2 positive cardiomyocytes were found, which were signifi-
cantly higher (p = 0.002) than the numbers of CD66b positive
cardiomyocytes (fig 4A). In these internal control areas, the
numbers of Nox2 positive cardiomyocytes were comparable to
the numbers of Nox2 positive cardiomyocytes in non-
infarcted hearts (data not shown).
In the macroscopically infarcted, but microscopically
complement negative, areas of all AMI phases, low numbers of
CD66b positive cardiomyocytes were also found. In addition,
in these areas the number of Nox2 positive myofibres was sig-
nificantly higher (p < 0.05) than the number of CD66b posi-
tive myofibres.
To correct for the contribution of PMNs to the presence of
Nox2 on cardiomyocytes, the number of CD66b positive
cardiomyocytes was subtracted from the number of Nox2
positive cardiomyocytes (fig 4B). In all phases of AMI, the
number of Nox2 positive myofibres was significantly higher
(p < 0.05) than in the internal control. Notably, no significant
differences in the number of Nox2 positive cardiomyocytes
were found between the different phases of AMI.
Expression of Nox2 in complement positive
(jeopardised) areas of the macroscopical infarct
As mentioned earlier, no complement positivity was found in
the early AMI phase. In the chronic phase and in the early
reinfarction phase, only two patients showed complement
deposition (the area of positivity was maximally 10%, not
shown). Therefore, the number of patients was too small for
statistical analysis. However, in these patients the number of
Nox2 positive myofibres was much lower than that seen in the
PMN and PMN reinfarction phase, but was still higher than
the number of CD66b positive myofibres (data not shown).
In the two phases of myocardial infarction that are accom-
panied by the most extensive complement deposition—the
PMN and PMN reinfarction phases—the number of Nox2
positive myofibres was higher than the number of CD66b
positive myofibres (fig 5A), although this was only significant
in the PMN phase.
Again, the number of CD66b positive cardiomyocytes was
subtracted from the number of Nox2 expressing cardiomyocytes
to correct for interference by PMNs (fig 5B). In both the PMN
and the PMN reinfarction phases, the number of Nox2 positive
cardiomyocytes was significantly higher (p < 0.05) than in the
internal control. However, the number of Nox2 positive
myofibres did not significantly differ between the PMN and
PMN reinfarction phases. The number of cardiomyocytes
positive for Nox2 in the complement positive areas of the
infarction site was higher than was seen in the complement
negative areas (1.1 fold for the PMN phase and 1.6 fold for the
PMN reinfarction phase), although this difference was not sig-
nificant. However, it should be noted that in both the PMN and
the PMN reinfarction phase, the number of CD66b positive car-
diomyocytes was significantly (p < 0.05) higher in complement
positive areas than in complement negative areas (approxi-
mately seven and 17 fold, respectively). Despite this high
number of CD66b positive cardiomyocytes, the number of
cardiomyocytes positive for Nox2 but negative for CD66b in
complement positive areas during both the PMN and PMN
reinfarction phases was higher than that seen in the comple-
ment negative areas, although not significantly. Because we
excluded the cardiomyocytes that were positive for CD66b and
thus also for Nox2, our data probably represent an underestima-
tion of Nox2 expressing cardiomyocytes in complement positive
areas of the infarct as compared with that in complement nega-
tive areas.
Thus, our data indicate that Nox2 expression is upregulated,
both in jeopardised and in non-jeopardised cardiomyocytes
Figure 3 Example of (A) an infarcted human heart and (B) complement deposition in the infarction area. (A) Cross section of the heart of a
patient who had died from acute myocardial infarction. Diminished lactate dehydrogenase (LD) staining is indicative of infarction (I), normal LD
content is indicative of unaffected myocardium (NI). (B) Microscopical analysis of complement deposition (complement factor C3d) in the
macroscopically determined infarcted myocardium.
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within the macroscopic infarction area of patients with AMI.
The number of Nox2 expressing cardiomyocytes was signifi-
cantly higher in this macroscopic infarction area than in the
macroscopic control areas.
DISCUSSION
Recent studies have described cell specific homologues of
gp91phox (Nox2) as a new source of ROS.8–11 To the best of our
knowledge, we have shown for the first time: (1) the presence
of Nox2 in non-pathological human cardiomyocytes, using
western blot and immunohistochemical analysis and two dif-
ferent antibodies for detection; and (2) an increase in expres-
sion of Nox2 in human cardiomyocytes in a pathological con-
dition, namely AMI.
On western blotting, Nox2 was found in human cardiomyo-
cytes as multiple bands; that is, an intense band between
55 kDa and 65 kDa and two bands around 80 kDa. The signal
between 55 and 65 kDa is probably the unglycosylated
protein, because the predicted molecular weight of unglyco-
sylated Nox2 protein is approximately 58 kDa16 to 65 kDa in
phagocytes.19 20 In human B cells21 and rat endothelial cells,19
Nox2 was also detected at approximately 60 to 65 kDa. The
bands around 80 kDa probably represent glycosylated Nox2,
as has also been shown in human umbilical vein endothelial
cells.8
“Nox2 might play a role in signal transduction processes
in normal cardiomyocytes”
Although two phagocyte Nox2 specific antibodies yielded
comparable results in human cardiomyocytes, we cannot
exclude the possibility that the epitope detected by the
antibodies in the cardiomyocytes actually belongs to one or
more homologue(s) of Nox2. Also unknown is the function of
Figure 4 Summary of Nox2 expression in relation to the presence
of CD66b in complement negative areas within the macroscopical
infarction area. Box plots in which the error bars represent minimum
and maximum values and in which the boxes represent the lower
and upper quartiles. The black lines within the boxes represent the
medians. N is the number of patients examined. For each patient the
average number of positive cardiomyocytes in each high power field
(HPF) was determined from 25 HPFs scored. (A) Box plot of the
number of Nox2 (shaded bars) and CD66b (open bars) positive
cardiomyocytes in each HPF in the different phases of infarction. (B)
Box plot of the number of Nox2 positive cardiomyocytes in each HPF
after subtraction of CD66b positive cardiomyocytes. PMN,
polymorphonuclear leucocytes.
Figure 5 Statistical analysis of Nox2 and CD66b in complement
positive areas within the macroscopical infarction area. Box plots in
which the error bars represent minimum and maximum values and in
which the boxes represent the lower and upper quartiles. The black
lines within the boxes represent the medians. N is the number of
patients examined. For each patient the average number of positive
cardiomyocytes in each high power field (HPF) was determined from
25 HPFs scored. (A) Box plot of the number of Nox2 (shaded bars)
and CD66b (open bars) positive cardiomyocytes in each HPF in the
different phases of infarction. (B) Number of Nox2 positive
cardiomyocytes in each HPF after subtraction of CD66b positive
cardiomyocytes. PMN, polymorphonuclear leucocytes.
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Nox2 or its homologue(s) in cardiomyocytes. Although Nox2
was present in some of the non-pathological cardiomyocytes,
a significant increase in Nox2 positivity was detected in
patients with AMI.
AMI induced upregulation of Nox2 is probably related to
ROS production. Indeed, in rat cardiomyoblast cells (H9c2) it
has already been shown that diphenylene iodonium, a
non-specific inhibitor of NADPH oxidase, results in a decrease
in ROS production.22 Studies of Mox1 (= Nox1) suggested that
these Nox2 homologues produce much lower quantities of
ROS when compared with the amount of ROS produced by
Nox2 in phagocytes.23 Because in our study Nox2 was found
also in the jeopardised (complement positive) cardiomyocytes,
the possibility that ROS produced via Nox2 in cardiomyocytes
plays a role in the process of cell damage cannot be excluded.
However, cardiomyocytes in the non-jeopardised (comple-
ment negative) part of the macroscopical AMI infarction area
also strongly expressed Nox2. Because some of these
cardiomyocytes become secondarily hypertrophic in time, a
role for ROS produced via Nox2 in the process of hypertrophy
can be postulated. This is in line with other studies in which
Nox2 or Nox2 homologues were shown to be involved in the
process of hypertrophy.24–27 The role of Nox2 in non-infarcted,
morphological normal cardiomyocytes at this moment is
difficult to predict. However, as suggested in studies of Nox2
homologues in other cell types, Nox2 might play a role in sig-
nal transduction processes in normal cardiomyocytes.
In conclusion, we have shown the expression of Nox2 in
human cardiomyocytes, which increases during myocardial
infarction. The pathophysiological role of this myocardial
Nox2 is the subject of further study.
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Take home messages
• Nox2 or its homologue(s) is expressed in both normal and
jeopardised human cardiomyocytes
• This expression is increased in patients with acute myocar-
dial infarction (AMI), suggesting a role for this reactive oxy-
gen species producing Nox2 homologue(s) in the human
heart after AMI
79
 80
Chapter 8 
 
Ischemia induces nuclear Nox2 expression 
in cardiomyocytes and subsequently 
activates apoptosis 
 
Meischl C*, Krijnen PAJ*, Cillessen SAGM, Munoz IG, Okroj MS, 
Ramska M, Muller A, Visser CA, Musters RJ, Simonides WS, Hack 
CE, Roos D, Niessen HWM. 
 
Apoptosis 2006 Jun;11(6):913-921. 
81
Apoptosis 2006; 11: 913–921
C© 2006 Springer Science + Business Media, LLC. Manufactured in The United States.
DOI: 10.1007/s10495-006-6304-7
Ischemia induces nuclear NOX2 expression
in cardiomyocytes and subsequently activates apoptosis
C. Meischl∗, P. A. J. Krijnen∗, J. A. Sipkens, S. A. G. M. Cillessen, I. Ga´mez Mun˜oz, M. Okroj, M. Ramska,
A. Muller, C. A. Visser, R. J. P. Musters, W. S. Simonides, C. E. Hack, D. Roos and H. W. M. Niessen
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands (C. Meischl, P. A. J. Krijnen, J. A.
Sipkens, S. A. G. M. Cillessen, I. Ga´mez Mun˜oz, M. Okroj, M. Ramska, H. W. M. Niessen); Department of Physiology, VU
University Medical Center, Amsterdam, The Netherlands (A. Muller, R. J. P. Musters, W. S. Simonides); Department of
Cardiology, VU University Medical Center, Amsterdam, The Netherlands (C. A. Visser); Department of Immunopathology,
Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam,
The Netherlands (C. E. Hack); Department of Blood Cell Research, Sanquin Research at CLB and Landsteiner Laboratory,
Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands (D. Roos); ICaR-VU, VU University
Medical Center, Amsterdam, The Netherlands (C. Meischl, P. A. J. Krijnen, J. A. Sipkens, I. Ga´mez Mun˜oz, M. Okroj, M.
Ramska, A. Muller, C. A. Visser, R. J. P. Musters, W. S. Simonides, C. E. Hack, H. W. M. Niessen)
Published online: 14 March 2006
In previous work we have demonstrated increased expres-
sion of NOX2 in cardiomyocytes of infarcted human hearts.
In the present manuscript we investigated the functional
role of NOX2 in ischemically challenged H9c2 cells, a rat
cardiomyoblast cell line, and adult rat cardiomyocytes. Ex-
pression of NOX2 in H9c2 cells was confirmed by RT-PCR. In
Western-blot experiments, increased NOX2 expression was
detected during ischemia, which was inhibited by transcrip-
tion and translation inhibitors. Surprisingly, under ischemia,
in addition to an increased cytosolic expression, NOX2 was
localized mainly in the nucleus of apoptotic cardiomyocytes,
where it colocalized with nitrotyrosine residues and acti-
vated caspase 3. Inhibition of reactive-oxygen-species gen-
eration with the flavoenzyme inhibitor diphenylene iodo-
nium (DPI) and the NADPH-oxidase inhibitor apocynin led
to a significantly decreased induction of apoptosis as as-
sessed by quantification of caspase-3 activity and by TUNEL
analysis. These results demonstrate that NOX2 is expressed
in the nucleus of cardiomyocytes during apoptosis and
that it likely participates in proapoptotic signaling. To the
best of our knowledge, this is the first demonstration of
nuclear NOX2 expression and its involvement in cardiomy-
ocyte apoptosis.
Keywords: apoptosis; free radicals; ischemia; NADPH oxidase.
Introduction
Redox-based signaling has emerged in recent years as
an important and often essential part of most signal
transduction pathways. Disturbances of redox homeostasis,
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therefore, have been implicated in a multitude of disease
states.
A major advance in the elucidation of redox-based sig-
naling has been the recent discovery of a group of NADPH
oxidases as a principal source of signaling-related reactive
oxygen species (ROS).1 Described in almost all tissues since
their initial discovery, these highly homologous transmem-
brane proteins utilize NADPH to generate superoxide. Su-
peroxide, in turn, can give rise to most other ROS. While
these basic mechanisms now are quite well understood, the
regulation of the NADPH oxidases in different tissues and
their downstream signaling targets remain, for a large part,
unknown.
In cardiovascular pathology, ROS are well-recognized me-
diators of, for instance, atherosclerosis and hypertension.2
Consequently, several NADPH oxidases have been charac-
terized in the vasculature.3 In the heart itself, NADPH
oxidases have been implicated in hypertrophy or cardiac
failure. So far, NOX24,5 and NOX46 have been described
in human heart tissue and in non-human cardiomyocytes.
In human cardiomyocytes our group has recently been able
to demonstrate the presence of NOX2, and its upregula-
tion in patients with acute myocardial infarction (AMI).4
However, the functional significance of this upregulation
remained to be established. NOX2 has been described to
participate both in the regulation of proliferation7–9 and
of apoptosis10–12 in different cell types. However, the exact
role of the NADPH oxidases in the context of the pertain-
ing signal-transduction pathways seems to be isotype and
tissue dependent and remains largely unknown. Since both
ischemia- and reperfusion-induced apoptosis and compen-
sative proliferation/hypertrophy are processes that determine
the final extent of the tissue damage of an acute myocar-
dial infarction, we sought to determine which role NOX2
plays in cardiomyocytes that have been exposed to ischemia/
reperfusion.
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We now present evidence that nuclear upregulation of
NOX2 in cardiomyocytes is an important step in the induc-
tion of apoptosis in these cells.
Materials and methods
Cell culture
H9c2 cells were obtained from the American Type Cul-
ture Collection ((ATCC), Manassas, VA, USA) and cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM; Cam-
brex Corporation, East Rutherford, NJ, USA) containing
10% (v/v) heat inactivated fetal calf serum (FCS; Cam-
brex Corporation), 100 IU penicillin per ml (Yamanouchi,
Tokyo, Japan), 100 µg streptomycin per ml (Radiopharma-
Fisiopharma, Palomonte, Italy) and 2 mM L-glutamine (In-
vitrogen Corporation, Carlsbad, CA, USA), under 5% CO2
at 37◦C.
Isolation of adult rat cardiomyocytes
Animals were treated according to the national guidelines
and with permission of the Animal Experimental Committee
of the VU University of Amsterdam.
Wistar rats were heparinized by administering 10,000 U
heparin/kg body weight i.p. After deep anesthesia with
halothane, the heart was excised and perfused retrogradely
(Langendorff) at 37◦C for 2 min with Tyrode buffer (con-
taining 120 mM NaCl, 27 mM NaHCO3, 5.0 mM KCl,
2.0 mM NaH2PO4, 1.2 mM MgSO4, 10 mM glucose,
5 mM creatine, 5 mM taurine; gassed with 95% O2-5%
CO2) supplemented with 1 mM Ca2+, followed by perfu-
sion for 2 min with Tyrode buffer supplemented with 10 µM
Ca2+. Next, the heart was perfused with recirculating Ty-
rode buffer supplemented with 10 µM Ca2+, 150 U/ml
collagenase (Class II, Worthington Biochem. Corp.) and
0.5 mg/ml hyaluronidase (Sigma-Aldrich, St. Louis, MO,
USA) at a flow rate of 10 ml/min. After 20 min of per-
fusion, the heart was removed from the perfusion system,
the atria and large vessels were removed and the ventricu-
lar tissue was minced with scissors. Tissue fragments were
incubated with HEPES buffer (containing 116 mM NaCl,
20 mM HEPES, 5.3 mM KCl, 1.13 mM NaH2PO4, 1.2 mM
MgSO4, 10 mM glucose, 5 mM creatine, 5 mM taurine,
100 U/ml penicillin/streptomycin, 0.2% (w/v) fatty-acid-
free BSA and 10 µM Ca2+; pH 7.35) containing 150 U/ml
collagenase and 0.5 mg/ml hyaluronidase during 8 min in a
shaking water bath at 37◦C. Dissociated cells were removed
and the remaining tissue was incubated for another 8 min.
The obtained cell suspension was mixed 1:1 with HEPES
buffer supplemented with 0.4 mM Ca2+, passed through a
200-µm mesh nylon gauze and centrifuged for 1 min at 43 g.
The cells were suspended in 35 ml of a HEPES-buffer/M199
mixture containing 0.4 mM Ca2+ and were allowed to sedi-
ment (in a 50-ml test tube) during 10 min at room temper-
ature. This process was repeated with HEPES/M199 mix-
tures of 0.8 and 1.2 mM Ca2+, respectively. Finally, the
cells were resuspended in M199 (supplemented with 5 mM
creatine, 5 mM taurine, 100 U/ml penicillin/streptomycin
and 0.2% (w/v) fatty-acid-free BSA), seeded onto laminin-
coated Lab Tek II chamber slides (Nalge Nunc International,
Rochester, NY, USA) and allowed to adhere to the substra-
tum for 1–2 h. Medium was then changed to M199 supple-
mented with 5 mM creatine, 5 mM taurine, 100 U/ml peni-
cillin/streptomycin, 0.2% (w/v) fatty-acid-free BSA, 100 nM
insulin, 0,1 nM L-triiodothyronine and 2 mM carnitine.
Isolation of rat leukocytes
Rat leukocytes were isolated from 10 ml of EDTA-
anticoagulated blood by centrifugation at 1000 × g for
10 min, resuspension of the supernatant in 10 ml of
phosphate-buffered saline and renewed centrifugation at
1000 × g for 10 min. The resulting cell pellet was confirmed
by microscopic inspection to be highly enriched (>95%) in
leukocytes.
Isolation of mRNA, reverse transcription, PCR
and cycle sequencing
Total RNA from H9c2 cells and rat leukocytes was isolated
with the RNeasy Fibrous Tissue Kit (QIAGEN) and RNA-
Bee (Tel-Test, Inc., Friendswood, TX, USA), respectively,
and cDNA was synthesized. The coding region of CYBB was
then amplified by PCR in five overlapping fragments on the
Rapid Cycler (Idaho Technology, Idaho Falls, ID, USA) with
50 cycles at 95◦C for 10 s, 60◦C for 30 s and 72◦C for 50 s
and slope S9. The following primer combinations were used:
5′-ATGGGGAACTGGGCTGTGAATGAGG-3′ and 5′-A
TGGTGTGAATGGCCGTGTGAAGTG-3′; 5′-TTCACA
CGGCCATTCACACCATTGC-3′ and 5′-GTCCACGTAC
AATTCGCTCAGCTCC-3′; 5′-GGAGCTGAGCGAATT
GTACGTGGAC-3′ and 5′-GGTGCCACTCTAGCTTG
GATACCTG-3′; 5′-AGGTATCCAAGCTAGAGTGGCAC
CC-3′ and 5′-AACCACTCAAAAGCATGCGTGTCCC-
3′; 5′-GACACGCATGCTTTTGAGTGGTTCG-3′ and 5′-
TGTTGAAGATGAAGTGGACTCCACG-3′. The reaction
volume of 15 µl contained 2 U of Taq DNA polymerase
(Promega, Madison, WI, USA), 2 U of TaqStart antibody
(Clontech Laboratories, Palo Alto, CA, USA), 50 ng of each
primer, 3 nmol of each of the dNTP’s (Promega) and re-
action buffer (50 mM KCl, 1.5 mM MgCl2, 0.1% Triton
X-100, 10 mM Tris and 8% DMSO, pH 9 at 25◦C). The
PCR reaction took place in 10-µl glass capillaries (Idaho
Technology).
The purified templates were cycle-sequenced with the
above primers and the Big Dye Terminator Cycle Sequenc-
ing Ready Reaction kit (Perkin Elmer Applied Biosystems,
Warrington, Cheshire, UK) and run on an ABI 377 XL
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Automated DNA Sequencer (Perkin Elmer Applied Biosys-
tems). Sequence analysis was performed by means of the
Sequence Analysis, Sequence Navigator and Auto Assem-
bler software (all Perkin Elmer Applied Biosystems).
Metabolic inhibition
We used metabolic inhibition as an experimental in-vitro
model system for ischemia as described elsewhere.13 Briefly,
cells were exposed to metabolic-inhibition buffer (5 mM
NaCN, 20 mM 2-deoxyglucose, 0.9 mM CaCl2, 106 mM
NaCl, 38 mM NaHCO3, 4.4 mM KCl and 1 mM MgCl2,
pH 6.6) for 1 h (adult rat cardiomyocytes) or 2 h (H9c2
cells) under 5% CO2 at 37◦C. When analysing the effects
of inhibitors, the cells were preincubated for 1 h with acti-
nomycin D and/or cycloheximide (both 10 µM final con-
centration), diphenylene iodonium (DPI; 10 µM final con-
centration 14) or apocynin (100 µM final concentration 15)
prior to metabolic inhibition.
Western blotting
H9c2 cells were harvested into modified Laemmli sample
buffer (0.33 M Tris-HCl (pH 6.8), 30% (v/v) glycerol, 3.3%
(v/v) 2-mercaptoethanol) mixed rigorously and incubated
for 30 min on ice. After determination of the protein con-
centration of the samples with the Bio-Rad Protein As-
say (Bio-Rad, Hercules, CA, USA), 0.4 volumes of 10%
sodium dodecyl sulfate (SDS) with bromophenol blue were
added and the samples were mixed and heated at 95◦C for
10 min. The samples were then subjected to SDS-PAGE,
transferred to nitrocellulose membranes and immunoblot-
ted for NOX2 expression with monoclonal antibody 48
(Ref. 16 1:250 dilution) and subsequently with horseradish-
peroxidase-conjugated rabbit-anti-mouse immunoglobulins
(RaM-HRP; 1:1000 dilution; DakoCytomation, Glostrup,
Denmark). The blots were visualized by enhanced chemi-
luminescence (ECL; Amersham Biosciences AB; Uppsala;
Sweden).
Immunocytochemistry
Two days before metabolic inhibition, H9c2 cells were pas-
saged onto sterile Lab-Tek II chamber CC2 glass slides
(Nalge Nunc International, Naperville, IL, USA) to reach
about 80–90% confluency at the day of the experiment.
After treatment, the cells were washed, paraformalde-
hyde fixed, permeabilized with ice-cold acetone/methanol
(70/30% (v/v)) and, subsequently, incubated with the pri-
mary antibody. Primary antibodies were monoclonal an-
tibody 48 (used at a dilution of 1:50), anti-nitrotyrosine
antibody (Molecular Probes, Eugene, OR, USA; used at a
dilution of 1:50) and anti-active caspase-3 pAb (Promega;
used at a dilution of 1:100). The corresponding isotype con-
trols were purified mouse myeloma protein IgG1 MOPC21
(MP Biomedicals, Irvine, CA, USA) and polyclonal rabbit
anti-human calcitonin (DakoCytomation), used at the same
concentrations as the corresponding primary antibodies.
The cells were then incubated with Alexa-Fluor-568-labeled
goat-anti-mouse-IgG1 antibodies (Molecular Probes; used at
a dilution of 1:75) and FITC-conjugated polyclonal swine
F(ab′)2 anti-rabbit immunoglobulins (DakoCytomation;
used at a dilution of 1:10). Finally, nuclei were stained with
4′,6 diamidino-2-phenylindole (DAPI)-containing mount-
ing medium (H1200, Vectashield; Vector Laboratories,
Burlingame, CA, USA).
Sections were qualitatively analyzed by use of a 3I
MarianasTM digital imaging microscopy workstation (Zeiss
Axiovert 200 M inverted microscope; Carl Zeiss, Sliedrecht,
The Netherlands), equipped with a nanostepper motor (Z-
axis increaments: 10 nm) and a cooled CCD camera (Cooke
Sensicam, 1280 × 1024 pixels; Cooke Co., Tonawanda, NY,
USA). The motorized filter turret allowed acquisition of one
composite image of up to 4 different fluorescent wavelengths
as well as a brightfield image (several options). Exposures,
objective, montage, and pixel binning were automatically
recorded with each image and stored in memory (Dell Di-
mension workstation: 1.7 GHz Xenon dual processor, 2 GB
RAM). The microscope, camera and data viewing process
were controlled by SlideBookTM software (version 4.0.8.1;
Intelligent Imaging Innovations, Denver, CO, USA).
Caspase 3 activity assay
Caspase 3 activity was measured with a fluorometric ho-
mogeneous caspase assay from Roche (Basel, Switzerland)
according to the manufacturer’s recommendations. Briefly,
cells were lysed and incubated with DEVD-rhodamine-110
substrate for one hour at 37◦C. Subsequently the amount
of free rhodamine was determined fluorimetrically in a
microplate fluorescence reader (SPECTRAFluor, TECAN,
Durham, NC, USA). The developed fluorochrome was pro-
portional to the concentration of activated caspase and was
quantified by a calibration curve of diluted free rhodamine.
Caspase activation measurements were done in triplicate.
Statistics were performed with the SPSS statistics program
(Windows version 9.0). To evaluate whether observed dif-
ferences were significant, a one-way ANOVA analysis was
performed with Bonferroni’s multiple comparison test. A
p-value (two-sided) of less than 0.05 was considered to rep-
resent a significant difference.
TUNEL analysis
TUNEL analysis was performed with the APO-BrdUTM
TUNEL Assay Kit (Invitrogen) according to the manufac-
turer’s instructions. Briefly, ∼2 × 106 cells/ml in 0.5 ml
PBS were fixed in 5 ml 1% (w/v) paraformaldehyde for
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Figure 1. PCR amplification of NOX2-specific sequences from rat-
granulocyte- and H9c2-derived cDNA: Rat granulocyte- and H9c2-
derived cDNA was amplified as described under “Materials and
methods”. Shown are two PCR products for rat-leukocyte- and H9c2-
derived cDNA, representing the sequence of bp 992-1361 of the
NOX2 coding region for Rattus norvegicus (Genebank accession
code: AF298656).
15 min on ice and permeabilized with 70% ethanol for at
least 24 h at –20◦C. After washing of the permeabilized
cells, they were resuspended in 50 µl DNA-labeling so-
lution and incubated for 60 min at 37◦C. Subsequently
the samples were rinsed repeatedly, resuspended in 100 µl
antibody-staining solution and incubated for 30 min at room
temperature in the dark. For quantification of the viable and
apoptotic cell populations 105 cells were measured on a
FACS Calibur (BD Biosciences, San Jose, CA, USA). The
analysis of the results was performed with CellQuest Pro
software (BD Biosciences).
Positive and negative cells provided by the manufacturer
were used as positive and negative controls, respectively.
To evaluate whether observed differences were significant,
a one-way ANOVA analysis was performed with Bonferroni’s
multiple comparison test. A p-value (two-sided) of less than
0.05 was considered to represent a significant difference.
Results
NOX2 is expressed in H9c2 cells at the mRNA level
Although we have previously identified NOX2 in human
cardiomyocytes4 and although NOX2-mRNA expression
in adult rat ventricular myocytes has been described,17 we
first determined the presence of NOX2 in H9c2 cells. For
this purpose we amplified by RT-PCR about eighty percent
of the coding region of the NOX2 transcript from H9c2-
derived mRNA (Figure 1). Rat leukocyte mRNA was taken
along as positive control. The sequence of the PCR products,
as shown by cycle sequencing, was identical to the NOX2
sequence for Rattus norvegicus as deposited in Genebank (Ac-
cession code: AF298656).
NOX2 expression in H9c2 cells is upregulated
under metabolic inhibition
In a previous study we found upregulation of NOX2 in the
infarcted human heart.4 To investigate whether this upreg-
ulation resulted from ischemia, we analysed in vitro puta-
tive NOX2 expression by Western-blot analysis of H9c2
cells incubated with metabolic-inhibition buffer. We found
that NOX2 is constitutively present in H9c2 cells and is
clearly upregulated under metabolic inhibition, with maxi-
Figure 2. Western blot analysis of NOX2 expression under
metabolic inhibition: (A) Time course of NOX2 expression under
metabolic inhibition. H9c2 cells were treated with metabolic inhibition
buffer for the indicated periods. 8 µg of protein were added per lane.
(B) Effects of the DNA transcription inhibitor cycloheximide (10 µM)
and the RNA translation inhibitor actinomycin D (10 µM) on NOX2
expression after 2 h of metabolic inhibition. The blots and histograms
shown are representative of three experiments. They were analysed
with the “Advanced Image Data Analyzer” software, version 3.28.001
(raytest GmbH, Straubenhardt, Germany). The resulting histograms
represent the signal intensities of the relevant bands relative to that
of the controls ( = 1).
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sFigure 3. Digital-imaging microscopy of H9c2 cells: Fixed H9c2 cells were stained with antibodies against NOX2 (red) and nitrotyrosine
or active caspase 3 (green). DNA staining by DAPI is shown in blue (magnification 10 × ). (I) H9c2 cells at normoxia: (a) (weak) nuclear
expression of NOX2 is shown in pink; (b) (weak) nuclear presence of nitrotyrosine residues is shown in turquoise; (c: merge of a and b): (weak)
nuclear colocalization of NOX2 expression and nitrotyrosine residues is shown by a whitish staining. (II) H9c2 cells after 2 h of metabolic
inhibition: (a) nuclear expression of NOX2 is shown in pink; (b) nuclear presence of nitrotyrosine residues is shown in turquoise; (c: merge
of a and b): nuclear colocalization of NOX2 expression and nitrotyrosine residues is shown by a white staining. (III) H9c2 cells, exposed to
the flavoprotein inhibitor DPI, after 2 h of metabolic inhibition: (a) (uninhibited) nuclear expression of NOX2 is shown in pink; (b) inhibition of
nuclear generation of ROS by DPI is shown by absence of turquoise staining; (c: merge of a and b): only nuclear NOX2 expression is seen in
pink. (IV) H9c2 cells after 2 h of metabolic inhibition: (a) nuclear expression of NOX2 is shown in pink; (b) nuclear activation of caspase 3 is
shown in turquoise; (c: merge of a and b): (nuclear) colocalization of NOX2 expression and caspase-3 activation is shown by a white staining.
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Figure 4. Analysis by TUNEL of the effect of DPI and apocynin on
apoptosis of H9c2 cells induced by metabolic inhibition: The effect
of DPI (10 µM final concentration) or apocynin (100 µM final con-
centration) was analysed under control as well as under ischemic
(2 h of metabolic inhibition) conditions. Shown are the percentages
of apoptotic cells as assessed by TUNEL. Data represent mean and
standard error of mean. ∗p < 0.001, †p < 0.05, ‡p < 0.001, §p <
0.01.
mal NOX2 expression seen after 2 h (Figure 2A). To prove
putative local production within cardiomyocytes, inhibition
of transcription and/or translation was analysed by addition
of actinomycin D and/or cycloheximide, respectively. Both
inhibitors led to a clear inhibition of the increased NOX2
expression seen after 2 h of metabolic inhibition (Figure 2B),
indicating local synthesis of NOX2 under ischemic condi-
tions.
Figure 5. Effect of DPI on apoptosis induced by metabolic inhibi-
tion in H9c2 cells as assessed by measurement of caspase-3 activity:
Using fluorogenic DEVD-rhodamine-110 as substrate for the active
form of caspase 3, activation of the caspase under metabolic inhi-
bition and the inhibitory effect of 10 µM DPI were analysed. Data
represent mean and standard error of three experiments. Shown are
the differences in percent with the control; the average of the control
values was taken as 100% value and set at zero. ∗p < 0.001, †p <
0.001, ‡p < 0.01
Nuclear NOX2 upregulation is pronounced in
apoptotic H9c2 cells and colocalizes with
nitrotyrosine residues
To analyze the intracellular localization of NOX2, digital-
imaging microscopy was used. In control H9c2 cells a diffuse
cytosolic as well as some nuclear expression of NOX2 was
visible (Figure 3-I). Upon metabolic inhibition both cytoso-
lic and nuclear expression increased. The increase in nuclear
NOX2 expression seemed to be especially pronounced in
condensed, presumably apoptotic nuclei (Figure 3-IIa).
To analyze a possible relationship between NOX2 expres-
sion and apoptosis, we also analysed caspase-3 activation, a
marker of apoptosis, in H9c2 cells. Under metabolic inhi-
bition a clear increase in caspase 3-positive nuclei was seen
(Figure 3-IVb). This upregulation of caspase 3 in the ma-
jority of nuclei coincided with nuclear NOX2 expression
(Figure 3-IVc).
To determine whether NOX2 expression was associated
with functional oxidase activity, we probed the fixed H9c2
cells with an antiserum specific for nitrotyrosine residues.
3-Nitrotyrosine is formed when tyrosine residues are mod-
ified by peroxynitrite, the reaction product of nitric ox-
ide and superoxide.18 As can be seen in Figure 3-IIc, in
the majority of cells nitrotyrosine colocalized with NOX2
expression in the nucleus. No nitrotyrosine formation, in-
dicative of reactive-oxygen-species (ROS) production, was
observed in the cytosol (Figure 3-IIb). This suggested that
ROS production due to NOX2 activation was limited to
nuclei.
To assess whether the observed nuclear ROS was, indeed,
generated by NOX2, we tested the effect of the flavoenzyme
inhibitor DPI on the increase in nitrotyrosine formation. As
would be expected for NOX-dependent ROS generation, the
addition of 10 µM DPI had no effect on NOX2 expression
(Figure 3-IIIa) but led to a clear reduction of the metabol-
ically induced increase in nuclear nitrotyrosine formation
(Figure 3-IIIb).
To investigate the relationship between NOX2-generated
ROS and the putative activation of apoptosis, we analyzed
by TUNEL the effect of the NADPH-oxidase inhibitors
DPI and apocynin on apoptosis induced in H9c2 cells by
metabolic inhibition (ischemia). As shown in Figure 4, is-
chemia induced a significant increase in the percentage of
apoptotic cells (p < 0.001). Apocynin and DPI both signif-
icantly reduced apoptosis induced by metabolic inhibition
(p < 0.001 for apocynin and p < 0.01 for DPI). How-
ever, while apocynin reduced apoptosis to a level not sig-
nificantly different from control cells, DPI reduced apop-
tosis only to a level that still was significantly higher
than that in control cells (p < 0.05). Under normal cell-
culture conditions no effect on apoptosis was seen with both
inhibitors.
To confirm these results with a second, principally
different method, we also analyzed the effect of DPI
on caspase-3 activity in a fluorometric caspase assay
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Figure 6. Nuclear colocalization of NOX2 expression and nitrotyrosine residues in adult rat cardiomyocytes under ischemic conditions:
Isolated adult ventricular rat cardiomyocytes were subjected to 1 h of metabolic inhibition and then fixed and stained with antibodies against
NOX2 (red; a) and nitrotyrosine (green; b). DNA was stained blue by DAPI (magnification 63x). Picture a shows a vesicular or granular staining
pattern for NOX2 that is especially pronounced in the nucleus. While there is a diffuse background signal for nitrotyrosine in the cytosol (b),
only in the nucleus a granular staining pattern comparable to that of NOX2 is visible. The merged image (c) confirms the nuclear colocalization
of NOX2 and nitrotyrosine residues, which are indicative of ROS production (white signal). N = nucleus.
(Figure 5). Metabolic inhibition of H9c2 cells induced a
significant increase in caspase-3 activity (p < 0.001) com-
pared with control cells. DPI significantly inhibited the
metabolic-inhibition-induced upregulation of caspase-3 ac-
tivity (p < 0.01), but caspase-3 activity with DPI was again
significantly higher than in control cells (p < 0.001). These
results underscore the role of NOX2-generated ROS in
the induction of apoptosis in cardiomyocytes exposed to
ischemia.
Nuclear NOX2 expression and generation
of reactive oxygen species are also found in adult
rat cardiomyocytes
H9c2 cells are a rat cardiomyoblast cell line. To exclude
the possibility that our findings represent a cell-line- or
immortalisation-specific phenomenon, we also analyzed pri-
mary adult rat cardiomyocytes for NOX2 expression and
ROS generation. In these cells, at higher magnification,
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a granular or vesicular cytosolic as well as a clear nuclear
expression of NOX2 was seen under ischemic conditions
(Figure 6a). However, while there was a diffuse background
staining for nitrotyrosine visible in the cytosol, only in the
nucleus a vesicular staining pattern was seen that was in-
dicative of localized ROS production and colocalized with
the nuclear staining pattern of NOX2 (Figure 6b). The
white signal in the merged picture (Figure 6c) confirms the
nuclear colocalization of NOX2 expression and nitrotyro-
sine residues. In summary, therefore, adult rat cardiomy-
ocytes, just like H9c2 cells, under ischemic conditions dis-
play a pattern of less intense cytosolic NOX2 expression
and of dense nuclear expression. Also, as in H9c2 cells, ROS
production—as detected by the presence of nitrotyrosine
residues—can be seen only in the nucleus, where it colocal-
izes with NOX2 expression.
Discussion
In previous work we have demonstrated the expression of
NOX2 in human cardiomyocytes after acute myocardial in-
farction (AMI)4. In this follow-up study we investigated the
functional role of NOX2 upregulation under ischemic con-
ditions. We found that NOX2 in ischemia is upregulated
mainly in the nucleus of apoptotic cells where it colocal-
izes with nitrotyrosine residues, which are indicative of the
generation of reactive oxygen species (ROS). In line with
this observation, inhibition of ROS generation with the
flavoenzyme inhibitor diphenylene iodonium (DPI) or with
the NOX2 inhibitor apocynin led to significantly decreased
apoptosis as assessed by a decrease in caspase-3 activation
and by TUNEL. To the best of our knowledge, this is the
first demonstration of nuclear NOX2 expression and its in-
volvement in cardiomyocyte apoptosis induced by ischemia.
Reactive oxygen species are well-known mediators of
apoptosis,19 and considerable evidence has accumulated in
recent years concerning their role in cardiomyocyte cell
death20 and cardiovascular pathophysiology in general.21
However, the exact sources of the ROS as well as their
downstream targets are as yet unknown. NADPH oxidases
are an important source of redox signaling-related ROS, and
cardiac expression of NOX24,5 and NOX46 has been im-
plicated in cardiac hypertrophy and chronic heart failure.
Inhibition of the angiotensin II-initiated apoptotic cascade
in rat neonatal cardiomyocytes by DPI has also suggested
the involvement of an NADPH oxidase in this process.11
However, this latter article identified neither the exact iso-
type of the NADPH oxidase involved, nor its subcellular
localization.
Our results, therefore, represent the first evidence for
NOX2 participating in cardiomyocyte apoptosis. AMI-
induced cardiomyocyte apoptosis is known to arise primarily
during the reperfusion phase following ischemia, not during
ischemia itself.22 However, while the majority of apoptotic
events indeed probably takes place during the reperfusion
phase, apoptosis has also been described to take place during
the ischemic phase itself,23 a finding that is corroborated by
the present study.
Induction of apoptosis in general follows one of two path-
ways. The first pathway, the death-receptor or extrinsic path-
way, is activated by ligand binding of cell-surface-expressed
death receptors, while the second pathway, the mitochon-
drial or intrinsic pathway, is promoted by physical or chemi-
cal stress agents.24 However, the response of cardiomyocytes
to ischemia and reperfusion is complex, and the involved
pathways have not been fully described.25 Since activation
of caspase 3 is a late event of both apoptotic cascades, our
results do not allow an assessment as to which apoptotic
pathway is affected by NOX2 activation.
The new finding of NOX2 being expressed in the nu-
cleus is remarkable but makes sense on a functional and
biophysical level. There are numerous redox-sensitive tran-
scription factors that are either activated or inactivated by
redox modifications.26 On the other hand, ROS, via the
formation of peroxynitrite, introduce DNA damage and
thereby contribute to the apoptotic cascades.11 Given the
highly reducing intracellular milieu,1 it is hard to imagine
that these processes can be effectively controlled by cytoso-
lic generation of ROS. Our results support a scenario in
which cytosolic NOX2, upon induction of apoptotic signal-
ing, translocates to the nucleus and is activated to generate
superoxide. This signaling mechanism would eliminate the
necessity of ROS diffusing from the cytosol into the nucleus.
In our previous study we have described a primarily cy-
tosolic localization of NOX2 in cardiomyocytes,4 as have
others.5 However, in the present study cytosolic expression
of NOX2 did not coincide with ROS production. Further-
more, it is known that in human tissue sections only in rare
instances apoptotic nuclei can be found in cardiomyocytes.
This phenomenon has been explained by the fact that pri-
marily apoptotic cardiomyocytes quickly become secondar-
ily necrotic due to the rapidly arising lack of ATP.22 It is
to be expected, therefore, that in human tissue sections nu-
clear NOX2 staining is visible only exceptionally, since it is
restricted to apoptotic nuclei.
Conclusion
Taken together, our results present evidence that NOX2 is
expressed in the nucleus of cardiomyocytes and is likely in-
volved in the regulation of cardiomyocyte apoptosis. Future
research needs to elucidate in more detail the participants
and mechanisms of the apoptotic signaling cascade described
here and has to investigate the possibility of an indepen-
dent functional role of cytosolic NOX2 under non-ischemic
conditions.
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Abstract  
Reperfusion of ischemic myocardium after acute 
myocardial infarction (AMI) induces a local activation 
of inflammatory reactions that results in 
ischemia/reperfusion (I/R)-injury. I/R-injury 
contributes considerably to the total cell damage in 
the heart after AMI. Secretory phospolipase A2-IIA 
(sPLA2-IIA), C-reactive protein (CRP) and complement 
are inflammatory mediators that have been 
demonstrated to play key roles in I/R injury. From 
studies by us and others a mechanism emerged in 
which sPLA2-IIA binds to reversibly damaged 
cardiomyocytes and subsequently induces cell death, 
partly by potentiating binding of CRP and subsequent 
complement activation. Next to this, sPLA2-IIA also 
has a direct toxic effect, independent of CRP or 
complement. Therefore, these studies indicate a 
crucial role of inflammatory mediators in 
ischemia/reperfusion injury. This review will focus on 
the pathogenic effects of sPLA2-IIA, CRP and 
complement and on the putative therapeutic effects of 
inhibitors of these inflammatory mediators in acute 
myocardial infarction. 
 
Introduction 
Reperfusion of ischemic myocardium after acute 
myocardial infarction (AMI) induces 
ischemia/reperfusion (I/R)-injury, which results from 
local activation of inflammatory mediators. This injury 
causes additional myocardial damage and may 
significantly contribute  to myocardial infarction size. 
Secretory phospolipase A2-IIA (sPLA2-IIA), C-reactive 
protein (CRP) and complement are inflammatory 
mediators that supposedly play key roles in this I/R 
injury.  
Activation of the complement system on the 
cardiomyocytes during I/R injury in the heart has been 
demonstrated by us and others [1]. As a matter of fact 
therapeutic application of complement inhibitors can 
significantly reduce infarction size (up to 50%) in 
animals and humans [2]. The molecular mechanisms 
explaining this complement activation are under 
discussion. Possible mechanisms include the 
involvement of the acute phase protein C-reactive 
protein (CRP). We have found in humans who had died 
from AMI, that CRP co-localizes and subsequently 
activates complement on cardiomyocytes within the 
infarcted myocardium [3,4]. Though this does not prove 
that CRP-mediated complement activation indeed 
damages the ischemic myocardium, animal experiments 
suggest that CRP may do so. In a rat model it was 
shown that administration of human CRP increases 
infarct size in a complement dependent fashion [5]. CRP 
can bind to phosphorylcholine, which amongst others is 
present in membrane phospholipids [6]. We have found 
evidence that sPLA2-IIA induces binding sites for CRP 
on cardiomyocytes [7]. This probably is related to the 
lipolytic actions of sPLA2-IIA, which generate lyso-PC 
in the cell membrane, especially in disarranged or flip-
flopped membranes of (reversibly) damaged 
cardiomyocytes. As a result of the action of sPLA2-IIA, 
phosphorylcholine groups of phosphatidyl 
phospholipids become better accessible to become able 
to bind CRP which in its turn activates complement. 
Next to this pro-inflammatory action, sPLA2-IIA also 
can induce death of ischemic challenged 
cardiomyocytes, independently of other inflammatory 
mediators [8].  
This review will focus on the pathogenic role of sPLA2-
IIA, CRP and complement in AMI, and on therapeutic 
potential of inhibitors of sPLA2-IIA, CRP and 
complement in acute myocardial infarction. 
 
The PLA2 family 
The family of phospholipases A2 (PLA2) are widely 
distributed enzymes that generate non-esterified fatty 
acids (NEFA’s) and lysophospholipids by catalyzing the 
hydrolysis of the sn-2 ester bond in the glyceroacyl 
phospholipids present in cellular membranes and 
lipoproteins [9]. In general, the PLA2 family is divided 
into three subfamilies: the 14-kDa Ca2+-dependent 
secretory phospholipase A2 (sPLA2), the 85-kDa Ca2+-
dependent cytosolic phospholipase A2 (cPLA2) [10] and 
the 85-kDa cytosolic Ca2+-independent phospholipase 
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A2 (iPLA2) [11]. The discovery of more and more PLA2 
family members initiated the categorization of these 
enzymes into groups [12,13]. To date, eleven groups of 
PLA2 enzymes (I – XI) are recognized, which groups are 
further subdivided into subgroups (A, B, C, etc.). 
Groups I, II, III, V, IX, X and XI are secreted PLA2’s 
utilizing a catalytic histidine, group IV (cPLA2) and 
group VI (iPLA2) are intracellular PLA2’s utilizing a 
catalytic serine. Groups VII and VIII (platelet activating 
factor acetylhydrolases (PAF-AH)) are secreted or 
intracellular PLA2’s, also utilizing a catalytic serine [13]. 
Three subgroups of sPLA2 in particular have been 
implicated in cardiovascular disease: sPLA2-IIA, sPLA2-
V and sPLA2-X. sPLA2-IIA was first discovered in 
synovial fluid of rheumatoid arthritis (RA) patients. 
Circulating levels of the enzyme increase following 
surgery or trauma, and in various inflammatory 
diseases. Hence, the protein should be considered as an 
acute phase protein. In addition, human sPLA2-IIA is 
thought to contribute to antibacterial host-defense 
responses and binds tightly to the anionic membranes 
of several bacteria [14]. sPLA2-V and sPLA2-X were 
recently implicated in atherosclerosis [15]. sPLA2-V is 
abundantly expressed in the human heart and is more 
widely expressed in human tissues in response to 
inflammatory stimuli [16]. sPLA2-X mRNA was 
expressed in human thymus, spleen, blood leukocytes 
[17] and in lung alveolar endothelial cells [18]. Notably, 
many studies on sPLA2 do not distinguish between the 
different subgroups of sPLA2-II or even other groups of 
secreted PLA2 and just refer to it as sPLA2 and often just 
PLA2. In this review we will use sPLA2-IIA for group 
IIA sPLA2, or the terminology used by the referred 
studies. 
 
sPLA2-IIA: substrate interaction 
sPLA2-IIA propagates inflammation by liberating 
NEFA’s, which amongst others form precursors for the 
biosynthesis of eicosanoids and platelet activating factor 
(PAF). Functional coupling of particularly two sPLA2 
isozymes (sPLA2-IIA and sPLA2-V) with 
cyclooxygenase pathways may represent a key 
mechanism in the propagation of the inflammatory 
reaction [19].  
As for substrate affinity, sPLA2-IIA displays exceptional 
attraction for anionic phospholipids and strongly favors 
phosphatidic acid (PA) as substrate over other 
mammalian plasma membrane phospholipids, 
including phosphatidylethanolamine (PE), 
phosphatidylserine (PS), and phosphatidylcholine (PC). 
The order of preference is PA >> PE / PS > PC [20], 
which presumably reflects electrostatic interactions 
between the cationic amino acids of the enzyme and the 
head groups of the phospholipids [21,22,20]. 
The various phospholipids are asymmetrically 
distributed among the inner and outer leaflet of plasma 
membranes in most if not all eukaryotic cells under 
normal conditions. The outer leaflet predominantly 
contains hydrophobic phospholipids such as PC, 
whereas anionic phospholipids such as PS and, to a 
lesser extent, PE are actively kept within the inner 
leaflet. As mentioned earlier, sPLA2-IIA shows only low 
affinity for PC. This might be due to the hydrophobic 
nature of PC, which tightly packs the phospholipids in 
the outer leaflet. Under some conditions however, in a 
process called membrane flip-flop, the anionic 
phospholipids translocate from inner to outer leaflet. In 
this way anionic phospholipids become available as 
substrates in the outer leaflet (Figure 1). sPLA2-IIA has 
been shown to have high affinity for flip-flopped 
membranes [23]. Furthermore, the insertion of anionic 
phospholipids into the tightly packed hydrophobic 
phospholipid layer will loosen the mutual interactions 
between PC’s, making PC available for hydrolysis by 
sPLA2-IIA [23].  
Not only NEFA’s, as precursors for eicosanoids and 
PAF, but also the lysophospholipids are important for 
propagation of inflammation. For instance, lyso-PA can 
stimulate platelet aggregation, cell proliferation and 
SMC contraction [20].  
 
sPLA2-IIA: the acute phase protein 
During inflammatory diseases like RA, septic shock and 
infections, plasma levels of sPLA2-IIA may increase 
more than 100-fold. sPLA2-IIA plasma levels may also 
increase as a result of cardiovascular events such as 
atherosclerosis and AMI [7]. This implies that the 
protein should be regarded as an acute phase protein 
[19].  
Acute phase proteins are generally considered to 
represent a group of proteins in the blood of which the 
concentration changes in response to external or 
internal challenges, such as inflammation, infection, 
stress or surgical trauma [24]. The acute phase proteins 
are regarded as non-specific innate immune 
components involved in the restoration of homeostasis. 
Concentrations of circulating acute phase proteins are 
associated with the severity of the disorder and the 
extent of tissue damage, in part because their synthesis 
is stimulated by several cytokines generated in the 
jeopardized organ in response to the tissue damage [24]. 
sPLA2-IIA is constitutively expressed in organs dealing 
with inflammatory responses, such as spleen, thymus, 
intestine and liver. In addition, many different cell 
types, such as endothelial cells, platelets, smooth muscle 
cells, mast cells, neutrophils, macrophages and 
hepatocytes, are able to express sPLA2-IIA. Expression 
and subsequent secretion of sPLA2-IIA by such cells 
during acute phase responses may also contribute to 
elevated circulating sPLA2-IIA levels. 
 
sPLA2-IIA in acute myocardial infarction 
Over the years it has become increasingly clear that 
inflammation in the reperfused myocardium, a process 
called ischemia-reperfusion (I/R-)injury, contributes 
considerably to the extent of myocardial damage 
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following AMI. We have previously suggested a role for 
sPLA2-IIA in reperfusion injury, since we found sPLA2-
IIA to be deposited on cardiomyocytes in the infarcted 
human myocardium [7]. 
sPLA2-IIA
CRP
C
CRP
C
sPLA2-IIA
The deposited sPLA2-IIA in the infarcted human 
myocardium may originate from the blood, or may be 
produced locally by cardiomyocytes. Indeed, sPLA2-IIA 
mRNA was found in ventricular myocytes from the rat 
heart and in isolated neonatal rat cardiomyocytes, but 
not in cardiac endothelial cells [25,26]. However, since 
sPLA2-IIA depositions in the heart occur at a time point 
that plasma levels of this enzyme are rising as a result of 
the ensuing acute phase response [7], and considering 
the ischemic conditions of cardiomyocytes within the 
infarcted myocardium, it is more likely that the bulk of 
the sPLA2-IIA that is deposited in the infarcted human 
myocardium, originates from the blood. 
Within the macroscopical infarction area (specified by 
loss of lactate dehydrogenase activity) (Figure 1A) 
sPLA2-IIA was microscopically found to be deposited 
on necrotic cardiomyocytes. However, sPLA2-IIA also 
stained morphologically viable cardiomyocytes in the 
border zone of the infarcted area. [7] (Figure 1B) sPLA2-
IIA staining was not found outside of this 
macroscopical infarction area. This suggests that 
binding of sPLA2-IIA to cardiomyocytes may be among 
the first events during ischemia/reperfusion.     
In an in vitro model of AMI we found that sPLA2-IIA 
only bound to flip-flopped (annexin V positive) 
neonatal cardiomyoblasts (H9c2) and adult 
cardiomyocytes of the rabbit, but not to normal 
membranes of cardiomyocytes [8]. In this way, via its 
unique binding characteristics, sPLA2-IIA is able to 
discriminate between normal and jeopardized cells, and 
may direct the inflammatory response to the latter cells 
and not to normal cells.  
Interestingly, there is accumulating evidence that loss of 
membrane asymmetry resulting in annexin V positivity, 
is to a certain level reversible [27,28,29,30,31]. Indeed, 
we also found evidence for a reversible membrane flip-
flop in ischemically challenged cardiomyocytes, i.e. 
annexin V-positive cells that were negative for caspase 3 
or propidium iodide. Interestingly, sPLA2-IIA bound to 
these cells and induced additional cell death compared 
to cells deprived of sPLA2-IIA. This implicates that at 
least part of the annexin V-positive cells were not dead 
or dying, but were reversibly damaged [8]. These data 
thus suggest that sPLA2-IIA is cytotoxic and can induce 
cell death in human cardiomyocytes upon myocardial 
infarction. This further suggests that the border zone of 
infarctions is an area ‘at risk’ and that sPLA2-IIA 
depositions found in this area initiate expansion and 
deterioration of the border zone, resulting in an increase 
of the infarcted area. In addition, sPLA2-IIA is acting 
pro-inflammatory, for instance via potentiating the 
binding of other inflammatory mediators (CRP, 
complement) to ischemic jeopardized cardiomyocytes 
[8]. 
Notably, from a study in Langendorf perfused isolated 
mouse hearts it was concluded that sPLA2-IIA does not 
significantly contribute to the development of 
irreversible damage in ischemia/reperfused 
myocardium [32]. However, in this study the role of 
endogenous sPLA2-IIA was investigated, but not the 
effect of exogenous acute phase protein levels of sPLA2-
IIA.  
Polymorphonuclear neutrophils (PMN) also play an 
important role in post-AMI inflammation [33] and 
assessment of the role of sPLA2-IIA in the functioning of 
PMN is therefore important. sPLA2-IIA seems to be 
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Figure 1: Binding of sPLA2‐IIA, CRP and complement to 
cardiomyocytes after AMI. 
A:  The macroscopic  infarction    area  (I)  is  determined  by 
LDH  decoloration.  B:  within  the  macroscopic  infarction 
there are microscopically areas of necrotic cardiomyocytes 
(I)  that  bind  sPLA2‐IIA,  CRP  and  complement  (Comp.). 
Next  to  this, necrotic areas,  the border zones  (BZ)  can be 
found,  consisting  of  probably  reversibly  damaged 
cardiomyocytes  that  bind  sPLA2‐IIA,  but  not  CRP  or 
complement.  
C:  Ischemia  induces  loss  of  plasma  membrane  stability 
resulting  in  flip‐flop  of  the  cardiomyocyte  plasma 
membrane, resulting in translocation of phospatydylserine 
/  ‐ethanolamine  (black)  to  the  outer  layer.  sPLA2‐IIA  can 
bind to flip‐flopped plasma membranes of both reversibly 
(border  zone)  and  irreversibly  damaged  cardiomyocytes. 
CRP  and  complement  can  only  bind  to  membrane 
phospholipids  (probably  phosphatydylcholine)  that  are 
modified  (grey)  by  for  instance  sPLA2‐IIA.  In  this  way, 
sPLA2‐IIA  might  induce  the  transition  of  reversibly 
damaged  cardiomyocytes  into  irreversibly  damaged 
cardiomyocytes  that  then  also  can  bind  CRP  and 
complement.  
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involved in AA release and lipid mediator formation 
[34], degranulation [35,36] and the production of 
reactive oxygen species (ROS) [37,38] in PMN in vitro. 
Although, in another study it was found that the ROS 
production did not involve sPLA2-IIA activity [36]. All 
in all, these findings point to a regulatory role for 
sPLA2-IIA in PMN function.  
Based on our studies and on data published in the 
literature, we postulate that sPLA2-IIA in humans 
contributes significantly to I/R-damage of 
cardiomyocytes in the infarcted heart.  
Inhibition of sPLA2-IIA  
Different inhibitors 
A lot of effort has been invested into the search for 
chemical inhibitors of sPLA2-IIA activity and over the 
years numerous inhibitors have been described [39,40]. 
However, although many of these compounds yielded 
promising results in vitro, only part of them have been 
tested in in vivo models of inflammation until now 
(Table 1). Regrettably, no specific inhibitors of sPLA2-
IIA have yet been tested in in vivo models of AMI.  
 
Disease Human/Animal Inhibitor Ref Type of inhibitor 
Acute lung injury Rabbit  S-5920/LY315920 [119] Synthetic compound 
Acute pancreatitis Rat  S-5920/LY315920 [120] Synthetic compound 
Acute respiratory 
distress syndrome 
Guinea pig 
Mouse  LY311727 [121,122] Synthetic compound 
 Rat D-tyrosine derivatives [123] Synthetic compounds 
Arthritis Rat Cacospongionolide B [124,125] Natural product 
 Rabbit Manolide [126] Natural product 
Colitis Rat  S-5920/LY315920 [127] Synthetic compound 
Crohn’s disease Human  Anti-TNF chimeric mAb [128] Antibody 
Rat Alminoprofen [129] NSAIDs 
Rat Antisense oligonucleotides [130] Antisense 
Mouse Aristolochic acid [131] Natural product 
Mouse 
BMS-181162 analogues: 
  3,4-C(CH3)2CH2CH2(CH3)2C- 
  3,4-bis(n-C5H11O-) 
  4-(n-C10H21O-) 
[132] Synthetic compounds 
Mouse Cacospongionolide B [124,125] Natural product 
Mouse Farnesyl manoalide analogue [124] Natural products and derivatives 
Mouse 
Flavonoids: 
  Quercetagetin 
  Kaempferol-3-O-galactoside 
  Scutellarein 
  Scutellarein-7-O-glucuronide 
  Hispidulin 
  Hibifolin 
[133] Natural products and derivatives 
Mouse Morelloflavone [134] Natural product 
Mouse Petrosaspongiolide M  [135] Natural product 
Mouse 
2-polyprenyl-1,4-
hydroquinone derevatives IS1, 
IS2, IS3 
[136] Natural product derivatives 
Mouse P-PB.IIAI [137] Antiflammin 
Mouse 
Scalaradial, Ellagic acid, 
Luffariellolide, Aristolochic 
acid 
[138] Natural products 
 
Mouse 
 
Sesquiterpenoid derivative 
  Avarol [139] Natural product derivative 
Rat 4-tetradecyloxbenzamidine [140] Synthetic compound 
Mouse Variabilin [141] Natural product  
Mouse YM-26567-1 [142] Synthetic compound 
Paw oedema, Ear 
oedema 
Rat YM-26734 [143] Synthetic compound 
Human  S-5920/LY315920 [144] Synthetic compound 
Sepsis 
Mouse SB 203347 [145] Synthetic compound 
Skin inflammation Mouse BMS-181162 [146,147] Synthetic compound 
Table 1 
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The pros and cons of putative sPLA2-IIA 
inhibition in AMI 
Regarding the pathophysiological roles of sPLA2-IIA in 
AMI presented in this review, inhibition of sPLA2-IIA 
would be expected to have beneficial effects for patients 
suffering from this disease. Inhibition of sPLA2-IIA 
activity will diminish the destruction of cardiomyocytes 
in the reperfused myocardium, either through 
inhibition of cytotoxic effects of sPLA2-IIA itself or 
through inhibition of a subsequent induced pro-
inflammatory response like CRP-complement induced 
cell death [7,8,4]. Inhibition of sPLA2-IIA activity thus 
might inhibit expansion and deterioration of the border 
zone, which will limit ultimate infarction size. Therefore 
in patients that suffer from AMI, sPLA2-IIA inhibition 
might improve prognosis.  
Because of the widespread expression and actions of 
sPLA2-IIA, the outcome of its inhibition may not always 
be straightforward, as is the case for instance in blood 
coagulation. A thrombus can develop on the damaged 
endothelium of atherosclerotic lesions. These thrombi 
constitute the pathological substrate of atherosclerotic 
complications such as AMI. There is controversy 
regarding the role of sPLA2-IIA in thrombus formation. 
sPLA2-IIA was shown, independent of its lipolytic 
action, to inhibit blood coagulation by inhibiting the 
prothrombinase complex [41,42,43], or by generating 
lyso-PC [44]. In this view, therapeutic inhibition of 
sPLA2-IIA therefore should be complemented with 
anticoagulants such as heparin, the administration of 
which in fact is already common practice in AMI 
patients. In another study however, sPLA2 activity was 
found to be insufficient for inhibition of coagulation in 
vivo [45]. In contrast, human sPLA2-IIA was also found 
to be an activator of human platelets which adds to a 
pro-thrombotic profile of the enzyme [46]. 
In the reperfused myocardium after AMI, inflammatory 
reactions unequivocally contribute to the damage in the 
infarcted heart in many animal models, and likely also 
in humans. On the other hand, inflammatory reactions 
are necessary for the clearance of cellular debris, and in 
this way are essential for remodeling of the infarcted 
area in the heart. So whenever inhibition of 
inflammation is considered in the heart after AMI, it is 
imperative to balance the inhibition of infarct area 
expansion against allowing clearance of necrotic tissue. 
However, we believe that selective inhibition of sPLA2-
IIA would not necessarily inhibit remodeling, as other 
mediators still can have their effect on the necrotic 
cardiomyocytes.  
PMN play an important role in post-infarct 
inflammation and clearance, and sPLA2-IIA seems to be 
involved in the functioning of PMN. Inhibition of 
sPLA2-IIA may therefore partly impair PMN 
functioning, suggesting that PMN inhibition (through 
sPLA2-IIA inhibition) could have a negative effect on 
the clearance of the necrotic myocardium. In the 
infarcted myocardium however, other mechanisms are 
involved in the clearance that may not be affected by 
sPLA2-IIA inhibition. In addition, we have previously 
shown that PMN may contribute to infarct size in 
humans [33]. On a positive note therefore, impaired 
PMN function would certainly reduce aspecific damage 
to viable cardiomyocytes and would consequently lead 
to a better prognosis for the patient.  
 
C-reactive protein 
C-reactive protein (CRP) is a member of the 
phylogenetically ancient and highly conserved 
pentraxin family of proteins and is, in man and some 
other animal species, a major acute-phase protein. As all 
members of the pentraxin family it is comprised of five 
identical subunits that are arranged symmetrically 
around a central pore. The five 24-kDa protomers 
consist of 206 amino acids and are noncovalently linked 
[47]. The crystal structure of CRP has been determined 
and the topology of its ligand-binding site determined 
[48,49]. In the presence of calcium it binds PC with high 
affinity, but also fibronectin, chromatin, histones and 
ribonucleoprotein [50]. The wide distribution of PC in 
polysaccharides of pathogens and in eukaryotic cell 
membranes enables CRP to target a range of pathogens 
as well as membranes of damaged and necrotic host 
cells. Indeed, CRP was discovered because of and after  
its reactivity with the PC residues of C-polysaccharide 
of Streptococcus pneumoniae [51]. 
CRP bound to a multivalent ligand in its turn binds C1q 
(Figure 2), and it appears that several CRP pentamers in 
close proximity to each other can efficiently initiate the 
formation of a C3 convertase through the classical 
pathway [52,53]. In this way CRP-initiated activation of 
the classical pathway results in fixation of opsonic 
fragments of C3 and C4 onto the surface of pathogens or 
damaged cells and triggers phagocytosis of the ligand. 
In this way CRP functions as an opsonin.  However, 
other results indicate that CRP does not favor the 
formation of a C5 convertase, and it has, therefore, 
hypothesized that CRP-initiated complement activation 
only yields moderate acute inflammatory reactions and 
limited membrane damage [47]. 
In addition to complement-dependent interactions with 
phagocytic cells CRP may also function as a ligand for 
the Fc receptors for IgG, the main receptor being FcγRIIa 
[54]. It has been speculated that the seemingly 
contradictory results on the effects of CRP on leukocytes 
might, in fact, be the consequence of differential 
expression and/or differential aggregation patterns of 
various FcRs, each FcR subtype having different 
(inhibitory or stimulatory) effects on the receptor-
expressing cell [89,81]. So has it been observed that CRP 
binding enhances phagocytosis in monocyte-derived 
cells, while on neutrophils it primarily inhibits cellular 
functions [54,56,57]. 
Thus, in summary, the main biological function of CRP 
appears to be its ability to recognize pathogens and to 
facilitate their elimination by recruiting the complement 
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system and phagocytic cells. This makes CRP, together 
with other acute-phase proteins, an important 
component of the first line of innate host defense. 
Additionally, the protein seems to play a role in the 
clearance of damaged (necrotic and/or apoptotic) host 
cells, and thus contributes to restoration of normal 
structure and function of injured tissues. 
Traditionally, CRP is mainly known as a very sensitive 
marker of severe bacterial infections, several forms of 
trauma and other inflammatory conditions. Synthesis in 
the liver is responsible for blood CRP levels [58]. These 
blood CRP levels dramatically increase 6 – 12  hours 
after onset of AMI as part of the acute phase response 
[7]. Expression of CRP is regulated mainly at the 
transcriptional level, but posttranslational mechanisms 
such as a greatly accelerated protein-secretion rate 
during the acute phase also play a role. For example, the 
half time for exit of pulse-labeled CRP from the ER is 
reduced from normally 18 h to 75 min during the acute 
phase [59,47]. 
Recent years the view on the role of CRP has shifted 
from a pathophysiologically innocent marker protein to 
a mediator of tissue damage [60], Also, local, 
extrahepatic production of CRP has been claimed to 
contribute to this negative effect of CRP [61]. 
 
CRP in acute myocardial infarction 
The first association of CRP with acute myocardial 
infarction (AMI) comes from the observation that the 
course of blood CRP levels have prognostic impact in 
patients with AMI [62 ]. 
Among the first indications that CRP is not only an 
innocent bystander but in fact actively involved in the 
pathogenetic process of AMI and reperfusion injury 
were observations by Kushner et al. who found CRP 
localized in infarcted rabbit myocardium [63,64]. Later, 
we showed that CRP and activated complement 
fragments co-localize immunohistochemically in 
infarcted, but not in normal myocardium of patients 
that had died from AMI [3]. These results suggest a 
causal relationship between cardiomyocyte-bound CRP 
and local complement activation in human AMI. Strong 
support for this idea was provided by a study 
demonstrating that injection of human CRP into rats 
after ligation of the coronary artery reproducibly 
enlarged infarct size by about 40% [5]. We have since 
been able to present evidence indicating that, in humans 
also, complement activation in infarcted myocardium is 
in part mediated by CRP. Measurement of CRP-C3d 
and CRP-C4d complexes, activation products that 
reflect CRP-dependent complement activation, in serial 
plasma samples of patients with AMI or unstable 
angina pectoris, showed that circulating levels of these 
complexes were significantly higher in patients with 
AMI compared to those in normal controls or in 
patients with unstable angina pectoris and correlated 
with infarction size as measured by cumulative 48-h 
LDH release [7]. These findings were corroborated by 
another study demonstrating depositions of CRP, 
complement and their complexes in tissue samples of 
infarcted myocardium of patients that had died after 
AMI. These depositions were more extensive in patients 
that had undergone reperfusion therapy or had suffered 
from reinfarction after the primary AMI [65]. 
Another recent study demonstrated that different forms 
of preconditioning prevented the increase of serum CRP 
seen during reperfusion [66]. Preconditioning is the 
collective term for cell-protective intracellular signal-
transduction processes and effector mechanisms 
induced by short and sublethal periods of ischemia. 
Taken together, these results strongly suggest that CRP 
is a major determinant of myocardial-injury size after 
acute myocardial infarction. 
We have found in vitro that CRP binds to ischemic 
jeopardized cardiomyocytes but, in contrast to sPLA2-
IIA, only in case these cells are necrotic. 
 
Inhibition of CRP 
To the best of our knowledge no reports of specific 
inhibitors of CRP have been published. 
As with sPLA2-IIA, therefore, we cannot but speculate 
on the effects of inhibition of CRP on the severity and 
clinical course of AMI. Again, because of the different 
roles of the acute phase protein in the pathogenesis of 
AMI detailed above, one would expect a mainly 
beneficial effect of CRP inhibitors on the outcome of 
AMI. Indirect evidence of a putative therapeutic effect 
of CRP-lowering drugs in patients with AMI has been 
obtained with, for instance, corticosteroids or HMG-
CoA reductase inhibitors (statins) [67,68,69,70,71]. These 
drugs lower serum CRP levels and, in a recent study, 
have been shown to have beneficial effects directly 
related to their CRP-lowering capacity, in patients with 
AMI [70]. 
These findings support our conviction that studies with 
a specific inhibitor of CRP are desirable in AMI. 
 
The complement system 
The complement system essentially can be activated by 
three distinct routes of activation, the classical, 
alternative and lectin pathways. The classical pathway 
(involving C1q, C1r, C1s, C4, C2 and C3) is activated 
primarily by the interaction of C1q with immune 
complexes but can also be initiated upon interaction of 
C1q with other proteins, such as, for example, ligand-
bound CRP [72] (Figure 2). The activation of the 
alternative pathway (involving C3, factor B, factor D 
and properdin) is not dependent on the presence of 
immune complexes but is effected by interactions with 
carbohydrate-rich particles that lack sialic acid [73]. 
Mannose-binding lectin (MBL) binds to terminal 
mannose groups on a variety of bacteria and 
subsequently activates the lectin pathway (MASP1, 
MASP2, C4, C2 and C3). 
These three pathways converge at the level of C3 to 
activate the terminal pathway (involving C5, C6, C7, C8 
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and C9) and result in the formation of the membrane 
attack complex (MAC). Insertion of this complex in the 
cell membrane disrupts the phospholipid bilayer of the 
target cells to form a pore and induce lysis [74]. In 
addition, complement proteins fixed onto the activating 
cell (C1q and C3 fragments: C3b and iC3b) stimulate 
phagocytosis by macrophages via membrane receptors 
for complement proteins (CR1, CR3 and CR4). 
 
The complement system and acute 
myocardial infarction 
As early as 1971 Hill and Ward demonstrated in a rat 
model that complement was activated locally in 
ischemic myocardium and contributed to the local 
inflammatory response [75]. Since then an 
overwhelming body of evidence has accumulated 
supporting a role of the complement system as an 
important mediator of inflammation and subsequent 
cell death in AMI. For instance, local activation of the 
classical pathway of complement occurs in various 
animal models of AMI as reflected by deposition of 
activated fragments of this pathway in infarcted 
myocardium [76,77,78]. This activation occurs 
independently of reperfusion. Furthermore, some 
reports postulate involvement of the alternative and the 
lectin pathways as well in the activation of the 
complement system during AMI [79,80]. Other studies 
performed in rabbits furthermore demonstrated the 
presence of the MAC on cardiomyocytes and 
endothelial cells in ischemic areas [81]. The appearance 
of these depositions was accelerated by reperfusion 
following ischemia. 
In studies on human tissues obtained post mortem from 
patients that had died subsequent to AMI, deposition of 
activated fragments of the classical pathway of 
complement activation and of the MAC has been 
demonstrated in the ischemic areas of the heart [3,82]. 
Studies in animal models of AMI and human post-
mortem material also demonstrated expression of 
mRNA transcripts for C3 and C9 that was further 
enhanced upon ischemia, indicating that complement 
proteins locally produced in the myocardial tissue may 
contribute to the ischemic damage [83]. 
It is assumed that the deposition of MAC complexes on 
damaged cardiomyocytes observed in ischemic 
myocardial areas is detrimental to survival of these 
cells, and support for this idea comes from studies 
performed in rabbits deficient of complement factor C6. 
These animals are unable to assemble a fully active 
MAC and indeed displayed a reduced infarct size in 
models of cardiac ischemia and reperfusion as 
compared with the tissue damage in C6-sufficient 
rabbits [84]. 
Other animal studies have shown an important role of 
PMN as determinants of infarct size, in particular 
because of their capacity to generate reactive oxygen 
species and tissue-damaging enzymes [85,86]. The 
complement activation product C5a has been implicated 
in the upregulation of the adhesion molecule ICAM-1 
on endothelial cells [87,88,89]. ICAM-1 effectively 
promotes the adherence of activated leukocytes, 
including PMN, to cells expressing this adhesion 
molecule. Complement and its activation products, in 
particular C5a, further have the ability to induce 
stimulation, extravasation aggregation and 
degranulation of PMN. Collectively, these findings 
suggest that the complement system may contribute to 
the mechanisms favoring PMN-induced tissue damage 
[90]. 
In conclusion, the evidence presented here and in the 
section about CRP and AMI unequivocally implies a 
pivotal role of complement in determining the extent of 
myocardial infarction in AMI and after reperfusion. 
 
Inhibition of the complement system 
Different inhibitors 
Several groups of inhibitors of the complement system 
have been tested in animal studies and human clinical 
trials (Table 2). 
The first were corticosteroids such as prednisone and 
dexamethasone. Already in 1953 Johnson and 
colleagues reported a profound effect of cortisone on 
limiting infarct size during myocardial infarction [91], 
and other animal studies later confirmed these results 
[92,93]. Several clinical trials with both positive and 
inconclusive results followed [94,95]. However, because 
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Figure 2: Complement activation by CRP. 
CRP  can  bind  to  the  plasma  membrane  of  necrotic  cells. 
Ligand‐bound CRP  can  than  activate  complement  through 
the  classical  pathway  by  binding  C1q.  Binding  of  C1q 
initiates conformational changes in C1 leading to cleavage of 
C1r followed by C1s, which is than able to cleave C2 and C4, 
resulting  in  the  formation  of  the  C4b2a  complex.  This 
complex  facilitates  C3  cleavage,  wherafter  C3b  joins  with 
C4b2a  to  form  C4b2a3b.  This  in  turn  frees  C5b  from  C5, 
which joins with C6 and C7 to form the C5b67 complex. This 
complex,  toghether with C8  recruits multiple C9 molecules 
to  the  membrane  to  form  the  membrane  attack  complex, 
leading to cell lysis.  
100
Table 2
 
Human/Animal Inhibitor Ref Type of inhibitor Effect on infarct size 
Dog Cortisone [91] Natural product derivative Yes 
Dog Hydrocortisone [92] Natural product derivative Yes 
 Cat Methylprednisolone [93] Natural product derivative Yes 
Human Methylprednisolone [97] Natural product derivative Yes (negative effect) 
Baboon Cobra venom factor [101,104]  Natural product Yes 
Dog Cobra venom factor [103] Natural product Yes 
Rat Soluble CR1 [105,106] Natural product derivative Yes 
Rat 18A and 16C [148] Antibodies Yes 
Pig 288-26F7 [79] Antibody Yes 
Human Pexelizumab [109,110,111] Antibody No 
Cat C1 INH [112] Natural product Yes 
Pig C1 INH [113,114] Natural product Yes 
Human C1 INH [2] Natural product Yes 
Rabbit C1s-INH-248 [118] Synthetic compound Yes 
corticosteroids strongly impair wound healing, yielding 
an increased risk for left-ventricular rupture, these trials 
were discontinued [96,97,98]. 
Cobra venom factor (CoVF) that in vivo produces a 
rapid, profound and sustained depletion of C3 and C5 
has also been tested in animal studies [99,100]. A 
reduction in myocardial tissue damage, reduced 
deposition of complement factors except for C4 and 
positive hemodynamic effects have been described in 
these studies [101,102,103,104]. 
Complement receptor 1 (CR1/CD35) is a member of the 
regulator-of complement-activation protein super 
family, inhibiting all pathways of complement. For 
application as a systemic inhibitor of complement 
activation, a recombinant soluble version of the human 
transmembrane protein (sCR1) was produced and 
subsequently shown to retain the inhibitory functions of 
native CR1 [105,106]. Administration of sCR1 in a rat 
model of ischemia-reperfusion injury limited infarct size 
and MAC deposition and significantly reduced 
leukocyte infiltration in the ischemic area [105,107]. 
Another study essentially confirmed these results [107]. 
A recent randomized multicenter, prospective, placebo-
controlled, double-blind study on 564 high-risk patients 
undergoing cardiopulmonary-bypass surgery 
demonstrated inhibition of complement activation 
during cardiopulmonary-bypass surgery and a 
significant decrease in the incidence of mortality and 
myocardial infarction in male patients. However, there 
was no improvement seen in the female patients 
participating in the study. In addition, the incidence of 
adverse effects did not differ between the sCR1-treated 
and the placebo-treated patient groups [108]. 
Another therapeutic approach is inhibition of C5 
activation by inhibitory antibodies, which prevents 
formation of the most inflammatory complement 
components C5a and MAC. In a study performed in a 
rat model of myocardial ischemia and reperfusion, 
mAbs (18A and 16C) were shown to significantly 
reduce infarct size, myocardial injury and PMN 
infiltration [1]. Another mAb directed against C5a (288-
26F7) had favorable effects on infarct size hemodynamic 
parameters in a pig model of ischemia/reperfusion [79]. 
Subsequent clinical trials of an anti-C5 mAb 
(pexelizumab) in two different settings of 
postmyocardinfarct treatment (fibrinolysis and primary 
percutaneous coronary intervention) showed no 
beneficial effect of the antibody on infarct size but a 
significant reduction in mortality in the study of 
inhibition of C5 as adjunctive therapy to primary 
percutaneous coronary intervention [109,110,111]. 
C1 esterase inhibitor (C1-INH) is a main endogenous 
inhibitor of the classical pathway of complement 
activation, as well as a possible inhibitor of the lectin 
pathway of complement activation and an important 
regulator of the intrinsic pathway of coagulation, and 
thus inhibits other inflammatory systems as well. 
Moreover, this inhibitor does not impair the alternative 
pathway and does not prevent all defense functions of 
complement [90]. C1-INH prepared from human 
plasma has been given savely for 30 years to patients 
with angio-edama. Several studies in cat, pig and dog 
models of ischemia and reperfusion demonstrated a 
cardioprotective effect of C1-INH in that it reduced 
infarct size and improved contractility [112,113,90]. 
The safety of C1-INH [114,115] has been discussed 
following a report of thirteen newborns and babies that 
received high-dose C1-INH to prevent capillary-leak 
syndrome after cardiopulmonary bypass surgery for 
congenital heart disease. Vena cava thrombosis 
developed in all patients, and 9 patients died of embolic 
events, which had been observed once before [116,117]. 
However, a consensus has been reached that under 
adequate heparinization the risk of developing 
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thrombotic complications under C1-INH therapy is 
minimal [114]. 
There has since been a pilot study in a group of 22 
patients with AMI that received continuous 48-h C1-
INH treatment not earlier than 6h after AMI, in order to 
prevent interference with thrombolytic therapy. The 
inhibitor was shown to have the expected biological 
effect in reducing C4 activation, and the outcome was 
assessed by comparing the release of troponin T and 
creatine kinase-MBmass to that found in historical 
controls. The release of these enzymes was reduced by 
36% and 57%, respectively [2]. 
Finally, the effect of C1s-INH-248, a small non-peptide 
inhibitor has been tested in a rabbit model of ischemia 
and reperfusion. C1s-INH-248 is highly specific for C1s 
and acts as reversible and competitive inhibitor of 
activated C1s. In the rabbit model C1s-INH-248 showed 
a significant reduction in infarct size and neutrophil 
accumulation in the infarcted area [118]. 
 
The pros and cons of complement inhibition 
in AMI  
In contrast to situation for sPLA2-IIA and C-reactive 
protein, there have been a number of animal studies 
and human clinical trials investigating the safety and 
efficiency of complement inhibition to reduce the 
damaged inflicted by acute myocardial infarction. 
However, while complement inhibitors have a clear-cut 
and significant effect in animal models in that they 
reduce infarct size, these effects were observed in some 
of the human clinical trials, whereas in other they were 
not found (Table 2). Few explanations for these 
differences have yet been offered, and may include, for 
example, the different methodologies used to assess 
infarct size (i.e., direct histological examination vs. 
measurement of cardiospecific enzyme acitivities). 
Notably, in none of these studies severely adverse 
effects of complement inhibition were found.  
 
Concluding remarks 
All evidence presented in this review support 
prominent roles for sPLA2-IIA, CRP and complement in 
I/R-injury in the heart. Currently there are no data 
available on the effects of sPLA2-IIA- or CRP inhibition 
in the development and outcome of AMI. However, 
regarding the damaging roles of these mediators in I/R-
injury, inhibition of these mediators would in theory 
benefit the patient. Inhibition of complement has shown 
promising results in limiting infarction size in animals 
and to some extent also in humans. An important 
therapeutic action would be the inhibition of the border 
zone of the infarction area, without impediment of the 
clearance of cellular debris as this may obstruct 
myocardial remodeling. What then would be the best 
strategy? As mentioned earlier, inhibition of 
complement has shown promising results in limiting 
infarction size in animals and in humans. Inhibition of 
CRP should in theory have similar effects, since CRP 
activates complement within the infarcted myocardium. 
To the best of our knowledge there is to date no specific 
inhibitor for CRP, although some drugs, like statins 
induce lower plasma CRP levels, resulting in reduced 
death from myocardial infarction [70]. Therefore the 
development of specific CRP inhibitors may have 
therapeutical perspective.  
Perhaps the best candidate for inhibition then would be 
sPLA2-IIA. sPLA2-IIA is namely deposited earlier then 
CRP and complement within the infarcted human heart. 
Furthermore, sPLA2-IIA is found on reversibly 
damaged cardiomyocytes in the border zone of the 
infarct, and therefore appears to play a crucial role in 
the propagation of inflammation and the concomitant 
expansion of the infarction area. The search for potent 
and highly specific inhibitors of sPLA2-IIA is ongoing, 
several promising compounds being in the clinical trial 
stage of development. We strongly suggest evaluation 
of these inhibitors in models of AMI (animal/human) as 
well. 
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Abstract Background
 
Impaired perfusion of the heart induces a local inflammatory response, which
involves deposition of C-reactive protein and complement activation products C3d and C5b-
9. We investigated whether reperfusion or reinfarction enhances these phenomena in humans.
 
Materials and methods
 
Depositions of C-reactive protein and complement were quantified
in tissue samples of infarcted myocardium from 76 patients who had died after acute myocardial
infarction. The extent of depositions in patients treated with reperfusion or suffering from
reinfarction was compared with that in patients who had no reperfusion or reinfarction.
 
Results
 
Patients with reinfarction had significantly more extensive depositions of C-reactive
protein and complement (C3d and C5b-9) in the infarcted myocardium than patients
without reinfarction. Similarly, patients who received reperfusion therapy had more extensive
depositions also than those who had not received this therapy.
 
Conclusions
 
Both reinfarction and reperfusion therapy significantly increase the extent of
C-reactive protein and complement depositions in human myocardial infarcts.
 
Keywords
 
Complement, C-reactive protein, reinfarction, reperfusion therapy.
 
Eur J Clin Invest 2004; 34 (12): 803 –810
 
Introduction
 
Impaired perfusion of the myocardium may elicit a local
inflammatory response that involves the infiltration of
inflammatory cells and the release of cytokines [1,2]. Hill
and Ward were the first to demonstrate in a rat model that
the complement system is also activated locally in infarcted
myocardium, and that complement activation products
contribute to the infiltration of neutrophils [3]. Further
studies in animal models for acute myocardial infarction
(AMI) have confirmed these results [4–6]. Inhibition of
complement activation in these models not only attenuated
infiltration of the jeopardized myocardium by neutrophils,
but also reduced infarct size [7,8]. Also in man, complement
is activated locally in the heart during infarction [9–12].
Activation of complement in infarcted myocardium occurs
mainly via the classical pathway [4,5], and can lead to
depositions of the membrane attack complex (MAC;
C5b-9) [10]. Several activators, including cardiolipin and
mitochondrial components, have been implied to be involved
[13]. The acute-phase protein C-reactive protein (CRP) has
been shown to activate the classical pathway upon binding
to a suitable ligand [14,15]. C-reactive protein as well as
activated complement is deposited in the human myocardium
during infarction, which suggests that CRP contributes to
the activation process in the ischaemic myocardium during
AMI [16]. Indeed we have recently demonstrated the
presence of activation products specific for CRP-mediated
activation of complement in human myocardial infarcts [12].
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To what extent CRP or complement contributes to infarct
size in man is not known. Preliminary studies suggest that
inhibition of complement activation may indeed consider-
ably limit infarct size [17].
Reperfusion of ischaemic myocardium seems a logical
therapy for myocardial infarction. Animal studies, however,
have shown that the beneficial effects of reperfusion may
be limited, as restoration of flow in the ischaemic tissue,
particularly after longer periods of ischaemia, may elicit an
inflammatory response which leads to further tissue damage,
also known as ischaemia-reperfusion (I /R) injury [6,18].
Whether reperfusion of ischaemic heart tissue also is accom-
panied by I /R-injury in humans is currently unknown.
In the present study we investigated possible relations
between the extent of deposited CRP and complement
activation products C3d and C5b-9 and the duration and
presence of reinfarction in heart specimens of 76 patients
who had died within 14 days after onset of infarction. In
addition, we analyzed the effect of reperfusion treatment on
CRP and complement depositions.
 
Materials and methods
 
Patients
 
All patients included in the present study had died in the
hospital, and were admitted to the Department of Pathology
for autopsy. Patients were entered into the study when
autopsy could be performed within 24 h of the patient dying;
and when autopsy showed macroscopical evidence for AMI
(see below). Duration of infarction was estimated using
microscopical criteria (see below), as for some patients the
exact onset of complaints was unknown. Clinical parameters
and treatment were verified from medical records. Most
of the patients described here also participated in earlier
studies [12,15].
The study protocol was approved by the Ethics Commit-
tee of the VU Medical Center Amsterdam. Permission to
perform autopsy was obtained from patients’ relatives. Use
of left over material after the diagnostic pathology has been
completed is part of the standard patient contract in our
hospital.
 
Myocardial specimens
 
Myocardial tissue specimens were obtained as described
earlier [12,15], within 24 h of the patient dying. The
macroscopic infarcted area was identified as the area that
contained less or no lactate dehydrogenase (LD). This
macoscopical infarct area was included in the tissue samples
to be studied. Macroscopic heart slides were photographed
and infarct size was measured by means of the UTHSCSA
Image tool (UTHSCSA University). From the infarcted
area samples were taken and stored at 
 
−
 
196 
 
°
 
C (liquid N
 
2
 
).
For the actual analysis, cryo-sections of the samples were
prepared, using glass slides pretreated with 0·1%, w/v, poly
L-lysine (Sigma Chemical Co., St. Louis, MO) to enhance
adherence of the frozen tissue sections. In addition, paraffin
slides were also prepared, as morphology can be judged
more reliably with paraffin sections.
Microscopic criteria were used to estimate infarct duration
in the patients [19,20]. The following phases of infarction
were discriminated: the early phase, i.e. 0–12 h [no or only
minor polymorphonuclear leucocyte (PMN) infiltration];
PMN-phase, i.e. 12 h to 5 days (massive infiltration of PMN);
and the chronic phase, i.e. 5–14 days (infiltration of mono-
nuclear cells, proliferation of fibroblasts and vessels). Patients
with reinfarction were defined as patients with an AMI of
5–14 days with a more recent infarction. Patients with rein-
farction were divided into two separate categories: patients
with reinfarction in the early phase before PMN infiltration
(= early reinfarction), and those with reinfarction in the
PMN phase and thus influx of PMN in the macroscopic
infarction area (= PMN reinfarction).
 
Immunohistochemical analysis of complement and 
CRP depositions
 
Monoclonal antibodies (mAb) C3-15 against activated
complement C3d and 5G4 against CRP have been previously
used for immunohistochemical studies [15,21]. mAb
aE11 (subtype: IgG2a, Dako, Carpinteria, CA) was used
for detection of C5b-9, the terminal complex of comple-
ment. Four-
 
µ
 
m thick frozen sections were mounted onto
glass slides, dried for 1 h by exposure to air and fixed in
acetone (‘Baker Analyzed Reagent’, Mallinckrodt Baker
BV, Deventer, Holland). The slides for C3d and CRP stain-
ing were incubated for 10 min with normal rabbit serum
(Dakopatts A/S, Glostrup, Denmark) 1–50 diluted in phos-
phate buffered saline, pH 7·4 (PBS), containing 1%, w/v,
bovine serum albumin (PBS-BSA), while the slides for
C5b-9 staining were incubated for 10 min in 5% w/v BSA
in PBS, at room temperature after a rinse in PBS. The slides
were incubated with C3-15 diluted 1–1500 or with 5G4
1–300 in PBS-BSA for 60 min at room temperature or
incubated overnight with aE11 diluted 1–50 at 4 
 
°
 
C. In control
experiments, similar incubations were performed with
irrelevant monoclonal antibodies: IgG1 and IgG2a against
mouse myeloma protein, MOPC (Cappel, Organon Teknika,
Turnhout, Belgium). Thereafter the slides were washed for
30 min with PBS and incubated with horseradish-peroxide
conjugated rabbit-antimouse immunoglobulins (RaM-HRP,
Dakopatts A/S, Glostrup, Denmark), 1–25 diluted in PBS-
BSA, except for mAb aE11, which was detected using
EnVision (Dako, Carpinteria, CA). The slides were washed
again in PBS and incubated for 4 min in 0·5 mg mL
 
−
 
1
 
 3,3
 
′
 
-
diamine-Benzedrine-tetrahydrochloride (DAB, Sigma) in
PBS containing 0·01%, v/v, H
 
2
 
O
 
2
 
, washed again, counter-
stained with haematoxylin for 40 s, dehydrated and finally
mounted.
The area occupied by complement and CRP depositions
was assessed quantitatively by dividing the slides into four
parts at magnification 
 
×
 
250. The percentage of each part
occupied by complement or CRP was then estimated.
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Subsequently, these percentages were averaged to yield a
mean area of deposition. Two independent investigators
(R.N. and H.W.M.N.) each judged and scored all slides for
infarct duration and anatomical localization of complement
or CRP antibodies as visualized by immunohistochemical
staining. For the final scoring results, consensus between
the two investigators was achieved.
 
Statistics
 
Statistics were performed with the SPSS statistics program
(windows version 9; SPSS Inc., Chicago, Illinois). To
evaluate whether observed differences were significant a
Student’s 
 
t
 
-test and chi-squared tests were used. In case
data were not normally distributed, as evaluated with the
Kolmogorov-Smirnov test, a nonparametrical test (Mann–
Whitney ‘U’) was used. Correlations were analyzed with
Spearman’s rho test.
 
Results
 
Patient demographics
 
Seventy-six patients referred to the Department of Pathology
for autopsy, and who had macroscopic evidence of AMI, were
included: 58 males (average age 66·3 year 
 
±
 
 11·4) and 18
females (average age 72·2 year 
 
±
 
 11·7). Twenty-two patients
had received reperfusion therapy: four of them streptoki-
nase, seven percutaneous transluminal coronary angioplasty
(PTCA) and eight patients underwent coronary artery
bypass graft surgery (CABG). Three of the patients had
been treated with double reperfusion therapy: one with
thrombolysis followed by PTCA, whereas two had had
PTCA followed by CABG. The CABG procedure was
performed within 14 days before death of the patients.
Fourteen patients had hypertension, 16 patients suffered
from diabetes mellitus (DM), 16 others from malignancies
while 19 patients had sepsis.
 
Infarct size and deposition of inflammatory 
mediators
 
The mean infarct size was 41% (standard deviation 17%)
with a minimum of 10% and a maximum of 72% of the
total macroscopic slide area. Infarct duration and infarct
size were not correlated with each other. Furthermore, the
extent of CRP, C3d and C5b-9 depositions did not correlate
with infarct size.
 
CRP, C3d and C5b-9 depositions in patients with 
reinfarction
 
C-reactive protein and complement factors C3d and
C5b-9 were found to be deposited on cardiomyocytes in
Figure 1 Immunohistochemical localization of C-reactive protein 
(CRP) (a) complement activation fragment C3d (b) membrane 
attack complex member C5b-9 (c) in infarcted myocardium 
(I = infarcted, N = normal myocardium) using, respectively, mAbs 
5G4 and C3-15 and aE11, as described in Methods. 
Magnification ×100.
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the infarcted area (Fig. 1). Depositions of all three factors
were found on the plasma-membrane, cross-striations and
cytosol (not shown, for details see Lagrand 
 
et al
 
. [15]) In
all studied patients irrespective of infarction phase, rein-
farction or reperfusion, complete colocalization of CRP and
complement factors C3d and C5b-9 were found. Patients
who had died from other causes than AMI were studied as
controls. No depositions of C3d, C5b-9 or CRP were found
in the heart of these patients (not shown), indicating that
the observed staining patterns were not owing to specific
postmortem changes. In the AMI patients, depositions were
also observed on the endothelium. In case of CRP, these
depositions were focal, in agreement with our earlier studies
[15,21]. These studies have also shown that complement
depositions in patients without reinfarction are most exten-
sive in the PMN phase. Again this was found in the present
study.
C-reactive protein, C3d and C5b-9 occupied significantly
larger areas in the heart of patients with reinfarction than
in those of patients with single infarcts (CRP 
 
P
 
 < 0·001;
complement 
 
P
 
 < 0·001; see, Fig. 2). Similarly as in single
infarcts, also in reinfarction the extent of the depositions
was dependent on the phase, in that depositions were sig-
nificantly more extensive in reinfarctions during the PMN
phase than during the early phase. This was found for both
CRP (
 
P <
 
 0·02) and complement factors C3d and C5b-9
(
 
P <
 
 0·03; Fig. 3).
 
Relation of CRP, C3d and C5b-9 to clinical 
parameters
 
We found no relationship between the extent of CRP or
complement (C3d and C5b-9) depositions and parameters
like the presence of sepsis, malignancy, hypertension, or
diabetes (Tables 1 and 2). From animal experiments it is
known that reperfusion induces complement activation [4,7]
although this has never been demonstrated convincingly
in humans. Interestingly, in patients with 
 
single
 
 infarcts,
depositions of CRP, C3d and C5b-9 were larger in the patients
who had been treated with reperfusion therapy than in those
without this therapy [CRP 
 
P
 
 < 0·03; complement (C3d and
C5b-9) 
 
P
 
 < 0·001; Fig. 4a,b]. The more extensive deposi-
tions of CRP, C3d and C5b-9 in patients with reinfarction,
as discussed earlier, were not owing to the fact that most
of these patients had received reperfusion therapy. Patients
with reinfarction who had not been treated with reperfusion
therapy had significantly more extensive depositions of CRP
C3d and C5b-9 than patients with a single infarct without
reperfusion therapy [CRP: 
 
P
 
 < 0·001, and complement (C3d
and C5b-9): 
 
P
 
 < 0·001; see Fig. 4a,b]. However, in the group
Figure 2 Extent of deposition of C-reactive protein (CRP; ) and 
complement factors C3d and C5b-9 () in patients with single 
infarcts or reinfarction. *P < 0·001, **P < 0·001.
Figure 3 Influence of the stage of the initial ischaemic event on 
the extent of deposition of C-reactive protein (CRP; ) and 
complement factors C3d and C5b-9 () during reinfarction. 
* and **P < 0·03.
Table 1 Extent of depositions of C-Reactive protein in patients 
suffering from acute myocardial infarction with different clinical 
conditions
 
Condition
Absent –/
present + n Median
25–75th 
percentiles P*
Sepsis – 57 15  (0–50) 0·67
+ 19 10  (0–50)
Reanimation – 55 5  (0–50) 0·09
+ 21 20 (3·8–50)
Acute infection – 44 22·5  (0–60) 0·37
+ 32 5  (0–45)
Hypertension – 62 12·5  (0–50) 0·57
+ 14 20  (0–60)
Diabetes – 60 12·5  (0–53·8) 0·71
+ 16 15 (1·3–50)
Malignancy – 60 20  (0–50) 0·09
+ 16 0  (0–37·5)
Sex Female 18 20  (0–50) 0·53
Male 58 5  (0–50)
*P-values according to Mann–Whitney ‘U ’ test.
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of patients with reinfarctions, no significant differences
between patients with or without reperfusion therapy were
observed (Fig. 4a,b). Conversely, the median area of com-
plement (C3d and C5b-9) deposition tended to be smaller
in patients with reinfarction and reperfusion therapy as
compared with that in patients with reinfarctions not treated
with reperfusion therapy.
Various types of reperfusion therapy may have a different
effect on the complement system. Therefore, we analyzed
the influence of the type of reperfusion therapy on comple-
ment and CRP depositions (Fig. 5). In patients with single
infarcts, the area containing CRP and complement factors
C3d and C5b-9 was significantly larger in patients with
CABG or streptokinase therapy, compared with that in
patients without reperfusion therapy [CRP 
 
P
 
 < 0·02;
complement (C3d and C5b-9) 
 
P
 
 < 0·001; Fig. 5(a,b)]. In
contrast, patients who had been treated with PTCA did not
have significantly increased C3d, C5b-9 or CRP depositions
as compared with patients without reperfusion therapy.
Remarkably, in patients with reinfarctions no differences
were observed in the extent of CRP or C3d and C5b-9
deposition when comparing patients without reperfusion
therapy with those treated with PTCA or CABG/streptokinase.
In the PTCA group the median area of CRP, C3d and C5b-
9 depositions tended to be smaller than those in patients
without reperfusion therapy.
 
Discussion
 
Reperfusion of ischaemic tissues may not always rescue the
jeopardized tissue but can, particularly after longer periods
of ischaemia, cause additional tissue damage. Among the
mechanisms involved in this ischaemia-reperfusion injury is
activation of complement [7,8,22]. To what extent ischaemia-
reperfusion injury occurs in humans is not well known.
In the present study we show that reperfusion therapy in
humans who suffer and subsequently die from AMI is
associated with significantly more extensive complement
depositions, suggesting that activation of complement in
the ischaemic human myocardium may be enhanced by
reperfusion. In addition, extended depositions of comple-
ment in these patients were accompanied by more extensive
CRP depositions, suggesting a role for this acute-phase pro-
tein in reperfusion-induced activation of complement in the
ischaemic myocardium in the patients with AMI. Although
recent studies suggest that CRP prevents the formation
of the membrane attack complex of complement (MAC)
[23,24], in the present study CRP fully colocalized with
complement factor C3d as well as with MAC (Fig. 1). Schäfer
 
et al
 
. also demonstrated that localization of C5b-9 was
restricted to the infarcted areas of the human heart
[10]. Furthermore, in homogenates of infarcted human
Table 2 Extent of depositions of complement factors C3d and 
C5b-9 in patients suffering from acute myocardial infarction with 
different clinical conditions
 
Condition
Absent –/
present + n Median
25–75th 
percentiles P*
Sepsis – 57 10 (5–50) 0·78
+ 19 10 (5–50)
Reanimation – 55 10 (5–30) 0·21
+ 21 10 (5–61·3)
Acute infection – 57 10 (5–50) 0·08
+ 19 10 (5–30)
Hypertension – 62 10 (5–50) 0·87
+ 14 17·5 (5–30)
Diabetes – 60 10 (5–50) 0·56
+ 16 10 (5–25)
Malignancy – 60 15 (5–50) 0·17
+ 16 5 (5–21·3)
Sex Male 58 10 (5–50) 0·59
Female 18 10 (5–25)
*P-values according to Mann–Whitney ‘U ’ test.
Figure 4 Extent of deposition of C-reactive protein (CRP) (a) or 
complement factors C3d and C5b-9 (b) in single infarcts (two left 
bars) or re-infarctions (two right bars), without ( ) or with 
reperfusion (). (a) *P < 0·03, **P < 0·001, ***P < 0·04; 
(b) *P < 0·001, **P < 0·001.
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myocardium we demonstrated CRP-complement complexes
indicative for CRP-mediated complement activation [12].
Therefore, on the basis of this immunohistochemical colo-
calization of CRP and C5b-9 we have no indication that
CRP inhibits the formation of the terminal complex of
complement. Finally, we report more extensive depositions of
complement (C3d and C5b-9) and CRP in patients suffer-
ing from reinfarction. Notably, no relation was found at any
infarction stage between infarct size and the extent of CRP
or C3d and C5b-9 depositions.
Various forms of reperfusion therapy may have a different
effect on complement activation. Plasminogen activators
like streptokinase activate the classical pathway of comple-
ment by cleaving C1r [25–27]. Conversely, coronary artery
bypass grafting (CABG) is often accompanied by strong
complement activation via the alternative pathway resulting
from the contact of blood with the extra-corporal circulation
[28]. In this study we found significantly larger C3d and
C5b-9 depositions in AMI patients who either had received
streptokinase or were treated with CABG, suggesting that
the local activation of complement in the ischaemic myo-
cardium is enhanced by reperfusion. Notably, enhanced
complement activation was accompanied by more extensive
CRP depositions in the infarcted myocardium. In contrast,
PTCA was not associated with more extensive C3d and
C5b-9 depositions in the ischaemic myocardium. These vari-
able effects of reperfusion therapies on local complement
activation in the ischaemic myocardium agrees well with
circulating levels of complement activation products, which
are increased in patients receiving streptokinase or under-
going CABG, but remain normal in patients with PTCA
(Lagrand 
 
et al.
 
, submitted). Why different methods of reper-
fusion therapy have variable effects on the local activation
of complement in the ischaemic myocardium is not clear at
the moment.
In the present study we did not confirm whether reper-
fusion therapy actually resulted in enhanced reperfusion.
Thus, different effects of the various forms of reperfusion
therapy on complement activation in the heart may reflect
the different efficacies of these therapies to restore blood
flow to the ischaemic region. However, we found a throm-
bus in the coronary artery in only one of the 25 patients
treated with reperfusion therapy, indicating that in the
other 24 patients morphological evidence for unsuccessful
reperfusion was lacking.
Interestingly we observed significantly increased deposi-
tions of both CRP and complement factors C3d and
C5b-9 in the patients with reinfarction. In an earlier study
we also observed this phenomenon [21], but the limited
number of patients with reinfarction (
 
n
 
 = 3) in that study
did not allow definite conclusions. It is known that myocar-
dial infarction triggers the inflammatory and acute-phase
responses [1,2]. The extent of these postinfarct responses
is associated with clinical outcome. For example, postinfarct
leucocyte counts [29] or circulating CRP constitute risk
markers for further cardiac events [30,31]. Hence, plasma
levels of CRP in general will be higher during reinfarction then
during a single infarct. We observed increased depositions
of CRP, C3d and C5b-9 in the patients with reinfarction
as compared with those with single infarcts. An intriguing
explanation for this phenomenon may be that an ischaemic
event in the myocardium in the presence of elevated CRP
levels results in more pronounced deposition of this acute-
phase protein, and subsequently in more intense activation
of complement.
Co-localization of complement and CRP in the ischaemic
myocardium, and the potentiating effect of reperfusion ther-
apy or reinfarction on this process, put forward the hypoth-
esis that inhibition of CRP and or complement may be a
therapeutic option in patients with AMI, in particular when
treated with reperfusion therapy or when suffering from
reinfarction. However, other factors may also play a role in
the activation of complement in myocardial I /R injury. In I /R
models of the intestine and skeletal muscle, IgM-deficient
mice developed substantially less I /R-injury than their
wild-type littermates; this injury was restored in the deficient
mice by supplementation with normal murine IgM [32,33].
Hence it is not unthinkable that natural IgM may play a
Figure 5 Extent of deposition of C-reactive protein (CRP) (a) and 
complement factors C3d and C5b-9 (b) in patients with single 
infarcts (three left bars) or re-infarctions (three right bars) without 
reperfusion therapy ( ) or treated with CABG or streptokinase () 
or PTCA ( ). *P < 0·02, **P < 0·001.
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role in complement activation in myocardial I /R injury
in humans. Also, the lectin complement pathway has been
shown to be activated after myocardial ischaemia-reperfusion
and was shown to lead to tissue injury [34]. To what
extent these factors contribute to complement activation
in myocardial I /R injury is not known. Until now, inhibitors
of CRP have not been applied in animals or humans with
AMI. In contrast, complement inhibitors like C1-inhibitor,
anti-C5 or soluble CR1 have been proven to limit infarction
size in animals undergoing myocardial ischaemia/reperfusion
[7,35–37]. In a limited clinical trial with C1 esterase inhi-
bitor in patients with AMI, we observed promising effects
with respect to infarct size [16]. Whether all patients or only
specific subgroups with AMI may benefit from these novel
therapies is not clear. Our data suggest that AMI patients
suffering from reinfarction or receiving reperfusion therapy
are among the candidates who benefit from complement or
CRP inhibitors.
Acknowledgements
This study was financially supported by the Netherlands
Heart Foundation, grant no. 97–088 and grant no. 93–119.
Dr Niessen is a recipient of the Dr E. Dekker program of
the Netherlands Heart Foundation (D99025).
References
1 Entman ML, Michael L, Rossen RD, Dreyer WJ, 
Anderson DC, Taylor AA et al. Inflammation in the course 
of early myocardial ischemia. FASEB J 1991;5:2529–37.
2 Entman ML, Smith CW. Postreperfusion inflammation: a 
model for reaction to injury in cardiovascular disease. 
Cardiovasc Res 1994;28:1301–11.
3 Hill JH, Ward PA. The phlogistic role of C3 leukotactic 
fragments in myocardial infarcts of rats. J Exp Med 
1971;133:885–900.
4 Mathey D, Schofer J, Schafer HJ, Hamdoch T, Joachim HC, 
Ritgen A et al. Early accumulation of the terminal complement-
complex in the ischaemic myocardium after reperfusion. Eur 
Heart J 1994;15:418–23.
5 McManus LM, Kolb WP, Crawford MH, O’Rourke RA, 
Grover FL, Pinckard RN. Complement localization in ischemic 
baboon myocardium. Lab Invest 1983;48:436–47.
6 Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, 
Entman ML. Selective accumulation of the first component of 
complement and leukocytes in ischemic canine heart muscle. 
A possible initiator of an extra myocardial mechanism of 
ischemic injury. Circ Res 1985;57:119–30.
7 Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, 
Longhurst JC. Limitation of reperfusion injury by a monoclonal 
antibody to C5a during myocardial infarction in pigs. Am J 
Physiol 1995;268:H448–57.
8 Horstick G, Heimann A, Gotze O, Hafner G, Berg O, 
Boehmer P et al. Intracoronary application of C1 esterase 
inhibitor improves cardiac function and reduces myocardial 
necrosis in an experimental model of ischemia and reperfusion. 
Circulation 1997;95:701–8.
9 Hugo F, Hamdoch T, Mathey D, Schafer H, Bhakdi S. 
Quantitative measurement of SC5b-9 and C5b-9 (m) in 
infarcted areas of human myocardium. Clin Exp Immunol 
1990;81:132–6.
10 Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the 
terminal C5b-9 complement complex in infarcted areas of 
human myocardium. J Immunol 1986;137:1945–9.
11 Yasojima K, Schwab C, McGeer EG, McGeer PL. Human 
heart generates complement proteins that are upregulated 
and activated after myocardial infarction. Circ Res 
1998;83:860–9.
12 Nijmeijer R, Lagrand WK, Lubbers YTP, Visser CA, 
Meijer CJLM, Niessen HWM et al. C-reactive protein 
activates complement in infracted human myocardium. 
Am J Pathol 2003;163:269–75.
13 Kagiyama A, Savage HE, Michael LH, Hanson G, 
Entman ML, Rossen RD. Molecular basis of complement 
activation in ischemic myocardium: identification of specific 
molecules of mitochondrial origin that bind human C1q 
and fix complement. Circ Res 1989;64:607–15.
14 Volanakis JE. Complement activation by C-reactive protein 
complexes. Ann N Y Acad Sci 1982;389:235–50.
15 Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, 
Hack CE. CRP-mediated activation of complement in vivo: 
assessment by measuring circulating complement-C-reactive 
protein complexes. J Immunol 1996;157:473–9.
16 Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, 
Visser CA, Verheugt FW et al. C-reactive protein colocalizes 
with complement in human hearts during acute myocardial 
infarction. Circulation 1997;95:97–103.
17 De Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, 
Sprengers PF et al. Continuous 48-h C1 inhibitor treatment, 
following reperfusion therapy, in patients with acute myocardial 
infarction. Eur Heart J 2002;23:1670–7.
18 Dreyer WJ, Michael LH, Nguyen T, Smith CW, Anderson DC, 
Entman ML. Kinetics of C5a release in cardiac lymph of dogs 
experiencing coronary artery ischemia-reperfusion injury. Circ 
Res 1992;71:1518–24.
19 Schoen FJ. The heart. In: Coltran C, Komer V, Robbins LR, 
editors. Robbins Pathologic Basis of Disease. Philadelphia, 
PA: WB Saunders; 1989.pp. 605–14.
20 Mallory GK, White PD, Salcedo-Salgar J. The speed of healing 
of myocardial infarction. Am Heart J 1939;18:647–51.
21 Niessen HW, Lagrand WK, Visser CA, Meijer CJLM, 
Hack CE. Upregulation of ICAM-1 on cardiomyocytes in 
jeopardized human myocardium during infarction. Cardiovasc 
Res 1999;41:603–10.
22 Ito W, Schafer HJ, Bhakdi S, Klask R, Hansen S, 
Schaarschmidt S et al. Influence of the terminal complement-
complex on reperfusion injury, no-reflow and arrhythmias: a 
comparison between C6-competent and C6- deficient rabbits. 
Cardiovasc Res 1996;32:294–305.
23 Gershov D, Sunjung K, Brot N, Elkon KB. C-reactive protein 
binds to apoptotic cells, protects the cells from assembly of the 
terminal complement components, and sustains an 
antiinflammatory innate immune response: Implications for 
systemic autoimmunity. J Exp Med 2000;192:1353–63.
24 Bhakdi S, Torzewski M, Paprotka K, Schmitt S, Barsoom H, 
Suriyaphol P et al. Possible protective role for C-reaction 
protein in atherogenesis. Complement activation by modified 
lipoproteins halts before detrimental terminal sequence. 
Circulation 2004;109:1870–6.
25 Agostoni A, Gardinali M, Frangi D, Cafaro C, Conciato L, 
Sponzilli C et al. Activation of complement and kinin systems 
after thrombolytic therapy in patients with acute myocardial 
114
infarction. A comparison between streptokinase and 
recombinant tissue-type plasminogen activator. Circulation 
1994;90:2666–70.
26 Bennett WR, Yawn DH, Migliore PJ, Young JB, Pratt CM, 
Raizner AE et al. Activation of the complement system by 
recombinant tissue plasminogen activator. J Am Coll Cardiol 
1987;10:627–32.
27 Ratnoff OD, Naff GB. The conversion of C’IS to C’1 esterase 
by plasmin and trypsin. J Exp Med 1967;125:337–58.
28 Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van 
Hardevelt FW, de Beaumont EM et al. Activation of the 
complement system during and after cardiopulmonary bypass 
surgery: postsurgery activation involves C-reactive protein and 
is associated with postoperative arrhythmia. Circulation 
1997;96:3542–8.
29 Hajj-Ali R, Zareba W, Ezzeddine R, Moss AJ. Relation of 
the leukocyte count to recurrent cardiac events in stable 
patients after acute myocardial infarction. Am J Cardiol 
2001;88:1221–4.
30 Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum 
C-reactive protein concentration in acute myocardial infarction 
and its relationship to mortality during 24 months of follow-
up in patients under thrombolytic treatment. Eur Heart J 
1996;17:1345–9.
31 Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, 
Mitamura H et al. C-reactive protein as a predictor of infarct 
expansion and cardiac rupture after a first Q-wave acute 
myocardial infarction. Circulation 1997;96:778–84.
32 Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, 
Moore FD Jr et al. Intestinal reperfusion injury is 
mediated by IgM and complement. J Appl Physiol 
1999;86:938–42.
33 Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, 
Hechtman HB et al. Reperfusion injury of ischemic skeletal 
muscle is mediated by natural antibody and complement. J Exp 
Med 1996;183:2343–8.
34 Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-
binding lectin reduces postischemic myocardial reperfusion 
injury. Circulation 2001;104:1413–8.
35 Buerke M, Murohara T, Lefer AM. Cardioprotective effects of 
a C1 esterase inhibitor in myocardial ischemia and reperfusion. 
Circulation 1995;91:393–402.
36 Shandelya SM, Kuppusamy P, Herskowitz A, Weisfeldt ML, 
Zweier JL. Soluble complement receptor type 1 inhibits the 
complement pathway and prevents contractile failure in the 
postischemic heart. Evidence that complement activation is 
required for neutrophil-mediated reperfusion injury. Circulation 
1993;88:2812–26.
37 Smith EF 3rd, Griswold DE, Egan JW, Hillegass LM, 
Smith RA, Hibbs MJ et al. Reduction of myocardial reperfusion 
injury with human soluble complement receptor type 1 (BRL 
55730). Eur J Pharmacol 1993;236:477–81.
115
 116
Chapter 11 
 
IgM co-localizes with complement and C-
reactive protein in the infarcted human 
myocardium 
 
Krijnen PAJ, Ciurana C, Cramer T, Hazes T, Meijer CJLM, Visser 
CA, Niessen HWM, Hack CE.  
 
Journal of Clinical Pathology 2005 Apr;58(4):382-388. 
117
ORIGINAL ARTICLE
IgM colocalises with complement and C reactive protein in
infarcted human myocardium
P A J Krijnen, C Ciurana, T Cramer, T Hazes, C J L M Meijer, C A Visser, H W M Niessen, C E Hack
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr P A J Krijnen, VU
Medical Centre,
Department of Pathology,
Room 0E16, De Boelelaan
1117, 1007 MB
Amsterdam, The
Netherlands; paj.krijnen@
vumc.nl
Accepted for publication
4 October 2004
. . . . . . . . . . . . . . . . . . . . . . .
J Clin Pathol 2005;58:382–388. doi: 10.1136/jcp.2004.022988
Aims: Reperfusion of ischaemic myocardium after acute myocardial infarction (AMI) can induce
ischaemia/reperfusion (I/R) injury, as a result of local activation of the complement system. C reactive
protein (CRP) is involved in this activation. This study analysed the potential role of IgM in complement
activation in the infarcted human myocardium.
Methods: Immunochemical analysis was carried out on heart specimens from 59 patients who died from
AMI. Serial slides of frozen tissue from the infarction site were stained for IgM, complement factors C3d
and C5b–9 (membrane attack complex), and CRP.
Results: IgM deposits were found on the plasma membrane, cross striations, and in the cytoplasm of
jeopardised cardiomyocytes in infarcts of one to five days duration. IgM depositions were remarkably
similar to those of CRP and both complement factors. The relative staining intensities of IgM and CRP
varied greatly among patients.
Conclusions: Similar to CRP, IgM targets complement locally to jeopardised cardiomyocytes in the human
heart after AMI. Localisation patterns and relative staining intensities suggest that IgM and CRP recognise
similar epitopes in the ischaemic heart, but that the relative contribution of each protein to complement
activation in the ischaemic myocardium differs among patients.
R
eperfusion of the impaired myocardium after acute
myocardial infarction (AMI) results in a local inflam-
matory response.1 This inflammatory response damages
the ischaemic tissue, a phenomenon also designated ischae-
mia/reperfusion (I/R) injury. Prevention of this I/R induced
inflammation has been shown to reduce the infarct size by as
much as 50% in animal models,1 and may offer new
therapeutic opportunities for patients with AMI. Hence,
knowledge of the mechanisms of I/R injury in humans is
warranted.
The complement system is an important mediator involved
in experimental I/R injury in animals. In a rat model of
reperfusion injury of ischaemic myocardium, prevention of
complement activation resulted in a pronounced reduction of
I/R related injury.2 In addition, there is preliminary evidence
that the inhibition of complement by C1 inhibitor reduces
infarction size by up to 57% in humans.3 These results point
to complement as an attractive target for limiting I/R injury.
However, the molecular basis of I/R induced complement
activation is not completely understood.
‘‘Prevention of ischaemia/reperfusion induced inflamma-
tion has been shown to reduce the infarct size by as much
as 50% in animal models, and may offer new therapeutic
opportunities for patients with acute myocardial infarc-
tion’’
Various molecules have been claimed to target activated
complement to the ischaemic myocardium during I/R injury.
One of these molecules is C reactive protein (CRP), which
activates complement via the classical pathway.4–6 In rabbits,
CRP was localised to the inflamed myocardium after AMI.7 8
Administration of human CRP in rats challenged with
coronary artery occlusion enhances infarction size in a
complement dependent manner.9 In myocardial tissue
specimens from patients that died from AMI, CRP colocalises
with complement,10 suggesting that in humans this acute
phase protein contributes to complement activation in the
ischaemic myocardium. This notion is supported by observa-
tions that during AMI the human heart contains increased
amounts of activation products that specifically reflect
complement activation induced by CRP.11
In mice, IgM was also shown to be involved in complement
activation induced during I/R injury.12 13 In I/R models of the
intestine and skeletal muscle, IgM deficient mice developed
substantially less I/R injury than their wild-type littermates,
and this injury was restored in the deficient mice by
supplementation with normal murine IgM. The specificity
of the IgM mediating I/R injury in mice is not known. It is
also not known whether a similar IgM dependent mechanism
occurs in humans during I/R. We hypothesised that in
humans IgM might also contribute to ischaemic injury in the
heart after AMI. Therefore, in our study we analysed tissue
specimens from the hearts of patients who had died from
AMI. These specimens were analysed for the presence of IgM,
CRP, complement factor C3d, and complement factor C5b–9
of the membrane attack complex.
METHODS
Patients
Patients referred to the department of pathology, VU Medical
Centre, Amsterdam, the Netherlands for necropsy were
included in our study if this was performed within 24 hours
of death, and when at necropsy they showed signs of a
recently developed AMI—that is, on histochemical examina-
tion they had decreased lactate dehydrogenase staining
(decoloration) of the affected myocardium. Our study was
approved by the ethics committee of the VU Medical Centre,
Amsterdam, and complied with the principles of the
Declaration of Helsinki. Use of leftover material after
Abbreviations: AMI, acute myocardial infarction; BSA, bovine serum
albumin; CRP, C reactive protein; I/R, ischaemia/reperfusion; mAb,
monoclonal antibody; PBS, phosphate buffered saline; PLA2,
phospholipase A2; PMN, polymorphonuclear leucocyte
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pathological examination is part of the standard patient
contract in our hospital.
Processing of tissue specimens
Myocardial tissue specimens were obtained from the
infarcted zone and from remote sites of the healthy part of
the heart. These remote sites showed normal lactate
dehydrogenase staining patterns and were studied as internal
non-infarcted controls. A control heart tissue sample from
the left ventricle was obtained from a patient who died from
a cause not related to heart disease. Before being prepared as
cryosections, tissue specimens were stored at 2196 C˚ (liquid
N2). Frozen sections were mounted on to SuperFrostHPlus
glass slides (Menzel-Gla¨ser, Braunschweig, Germany).
Assessment of infarct phase
Microscopic criteria14 15 were used to estimate infarct duration
and viability of cardiomyocytes in all myocardial tissue
specimens. Because morphological judgment is more reliable
with paraffin wax embedded slides, corresponding paraffin
wax slides were also made. Jeopardised myocardium was
characterised by the intensity of eosinophilic staining of
involved myofibres, condensation, loss of nuclei, and cross
striation. We characterised jeopardised myocardium without
microscopic changes but with macroscopic lactate dehydro-
genase decolorisation as an early phase infarct (phase 1),
infiltration of polymorphonuclear leucocytes (PMNs) as a
PMN phase infarct (phase 2), and infiltration of lymphocytes
and macrophages and fibrosis as a chronic phase infarct
(phase 3). Furthermore, patients showing typical changes of
phase 3 morphology together with those of phase 1
morphology were classified as reinfarct early phase (phase
4). Patients with phase 3 morphology and phase 2
morphology were classified as reinfarct PMN phase (phase
5). Two investigators (PAJK and HWMN) judged and scored
independently all slides for the infarct phase. Table 1 shows
the distribution of the various infarct phases among the
patients. In all cases, infarct age as assessed by histology
corresponded with the clinical course.
Antibodies
Horseradish peroxidase conjugated rabbit polyclonal antihu-
man IgM antibody (American Qualex, San Clemente,
California, USA) was used for immunohistochemical detec-
tion of IgM. Monoclonal antibodies (mAbs) against the
complement factor C3d (mAb C3-15; subtype, IgG1) and
against CRP (mAb 5G4; subtype, IgG2a) have been used
previously for immunohistochemical studies.10 mAb aE11
(subtype, IgG2a; Dako, Carpinteria, California, USA) was
used for the detection of complement factor C5b–9. The mAbs
were stored at 1 mg/ml in phosphate buffered saline (PBS),
pH 7.4. Irrelevant mAbs (two IgG1, one IgG2a, and one IgM)
were used as negative controls, and tested at concentrations
similar to those used for the anti-complement and anti-CRP
mAbs. These controls yielded negative results.
Immunohistochemistry
Frozen sections (5 mm thick) were mounted on to glass
slides, dried for one hour by exposure to air, and fixed in
acetone (‘‘Baker analysed reagent’’; Mallinckrodt Baker,
Deventer, the Netherlands). After rinsing in PBS, the slides
were incubated at room temperature for 10 minutes with
normal swine serum (for IgM), normal rabbit serum (for
complement and CRP) (both Dakopatts, Glostrup, Denmark),
or 5% (wt/vol) bovine serum albumin (BSA; Boehringer,
Mannheim, Germany) in PBS (for C5b–9), diluted 1/10
(normal swine serum) or 1/50 (normal rabbit serum) in 1%
(wt/vol) BSA in PBS (PBS-BSA). Incubation of the slides
with specific antibody solutions (diluted in PBS-BSA) was
performed for 60 minutes except for mAb aE11, which was
incubated overnight at 4 C˚ (the polyclonal antibody against
IgM was diluted 1/400; mAb C3-15 was diluted 1/1500; mAb
5G4 was diluted 1/300; mAb aE11 was diluted 1/50). The
slides were washed for 30 minutes with PBS and slides
stained with mAbs were incubated with horseradish perox-
idase conjugated rabbit antimouse immunoglobulins
(Dakopatts), diluted 1/25 in PBS-BSA except for mAb aE11,
which was detected using EnVision (Dako). Thereafter, the
slides were washed again in PBS and incubated for three
minutes in 0.5 mg/ml 3,39-diaminobenzidine tetrahy-
drochloride (Sigma, St Louis, Missouri, USA) in PBS,
pH 7.4, containing 0.01% (vol/vol) H2O2, washed again,
counterstained with haematoxylin for one minute, dehy-
drated, cleared, and finally mounted.
Colocalisation of IgM, C3d, C5b–9, and CRP, in addition to
the relative staining intensities of IgM and CRP were
evaluated in each patient. Furthermore, the percentage of
positive surface area was determined, by subdividing the total
area of the slide into four equal parts and then estimating the
percentage of positive area in each visual field. Finally, an
average percentage of positive surface area was calculated
from these subdivisions. The slides stained with the
polyclonal antibody against IgM, or with mAbs C3-15, 5G4,
or aE11 were serial slides.
Two investigators (PAJK and HWMN) assessed the
anatomical localisation of the specific antibodies, as visua-
lised by immunohistochemical staining. For the final scoring
results, consensus was achieved by the two investigators.
Statistics
Statistical analysis was performed with the SPSS statistical
program (Windows version 9.0). To evaluate whether
observed differences were significant, paired or non-paired
t tests were used when appropriate. A p value (two sided) of
less than 0.05 was considered to represent a significant
difference.
RESULTS
IgM deposits in the human heart
Immunohistochemical deposits of IgM were found on
cardiomyocytes that were morphologically characterised as
jeopardised (fig 1). IgM deposits were found on the plasma
membrane and were strikingly intense in different areas of
Table 1 Distribution of various phases of AMI in the patients
AMI phase Infarct age Number of patients Male/female Age range
Early phase 0–12 hours 27 17/10 23–98
PMN phase 12 hours to 5 days 11 6/5 42–85
Chronic phase 5–14 days 5 3/2 58–83
Reinfarction Chronic phase +
Early phase 0–12 hours 5 3/2 63–85
PMN phase 12 hours to 5 days 7 3/4 30–89
AMI, acute myocardial infarction; PMN, polymorphonuclear leucocyte.
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the macroscopic infarction zone (fig 1A–C), on cross
striations (fig 1A), and in the cytoplasm (fig 1A) of
cardiomyocytes. We used an IgM subtype antibody against
Leu7 (which is not present in cardiomyocytes of the left
ventricle of the adult heart) as a negative control, and the
results were negative (fig 1G).
Focal IgM deposits were found inconsistently on the
endothelium of blood vessels in the heart of patients who
died of AMI (not shown). This endothelial IgM staining was
independent of the phase of infarction, because within each
phase a subgroup of patients had no IgM staining of the
endothelium, whereas others had varying amounts of IgM
positive vessels. Moreover, endothelial staining for IgM was
not limited to the infarction area, but also occurred at
adjacent sites and remote areas of the healthy part of the
heart.
Figure 1 Localisation of IgM on cardiomyocytes in myocardial infarct and colocalisation of IgM, C3d, C5b–9, and C reactive protein (CRP) in the
human heart. Localisation of IgM on cardiomyocytes in the heart of a patient who had died from acute myocardial infarction (AMI): (A) IgM deposited
on the plasma membrane (arrow I), on cross striations (arrow II), and in the cytoplasm (arrow III) of jeopardised cardiomyocytes (original
magnification,6630); (B, C) high power view of IgM staining of the plasma membrane of jeopardised cardiomyocytes (arrows IV, V, and VI) (original
magnification,61000). (D, H) Localisation of IgM; (E) localisation of complement factor C3d; (F) localisation of CRP; (I) localisation of complement
factor C5b–9 in the heart of a patient who died after AMI (original magnification,6100). (G) Negative staining using an IgM subtype monoclonal
antibody against Leu7 (negative control).
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IgM deposits on cardiomyocytes were found in the
infarcted myocardium of patients with PMN phase infarcts
and PMN phase reinfarcts. No depositions of IgM were found
in the infarcted myocardium of patients with early or chronic
phase infarcts or early reinfarcts. IgM deposits were never
found in the healthy, remote myocardium. In addition, no
IgM was found on the cardiomyocytes of a heart from a
patient who died of non-heart disease related causes. As
discussed earlier, no staining with IgG1 or IgG2a was found
on cardiomyocytes. The replacement of specific antibody with
IgG1 or IgG2a isotype controls yielded negative results in the
cardiomyocytes.
Colocalisation of IgM, complement, and CRP
To test for the putative colocalisation of IgM, complement,
and CRP in the infarcted myocardium, we stained serial
slides of the tissue specimens. IgM (fig 1D, H) colocalised
with complement factor C3d (fig 1E), complement factor
C5b–9 (fig 1I), and CRP (fig 1F)—the staining patterns of
IgM, CRP, and complement were strikingly similar. As was
found for IgM, no complement or CRP deposits occurred at
sites remote from the infarction area.
We also determined the extent of the deposits by
estimating the mean surface area occupied by cardiomyocytes
that were positive for IgM, complement, or CRP as a
percentage of the total surface area of the slides in the
infarcted region (fig 2). The IgM/complement/CRP positive
surface area in patients with PMN phase infarcts or PMN
phase reinfarcts was significantly greater than that of
patients with early phase infarcts (p = 0.001) or early phase
reinfarcts (p , 0.02). Moreover, this IgM/complement/CRP
positive area tended to be greater in PMN phase reinfarcts
than in PMN phase infarcts (p = 0.54 for IgM, p = 0.58 for
complement; p = 0.70 for CRP). To analyse the correlation
between deposits of IgM, CRP, and complement, we designed
scatter plots in which the IgM/complement/CRP positive
surface area of each patient was plotted, irrespective of
infarct phase. This analysis revealed a linear relation between
the sizes of the IgM and complement deposits (fig 3A;
R = 0.999; p = 0.000), those of IgM and CRP (fig 3B;
R = 0.994; p = 0.000), and those of complement and CRP
(fig 3C; R = 0.996; p = 0.000).
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Figure 2 Extent of IgM, complement, and C reactive protein (CRP)
deposition in the infarcted myocardium. Box plot presentation of the
percentage of IgM (grey bars), complement (white bars), and CRP
(shaded bars) positive myocardium. For each patient, the percentage of
positive surface area for the particular antibody in relation to the total
area of the examined tissue was calculated. The error bars represent
minimum and maximum values, whereas the boxes represent the lower
and upper quartiles. The black lines within the boxes represent the
medians (N, the number of patients examined). PMN,
polymorphonuclear leucocyte.
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Figure 3 Scatter plots of the extent of IgM/complement/C reactive
protein (CRP) positive areas in individual patients. Scatter plots in which
the extent of deposition (expressed as per cent of surface) of IgM,
complement, and CRP for each patient are plotted against each other.
(A) IgM versus complement; (B) IgM versus CRP; (C) CRP versus
complement. For each plot, the corresponding correlation coefficient (R)
and the two tailed significance (p value) are given.
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Staining intensity of IgM versus CRP
Because both IgM and CRP can activate complement, we
attempted to assess the contribution of either adaptor
molecule in complement activation by comparing the relative
intensities of staining (fig 4). For this, only PMN phase
infarcts and PMN reinfarcts were analysed because only
these had IgM and CRP deposits. The staining intensity of
IgM and CRP clearly varied between different patients (not
shown). In the 11 examined patients with PMN phase
infarcts, four patients had almost identical IgM and CRP
staining intensity (IgM = CRP). In another four patients,
IgM staining was less intense than that of CRP (IgM , CRP),
whereas in three patients IgM staining was more intense
than that of CRP (IgM . CRP). In three of the seven
examined patients with PMN phase reinfarctions, IgM and
CRP staining intensities were comparable, in one IgM
staining was less intense than that of CRP, and in three
patients IgM stained more intensely than CRP.
DISCUSSION
The observation that complement is locally activated by
infarcted myocardium goes back over 30 years.16 Since then,
it has become apparent that the complement system is an
important mediator of I/R injury in the heart during AMI,
and also in other organs. Studies on the molecular mechan-
isms of I/R induced activation of complement may offer new
clues for treatment. Recent evidence shows that CRP is a
complement activator in human myocardial infarcts.11 Here,
we also provide evidence for the involvement of IgM in this
activation. IgM is a known activator of complement,17–21 and
appeared to be deposited in the infarcted human myocar-
dium. In contrast to Schafer et al,22 who found only weak and
irregular staining of IgM in the infarcted human myocar-
dium, we found complete colocalisation of IgM with
activated C3d and C5b–9, indicative of membrane attack
complex formation. Irrelevant antibody controls indicated
the specificity of the staining for IgM, and IgG staining
yielded negative results. To our knowledge, this is the first
study showing the involvement of IgM in ischaemic injury in
humans.
The deposition of IgM showed a remarkable colocalisation
with that of complement and CRP, strongly suggesting that
the deposited IgM had bound to the same ligands in the
ischaemic heart as CRP. It appears that these ligands are only
exposed during the PMN phase of (re)infarction, because
deposition of CRP and IgM was rarely seen during the other
phases. Currently, we can only speculate about the nature of
these ligands. However, microscopic evaluation revealed that
the plasma membrane of the ischaemic cardiomyocytes in
particular harboured the ligands for IgM and CRP, because
these proteins bound to the plasma membrane of cardio-
myocytes in the infarcted zone. In an earlier study, we
showed that apolipoprotein H, which binds to phosphatidyl-
serine in flip flopped membranes, colocalises with CRP in
ischaemic myocardium.23 Loss of plasma membrane integrity
is a feature of jeopardised cells,24 so that structures exposed in
the flip flopped membrane of jeopardised cardiomyocytes
might serve as ligands for CRP and IgM. Phosphorylcholine is
a good candidate for such a structure because CRP is known
to bind to phosphatidylcholine and particularly to lyso-
phosphatidylcholine via this chemical group.4 6 25 Indeed, a
considerable amount of lyso-phospholipid is generated in the
infarcted myocardium.26 In addition, we have recently
revealed that type II secretory phospholipase A2 (PLA2),
which generates lyso-phospholipids, enhances the binding of
CRP to the plasma membrane of ischaemically challenged rat
cardiomyoblasts.27 Furthermore, we have found that secre-
tory PLA2 colocalises in the infarcted human myocardium
with complement and CRP,28 and therefore also with IgM. A
similar specificity (preferential binding to lyso-phosphatidyl-
choline) has recently be described for anti-phosphorylcholine
IgM.29 This IgM failed to recognise phosphatidyl lipids but did
bind to lyso-phosphatidylcholine on murine apoptotic T cells,
and this binding was dependent on calcium independent
PLA2 activity.
29 It was also revealed that increased IgM
binding to the apoptotic cells was accompanied by comple-
ment activation.29 In addition to lyso-phospholipids, oxidised
phospholipids in membranes may also expose phosphor-
ylcholine in a way that allows the binding of IgM and
CRP,30 31 and increased amounts of oxygen radicals are
known to be generated in myocardial ischaemia.32 Its
supposed specificity for phosphorylcholine is consistent with
the idea that this IgM is natural IgM. Taken together, a
mechanism emerges in which increased production of oxygen
radicals together with enhanced PLA2 activity generates
binding sites in the membrane of cardiomyocytes in the
ischaemic myocardium, which promotes the binding of both
natural IgM and CRP, and which ultimately leads to
activation of complement and subsequent irreversible injury
to the tissue.
We found differences in the staining intensity of CRP and
IgM between patients, suggesting that IgM and CRP
recognise and even compete for the same epitopes on the
membranes of ischaemic cardiomyocytes. Serum levels of
natural IgM vary between people.33 In addition, there are
variations in the magnitude of the CRP response among
patients suffering from AMI.10 Unfortunately, we did not
have the opportunity to analyse the blood samples of the
patients included in our study. Hence, the relation between
circulating IgM and CRP values and the relative contribution
of either protein to complement activation in the ischaemic
myocardium remains to be established in further studies.
Autoimmune diseases such as systemic lupus erythemato-
sus, rheumatoid arthritis, and mixed connective tissue
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Figure 4 Intensity of IgM versus C reactive protein (CRP) deposition in
infarcted areas of the heart. Patients were divided into one of three
groups according to staining intensity: IgM staining intensity comparable
to that of CRP (IgM = CRP, shaded bars), IgM staining less intense than
that of CRP (IgM , CRP, white bars), and IgM staining more intense
than that of CRP (IgM . CRP, grey bars). The numbers of patients in
each group are given within the bars. PMN, polymorphonuclear
leucocyte.
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disease are accompanied by raised concentrations of IgM in
the circulation,34 35 and an increased risk for cardiovascular
events.36 37 In particular, increased concentrations of IgM
autoantibodies against cardiolipin are thought to be the link
between cardiovascular events and IgM in these diseases,
particularly because patients with ischaemic heart disease
may also have raised concentrations of these antibodies.38 39
Our findings could mean that in patients with autoimmune
diseases, during AMI, higher IgM serum values result in
greater IgM deposition in the ischaemic myocardium, thereby
contributing to more extensive injury and a higher mortality.
We included only one patient with autoimmune disease
(scleroderma) in our study. Although this patient did have
very intense staining for IgM in the infarcted myocardium,
the causal link between increased concentrations of anti-
phospholipid IgM autoantibodies and cardiovascular events
in autoimmune disorders needs to be studied further.
Several studies have shown surprising similarities between
CRP and IgM in cardiovascular disease. CRP has been shown
to localise in ischaemic myocardium and to enhance I/R
injury in the heart in a complement dependent manner.9 10 As
we have shown here, IgM also localises in ischaemic
myocardium, and in mouse models enhances I/R injury.12 13
CRP and IgM both enhance foam cell formation by
interacting with lipoprotein particles.40 41 Furthermore, anti-
cardiolipin IgM concentrations constitute a risk factor for
atherosclerotic vascular disease,42 similar to CRP.
The role of natural IgM in vascular disease is not clear,43
and might be considered as two sides of a coin: on the one
hand natural IgM antibodies against oxidised LDL protect
against atherosclerosis, as was found in mice,30 rabbits44 and
in humans,45 supporting the recent view that the induction of
a humoral immune response to oxidised neoepitopes may be
beneficial.46 On the other hand, our results suggest that IgM
antibodies against epitopes in the membranes of ischaemic
cardiomyocytes may enhance cardiac injury during infarction
and constitute an increased risk for cardiovascular disease.
Future studies should reveal the relative contribution of the
effects of IgM on cardiovascular disease in humans.
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During acute myocardial infarction (AMI), ischemia 
leads to necrotic areas surrounded by border zones of 
reversibly damaged cardiomyocytes, showing 
membrane flip-flop. During reperfusion type IIA 
secretory phopholipase A2 (sPLA2-IIA) induces direct 
cell-toxicity and facilitates binding of other 
inflammatory mediators on these reversibly damaged 
cardiomyocytes. Therefore, we hypothesized that the 
specific sPLA2-IIA-inhibitor PX-18 would reduce 
infarct size. AMI rats (40 minutes ligation) were 
treated with either PX-18 or vehicle intravenously, for 
3 days post AMI. After 4 weeks hearts were analyzed. 
To investigate a putative effect of PX-18 on 
cardiomyocytes in more detail, the effect of PX-18 on 
membrane flip-flop and apoptosis was investigated in 
vitro. We found that PX-18 significantly inhibited 
sPLA2-IIA activity and reduced infarct size (reduction 
73% ± SEM 9, P<0.05), and mortality (0% vs. 23%, 
P<0.05), compared to the vehicle-treated group. 
Importantly, histochemical and wall thickness 
analysis showed no signs of impaired wound healing 
in the PX-18 group. In vitro PX-18 significantly 
reduced both reversible membrane flip-flop and 
apoptosis in cardiomyocytes. However, no sPLA2-IIA 
activity, nor expression, could be detected, suggesting 
that PX-18 also exerted a protective effect independent 
of sPLA2-IIA. Thus, we show for the first time that PX-
18 decreases myocardial infarct size, without 
impairing wound healing. Further, PX-18 reduces 
membrane flip-flop and apoptosis in vitro 
independent of sPLA2-IIA. Thus PX-18 is a potent 
therapeutic to reduce infarct size by inhibiting sPLA2-
IIA, and possibly also by inhibiting membrane flip-
flop of cardiomyocytes in a sPLA2-IIA independent 
manner. 
   
Introduction 
Cardiovascular diseases are a leading cause of 
morbidity and mortality in the western world, with 
heart failure due to acute myocardial infarction (AMI) 
being the most common etiology.1;2 Current AMI 
treatment focuses on reperfusion of the ischemic 
myocardium. This reperfusion however, results in the 
induction of inflammation in the heart, which has been 
shown to inflict additional damage to the myocardium, 
hence termed ischemia/reperfusion (I/R)-injury.1;3;4 
Thus, ischemia not only results in areas of irreversibly 
damaged (necrotic) cardiomyocytes, but also in border 
zones of morphologically normal, reversibly damaged 
cardiomyocytes that surround these necrotic areas. It 
can be speculated that inflammation targets these 
reversibly damaged cardiomyocytes in the border zones 
of infarction, presumably subsequent to alterations in 
the plasma membrane.  
After AMI, reversibly damaged cardiomyocytes in the 
border zones of infarction, as well as irreversibly 
damaged cardiomyocytes within the necrotic areas, 
loose their membrane phospholipid asymmetry.5 As a 
result, the anionic phospholipids phosphatidylserine 
(PS) and phosphatidylethanolamine (PE), which under 
normal conditions are kept within the inner plasma 
membrane leaflet, are exposed in the outer membrane 
leaflet, a process called flip-flop.6 We and others have 
shown that this flip-flop can be reversible.7-9 However, 
during reperfusion the inflammatory mediator type IIA 
secretory-type phospholipase A2 (sPLA2-IIA) was 
shown to bind to and to induce death in these flip-
flopped cardiomyocytes.4;9-12   
sPLA2-IIA is a 14 kDa acute-phase protein that catalyses 
the hydrolysis of cellular phospholipids to  liberate non-
esterified fatty acids.13 The concomitant formation of 
lysophospholipids facilitates binding of another acute 
phase protein, namely C–reactive protein (CRP).14 This 
binding of CRP in the heart after AMI  then induces 
binding and activation of complement, resulting in 
further tissue damage via activation of the membrane 
attack complex or induction of chemotaxis of 
neutrophilic granulocytes.15-17 In addition sPLA2-IIA can 
not only induce cell death via CRP and complement 
activation, but also via a direct cytotoxic effect, 
independent of other inflammatory mediators.9
We hypothesized that inhibition of sPLA2-IIA by the 
specific sPLA2-IIA-inhibitor PX-18, may reduce 
cardiomyocyte death and infarct size in vivo. We further 
hypothesized that inhibition of  sPLA2-IIA would not 
impair wound healing after AMI, since sPLA2-IIA 
inhibition would protect the reversibly damaged 
cardiomyocytes while the irreversibly damaged 
cardiomyocytes would still be cleared from the 
myocardium independent of sPLA2-IIA.9 In this study, 
we therefore analyzed the effect of PX-18 on membrane 
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flip-flop (reversibly damaged and/or apoptotic cells), 
both in vitro and in vivo. In vivo the effect of PX-18 on 
infarct size, heart function and wound healing in the 
heart after AMI was studied in a rat AMI model. In vitro 
the mechanism of the effect of  PX-18 on membrane flip-
flop and apoptosis was studied in rat cardiomyoblasts. 
 
Materials and methods 
Rat AMI 
This study was approved by the VU animal ethics and 
welfare committee. Female Wistar rats (Harlan 
Laboratories, Horst, The Netherlands, 240-280 grams) 
were anaesthetised using 3% isoflurane (for initiation, 
maximal 10 minutes) and subcutaneous 
hypnorm/dormicum (fentanyl + fluanisone 0.5 ml/kg, 
midazolam 5 mg/kg) injection. Rats were ventilated (70 
breaths/min, 10-0.5 mbar, Zoovent ventilator, Instruvet, 
Amerongen, The Netherlands), and heart rate was 
monitored using Einthoven I ECG. A left thoracothomy 
was performed between the fourth and fifth rib, after 
which a 6.0 ethilon suture was placed around the left 
anterior descending coronary artery. Ischemia was 
maintained for 40 minutes, followed by reperfusion. 
Rats were blindly divided into 2 groups, the treatment 
group (n=17) received the sPLA2-IIA inhibitor PX-18 (30 
mg/kg, kindly provided by RBA Pharma, LLC, 
Bethesda, Maryland, USA in a formulation by Supratek 
Pharma Inc, Quebec, Canada), the control group (n=13) 
received vehicle (NaCl 0.9%). Treatment was given in 
three daily intravenous doses, starting directly after 
reperfusion. 28 days after AMI Heart function was 
analyzed with 2D-echocardiography using a 13 MHz 
linear-array transducer (ProSound SSD-4000 PureHD, 
Aloka, Tokyo, Japan), and rats were sacrificed. Blood 
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Figure 1: PX‐18 reduces infarct size in a rat model of AMI
A: Schematic overview of rat heart. Hearts were cut into 5 transverse slices. For histochemical analysis, microscopic slides were cut 
from the upper surface of each slice. Only the lower three slides were used for infarct area quantification, since no infarct was found in 
the slides cut from the area above the ligature. PTAH staining of the anterior wall of sham operated (B) and vehicle‐treated (C) rats. 
Vital myocardium is stained blue, fibrosis red (see arrows). B: Epicardial scar tissue and granulation tissue due to suture placement is 
visible  in  sham‐operated  rat  heart  (see  arrows).  Magnification  50x.  C:  Infarcted  myocardium  contains  sites  of  fibrosis  (*)  and 
infiltration of inflammatory cells (#). Magnification 200x. D: Relative infarct size compared to the vehicle group (100%) was decreased 
with 73% ± 9 in rats receiving PX‐18 (P<0.05, one‐sided t‐test).
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was obtained from rats 5 days after AMI. Also sham 
operated controls were included in this study (n=4). 
 
Histological staining   
Hearts were cut into 5 equal slices (figure1A), fixed in 
4% formaldehyde and embedded in paraffin. Then a 
phosphotungstic acid haematoxylin (PTAH)-
histological staining was performed on 4 μm sections. In 
brief, after deparaffinisation and hydration, slides were 
incubated in Bouin-solution (73% v/v saturated picrinic 
acid solution, 25% v/v formaldehyde (37%), 2% v/v 
glacial acetic acid) at 56-70°C for 30 minutes. Then slides 
were washed in water, and incubated in PTAH-solution 
(0.1% v/v hematoxilin, 1% v/v phosphotungstic acid in 
distilled water) at 56-70°C for 60 minutes. Infarct size, 
total left-ventricle area and wall-thickness were 
quantified in the lower 3 slides (figure 1A) using Q-
PRODIT analysis (Leica micro-systems, Cambridge, 
UK). Slides cut from above the ligature were not 
analyzed, since no infarcted tissue was found in this 
area of the heart. Infarcted areas were defined as sites of 
fibrosis with or without inflammatory cell infiltration. 
Effect of suture placement on the heart, independent of 
infarct induction, was determined in sham operated 
rats. It was found that suture placement itself caused 
area of maximal 0.01% of the total left ventricle area. 
Therefore, rats with infarct size <0.01% of the total left 
ventricle area, were excluded from further analysis (in 
total 2 rats in the vehicle group). 
 
granulation tissue formation and fibrosis in the suture 
mmunohistochemistry 
18 on the infiltration of 
ell culture 
cardiomyoblasts (H9c2 (2-1) cells; ATCC, 
brane flip-flop analysis 
s analyzed using flow 
I
To investigate the effect of PX-
inflammatory cells we analyzed the presence of 
neutrophilic granulocytes and macrophages, using a 
rabbit-anti-human MPO antibody (1:500 dilution, 
DakoCytomation, Eindhoven, The Netherlands) and 
mouse-anti-rat-CD68 antibody (1:100 dilution, 
MCA341R Serotec, Kidlington, UK). Antigen retrieval 
was performed using 0.1% pepsin for cd68 (in 0.02 M 
HCl, 30’, 37°C), or by heat activation in Citrate (pH 6) 
for MPO. Primary antibodies were incubated for 60 
minutes. For secundary antibody anti-rabbit and anti-
mouse EnVision-HRP (DakoCytomation) was used. 
Staining was visualized using EnVision-
diaminobenzidin (DakoCytomation). Control sections 
were incubated with PBS instead of the primary 
antibody, and yielded no staining at all (not shown). 
Numbers of extravascular positive cells were quantified 
in the entire left ventricle of the cross sections, 
distinguishing between viable and infarcted areas.   
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Figure 2: Effects of PX‐18 on heart function
A: Relative cardiac output (CO) compared to the normal value 
(46.3 mL/min.) was  increased  from 85% ± 7  to 97% ± 6 of  the 
normal  value  in  rats  receiving  PX‐18,  compared  to  vehicle‐
treated rats (P=0.27, one‐sided Mann‐Whitney test). B: Relative 
stroke  volume  compared  to  vehicle‐treated  rats  (100%)  was 
increased with 15% ± 6 (P=0.10, one‐sided t‐test)  in the group 
receiving PX‐18.
C
O
 r
el
at
iv
e 
to
 n
or
m
al
 (%
)
re
la
tiv
e 
st
ro
ke
 v
ol
um
e 
(%
)
C
O
 r
el
at
iv
e 
to
 n
or
m
al
 (%
)
re
la
tiv
e 
st
ro
ke
 v
ol
um
e 
(%
)
C
O
 r
el
at
iv
e 
to
 n
or
m
al
 (%
)
re
la
tiv
e 
st
ro
ke
 v
ol
um
e 
(%
)
Neonatal rat 
Manassas, Virginia, USA) were cultured in Dulbecco’s 
Modified Eagles Medium (DMEM; BioWhittaker, 
Verviers, Belgium) containing 10% heat inactivated 
Fetal Calf Serum (FCS; BioWhittaker), 100 IU/mL 
penicillin (Yamanouchi Europe BV, Leiderdorp, 
Netherlands), 100 µg/mL streptomycin (Radiopharma-
Fisiopharma, Palomonte, Italy) and 2 mM L-Glutamin 
(Gibco, Paisly, England), in a humidified atmosphere of  
5% CO2 at 37°C. Cells were used at 60 – 80% confluency. 
Simvastatin (25 μM, simvastatin-lactone, a gift from 
Merck & Co., Inc, Rahway NJ, USA), mevalonate (250 
μM, Sigma, St. Louis, MO, USA), zVAD-fmk (a pan-
caspase iinhibitor, 25 μM, zVAD; Alexis Biochemicals, 
San Diego, CA, USA) and PX-18 (0.2 mg/ml) were all 
added to the cultures 24 hours before harvesting. 
Simvastatin was activated by dilution to 1 mM 
concentration) in 0.1 mol/L NaOH pH=7.4 for 30 
minutes prior to incubation. As a stock solution, PX-18 
was dissolved in PBS containing 10 mM NaOH, pH = 
7.4. 
Mem
Flip-flop in H9c2 cells wa
cytometry. For this cells (attached- as well as detached 
cells) were collected and stained with annexin V-FITC 
or annexin V-PE (both 1:40 dilution, Bender Med 
Systems, Vienna, Austria) for 30 minutes at 37°C in 
serum-free medium. Annexin V was used to assess flip-
flop of the cell membrane.  Propidium iodide was 
added immediately prior to measurement (PI; 1:40 
dilution, Bender Med Systems) and was used to assess 
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membrane permeability, and thus cell death. Cells were 
analyzed using a FACSCalibur flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA).  
Active Caspase 3 concentration measurements  
luorimetric 
LA2-IIA activity measurements 
oth in the lysates of 
estern blot analysis 
s-buffer containing 0.001% NP-
tatistical analysis 
was performed using GraphPad 
Caspase 3 activity was determined using a f
homogeneous caspase assay (Roche, Mannheim, 
Germany), according to the manufacturer’s instructions. 
In brief, cells were lysed and incubated with DEVD-
rhodamine 110 substrate for one hour at 37°C. 
Subsequently, the amount of free rhodamine was 
determined in a microplate fluorescence reader 
(TECAN spectrafluor, Hombrektikon, Switzerland). The 
developed fluorochrome was proportional to the 
concentration of activated caspase 3 and could be 
quantified by a calibration curve of diluted free 
rhodamine.  
 
sP
sPLA2-IIA activity was measured b
cells subjected for 24 hours to simvastatin (25μM) 
and/or PX-18 (0.2 mg/ml), and in serum of rats 5 days 
after AMI, since theoretically then sPLA2-IIA activity is 
maximal, according to human data.11 Activity was 
measured with or without adding of PX-18, according 
to manufacturer’s protocol (Cayman Chemical, Ann 
Arbor, MI, USA). In brief 10 μl of cell lysate or serum 
was added to an assay mix containing the substrate 
diheptanoyl phosphatidylcholine, and 5,5-dithio-bis-2-
nitrobenzoic acid (DTNB). sPLA2-IIA activity was 
determined by measuring the release of free thiols over 
time in 8 consecutive measurements in a microplate 
fluorescence reader (TECAN spectrafluor, 
Hombrektikon, Switzerland).  
 
W
Cells were lysed in lysi
40, 2.5 mM Tris-HCl, 150 mM NaCl, and 5mM EDTA in 
water. Protein concentration was determined using the 
BCA protein assay kit (Pierce, Rockford, IL, USA). Then 
reducing sample loading buffer (0.25 M TRIS pH 6.8, 
sodium dodecyl sulfate (SDS), glycerol, 2-
mercaptoethanol, bromophenol blue) was added and 
the samples were mixed and heated at 95˚C for 5 min. 
Proteins were then subjected to SDS-PAGE, and 
transferred to nitrocellulose membranes. Membranes 
were incubated with primary antibodies overnight at 
4˚C (mouse-anti-rat sPLA2-IIA, 1:250, 2B7/2E7, kindly 
provided by Dr. CG Schalkwijk, Department of Internal 
Medicine, University Hospital Maastricht, the 
Netherlands, and β-actin, 1:4000, BD Biosciences, 
Franklin Lakes, NJ, USA). After washing membranes 
were incubated with rabbit-anti-mouse antibody 
horseradish peroxidase conjugated for 1 hour at room 
temperature (DakoCytomation, Glostrup, Denmark, 
1:1000). The blots were visualised by enhanced 
chemiluminescence (1:40, ECL; Amersham Bioscience 
AB, Buckinghamshire, UK). Staining was quantified 
using a charge couple device camera (Fuji Science 
Imaging Systems) in combination with AIDA Image 
Analyzer software (Isotopenmessgeräte; Staubenhardt, 
Germany).   
 
S
Statistical analysis 
Prism 4 software. A t-test or ANOVA was used if scores 
were distributed normally, if not, a Mann-Whitney test 
or Kruskall-Wallis test was used for analysis. A Pearson 
chi-square test was used for analysis of discrete values. 
A p-value of less than 0.05 was considered to be 
statistically significant. In the text and figures values are 
given as mean ± standard error. The authors had full 
access to the data and take responsibility for its 
integrity. All authors have read and agree to the 
manuscript as written. 
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Figure  3:  Effects  of  PX‐18  on  neutrophilic granulocyte and 
macrophage infiltration
unt  of  neutrophilic granulocytes  (A+B)  and macrophages 
D)  in  the  heart  28  days  after  MI  in  rats  treated  with  or 
without PX‐18. A: Amount of neutrophilic granulocytes  in  the 
noninfarcted areas  of  the  left  ventricle.  Significantly  more 
neutrophilic granulocytes  were  found  in  infarcted  animals, 
compared to sham operated animals. B: Amount of neutrophilic
granulocytes  in  the  infarcted  area  of  the  left  ventricle.  No 
significant differences were  found  between  PX‐18  treated  and 
untreated  animals.  C:  Amount  of  macrophages  in  the 
noninfarcted areas  of  the  left  ventricle.  Significantly  more 
macrophages were found in PX‐18 treated animals, compared to 
sham  operated  and  vehicle  treated  animals.  D:  Amount  of 
macrophages  in  the  infarcted  area  of  the  left  ventricle. 
Significantly more macrophages were  found  in  PX‐18  treated 
animals, compared to vehicle treated animals.
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Results 
ces infarct size and mortality in a rat model 
 operated rats, superficial wounds including 
hat PX-18 is a specific 
was significantly 
 using echocardiography 
alue 0.46) was not 
X-18 does not affect neutrophilic granulocyte 
ate the effect of PX-18 on wound healing and 
thus inflammatory cell infiltration we analyzed the 
ount of 
PX-18 redu
of AMI 
In sham
fibrosis and granulation tissue formation were induced, 
but only at the epicardial site of the heart (figure 1B). In 
contrast, in rats with AMI areas of fibrosis with or 
without inflammatory cells were found in all areas of 
the ventricular wall (figure 1C).  
It has been described recently t
sPLA2-IIA inhibitor.18 We validated this inhibitory effect 
of PX-18 in vivo in the plasma of rats 5 days after MI and 
found that PX-18 indeed significantly reduced sPLA2-
IIA activity in the serum (not shown). 
In rats treated with PX-18 infarct size 
decreased by 73 ± 9 % when compared to vehicle 
treated rats (p<0.05; figure 1D). As theoretically AMI 
can result in a decrease of wall thickness, this was also 
quantified. We however did not find significant 
differences in wall thickness between groups receiving 
PX-18 or vehicle, nor between these groups and sham-
operated rats (not shown). Also no immunohistological 
differences in scar tissue formation (amount of fibrosis 
and granulation tissue) were found between the groups. 
Interestingly, rats treated with PX-18 (n=17) all survived 
AMI and the 28 day follow-up period. In contrast, in 
rats receiving vehicle (n=13) a mortality rate of 23% was 
found, which was significantly higher than in the PX-18 
treated group (p<0.05). In the vehicle group, namely 3 
out of 13 rats died within 2 days after myocardial 
infarction, respectively 2 rats during the first day and 1 
rat during the second day after AMI, thus during the 
acute inflammation period.  
Heart function was analyzed
just before the rats were sacrificed. Cardiac output was 
calculated using parasternal short axis left ventricular 
systolic and diastolic diameters as has been described, 
and compared to standard values in the literature of 
rats of the same weight.19 In vehicle treated rats the 
cardiac output was reduced to 85 ± 7 %  of the normal 
value (46.3 mL/min), whereas in PX-18 treated animals 
the cardiac output was 97 ± 6 % of the normal value 
(p=0.27 PX-18 versus vehicle; figure 2A). In addition, in 
PX-18 treated rats stroke volume was 15 ± 6 % higher 
compared to vehicle treated rats (p=0.10; figure 2B), 
however, neither of these parameters differed 
significantly between the groups.  
Fractional shortening (normal v
affected by AMI and was not significantly different 
between groups (vehicle group 108 ± 3 % compared to 
normal, PX-18 group 102 ± 7  % compared to normal, 
p=0.58).  
 
P
infiltration, but does increase macrophage infiltration 
after AMI 
To investig
presence of neutrophilic granulocytes and macrophages 
in both the infarcted myocardium (infarcted area and 
borderzone) as well as viable myocardium (rest) of the 
left ventricle (figure 3).  
The total amount of neutrophilic granulocytes in the 
non-infarcted areas of the left ventricle of AMI rats was 
significantly higher than in the hearts of the sham 
operated controls, however the total am
neutrophilic granulocytes was still low (vehicle 0.8  
versus 0.1 neutrophilic granulocytes/mm2 in sham 
operated, p<0.05, figure 3A). No differences in total 
neutrophilic granulocyte amount were found between 
the vehicle and PX-18 AMI groups (figure 3B).  
Macrophages were predominantly found in infarcted 
areas of the heart, with numbers being up to 60 times 
higher in infarcted myocardium compared to viable 
myocardium  Also the distribution of macrophages 
differed between infarcted and viable myocardium. In 
viable myocardium macrophages were diffusely 
solitary present within the tissue, whereas in the 
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re  4:  PX18  decreases  simvastatin  induced  membrane 
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infarcted myocardium the macrophages were 
predominantly found in large conglomerates. The 
PX-18 resulted in a significant 
duction of sPLA2-IIA activity in rat serum, a 
y 
e 
As the HMG-CoA 
hat PX-18 
, that was significantly reduced by 
ne with this, sPLA2-
A expression could not be detected in any of the 
 western blot (figure 5). This therefore 
vo, treatment with PX-18 
amount of macrophages was significantly increased 
after treatment with PX-18 compared to vehicle-treated 
rats, in both the infarction areas (p<0.05) as well as the 
viable myocardium of the left ventricle (p<0.01, figures 
3C,D).   
Thus, inhibition of sPLA2-IIA in vivo using the specific 
sPLA2-IIA inhibitor 
re
significant reduction of infarct size, a significantl
higher survival rate and a significant increase in th
amount of infiltrating macrophages compared to 
vehicle treated rats.  
 
PX-18 decreases membrane flip-flop and apoptosis in 
rat cardiomyoblasts in vitro independent of sPLA2-IIA 
Since RNA expression of sPLA2-IIA has been shown in 
cardiomyocytes under conditions of stress,20;21 we also 
investigated the putative effect of PX-18 on rat 
cardiomyoblasts in vitro. In a previous study we found 
that ischemia resulted mainly in an increase in annexin 
V/PI positive H9C2 cells indicating late apoptotic/dead 
cells, whereas the induced number of single-annexin V 
positive cells, indicating early apoptotic or reversibly 
damaged cells, was limited.9 
reductase inhibitor simvastatin has been shown 
previously to induce apoptosis and membrane flip-flop 
in cardiomyocytes,22;23 we studied the effect of PX-18 on 
simvastatin induced (reversible) plasma membrane flip-
flop in H9c2 cells and apoptosis.  
Simvastatin (25 μM, 24 hours incubation) significantly 
increased the percentage of single-annexin V positive 
cells to 23 ± 2 % compared with 5 ± 1% in control cells 
(p<0.001; figure 4A). This effect was completely 
neutralized by mevalonate (6 ± 0 % single annexin V 
positive cells), indicating that the effects induced by 
simvastatin are indeed the result of its inhibition of 
HMG-CoA reductase. Simvastatin induced a significant 
decrease in the percentage of viable cells (p<0.01), 
whereas no significant differences were found in the 
percentages of annexin V/PI or single-PI positive cells 
between control, simvastatin or simvastatin and either 
mevalonate, zVAD or PX-18 treated cells (not shown). 
zVAD (a pan-caspase inhibitor) significantly reduced 
the percentage of single-annexin V-positive cells to 13 ± 
0 % (p<0.001; figure 4B). Interestingly however, the 
percentages of single-annexin V positive cells after 
treatment with simvastatin and zVAD were still 
significantly higher than in control cells (p<0.001). This 
indicates that part of the simvastatin-induced 
membrane flip-flop was reversible, and a part apoptotic. 
In line with this, in a double labeling experiment with 
RPE–labeled human recombinant annexin V (annexin 
V-PE) and a green fluorescent probe that binds active 
caspase 3 (FAM-DEVD-fmk) we found that simvastatin, 
in addition to a population of cells positive for both 
annexin V-PE and active caspase 3 (thus apoptotic cells 
), indeed induced a population of cells positive for 
annexin V-PE but negative for active caspase 3 (not 
shown), suggesting that this population showed 
reversible membrane flip-flop. We next analyzed the 
effect of PX-18 hereon. We found t
significantly reduced the percentage of simvastatin 
induced single-annexin V positive cells completely from 
21 ± 2 % to 2 ± 0 %  (control level  3 ± 1 %, p<0.001; 
figure 4C). This suggest that PX-18 both protected 
reversibly damaged and apoptotic cells. 
The anti-apoptotic effect of PX-18 was further validated 
by measuring active caspase 3 in a caspase 3 assay. 
Simvastatin indeed significantly increased active 
caspase 3 concentration with 546 ± 81 nM compared to 
control cells (p<0.001)
PX-18 to 136 ± 57 nM above control level (p<0.001; 
figure 4D). PX-18 treated group did not differ 
significantly from the control group. As a positive 
control, zVAD completely inhibited the caspase 3 
activation (p<0.001).  
To investigate whether this effect of PX-18 on 
simvastatin induced membrane flip-flop was sPLA2-IIA 
mediatedsPLA2-IIA activity was quantified in H9c2 
cells. Remarkably, no sPLA2-IIA activity was detected in 
untreated H9c2 cells, cells subjected to simvastatin, cells 
subjected to only PX-18, neither in cells subjected to PX-
18 and simvastatin (not shown). In li
II
samples using
suggests that the PX-18 inhibitory effect on simvastatin-
induced membrane flip-flop and apoptosis was 
independent of sPLA2-IIA activity.  
 
Discussion 
In this study, we analyzed the effect of the sPLA2-IIA 
inhibitor PX-18 on infarct size and heart function in a rat 
AMI-model, and on membrane flip-flop and apoptosis 
in cardiomyocytes in vitro. In vi
significantly reduced sPLA2-IIA activity, infarct size and 
mortality, without impairment of wound healing. In 
vitro, PX-18 treatment significantly reduced membrane 
+ c     s     p     
14 kD
+ c     s     p     
42 kD
A
B
Figure 5: sPLA2‐IIA is not expressed in H9c2 cells
Western  blot  analysis  of  sPLA2‐IIA  expression  in H9c2  cells. 
Cells were  incubated with  or without  simvastatin  (25  μM)  ±
PX18  (1  mg/ml)  for  24h.  A:  sPLA2‐IIA  expression  is  only 
detected in the positive control (serum of rat 5 days after AMI). 
B:  Loading  control  β‐actin is  expressed  in  all  samples.  +  = 
positive control, rat serum 5 days after AMI, C = unstimulated
H9c2 cells, S = H9c2 cells with simvastatin, P = H9c2 cells with
simvastatin and PX‐18.
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flip-flop, as well as apoptosis in cardiomyocytes, 
independent of sPLA2-IIA. 
Previously we have shown that sPLA2-IIA deposits in 
the infarcted heart after AMI in the infarcted areas, 
where CRP and complement also bind.11 In addition, 
sPLA2-IIA was also found to bind to reversibly 
damaged, flip-flopped cardiomyocytes in the 
borderzones of infarction, and then induced cell death 
either dependent or independent of CRP and 
9
hea
my
ickness, 
wound healing after AMI, which is thus positively 
affected by PX-18. Roles for macrophages in wound 
healing after AMI are digestion of damaged tissue, 
promotion of angiogenesis, production of anti-
inflammatory mediators, and regulation of extracellular 
matrix metabolism through synthesis of matrix 
complement.  This led to the hypothesis that in the 
rt after AMI, sPLA2-IIA inhibition would result in 
decreased cardiomyocyte death and hence would 
reduce infarct size. We now for the first time show that 
a specific inhibitor of sPLA2-IIA indeed decreased 
ocardial infarct size in vivo.  
The inflammatory response in the heart after AMI is 
essential for myocardial remodeling and wound 
healing. Inhibition of this inflammatory response has 
been shown to impair wound healing and to induce 
severe consequences such as wall rupture.24-26 
Importantly, in our study, sPLA2-IIA inhibition by PX-
18 did not result in reduced ventricular wall th
nor in aneurysmatic infarcts, indicating that wound 
healing was not impaired. This is in agreement with 
findings that in the absence of sPLA2-IIA, CRP did bind 
to necrotic cardiomyocytes 9, indicating that necrotic 
tissue can still be cleared via CRP-complement 
dependent interactions with phagocytic cells.4  
In addition, we found that PX-18 treatment did not 
significantly affect the amount of neutrophilic 
granulocytes in the heart 28 days after MI, suggesting 
that neutrophilic granulocyte infiltration was also not 
delayed. Interestingly, the amount of macrophages in 
both the infarcted and non-infarcted areas of the heart 
were significantly increased 28 days after AMI in rats 
treated with PX-18 compared with vehicle treated rats. 
It is known that macrophages play an important role in 
metalloproteinases and their inhibitors.27;28  
In this study we also found a trend towards increased 
cardiac output and stroke volume in the PX-18 treated 
group, compared to the vehicle treated group, although 
this was not statistically significant. It has been 
described that heart function parameters such as stroke 
volume are correlated to infarct size.29-31 However 
cardiac output was found to be significantly decreased 
only in large infarcts32;33, just as heart function 
parameters were shown to be most improved after 
treatments of relatively large infarcts.12;29 In our study, 
the infarcts were non-aneurysmatic, which could 
explain its small effect on heart function after AMI and 
CRP
C
sPLA2
-IIA
sPLA2
-IIA
CRP
C
sPLA2
-IIA sPLA2-IIA
intra cellular
extra cellular
plasma membrane
in control cells
plasma membrane
during ischemia
plasma membrane during
post-ischemic inflammation
C
phosphatidylcholine
phosphatidylserine
modified phospholipid
complement
PX18
PX18
PX18
CRP
C
reversibly damaged
irreversibly damaged
Figure 6: In vivo mechanisms of cell death during AMI and the effect of sPLA2‐IIA inhibition by PX18
Ischemia induces reversible or irreversible membrane flip‐flop  in  cardiomyocytes. Flip‐flop  results in  the  loss of  the 
asymmetrical distribution  of  phospholipidsin the  outer and  inner  plasma membrane leaflets.  Consequently anionic
quent
f
li
phospholipids such as  phosphatidylserine  are  exposed in
inflammatory reaction,  sPLA2‐IIA  binds to flip‐flopped mem
activation of C‐reactive protein (CRP) and complement ©, as 
reversibly and irreversibly damaged cardiomyocytes. PX18 pre
by inhibiting direct  cytotoxic  effects of  sPLA2‐IIA,  and  also
complement.  Importantly,  CRP  can bind  to irreversibly
enabelingclearance of these cells and thus normal wound hea
  the  outer membrane leaflet.  During the  subse
branes and  induces cell death both via  binding  and 
via direct cytotoxic effects. This results in death of both
vents cell death of reversibly flip‐flopped cardiomyocytes 
by inhibiting sPLA2‐IIA‐facilitated  binding  of  CRP  and 
lip‐flopped cardiomyocytes  independent  of  sPLA2‐IIA, 
ng during sPLA2‐IIA inhibition.
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in turn the small effect of PX-18 treatment on the 
reduced function. We deliberately induced non-
aneurysmatic infarcts in a reperfusion model since in 
ocytes independent of  sPLA2-IIA 
t. PX-18 has a protective effect on 
 
an effective therapy in reducing post-infarct 
t 
also 
e in 
farct mediated damage of cardiomyocytes, and that 
his membrane flip-flop is promising. 
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patients most infarcts are non-aneurysmatic, because of 
widespread use of revascularization therapy. In 
addition we had found in a pilot study that complement 
inhibition most profoundly reduced infarct size in small 
to moderately sized infarcts, rather than in large 
aneurysmatic infarcts (unpublished results). 
The effects of the sPLA2-IIA inhibitor PX-18 on 
cardiomyocyte flip-flop and apoptosis were further 
investigated in vitro. Recently we and others have 
shown that membrane flip-flop can be a reversible 
phenomenon7;8;34, also in cardiomyocytes35. We now 
found that a significant proportion of the simvastatin 
induced flip-flopped cardiomyocytes were reversibly 
damaged cells, whereas another significant proportion 
was apoptotic and thus irreversibly damaged. PX18 did 
prevent apoptosis and membrane flip-flop in reversibly 
damaged cardiomy
inhibition, as no activity nor expression of sPLA2-IIA 
could be detected in the H9c2 cells under the 
investigated conditions. This is in agreement with 
previous studies in which mRNA expression, but no 
protein expression, of sPLA2-IIA was detected in 
cardiomyocytes.20;21
 In this study we thus show several protective roles for 
PX-18 after AMI as depicted in figure 6. After AMI 
reversibly and irreversibly damaged cardiomyocytes 
are induced. Due to the inflammation cascade both 
these type of cells are removed from the infarcted area. 
The reversibly damaged cells are removed due to 
binding of sPLA2-IIA, and to the subsequent binding of 
CRP and complement. The irreversibly damaged cells 
can also be removed due to direct binding of CRP 
and/or complemen
three different levels: 1) PX-18 inhibits membrane flip-
flop, and thus the pro-inflammatory state of the plasma 
membrane. 2) PX-18 inhibits sPLA2-IIA activity, and 
thus prohibits sPLA2-IIA mediated cell death of at that 
moment reversibly damaged cardiomyocytes. 3) PX-18 
inhibits apoptosis.  
These results thus show that administration of PX-18 is
inflammatory damage to the myocardium, withou
impairing normal wound healing. These results 
how that membrane flipflop plays a major rols
in
therapy targeting t
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Visser, C. J. L. M. Meijer, R. J. P. Musters, C. E. Hack, L. A. Aarden,
and H. W. M. Niessen. Clusterin: a protective mediator for ischemic
cardiomyocytes? Am J Physiol Heart Circ Physiol 289: H2193–H2202,
2005. First published July 1, 2005; doi:10.1152/ajpheart.00355.2005.—We
examined the relationship between clusterin and activated comple-
ment in human heart infarction and evaluated the effect of this protein
on ischemic rat neonatal cardiomyoblasts (H9c2) and isolated adult
ventricular rat cardiomyocytes as in vitro models of acute myocardial
infarction. Clusterin protects cells by inhibiting complement and
colocalizes with complement on jeopardized human cardiomyocytes
after infarction. The distribution of clusterin and complement factor
C3d was evaluated in the infarcted human heart. We also analyzed the
protein expression of clusterin in ischemic H9c2 cells. The binding of
endogenous and purified human clusterin on H9c2 cells was analyzed
by flow cytometry. Furthermore, the effect of clusterin on the viability
of ischemically challenged H9c2 cells and isolated adult ventricular
rat cardiomyocytes was analyzed. In human myocardial infarcts,
clusterin was found on scattered, morphologically viable cardiomyo-
cytes within the infarcted area that were negative for complement. In
H9c2 cells, clusterin was rapidly expressed after ischemia. Its expres-
sion was reduced after reperfusion. Clusterin bound to single annexin
V-positive or annexin V and propidium iodide-positive H9c2 cells.
Clusterin inhibited ischemia-induced death in H9c2 cells as well as in
isolated adult ventricular rat cardiomyocytes in the absence of com-
plement. We conclude that ischemia induces the upregulation of
clusterin in ischemically challenged, but viable, cardiomyocytes. Our
data suggest that clusterin protects cardiomyocytes against ischemic
cell death via a complement-independent pathway.
ischemia; acute myocardial infarction; membrane flip-flop
CLUSTERIN (also designated apolipoprotein J) is an extracellular,
highly conserved and heavily glycosylated, disulfide-linked
heterodimer with an apparent molecular mass of 75–80 kDa.
Clusterin is constitutively expressed in almost all mammalian
tissues by different cell types, including epithelial and specific
neuronal cells. Furthermore, clusterin is found in all body
fluids, including plasma, seminal plasma, milk, urine, and
cerebrospinal fluid (1, 17).
Clusterin has been reported to play a role in a wide variety
of processes and has been shown to interact with a wide range
of molecules, including lipids (7, 8) and several components of
the membrane attack complex (MAC) of complement (5, 18,
25, 32, 38, 43). In the blood, clusterin is associated with
subclasses of high-density lipoproteins, which also contain
apolipoprotein A1 and cholesteryl ester transfer activity (7).
Furthermore, expression of clusterin is upregulated in acute
myocardial infarction (37), atherosclerosis (15, 37), myocardi-
tis (36), oxidative stress and heat shock (40), Alzheimer’s
disease (26), several cancers (19), and after injury in general
(17).
Clusterin deposition was previously reported in the human
heart after acute myocardial infarction (AMI) (39), where it is
colocalized with complement factors C1q, C4, C3d, and C9 on
cardiomyocytes within the infarcted area. In contrast, in an
experimental myocardial infarction model in the rat, deposi-
tions of clusterin were only found in the peri-infarct zone
cardiomyocytes that did not stain for MAC (35). Moreover,
these myocytes appeared to synthesize clusterin as detected
with in situ hybridization. Expression of the clusterin gene was
also induced in ventricular myocytes in a mouse model of
myocarditis (36).
Considering the conflicting data on its distribution in rat
versus human myocardial infarction, we decided to examine in
more detail the functional role of clusterin in the human heart.
In addition, we investigated its effect on ischemic rat neonatal
myoblast cells (H9c2 cells), as well as on ischemic isolated
adult ventricular rat cardiomyocytes as in vitro models of AMI.
MATERIALS AND METHODS
Subjects. Recently deceased patients included in the study (Table 1)
were transferred to the Department of Pathology for autopsy (Vrije
Universiteit Medical Center). At autopsy the deceased subjects
showed signs of a recently developed AMI, i.e., on histochemical
examination they had decreased lactate dehydrogenase (LDH) stain-
ing (decoloration) of the affected myocardium. Different infarct du-
rations were categorized into different phases, as is explained in the
next paragraph. Clinical data with respect to the duration of AMI
corresponded to the different morphological stages of AMI. Autopsies
were performed as soon as possible, but at least within 24 h after
death. The study was approved by the ethics committee of the Vrije
Universiteit Medical Center, Amsterdam, The Netherlands. The in-
vestigation conforms to the principles of the Declaration of Helsinki.
Use of leftover material after the pathological examination is part of
the standard patient contract in our hospital.
Cell culture and metabolic inhibition. Neonatal rat cardiomyoblasts
[H9c2 (2–1) cells; American Type Culture Collection, Manassas, VA]
were cultured in culture medium as described previously (31). For
experiments, cells grown at confluency of 60–80% were used. Met-
abolic inhibition was achieved by incubating the cells in ischemic
buffer containing (in mM) 0.9 CaCl2 H2O, 20 2-deoxy-D-glucose
(Sigma, St. Louis, MO), 106 NaCl, 5 NaCN, 3.8 NaHCO3, 4.4 KCl,
Address for reprint requests and other correspondence: P. A. J. Krijnen, VU
Univ. Medical Center, Dept. of Pathology, De Boelelaan 1117, 1007 MB
Amsterdam, The Netherlands (e-mail: paj.krijnen@vumc.nl).
The costs of publication of this article were defrayed in part by the payment
of page charges. The article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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and 1 MgCl2 H2O in H2O, pH 6.6 under a 5% CO2 atmosphere at
37°C. Reperfusion was mimicked by incubating the cells subsequent
to metabolic inhibition in normal culture medium under a 5% CO2
atmosphere at 37°C.
Processing of tissue specimens. For immunohistochemistry we
obtained heart tissue samples from patients who died after AMI.
Myocardial tissue specimens were obtained from each subject from
the infarcted site, as well as from the adjacent zone and from remote
sites in the healthy part of the heart. These remote sites showed
normal LDH-staining patterns and were studied as internal nonin-
farcted controls. Heart tissue samples from the left ventricle of
patients who had died from other causes, not related to heart disease,
were used as a control. None of these subjects had sepsis or malig-
nancies. Before being prepared as cryosections, tissue specimens were
stored at 196°C (liquid N2). Frozen sections were mounted on
SuperFrost Plus glass slides (Menzel-Gla¨ser, Braunschweig, Ger-
many).
Antibodies. A MAb against human clusterin (MAb G7) was used
for immunohistochemical analysis (gift of Dr. Brendan Murphy,
Melbourne, Australia) and has been described previously (29). MAb
against the -chain of rat clusterin (Upstate Biotechnology, Waltham,
MA) and MAb G7 were used for Western blot and fluorescence-
activated cell sorting (FACS) analysis. MAb C3–15 against the
complement factor C3d has been used previously for immunohisto-
chemical studies (22). In FACS analysis, phycoerythrin (PE)-conju-
gated goat anti-mouse immunoglobulins (GAM-RPE; Dakopatts,
Glostrup, Denmark) were used as a secondary antibody. In Western
blot analysis, horseradish peroxidase-conjugated rabbit anti-mouse
immunoglobulins (RAM-HRP, Dakopatts) were used as a secondary
antibody. The MAbs were stored in PBS (1 mg/ml, pH 7.4). As
controls, irrelevant MAbs (2 IgG1 and 1 IgG2a) were tested at
concentrations similar to those used for the MAbs. Staining with these
control MAbs always yielded negative results.
Immunohistochemistry. Frozen sections were stained as described
previously (20, 21) as primary antibodies were used (anti-clusterin
MAb, 1 to 750; MAb, C3–15 1 to 1500).
Microscopic criteria (6, 24) were used to estimate infarct duration
in all myocardial tissue specimens. To allow a more reliable morpho-
logical judgment, corresponding paraffin slides were also made. We
characterized jeopardized myocardium with macroscopic LDH-decol-
orization (but without microscopical changes as an early-phase infarc-
tion), with macroscopic LDH-decolorization with infiltration of poly-
morphonuclear neutrophils (leukocytes, PMNs) as a PMN-phase in-
farction, and with macroscopic LDH-decolorization with infiltration
of lymphocytes and macrophages and with signs of fibrosis as a
chronic-phase infarction. We categorized as reinfarctions those sub-
jects with an explicit medical history of a second myocardial infarc-
tion within 2 wk after the first; one subject with chronic-phase
morphology and one with early-phase morphology were classified as
early-phase reinfarctions, whereas those subjects with chronic-phase
morphology combined with PMN-phase morphology were classified
as PMN-phase reinfarctions. In all cases, histologically assessed
infarct duration corresponded with the clinical course.
Two investigators (P. A. J. Krijnen and H. W. M. Niessen) each
independently judged and scored all slides for infarct age and ana-
tomic localization of the proteins, as visualized by immunohistochem-
ical staining. Scattered clusterin and complement single positive
cardiomyocytes were counted at a high-powered field (HPF; 400
magnification) in 25 HPFs. The average number of positive cardio-
myocytes per HPF was used in the calculations. To assess the
anatomic relation between clusterin and complement depositions,
serial slides were used. For the final scores, consensus was achieved
by the two investigators.
Western blot analysis. H9c2 cardiomyoblasts were dissolved in
SDS sample buffer containing -mercaptoethanol as a reducing agent,
stirred, and heated for 10 min at 95°C. The samples were subjected to
SDS-PAGE using 10% gels, transferred to nitrocellulose membranes,
and immunoblotted by subsequent incubation with MAb against rat
clusterin (1:1,000) and RAM-HRP (1:1,000). The blots were then
visualized by enhanced chemiluminescence (Amersham, Bucking-
hamshire, UK). For experiments with cycloheximide (CH) and acti-
nomycin D (AMD; both from Sigma, St. Louis, MO), H9c2 cells were
incubated with 0.21 M CH and 10 M AMD before (1 h) and during
metabolic inhibition (2 h). Lysates were subsequently made in reduc-
ing Laemmli buffer and were analyzed through Western blot analysis.
ATP measurements. H9c2 cardiomyoblasts were subjected to in-
creasing periods of metabolic inhibition (0, 20 min, 40 min, 1 h, 1.5 h,
and 2 h) and subsequent reperfusion (2 h) as described in Cell culture
and metabolic inhibition. The following steps were all performed at
4°C. The cells were collected and counted, and the cell concentrations
were equalized accordingly. After centrifugation (400 g) the cells
were incubated in 150 l of 0.4 M perchloric acid (Sigma) for 30 min
and subsequently centrifuged (2,000 g). The supernatants were col-
lected, and the pH was restored to 7 by adding 10 l of 5 M K2CO3
(Sigma). The samples were frozen (80°C) until measurements were
taken. ATP levels were measured in a bioluminescence assay, using a
sensitive ATP determination kit (Biaffin, Kassel, Germany) and fol-
lowing the manufacturer’s protocol. Samples were measured in a
FluoroNunc MaxiSorp plate (Nalge Nunc International, Rochester,
NY). Luminescence was measured by using a Tecan GENios Plus
reader (Tecan Benelux, Mechelen, Belgium).
Purification of human serum clusterin. Human clusterin was puri-
fied from human serum by affinity chromatography on MAb G7
coupled to sepharose, essentially as described previously (29). After
elution at pH 2.8, the eluate was dialyzed against PBS and stored at a
concentration of 200 g/ml at 20°C.
Flow cytometry. Annexin V (AV)-FITC (Bender Med Systems,
Vienna, Austria) was used to assess flip-flop of the cell membrane.
Propidium iodide (PI; Bender Med Systems) was used to assess
membrane permeability and thus cell death. H9c2 cells were incu-
bated in culture medium or ischemic buffer (see Cell culture and
metabolic inhibition). To assess binding of human serum clusterin, the
cells were subsequently incubated for 30 min at 37°C in serum-free
medium containing 20 g purified human serum clusterin/ml. The
cells were then incubated with MAb G7 against human clusterin
(1:100) or with the MAb against the -chain of rat clusterin (1:100)
for 30 min at 4°C and subsequently labeled with GAM-RPE (1:20) for
30 min at 4°C. Finally, the cells were stained with AV-FITC (1:40) for
30 min at 4°C and subsequently washed twice with PBS. PI (1:40) was
added only a few minutes before measurement. The cells were then
analyzed by flow cytrometry (FACStar; Becton Dickinson).
Live cell imaging of AV-FITC-labeled H9c2 cells. H9c2 cells were
grown in Delta T culture dishes (Bioptechs, Butler, PA) and subjected
to metabolic inhibition (2 h) as described in Cell culture and meta-
bolic inhibition. The cells were then incubated with AV-FITC (1:40)
in serum-free medium for 30 min at 37°C. The cells were subse-
quently washed twice with PBS (37°C) and then incubated with
normal culture medium at 37°C. The cells were qualitatively analyzed
by the use of a 3I Marianas digital imaging microscopy workstation
(41). Pictures were taken immediately after several locations were
stained, and these locations were memorized by the software. The
culture dishes were then returned to a 5% CO2, completely dark
Table 1. Subjects characteristics
AMI Phase Infarct Age n Men/Women Age Range
Early phase 0–12 h 27 19/8 23–98
PMN phase 12 h–5 days 17 8/9 43–88
Chronic phase 5–14 days 4 3/1 60–74
Reinfarction early phase 0–12 h 10 7/3 48–85
Reinfarction PMN phase 12 h–5 days 14 8/6 30–89
n, number of subjects; AMI, acute myocardial infarction; PMN, polymor-
phonuclear neutrophils (leukocytes).
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atmosphere at 37°C. After 2 h and 4.5 h, pictures were taken at the
memorized locations with a similar camera setup.
Morphologic analysis of effects of purified human serum clusterin
on H9c2 cell viability. H9c2 cells, grown in 12-well plates, were
subjected to culture medium or ischemic buffer for 2 h in the absence
or presence of 20 g purified human serum clusterin/ml. Pictures of
the cells in culture were subsequently taken by using a Leica DM-R
microscope (Leica, Wetzlar, Germany; 25 magnification). The cells
were then counted, distinguishing between cells with normal mor-
phology or rounded cells. The percentage of rounded cells of the total
number of cells was then calculated.
Analysis of effects of purified human serum clusterin on viability of
isolated adult rat cardiomyocytes. Animals were treated according to
the national guidelines and with permission of the Animal Experi-
mental Committee of the Vrije Universiteit.
Hearts were excized from Wistar rats and were perfused retro-
gradely (Langendorff) at 37°C for 2 min with Tyrode buffer contain-
ing (in mM: 120 NaCl, 27 NaHCO3, 5.0 KCl, 2.0 NaH2PO4, 1.2
MgSO4, 10 glucose, 5 creatine, and 5 taurine; gassed with 95% O2-5%
CO2) supplemented with 1 mM Ca2, and followed by perfusion for
2 min with Tyrode buffer supplemented with 10 M Ca2. The heart
was then perfused with recirculating Tyrode buffer supplemented with
10 M Ca2, 150 U/ml collagenase (class II, Worthington Biochem),
and 0.5 mg/ml hyaluronidase (Sigma-Aldrich) at a flow rate of 10
ml/min for 20 min. Ventricular tissue fragments were incubated with
HEPES buffer containing (in mM) 116 NaCl, 20 HEPES, 5.3 KCl,
1.13 NaH2PO4, 1.2 MgSO4, 10 glucose, 5 creatine, and 5 taurine, and
100 U/ml penicillin-streptomycin, 0.2% (wt/vol) fatty acid-free BSA,
and 10 mol/l Ca2; pH 7.35), containing 150 U/ml collagenase and
0.5 mg/ml hyaluronidase during 8 min in a shaking water bath at
37°C. The obtained cell suspension was mixed (1:1) with HEPES
buffer supplemented with 0.4 mM Ca2, passed through a 200-m
mesh nylon gauze, and centrifuged for 1 min at 43 g. The cells were
suspended in 35 ml of a HEPES-medium 199 mixture containing 0.4
mM Ca2 and were allowed to sediment during 10 min at room
temperature. This process was repeated with HEPES-M199 mixtures
of 0.8 and 1.2 mM Ca2, respectively. Finally, the cells were resus-
pended in M199 [supplemented with 5 mM creatine, 5 mM taurine,
100 U/ml penicillin-streptomycin, and 0.2% (wt/vol) fatty acid-free
BSA], seeded onto laminin-coated Lab Tek II chamber slides (Nalge
Nunc International, Rochester, NY), and allowed to adhere to the
substratum for 1–2 h. Medium was then changed to supplemented
M199 [i.e., M199 was supplemented with 5 mM creatine, 5 mM
taurine, 100 U/ml penicillin-streptomycin, 0.2% (wt/vol) fatty acid-
free BSA, 100 nM insulin, 0.1 nM L-triiodothyronine, and 2 mM
carnitine].
Isolated ventricular rat cardiomyocytes were subjected to supple-
mented M199 or ischemic buffer for 30 min in the absence or
presence of 20 g purified human serum clusterin/ml, under a 5%
CO2 atmosphere at 37°C. The cells were subsequently incubated with
AV-FITC (1:40) in serum-free DMEM (containing 100 IU penicillin/
ml, 100 g streptomycin/ml, and 2 mM L-glutamin) for 30 min under
a 5% CO2 atmosphere at 37°C. Afterward, the cells were washed
twice with PBS (37°C) and then incubated with supplemented M199.
PI was added immediately before analysis. The cells were analyzed by
fluorescence microscopy using the three-dimensional live-imaging
microscope.
Statistics. Statistics were performed with the SPSS statistical pro-
gram (Windows version 9.0). To evaluate whether observed differ-
ences were significant, paired or nonpaired t-tests were used when
appropriate. A P value (2-sided) of0.05 was considered to represent
a significant difference.
RESULTS
Distribution of clusterin in human hearts after AMI. In
agreement with a former study (39), we also found colocaliza-
tion of clusterin and complement in the infarcted areas of the
human heart in PMN-phase infarctions and PMN-phase rein-
farctions (Fig. 1). In these large areas, complete colocalization
of complement and clusterin was found. In addition, we also
found cardiomyocytes within the infarcted area that stained
positive for clusterin (Fig. 1C) but were negative for comple-
ment factor C3d (Fig. 1D). In contrast with the large areas that
were positive for complement and clusterin, these clusterin-
positive and complement-negative cardiomyocytes were found
in all phases of infarction or reinfarction. Remarkably, the
morphology of these cells was that of viable cells. Further-
more, these clusterin-positive and complement-negative cardi-
omyocytes were also found in the border zone and in the
remote zone, although at lower numbers (data not shown).
Notably, in the hearts of control subjects, almost no clusterin-
positive cardiomyocytes were found (mean  0.19 positive
cardiomyocytes/HPF compared with a mean of 1.62 (chronic
phase) or higher in the infarcted areas of AMI subjects).
There was a marked difference in the pattern of clusterin
staining between the clusterin-positive and complement-posi-
tive fibers and the clusterin-positive and complement-negative
fibers. In the former, clusterin was predominantly located on
the plasma membrane (Fig. 1E) and to a much lesser extent in
the cytoplasm, whereas in the latter, clusterin staining was
weaker and predominantly found in the cytoplasm of the
cardiomyocytes (Fig. 1F). At this moment we do not know
whether intracellular positivity of clusterin is derived from a
local production by cardiomyocytes and/or whether it enters
cardiomyocytes from the circulation in the human heart. No-
tably, local synthesis of clusterin within cardiomyocytes has
been shown in the rat (35, 36).
In the infarcted area of early-phase and PMN-phase infarc-
tions and of early-phase reinfarctions, the numbers of single
clusterin-positive cardiomyocytes were significantly higher
than those of single complement-positive cardiomyocytes (P
0.000, P  0.013, and P  0.037, respectively; Fig. 2).
Although we observed single clusterin-positive cardiomyo-
cytes within the border zone and remote area, the numbers of
single clusterin-positive versus single complement-positive
cardiomyocytes in these areas did not significantly differ (data
not shown), except for the border zones of early-phase rein-
farctions (P  0.007), although this group consisted of only
three subjects.
The numbers of clusterin-positive cardiomyocytes within the
infarcted area of all phases of infarction and reinfarction were
significantly higher than in control subjects (early phase, P 
0.000; PMN phase, P  0.000; chronic phase, P  0.002;
early-phase reinfarction, P  0.009; and PMN-phase reinfarc-
tion, P  0.014). Outside the infarcted area, only in the border
zones of PMN-phase infarctions was the number of clusterin-
positive cardiomyocytes significantly higher than in control
subjects (P  0.027).
Increased expression of clusterin in H9c2 cells after ische-
mia. To further establish putative local production of clusterin
in ischemically challenged solitary cardiomyocytes, we applied
Western blot analysis of reduced samples of H9c2 lysates. The
-chain of rat clusterin migrated to a height of	40 kDa as was
reported earlier (4), confirming that the blot detected clusterin.
Figure 3A, lane 1, shows a low basal level of clusterin in H9c2
cells under control conditions. The expression of clusterin was
increased during ischemia. As soon as 20 min after ischemia,
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clusterin levels were markedly increased. After 4 h of ische-
mia, the expression levels of clusterin were still elevated
compared with baseline expression but was not further in-
creased compared with 20 min of ischemia. Remarkably, the
expression of clusterin decreased rapidly, i.e., as soon as 20
min after reperfusion with culture medium (Fig. 3B). The
expression of clusterin was inhibited by translation inhibitor
CH and also by transcription inhibitor AMD (Fig. 3C). Ex-
pression of clusterin was very low in the control (first lane) and
in the control plus CH (second lane). AMD appeared to induce
a slight increase in clusterin expression when added to control
cells (third and fourth lanes). One hour of ischemia markedly
increased clusterin levels (fifth lane), whereas both CH and
AMD decreased the expression of clusterin to almost the
control levels (sixth, seventh, and eighth lanes). Notably,
although the metabolic inhibition resulted in ATP depletion,
after 40 min of ischemia, ATP was still left to allow protein
synthesis (data not shown).
Binding of clusterin on jeopardized H9c2 cells. Using flow
cytometry, we analyzed whether clusterin could bind to H9c2
cardiomyoblast cells and assessed the conditions for such
binding. FITC-labeled human recombinant AV (a marker for
membrane flip-flop) and PI (a marker for cell death) were used
to determine whether cells were viable (negative for both AV
and PI), damaged (single AV positive), or dead (AV/PI posi-
tive or single PI positive). Anti-rat clusterin MAb or MAb G7
against human clusterin were used to detect binding of endog-
enous or purified human clusterin, respectively. With the use of
Western blot analysis, MAb G7 was found not to cross-react
with rat clusterin (data not shown). In control and ischemic
conditions, endogenous rat clusterin was found to bind pre-
dominantly to H9c2 cells that were PI positive (Fig. 4, A and
Fig. 1. Localization of clusterin and comple-
ment factor C3d on cardiomyocytes within
infarcted area of the human heart. Colocaliza-
tion of clusterin (A) and complement factor
C3d (B) in the human heart in a polymorpho-
nuclear neutrophils (leukocytes; PMN)-phase
infarction (magnification25). Scattered car-
diomyocytes positive for clusterin (C), but
negative for complement factor C3d (D),
within infarcted area of early-phase infarction
(magnification400). Detail of clusterin pos-
itive cardiomyocytes with predominantly
membranous (E, arrows) or predominantly
cytosolic (F, arrow) staining (magnification
630).
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B, right). Only a minority of the clusterin-positive cells were
single AV positive (5%). Ischemia increased the number of
PI-positive cells that bound clusterin (Fig. 5B, right). However,
clusterin is also present in blood (7), and, therefore, we estab-
lished the role of the exogenous clusterin by analyzing the
binding of purified human serum clusterin to these H9c2 cells
(Fig. 4, C and D). Also with exogenous clusterin, of the cells
that were positive for human clusterin, one population was PI
positive; another was PI negative (Fig. 6, A and B, left). The
PI-negative cells that were positive for human clusterin were
all positive for AV, which was also found for endogenous rat
clusterin. The numbers of single AV, but clusterin-positive,
cells were substantially higher when human clusterin was
added than with endogenous clusterin. Because endogenous
clusterin was found predominantly in and on H9c2 cells that
were positive for PI, it seems, therefore, that endogenous
clusterin is not secreted in high amounts to subsequently bind
single AV-positive cells but rather resides within cells and is
presumably only visualized in irreversible-damaged cells with
leaking membranes.
Cells were also analyzed with MAb G7 against human
clusterin in the absence of purified human serum clusterin or in
the absence of the primary MAbs against rat or human clus-
terin. In both cases, no clusterin signal was recorded. Results of
these control experiments proved that the clusterin signal was
specific (data not shown).
Flip-flop of the membrane as reversible phenomenon. The
results described above indicate that clusterin can bind to H9c2
cells that were positive for AV, i.e., flip-flopped H9c2 cells.
The fate of these AV-positive H9c2 cells in time was analyzed
by live cell imaging (Fig. 5). Within a population of ische-
mically challenged (2 h) H9c2 cells, there were marked differ-
ences in AV-FITC positivity between cells, varying from a few
focal patches (Fig. 5A, arrows) to large aggregates (Fig. 5C,
arrows I and II) to cells that were entirely AV-FITC positive
(Fig. 5B). Cells with extensive AV positivity, as depicted in
Fig. 5B, died relatively soon (within 2 h) after staining. For
example, the cell shown in Fig. 5C died	30 min after staining
(Fig. 5D, arrows I and II depict the identical AV aggregates as
seen in Fig. 5C). Most cells with AV positivity, similar to those
in Fig. 5A, still had a normal morphology 4.5 h after staining,
the time frame in which experiments were performed with
clusterin, whereas other cells with similar AV positivity died
within that time frame. Cells that maintained normal morphol-
ogy and also appeared to lose their AV positivity over a period
of 4.5 h after staining were also recorded (Fig. 5, E–H). The
image of cells shown in Fig. 5E (see Fig. 5F for just the FITC
channel) taken 2 h after staining shows a number of cells that
were positive for AV. At 4.5 h after staining (Fig. 5, G and H),
the same cells as depicted in Fig. 5, E and F, appeared to have
lost AV positivity compared with 2 h after staining. Arrows III
and IV in Fig. 5, E–H, show the disappearance of AV aggre-
gates after 4.5 h. In addition, a lot of AV patches have
disappeared after 4.5 h. Arrows V in Fig. 5, F and H, show
aggregates that have not disappeared after 4.5 h, underlining
that there still is an AV-FITC signal.
Effect of purified human clusterin on ischemic cardiomyo-
cytes. The results described above indicated that part of ische-
mically challenged AV-positive cardiomyocytes appeared to
be reversibly damaged. We assessed the effect of clusterin
Fig. 2. Numbers of cardiomyocytes positive for complement or clusterin
during different phases of infarction in the human heart. Bars represent number
of complement-positive (white bars) or clusterin-positive (gray bars) cardio-
myocytes per high-powered field (HPF) in different phases of infarction of
infarction area. For each subject, average number of positive cardiomyocytes
per HPF was determined from 25 HPFs scored. Error bars represent means 

SE; n, number of subjects.
Fig. 3. Western blot analysis of clusterin expression in ischemically chal-
lenged H9c2 cells. A: H9c2 lysates, corrected for protein content, were
separated on SDS-PAGE under reducing conditions and analyzed for clusterin
by immunoblotting. I, metabolic inhibition. B: same experiment as in A, except
that I cells were exposed to a fixed time of ischemia (1 h) and increasing time
of reperfusion (R). C: effect of cycloheximide (CH) and/or actinomycin D
(AMD) on clusterin expression by H9c2 cells. Control cells (C) and cells
subjected to 2 h of I in absence or presence of 0.21 M CH and/or 10 M
AMD.
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Fig. 4. Flow cytometric analysis of binding of endogenous
rat clusterin to H9c2 cells. Control (A) or ischemically
challenged (B, 2 h) H9c2 cells were stained with MAb
against rat clusterin that was visualized with phycoerythrin
(PE)-conjugated goat anti-mouse (GAM). Control (C) and
ischemically challenged (D, 2 h) H9c2 cells were incu-
bated with 20 g purified human serum clusterin/ml and
stained with MAb G7 against human clusterin, followed by
PE-conjugated GAM. Cells were also stained with annexin
V (AV)-FITC and propidium iodide (PI) to assess cell
damage or cell death. Graphs were divided into four
quarters to define positivity for different stainings. C and
D, right: AV and clusterin staining of the gated clusterin-
positive and PI-negative cells.
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Fig. 5. Live cell imaging analysis of membrane flip-flop in
time, visualized by AV-FITC binding. H9c2 cells were ische-
mically challenged (2 h), stained with AV-FITC and analyzed
by live cell imaging. A–D: differences in AV-FITC positivity
between cells; focal patches (A, arrows), large aggregates (C
and D, arrows I and II), and entirely positive (B) (magnifica-
tion 16). E–H: loss of AV-FITC positivity, H9c2 cells 2 h
after staining [E, differential interference contrast (DIC) 
FITC channels; F, FITC channel], and same H9c2 cells 4.5 h
after staining (G, DIC  FITC channels; H, FITC channel)
(magnification 16). Arrows III and IV depict patches of
AV-FITC positivity that have disappeared after 4.5 h. Arrows
V depict patches of AV-FITC positivity that are still visible
after 4.5 h.
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binding on the viability of ischemic cardiomyocytes (Fig. 6).
We quantified morphologically viable and dead H9c2 cells
exposed to ischemic challenge in the presence or absence of 20
g clusterin/ml (Fig. 6A). Rounded cells were considered dead
because all these cells were AV/PI-positive in flow cytometry
analysis (not shown). Under control conditions, 4.08 
 0.46%
of the cells were rounded without clusterin, compared with
4.69 
 0.59% in the presence of clusterin. A marked increase
in the percentage of rounded cells (31.53 
 4.61%) was seen
after 2 h of ischemia in the absence of clusterin. Interestingly,
the presence of purified human serum clusterin during ischemia
significantly decreased the percentage of rounded cells to
12.75 
 1.99% (P  0.020).
In addition, we quantified isolated adult ventricular rat
cardiomyocytes, exposed to ischemic challenge, in the pres-
ence or absence of 20 g clusterin/ml with AV and PI staining
(Fig. 6B). Under control conditions, 61.46
 1.72% of the cells
were viable (i.e., negative for AV-FITC and/or PI), without
clusterin compared with 58.41 
 2.22% with clusterin. After
30 min of ischemia the percentage of viable cells was signif-
icantly decreased to 38.61 
 3.07% (P  0.001). Clusterin
significantly increased the percentage of viable cells to
58.38 
 2.75% (P  0.001) under ischemia.
DISCUSSION
Several studies have suggested a cytoprotective role for
clusterin via its inhibiting effect on complement (16, 25, 29,
38). A former study (39), in which clusterin was found to
colocalize with complement on jeopardized human cardiomy-
ocytes after AMI, suggests that this might also happen in the
infarcted human heart. In the present study we show for the
first time the existence of single cardiomyocytes that are
positive for clusterin but negative for complement within the
human heart after AMI, suggesting a role for clusterin irre-
spective of complement. Indeed, we found a protective effect
of clusterin on ischemically challenged H9c2 cells and isolated
adult ventricular rat cardiomyocytes in the absence of comple-
ment. Both the human tissue study and the in vitro experiments
therefore imply a function of clusterin independent of comple-
ment.
In the infarcted heart two sources of clusterin exist: an
exogenous source (namely, the blood) and an endogenous
source (namely, clusterin expressed by cardiomyocytes them-
selves) (35, 36). We have also found this endogenous source of
clusterin in H9c2 cells, which increased subsequent to ische-
mia. Notably, metabolic inhibition, a well-known method of
inducing ischemia (11), results in ATP depletion. Dependent of
the ischemic time frame, residual ATP does exist, which still
favors protein synthesis. Next to this, it has been shown by
others (42) that metabolic inhibition induces the synthesis of
stress proteins like heat-shock proteins. At this moment, how-
ever, we do not know the contribution of the endogenous
clusterin in the protection of ischemically challenged cardio-
myocytes. We did find that the addition of exogenous clusterin
to ischemically challenged H9c2 cells and isolated adult ven-
tricular rat cardiomyocytes resulted in a significant higher level
of protection compared with cells deprived of exogenous
clusterin. Using flow cytometry analysis, we found that clus-
terin bound predominantly to H9c2 cells that were positive for
AV. Part of this AV-positive population was PI negative.
Although AV is commonly regarded as an early marker for
apoptosis, evidence has been published suggesting that the loss
of membrane asymmetry resulting in AV positivity may to a
certain level be reversible (9, 12, 30). Indeed, our live cell
imaging experiments also show that in a population of ische-
mically challenged H9c2 cells, there were marked differences
in the amount of AV positivity, varying from a few patches to
large aggregates or even entire cell positivity. We also have
now shown (see Fig. 5) that AV positivity, specifically when
focal, is a reversible phenomenon. In concurrence with these
findings, in experiments measuring the cytotoxic effects of
type II secretory phospholipase A2 (sPLA2) on H9c2 cells, we
found evidence for a reversible membrane flip-flop. sPLA2
among others bound to single AV-positive cells and thereby
managed to induce extra cell death compared with cells de-
Fig. 6. Effect of purified human serum clusterin on viability of ischemically
challenged H9c2 cells and isolated adult rat cardiomyocytes. A: percentage of
rounded H9c2 cells upon ischemic challenge as assessed as a measure for cell
damage. Control and ischemically challenged H9c2 cells in presence or
absence of 20 g purified human serum clusterin/ml. Percentage of rounded
cells was calculated by dividing number of rounded cells by total number of
cells. Bars represent means percentage of rounded cells, and error bars
represent means 
 SE. B: percentage of viable isolated adult rat cardiomyo-
cytes was assessed by using an AV-FITC and PI staining. Control and
ischemically challenged cells in presence or absence of 20 g purified human
serum clusterin/ml were tested with fluorescence microscopy using three-
dimensional live imaging microscopy. Bars represent percentages of unstained
and thus viable cardiomyocytes, and error bars represent means 
 SE.
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prived of sPLA2, implicating that at least part of the AV-
positive cells apparently were not dead but were reversibly
damaged (31). Therefore, this implies a mechanism in which
clusterin binds to and possibly protects ischemically chal-
lenged cardiomyocytes. The mechanism whereby clusterin
protects these cardiomyocytes is not yet clear. In noncardio-
myocytes it was found that clusterin might protect reversibly
damaged cells in a way resembling the effect of small heat-
shock proteins (13, 23, 33, 34). Alternatively, it was suggested
that clusterin binds to cellular debris and thereby protects cells
from debris-inflicted damage (2, 3, 14). In renal proximal
tubule cells, clusterin provided complement-independent pro-
tection against gentamicin-induced cytotoxicity but offered
only marginal protection against ATP depletion-induced injury
(10). In contrast, we found protection of clusterin independent
of complement in ischemically challenged H9c2 cells in which
ATP was strongly depleted (data not shown). Therefore, this
suggests that the mechanism of the complement-independent
cell protective effect of clusterin differs between renal proxi-
mal tubule cells and cardiomyocytes. The mechanism of pro-
tection of clusterin in cardiomyocytes requires further study.
Nevertheless, the cytoprotective effect of clusterin on cardi-
omyocytes could have important therapeutic implications. Up-
regulation and cytoprotection of clusterin has been suggested
in a number of different cardiovascular-related pathophysio-
logical conditions, such as atherosclerosis (15, 28, 37) and
myocarditis (27, 36). An artificial enhancement of local clus-
terin levels and/or an increase of clusterin in the blood during
cardiovascular disease might therefore limit the severity of
damage and ultimately lead to a more favorable prognosis for
patients by saving reversibly damaged cardiomyocytes.
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Discussion
For some time now it is understood that inflammation is 
involved in both atherosclerosis and acute myocardial 
infarction. It becomes more and more clear that 
inflammatory processes are not innocent bystanders in 
these diseases, but to a great extent influence the 
outcome of these diseases. Even more than that, there 
are indications that inflammation in a broad sense is not 
a consequence of atherosclerosis and AMI, but in fact is 
a causative factor. In this thesis we focused on several 
inflammatory mediators/processes and their possible 
involvement in atherosclerosis and AMI. The results of 
these investigations are discussed here. 
 
The role of inflammation in the induction of 
AMI (figure 1) 
Secretory phospholipase A2 (sPLA2-IIA) has been 
thought to be involved in the formation of eicosanoids 1, 
2 (literature reference). We have postulated that the enzyme 
plays a role in tagging damaged cells for recognition by 
C-reactive protein (CRP) and complement 3-5. We found 
that culprit coronary atherosclerotic lesions of AMI 
patients contained significantly more sPLA2-IIA in the 
extracellular matrix than those of patients with stable or 
unstable angina pectoris, suggesting possible 
involvement of sPLA2-IIA in destabilizing the plaque 
leading to plaque complication in the coronary arteries 
(figure 1A, number (1)), ultimately resulting in AMI 6. 
Stable plaques (2) are generally characterized by a thick 
fibrous cap and a small lipid core, whereas unstable 
plaques (3) generally have a thin fibrous cap and a large 
lipid core. Increased amounts of sPLA2-IIA entrapped in 
the extracellular matrix of atherosclerotic plaques may 
lead to plaque instability. The origin of the entrapped 
sPLA2-IIA is unclear. It may have diffused from the 
circulation (4) and/or it may be produced locally by 
cells in the vessel wall (5). The actions of sPLA2-IIA in 
the extracellular matrix may lead to multiple effects. 
Increased presence of sPLA2-IIA in the extracellular 
matrix coincided with a significant reduction of 
vascular smooth muscle cells (VSMCs) in the plaque 
and it is known that a low content of VSMCs favors 
plaque instability 7. sPLA2-IIA is cytotoxic to some 
extent and can induce death in several cell types 8-10. 
Hence, the increase in extracellular sPLA2-IIA in the 
lesions from AMI patients could, therefore, have 
resulted in decreased numbers of smooth muscle cells 
through a toxic effect of the enzyme (6). In addition, 
coronary culprit lesions of AMI patients contain 
significantly more CRP and complement 11. Through its 
lypolytic action, the extracellular sPLA2-IIA may initiate 
and enhance CRP-mediated complement activation (7), 
thus intensifying an inflammatory response within the 
atherosclerotic plaque (8), which may result in a further 
demise of VSMCs in the plaque leading to plaque 
instability. The concurrently freed non-esterified fatty 
acids (NEFAs), such as arachidonic acid, form 
precursors for the synthesis of eicosanoids such as 
prostaglandins, thromboxanes and leukotrienes. Most 
of these eicosanoids are thought to intensify 
inflammation in the plaque (9) 12. Via these actions 
sPLA2-IIA may initiate plaque complication, clinically 
resulting in AMI (10).  
Branched off from the epicardial coronary arteries, 
embedded within the myocardium, lie the small 
intramyocardial arteries. We have found significantly 
more depositions of the advanced glycation end 
product (AGE) CML in these small intramyocardial 
arteries of AMI patients compared to controls 13 (figure 
1B).  
AGEs are formed by the nonenzymatic reaction of 
glucose and other reducing sugars with amino groups 
on biomolecules, impairing the functioning of these 
biomolecules. The presence of CML was not restricted 
to blood vessels within the infarction area (1), but was 
found in similar amounts in blood vessels throughout 
the heart (2). In addition, the extent of CML formation 
was not related to the degree of atherosclerosis in the 
epicardial coronary arteries (3). Furthermore, the CML 
likely is present in these intramyocardial arteries before 
the occurrence of AMI. These data suggest that apart 
from epicardial coronary arteries, intramyocardial 
arteries may also be involved in the induction of 
myocardial ischemia in AMI, independent from the 
epicardial coronary arteries.  
At this time we do not know how this intramyocardial 
CML is formed. MPO, a known generator of CML on 
proteins (4) 14, is not likely to be involved as most CML 
positive arteries were negative for MPO. Another 
possible generator is (chronic) inflammation (5) 15. 
Indeed, also in the hearts of myocarditis patients CML 
was significantly increased in intramyocardial arteries 
13.  
How can the formation of CML in intramyocardial 
arteries then contribute to the development of AMI? In 
patients with diabetes mellitus (DM), who have an 
increased risk of cardiovascular disease, circulatory 
levels of CML are elevated 16 and increased 
accumulation of CML was found in the hearts of DM 
patients 17. In DM patients the increased CML 
accumulation in intramyocardial arteries correlated 
with increased E-selectin expression on the endothelium 
(6), pointing to a pro-inflammatory activation of the 
endothelium 18. A principal means by which AGEs 
activate the endothelium is through interaction with its 
receptor (RAGE (7)) 19, 20. Through this interaction AGEs 
were found to activate the RAGE - NFκB pathway 
resulting amongst others in the upregulation of RAGE 
(8) 20. In addition CML was found to upregulate VCAM-
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Figure 1: Role of inflammation in the induction of AMI
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Induction of inflammation on 
cardiomyocytes after AMI (figure 2) 
Upon reperfusion of the infarcted myocardium an 
inflammatory response develops. During this 
inflammatory response acute phase reactants such as 
sPLA2-IIA, and CRP and other inflammatory mediators 
enter and deposit in the infarcted heart. These 
mediators bind to irreversibly and/or reversibly 
damaged cardiomyocytes, which signal their 
stressed/damaged state through membrane flip-flop (1) 
via which they display anionic phospholipids such as 
phosphatidylserine (2) in their outer membrane layer. 
These plasma membrane changes and further 
modifications thereof allow the inflammatory mediators 
to bind to irreversibly and reversibly damaged 
cardiomyocytes (3).  
We found evidence for a role for RhoA – ROCK 
signaling in maintaining asymmetrical membrane 
phospholipid distribution in cardiomyocytes, involving 
flippase activity (submitted). Toxin B from clostridium 
dificile (TcdB) (4) an inhibitor of the Rho protein family, 
which includes RhoA, induced membrane flip-flop in 
H9c2 cells, part of which was apoptotic (5) (activated 
caspase 3) and part of which was not apoptotic. ROCK 
inhibitors Y27632 and H1152 (6) both induced 
membrane flip-flop in H9c2 cells, but not apoptosis. 
These ROCK inhibitors also significantly reduced 
flippase activity. TcdB, Y27632 and H1152 all inhibited 
Akt phosphorylation. These data imply that a certain 
level of RhoA – ROCK activity is necessary to regulate 
the asymmetrical membrane phospholipid distribution 
in cardiomyocytes. 
In a recent study inhibition of RhoA by TcdB was 
shown to upregulate and activate RhoB in murine 
NIH3T3 fibroblasts 24. This activated RhoB was required 
for the TcdB-induced apoptosis in these cells. This data, 
combined with ours, may suggest a mechanism wherein 
impaired RhoA signaling by TcdB leads to membrane 
flip-flop, probably through impaired ROCK signaling, 
as assessed by Y27632 and H1152, and impaired 
flippase activity and in addition leads to apoptosis, 
perhaps through upregulation of RhoB (7) 24, 25. RhoA – 
ROCK signaling and flippase require respectively GTP 
or ATP to be active (8) 26, 27. During AMI intracellular 
ATP and GTP levels in cardiomyocytes to a variable 
extent become depleted in the infarction area, ATP and 
GTP levels to a higher or lesser degree deplete inside 
cardiomyocytes (28), thereby blocking the activity of 
RhoA, ROCK and flippase (9). In vitro we have shown 
that during reperfusion of cardiomyocytes can quite 
rapidly (within 2 hours of reperfusion after 2 hours of 
ischemia) restore their ATP and GTP levels 
(unpublished results). However, little is known about 
ATP – GTP levels locally in different areas of the 
infarcted heart in the days after reperfusion, including 
(reversibly damaged) cardiomyocytes in the border 
zones. We can therefore not be sure to what extent the 
membrane flip-flop in (reversibly damaged) border 
zone cardiomyocytes purely results from intracellular 
ATP – GTP depletion or, in case of available ATP – GTP, 
possibly from impaired RhoA – ROCK signaling. Our 
data shows that inhibition of ROCK leads to flippase 
inhibition and membrane flip-flop independent of ATP 
– GTP levels. We do not know how the activities of 
ROCK and flippase are connected (10), nor is it known 
which effectors are involved in inducing apoptose 
related flip-flop (11). 
In the heart after AMI reactive oxygen species (ROS) 
play multiple important roles 29. We have shown for the 
first time in human cardiomyocytes the expression of 
Nox2 (12) (or a homologue(s)), the catalytic core of the 
ROS producing NADPH oxidase complex 30. Nox2 was 
found in isolated non-ischemic human cardiomyocytes 
and in cardiomyocytes within non-infarcted human 
hearts. Within the macroscopical infarction area, the 
cardiomyocyte expression of Nox2 was increased in 
patients after AMI (13). The increased expression of 
Nox2 suggests a role of this ROS producing enzyme in 
the human heart after AMI. Indeed it is known that 
under conditions of ischemia cardiomyocytes produce 
ROS 31. And although the NADPH oxidase derived ROS 
have been shown to play a role in various signal 
transduction pathways in cardiomyocytes 32, 33, the 
role(s) of Nox2 in cardiomyocytes in different areas of 
the heart after AMI is not completely clear. We 
ourselves showed that in vitro in H9c2 cardiomyoblasts, 
ischemia induced a nuclear expression of Nox2, where 
it produced ROS (14) 34. Inhibition of the NADPH 
oxidase derived ROS resulted in decreased apoptosis 
(15), pointing to a role of this nuclear Nox2 derived ROS 
in the induction/regulation of apoptosis in 
cardiomyocytes under ischemia. In line with this, in 
H9c2 cells angiotensin II induced apoptosis was found 
to be mediated via NADPH oxidase derived ROS 35. 
And, again in H9c2 cells we ourselves were able to 
show that nuclear Nox2 derived ROS was involved also 
in homocystein induced apoptosis 36. In a rabbit in vivo 
model of AMI, inhibition of NADPH oxidase by 
apocynin reduced cardiomyocyte apoptosis and 
improved heart function 37. Thus (nuclear) 
Nox2/NADPH oxidase derived ROS is a mediator of 
apoptosis in cardiomyocytes after AMI. How nuclear 
NADPH oxidase derived ROS mediate apoptosis in 
cardiomyocytes is not known. Redox-sensitive 
transcription factors that are either activated or 
inactivated by redox modifications may be a means via 
which NADPH oxidase derived ROS influences 
apoptosis (16) 38. On the other hand, ROS, may 
introduce DNA damage, via the formation of 
peroxynitrite, and thereby contribute to apoptosis (17) 
39. To form a functional ROS producing NADPH 
oxidase Nox2 is required to form a complex with 
several other subunits, such as p22phox, p40phox, p47phox 
and  p67phox and also needs rac1 or rac2 for activation  
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(18) 40. These subunits, apart from p40phox, have been 
shown to be expressed in cardiomyocytes 41-45. How the 
formation and activation of NADPH oxidase in 
cardiomyocytes after AMI is regulated remains unclear, 
although the MAPK signalling pathway was shown to 
be involved in cardiomyocyte NADPH oxidase 
activation, involving ERK1/2, p38MAPK and jun-N-
terminal kinase (JNK), leading to reduced p47phox 
phosphorylation (19) 42. Indeed, the p47phox subunit may 
be a prime regulator of NADPH oxidase 
formation/activation in cardiomyocytes (20) 41, 42, 45, but 
the processes leading to NADPH oxidase activation in 
cardiomyocytes and the role(s) of different subunits 
herein are subject of further study. In addition, in 
cardiomyocytes, Nox2/NADPH oxidase derived ROS 
were implicated in other processes that may be a result 
of AMI such as hypertrophy (21) 46, 47 and contractile 
dysfunction 48. In the human infarcted heart increased 
Nox2 expression was found in both jeopardized 
cardiomyocytes in the necrotic (complement positive) 
regions as well as normal cardiomyocytes in the border 
zones 30. The function of NADPH oxidase derived ROS 
in cardiomyocytes after AMI therefore may depend on 
the location of these cardiomyocytes within the 
macroscopical infarction area; in cardiomyocytes in the 
necrotic areas NADPH oxidase derived ROS may be 
Figure 2: Induction of inflammation on cardiomyocytes after AMI
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involved in apoptosis whereas in certain 
cardiomyocytes in the border zones NADPH oxidase 
derived ROS may be involved in hypertrophy in 
addition to apoptosis. 
In the heart during AMI cardiomyocytes are exposed to 
varying degrees of ischemic stress resulting in various 
degrees of ATP depletion. As a result cardiomyocytes in 
the macroscopical infarction area may either die rapidly 
through necrosis, may become irreversibly damaged 
and enter apoptosis which in vivo is later converted to 
secondary necrosis) or may become reversibly 
damaged. All these cells, thus the irreversibly as well as 
reversibly damaged cardiomyocytes, show membrane 
flip-flop, in which impaired RhoA – ROCK signaling or 
NADPH oxidase derived ROS signaling may be 
involved. Albeit in the border zones not all 
cardiomyocytes bind sPLA2-IIA and although this 
binding requires membrane flip-flop it is not certain 
that membrane flip-flop is restricted to sPLA2-IIA  
binding cells. So far we cannot be certain about the 
degree of ‘well being’ of these cells. Notwithstanding 
this, as mentioned before the membrane flip-flop on 
(ir)reversibly damaged cardiomyocytes allows certain 
inflammatory mediators to bind to these cells after 
reperfusion. 
 
Inflammation after AMI (figure 3) 
In chapter 11 we observed that reperfusion therapy 
(especially streptokinase and coronary artery bypass 
graft (CABG) surgery) and reinfarction lead to increased 
CRP depositions and increased complement activation 
in the infarcted heart (1) as shown by the presence of 
complement activation product C3d and membrane 
attack complex C5b9. Previously we have published 
that CRP activates complement in the infarcted heart 49. 
It has been shown before that plasminogen activators 
like streptokinase activate the classical pathway of 
complement in the blood by cleaving C1r 50 and that 
coronary artery bypass grafting (CABG) is often 
accompanied by strong complement activation in the 
blood via the alternative pathway and elevated blood 
CRP levels 51 (2). In contrast to streptokinase and CABG 
surgery, PTCA did not result in increased CRP and 
complement depositions. In line herewith we have 
shown previously that in AMI patients blood levels of 
complement activation products did further increase in 
patients who underwent CABG surgery after AMI (2), 
but not in patients with PTCA (unpublished results). 
Why different kinds of reperfusion therapy have 
different effects on complement blood levels and on the 
local complement activation in the ischemic 
myocardium is not known at the moment.  
Reinfarction also leads to increased CRP depositions 
and increased complement activation in the infarcted 
heart. As a result of AMI, CRP levels in the blood rise as 
part of the acute phase response. It has been shown that 
these elevated CRP levels predict recurring cardiac 
events 52, 53.  It is known in general that blood levels of 
CRP and complement are related to post infarct 
mortality, reinfarction and heart failure 54-57.  
Therefore, reperfusion therapy, especially streptokinase 
and CABG surgery, in addition to their obvious benefit 
of restoring the circulation also induce potentially 
negative events such as elevated blood levels of CRP 
and complement and elevated activation of complement 
in the infarcted heart which may lead to a more intense 
local inflammation. For instance activated complement 
is an attractant for neutrophils and induces infiltration 
and activation of neutrophils in the ischemic heart (3) 58. 
This more intense inflammation in turn may lead to 
poorer prognosis. 
CRP is not the only known complement activator. 
Indeed in mice and rats, also IgM was shown to be 
involved in complement activation during ischemia-
reperfusion injury in the intestine and skeletal muscle 59-
61. We showed that IgM co-localizes with CRP and 
complement in the ischemic heart (4), suggesting that 
IgM in addition to CRP may activate complement in the 
heart after AMI 62. Indeed recently in mice it was 
revealed that natural IgM initiates reperfusion injury, 
either by activating complement or by inducing 
apoptosis (5), in the infarcted heart 63. Although IgM 
was shown in mice to initiate apoptosis in normal and 
tumor epithelial cells 64, the mechanisms involved are 
not yet clear. However, in the human infarcted heart 
IgM was only found on necrotic cells and only in the 
presence of CRP and complement. We did not find 
isolated IgM depositions, virtually excluding that IgM 
precedes CRP and complement entry into the infarcted 
heart. Thus, in humans we did not find conclusive 
evidence for a role for IgM as an apoptosis inducer, 
although it our findings also do not exclude such a role.   
The epitope(s) to which natural IgM binds on 
cardiomyocytes in the infarcted heart are not yet fully 
identified. Although we have found that plasma levels 
of natural IgM against phosphorylcholine are higher in 
patients with more intense inflammatory responses and 
larger infarct size in patients with AMI (submitted), 
suggesting that IgM with this specificity may be 
involved. Moreover, in addition to identifying CRP as a 
complement activator in myocardial reperfusion injury, 
our data suggest that IgM may play a similar role.  
The acute phase protein sPLA2-IIA is a cardiovascular 
risk marker and important mediator of IR injury in the 
heart after AMI 3, 5. And because of this role we 
hypothesized that inhibition of sPLA2-IIA may reduce 
IR injury and infarct size. We indeed found that specific 
inhibition of sPLA2-IIA using PX-18 (6) significantly 
reduced infarct size in an in vivo model of AMI in the 
rat.  
As stated earlier sPLA2-IIA binds to necrotic 
cardiomyocytes (7), but also to morphologically normal, 
but flip-flopped cardiomyocytes in the border zones (8) 
65, and is likely to precede the deposition of CRP and 
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complement. sPLA2-IIA through its lipolytic actions 
liberates NEFAs and thereby creates lysophospholipids 
(9). As mentioned before NEFAs are also precursors for 
the synthesis of eicosanoids. The effects of these 
eicosanoids in the heart after AMI are debated to be 
either protective or damaging 66-68. Lysophospholipids, 
specifically lyso-PC, provide binding sites for CRP 69 
and binding of CRP in the infarcted heart leads to 
complement activation 49. Therefore, binding of sPLA2-
IIA leads to the binding and activation of CRP and 
complement on these cells, which in case of reversibly 
damaged cardiomyocytes in the border zones results in 
cell death (10). In addition, sPLA2-IIA can induce 
cardiomyocyte death independent of CRP and 
complement (11) 10, whereas CRP and complement can 
bind to irreversibly damaged cardiomyocytes 
independent of sPLA2-IIA (12). From this, we can 
deduce that inhibition of sPLA2-IIA by PX-18 may 
prevent death of reversibly damaged cardiomyocytes in 
the border zones thereby preventing expansion of the 
infarction area. In our study sPLA2-IIA inhibition did 
not result in reduced ventricular wall thickness, nor in 
abnormal scar tissue formation or in aberrant left 
ventricular dimensions, ruling out a negative effect on 
tissue remodeling.  
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Interestingly, PX-18 treatment led to increased 
infiltration of macrophages (mΦ) into infarcted and 
non-infarcted areas of the heart (13). It has been shown 
that in addition to scavenging cellular debris, 
macrophages promote angiogenesis and produce anti-
inflammatory mediators under ischemic conditions 
leading to improved healing and heart function after 
AMI 70-73. In addition PX-18 inhibited simvastatin 
induced reversible membrane flip-flop (see also Figure 
2 nr (4)) and apoptosis in cardiomyoblasts in vitro (14). 
This suggests that PX-18 by inhibiting (reversible) flip-
flop, PX-18 inhibits the availability of sPLA2-IIA binding 
sites on cardiomyocytes, thereby indirectly inhibiting 
sPLA2-IIA. Thus inhibition of sPLA2-IIA in vivo after 
AMI, thereby inhibiting cardiomyocyte death in the 
border zones of infarction instigated either directly by 
sPLA2-IIA itself or through sPLA2-IIA initiated 
activation of CRP and complement, results in reduced 
infarct size without impaired wound healing.  
Clusterin, another inflammatory mediator, was shown 
before to co-localize with complement in the infarcted 
heart (15) 74. Furthermore, clusterin was found to bind 
to and inhibit complement (16) 75, characterizing it as an 
anti-inflammatory protein. We show that in addition to 
the microscopical infarction areas where it co-localized 
with complement, clusterin was found in scattered 
cardiomyocytes in the border zones and, to a lesser 
degree, in normal areas of the heart, suggesting a role 
for clusterin independent of complement. On the 
necrotic cells in the microscopical infarction areas 
clusterin was found predominantly on the plasma 
membrane whereas in the border zones clusterin was 
found predominantly in the cytoplasm (17). The 
clusterin in the microscopical infarction areas is likely to 
come from the blood (exogenous clusterin), serum 
levels of clusterin increase after AMI (18) 76, whereas in 
the border zones is not clear whether the clusterin 
originates from local expression (endogenous clusterin) 
or comes from the circulation. It was also shown in vitro 
(by us) as well as in vivo that cardiomyocytes can 
express clusterin 77. It is not easy to define the exact 
function(s) of clusterin in the heart after AMI as a 
substantial number of functions have been ascribed to 
the protein, such as the before mentioned complement 
inhibitory activity, a linking protein, a chaperone 
protein and an anti-apoptotic as well as pro-apoptotic 
protein 78, 79. In our study, in vitro exogenous (human) 
clusterin protected H9c2 cells against ischemic death by 
binding to both reversibly damaged (single-annexin V 
positive) and irreversibly damaged (annexin V/PI 
positive) cells. We do not know whether endogenous 
clusterin also protects against ischemic cell death. (19). 
How clusterin exerts this protective effect we do as yet 
not know. However, we have also shown that megalin, 
a known receptor for clusterin 80 is expressed on H9c2 
cells and co-localizes with added exogenous (human) 
clusterin and also rat clusterin (manuscript in 
preparation). Recently it was shown that secreted 
clusterin protects prostatic cells from TNF and 
actinomycine D induced apoptosis through megalin and 
the PI-3 kinase/Akt pathway 81 and that over-
expression of clusterin in fetal canine myoblasts 
restored mitochondrial membrane potential and 
reduced cytochrome c release after ethanol treatment 82. 
In addition, clusterin was shown to mediate the uptake 
of cellular debris via megalin in fibroblasts and 
epithelial cells 83, suggesting a possible role for clusterin 
by vital neighboring cells  in the clearance of debris in 
the heart after AMI. 
The protective effect of clusterin on cardiomyocytes 
proposes the idea that elevating clusterin levels in the 
heart after AMI might be beneficial. Recently in a report 
studying the endocrine protective effect of stem cells in 
the infarcted heart it was shown that clusterin (amongst 
others) excreted from stem cells inhibited H2O2 induced 
apoptosis in H9c2 cells 84, 85. We also tested the idea of 
elevated clusterin levels after AMI in the rat. In line 
with our previous results, elevating the blood levels of 
clusterin by intravenously injecting purified human 
clusterin after AMI, significantly reduced infarct size in 
the rat (manuscript in preparation).  
 
Considerations 
As stated at the beginning of this discussion, 
inflammation is involved in both atherosclerosis and 
acute myocardial infarction and the (combined) actions 
of inflammatory mediators may to great effect influence 
the outcome of these diseases and may indeed be a 
causative factor. In our studies we have strengthened 
this view. We have shown possible involvement of 
inflammatory mediator sPLA2-IIA in the induction of 
AMI. A similar role, but then intramyocardial, may be 
reserved for inflammation product CML. We have 
found evidence for the reversibility of membrane flip-
flop in some jeopardized cardiomyocytes, possible 
mechanisms controlling it and the importance of 
membrane flip-flop as a target for inflammatory 
mediators in the heart after AMI. We have identified 
Nox2 in cardiomyocytes and have shown it to be an 
important mediator of apoptotic signaling in 
cardiomyocytes. We have shown that CRP and 
complement levels in the heart after AMI are increased 
upon reperfusion therapy and that natural IgM may just 
as CRP activate complement and may therefore also be 
a cardiovascular risk factor. Finally we have shown in 
vivo and in vitro that the inhibition of post infarct 
inflammation in the heart can to a considerable extent 
limit myocardial damage and therefore constitutes a 
potential treatment of AMI. 
 
References 
  (1)   Akiba S, Hatazawa R, Ono K, Kitatani K, Hayama M, Sato 
T. Secretory phospholipase A2 mediates cooperative prostaglandin 
generation by growth factor and cytokine independently of preceding 
  
154
cytosolic phospholipase A2 expression in rat gastric epithelial cells J 
Biol Chem 2001;276:21854‐21862. 
  (2)   Murakami M, Kambe T, Shimbara S, Kudo I. Functional 
coupling between various phospholipase A2s and cyclooxygenases in 
immediate and delayed prostanoid biosynthetic pathways J Biol Chem 
1999;274:3103‐3115. 
  (3)   Krijnen PA, Meischl C, Nijmeijer R, Visser CA, Hack CE, 
Niessen HW. Inhibition of sPLA2‐IIA, C‐reactive protein or 
complement: new therapy for patients with acute myocardial 
infarction? Cardiovasc Hematol Disord Drug Targets 2006;6:113‐123. 
  (4)   Krijnen PA, Nijmeijer R, Hack CE, Niessen HW. Group II 
Secretory PLA2: A New Cardiovascular Risk Factor. Anti‐Inflam & 
Anti‐Allergy Agents in Med Chem 2006;5:163‐173. 
  (5)   Niessen HW, Krijnen PA, Visser CA, Meijer CJ, Erik HC. 
Type II secretory phospholipase A2 in cardiovascular disease: a 
mediator in atherosclerosis and ischemic damage to cardiomyocytes? 
Cardiovasc Res 2003;60:68‐77. 
  (6)   Nijmeijer R, Meuwissen M, Krijnen PA et al. Secretory type 
II phospholipase A2 in culprit coronary lesions is associated with 
myocardial infarction Eur J Clin Invest 2008;38:205‐210. 
  (7)   Bauriedel G, Hutter R, Welsch U, Bach R, Sievert H, 
Luderitz B. Role of smooth muscle cell death in advanced coronary 
primary lesions: implications for plaque instability Cardiovasc Res 
1999;41:480‐488. 
  (8)   Lee C, Park DW, Lee J et al. Secretory phospholipase A2 
induces apoptosis through TNF‐alpha and cytochrome c‐mediated 
caspase cascade in murine macrophage RAW 264.7 cells Eur J 
Pharmacol 2006;536:47‐53. 
  (9)   Mathisen GH, Thorkildsen IH, Paulsen RE. Secretory PLA2‐
IIA and ROS generation in peripheral mitochondria are critical for 
neuronal death Brain Res 2007;1153:43‐51. 
  (10)   Nijmeijer R, Willemsen M, Meijer CJ et al. Type II secretory 
phospholipase A2 binds to ischemic flip‐flopped cardiomyocytes and 
subsequently induces cell death Am J Physiol Heart Circ Physiol 
2003;285:H2218‐H2224. 
  (11)   Meuwissen M, van der Wal AC, Niessen HW et al. 
Colocalisation of intraplaque C reactive protein, complement, 
oxidised low density lipoprotein, and macrophages in stable and 
unstable angina and acute myocardial infarction J Clin Pathol 
2006;59:196‐201. 
  (12)   Natarajan R, Nadler JL. Lipid inflammatory mediators in 
diabetic vascular disease Arterioscler Thromb Vasc Biol 2004;24:1542‐
1548. 
  (13)   Baidoshvili A, Krijnen PA, Kupreishvili K et al. 
N(varepsilon)‐(carboxymethyl)lysine depositions in intramyocardial 
blood vessels in human and rat acute myocardial infarction: a 
predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 
2006;26:2497‐2503. 
  (14)   Anderson MM, Requena JR, Crowley JR, Thorpe SR, 
Heinecke JW. The myeloperoxidase system of human phagocytes 
generates Nepsilon‐(carboxymethyl)lysine on proteins: a mechanism 
for producing advanced glycation end products at sites of 
inflammation J Clin Invest 1999;104:103‐113. 
  (15)   Hudson BI, Bucciarelli LG, Wendt T et al. Blockade of 
receptor for advanced glycation endproducts: a new target for 
therapeutic intervention in diabetic complications and inflammatory 
disorders Arch Biochem Biophys 2003;419:80‐88. 
  (16)   Brownlee M. Advanced protein glycosylation in diabetes 
and aging Annu Rev Med 1995;46:223‐234. 
  (17)   Schalkwijk CG, Baidoshvili A, Stehouwer CD, van 
Hinsbergh V, Niessen HW. Increased accumulation of the 
glycoxidation product Nepsilon‐(carboxymethyl)lysine in hearts of 
diabetic patients: generation and characterisation of a monoclonal 
anti‐CML antibody Biochim Biophys Acta 2004;1636:82‐89. 
  (18)   van HL, Hamdani N, Handoko ML et al. Diastolic stiffness 
of the failing diabetic heart: importance of fibrosis, advanced 
glycation end products, and myocyte resting tension Circulation 
2008;117:43‐51. 
  (19)   Basta G, Lazzerini G, Massaro M et al. Advanced glycation 
end products activate endothelium through signal‐transduction 
receptor RAGE: a mechanism for amplification of inflammatory 
responses Circulation 2002;105:816‐822. 
  (20)   Bierhaus A, Humpert PM, Morcos M et al. Understanding 
RAGE, the receptor for advanced glycation end products J Mol Med 
2005;83:876‐886. 
  (21)   Enomoto M, Adachi H, Yamagishi S et al. Positive 
association of serum levels of advanced glycation end products with 
thrombogenic markers in humans Metabolism 2006;55:912‐917. 
  (22)   Niiya Y, Abumiya T, Shichinohe H et al. Susceptibility of 
brain microvascular endothelial cells to advanced glycation end 
products‐induced tissue factor upregulation is associated with 
intracellular reactive oxygen species Brain Res 2006;1108:179‐187. 
  (23)   Cai W, Zhu L, Chen X, Uribarri J, Peppa M. Association of 
advanced glycoxidation end products and inflammation markers with 
thrombosis of arteriovenous grafts in hemodialysis patients Am J 
Nephrol 2006;26:181‐185. 
  (24)   Huelsenbeck J, Dreger SC, Gerhard R, Fritz G, Just I, Genth 
H. Upregulation of the Immediate Early Gene Product RhoB by 
Exoenzyme C3 from Clostridium limosum and Toxin B from 
Clostridium difficile Biochemistry 2007;46:4923‐4931. 
  (25)   Genth H, Dreger SC, Huelsenbeck J, Just I. Clostridium 
difficile toxins: More than mere inhibitors of Rho proteins Int J 
Biochem Cell Biol 2008;40:592‐597. 
  (26)   Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, 
RhoB, RhoC, and cell motility Exp Cell Res 2004;301:43‐49. 
  (27)   Daleke DL. Regulation of transbilayer plasma membrane 
phospholipid asymmetry J Lipid Res 2003;44:233‐242. 
  (28)   Inagaki K, Chen L, Ikeno F et al. Inhibition of delta‐protein 
kinase C protects against reperfusion injury of the ischemic heart in 
vivo Circulation 2003;108:2304‐2307. 
  (29)   Becker LB. New concepts in reactive oxygen species and 
cardiovascular reperfusion physiology Cardiovasc Res 2004;61:461‐470. 
  (30)   Krijnen PA, Meischl C, Hack CE et al. Increased Nox2 
expression in human cardiomyocytes after acute myocardial 
infarction J Clin Pathol 2003;56:194‐199. 
  (31)   Duranteau J, Chandel NS, Kulisz A, Shao Z, Schumacker 
PT. Intracellular signaling by reactive oxygen species during hypoxia 
in cardiomyocytes J Biol Chem 1998;273:11619‐11624. 
  (32)   Sabri A, Hughie HH, Lucchesi PA. Regulation of 
hypertrophic and apoptotic signaling pathways by reactive oxygen 
species in cardiac myocytes Antioxid Redox Signal 2003;5:731‐740. 
  (33)   Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, 
Komuro I. Oxidative stress‐induced signal transduction pathways in 
  
155
cardiac myocytes: involvement of ROS in heart diseases Antioxid 
Redox Signal 2003;5:789‐794. 
  (34)   Meischl C, Krijnen PA, Sipkens JA et al. Ischemia induces 
nuclear NOX2 expression in cardiomyocytes and subsequently 
activates apoptosis Apoptosis 2006;11:913‐921. 
  (35)   Qin F, Patel R, Yan C, Liu W. NADPH oxidase is involved 
in angiotensin II‐induced apoptosis in H9C2 cardiac muscle cells: 
effects of apocynin Free Radic Biol Med 2006;40:236‐246. 
  (36)   Sipkens JA, Krijnen PA, Meischl C et al. Homocysteine 
affects cardiomyocyte viability: concentration‐dependent effects on 
reversible flip‐flop, apoptosis and necrosis Apoptosis 2007;12:1407‐
1418. 
  (37)   Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase 
reduces myocardial oxidative stress and apoptosis and improves 
cardiac function in heart failure after myocardial infarction Free Radic 
Biol Med 2007;43:271‐281. 
  (38)   Morel Y, Barouki R. Repression of gene expression by 
oxidative stress Biochem J 1999;342 Pt 3:481‐496. 
  (39)   Grishko V, Pastukh V, Solodushko V, Gillespie M, Azuma J, 
Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal 
cardiomyocytes: role of DNA damage Am J Physiol Heart Circ Physiol 
2003;285:H2364‐H2372. 
  (40)   Babior BM. NADPH oxidase Curr Opin Immunol 2004;16:42‐
47. 
  (41)   Doerries C, Grote K, Hilfiker‐Kleiner D et al. Critical role of 
the NAD(P)H oxidase subunit p47phox for left ventricular 
remodeling/dysfunction and survival after myocardial infarction Circ 
Res 2007;100:894‐903. 
  (42)   Ribe D, Sawbridge D, Thakur S et al. Adenosine A(2A) 
receptor signaling regulation of cardiac NADPH oxidase activity Free 
Radic Biol Med 2008. 
  (43)   Berges A, Van NL, Timmermans JP, Vrints C. Time‐
dependent expression pattern of nitric oxide and superoxide after 
myocardial infarction in rats Pharmacol Res 2007;55:72‐79. 
  (44)   Dong F, Zhang X, Ren J. Leptin regulates cardiomyocyte 
contractile function through endothelin‐1 receptor‐NADPH oxidase 
pathway Hypertension 2006;47:222‐229. 
  (45)   Heymes C, Bendall JK, Ratajczak P et al. Increased 
myocardial NADPH oxidase activity in human heart failure J Am Coll 
Cardiol 2003;41:2164‐2171. 
  (46)   Hingtgen SD, Tian X, Yang J et al. Nox2‐containing NADPH 
oxidase and Akt activation play a key role in angiotensin II‐induced 
cardiomyocyte hypertrophy Physiol Genomics 2006;26:180‐191. 
  (47)   Stas S, Whaley‐Connell A, Habibi J et al. Mineralocorticoid 
receptor blockade attenuates chronic overexpression of the renin‐
angiotensin‐aldosterone system stimulation of reduced nicotinamide 
adenine dinucleotide phosphate oxidase and cardiac remodeling 
Endocrinology 2007;148:3773‐3780. 
  (48)   Grieve DJ, Byrne JA, Siva A et al. Involvement of the 
nicotinamide adenosine dinucleotide phosphate oxidase isoform 
Nox2 in cardiac contractile dysfunction occurring in response to 
pressure overload J Am Coll Cardiol 2006;47:817‐826. 
  (49)   Nijmeijer R, Lagrand WK, Lubbers YT et al. C‐reactive 
protein activates complement in infarcted human myocardium Am J 
Pathol 2003;163:269‐275. 
  (50)   Agostoni A, Gardinali M, Frangi D et al. Activation of 
complement and kinin systems after thrombolytic therapy in patients 
with acute myocardial infarction. A comparison between 
streptokinase and recombinant tissue‐type plasminogen activator 
Circulation 1994;90:2666‐2670. 
  (51)   Bruins P, te VH, Yazdanbakhsh AP et al. Activation of the 
complement system during and after cardiopulmonary bypass 
surgery: postsurgery activation involves C‐reactive protein and is 
associated with postoperative arrhythmia Circulation 1997;96:3542‐
3548. 
  (52)   Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. 
Serum C‐reactive protein concentration in acute myocardial infarction 
and its relationship to mortality during 24 months of follow‐up in 
patients under thrombolytic treatment Eur Heart J 1996;17:1345‐1349. 
  (53)   Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, 
Fukuda N. Plasma concentrations of fibrinolytic factors in the 
subacute phase of myocardial infarction predict recurrent myocardial 
infarction or sudden cardiac death Int J Cardiol 2002;85:277‐283. 
  (54)   Bursi F, Weston SA, Killian JM, Gabriel SE, Jacobsen SJ, 
Roger VL. C‐reactive protein and heart failure after myocardial 
infarction in the community Am J Med 2007;120:616‐622. 
  (55)   Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, 
Palatini P. C‐reactive protein in acute myocardial infarction: 
association with heart failure Am Heart J 2003;145:1094‐1101. 
  (56)   Yip HK, Hang CL, Fang CY et al. Level of high‐sensitivity 
C‐reactive protein is predictive of 30‐day outcomes in patients with 
acute myocardial infarction undergoing primary coronary 
intervention Chest 2005;127:803‐808. 
  (57)   Szeplaki G, Prohaszka Z, Duba J et al. Association of high 
serum concentration of the third component of complement (C3) with 
pre‐existing severe coronary artery disease and new vascular events 
in women Atherosclerosis 2004;177:383‐389. 
  (58)   Ren G, Dewald O, Frangogiannis NG. Inflammatory 
mechanisms in myocardial infarction Curr Drug Targets Inflamm 
Allergy 2003;2:242‐256. 
  (59)   Weiser MR, Williams JP, Moore FD, Jr. et al. Reperfusion 
injury of ischemic skeletal muscle is mediated by natural antibody 
and complement J Exp Med 1996;183:2343‐2348. 
  (60)   Williams JP, Pechet TT, Weiser MR et al. Intestinal 
reperfusion injury is mediated by IgM and complement J Appl Physiol 
1999;86:938‐942. 
  (61)   Padilla ND, van Vliet AK, Schoots IG et al. C‐reactive 
protein and natural IgM antibodies are activators of complement in a 
rat model of intestinal ischemia and reperfusion Surgery 2007;142:722‐
733. 
  (62)   Krijnen PA, Ciurana C, Cramer T et al. IgM colocalises with 
complement and C reactive protein in infarcted human myocardium J 
Clin Pathol 2005;58:382‐388. 
  (63)   Zhang M, Michael LH, Grosjean SA, Kelly RA, Carroll MC, 
Entman ML. The role of natural IgM in myocardial ischemia‐
reperfusion injury J Mol Cell Cardiol 2006;41:62‐67. 
  (64)   Vollmers HP, Brandlein S. Death by stress: natural IgM‐
induced apoptosis Methods Find Exp Clin Pharmacol 2005;27:185‐191. 
  (65)   Nijmeijer R, Lagrand WK, Baidoshvili A et al. Secretory 
type II phospholipase A(2) binds to ischemic myocardium during 
myocardial infarction in humans Cardiovasc Res 2002;53:138‐146. 
  
156
  (66)   Birnbaum Y, Ye Y, Rosanio S et al. Prostaglandins mediate 
the cardioprotective effects of atorvastatin against ischemia‐
reperfusion injury Cardiovasc Res 2005;65:345‐355. 
  (67)   LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. 
Inhibition of cyclooxygenase‐2 improves cardiac function after 
myocardial infarction in the mouse Am J Physiol Heart Circ Physiol 
2004;286:H1416‐H1424. 
  (68)   Xiao CY, Yuhki K, Hara A et al. Prostaglandin E2 protects 
the heart from ischemia‐reperfusion injury via its receptor subtype 
EP4 Circulation 2004;109:2462‐2468. 
  (69)   Volanakis JE, Wirtz KW. Interaction of C‐reactive protein 
with artificial phosphatidylcholine bilayers Nature 1979;281:155‐157. 
  (70)   Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper 
W. Monocyte activation in angiogenesis and collateral growth in the 
rabbit hindlimb J Clin Invest 1998;101:40‐50. 
  (71)   Leor J, Rozen L, Zuloff‐Shani A et al. Ex vivo activated 
human macrophages improve healing, remodeling, and function of 
the infarcted heart Circulation 2006;114:I94‐100. 
  (72)   Lewis C, Murdoch C. Macrophage responses to hypoxia: 
implications for tumor progression and anti‐cancer therapies Am J 
Pathol 2005;167:627‐635. 
  (73)   Nahrendorf M, Swirski FK, Aikawa E et al. The healing 
myocardium sequentially mobilizes two monocyte subsets with 
divergent and complementary functions J Exp Med 2007;204:3037‐3047. 
  (74)   Vakeva A, Laurila P, Meri S. Co‐deposition of clusterin with 
the complement membrane attack complex in myocardial infarction 
Immunology 1993;80:177‐182. 
  (75)   McDonald JF, Nelsestuen GL. Potent inhibition of terminal 
complement assembly by clusterin: characterization of its impact on 
C9 polymerization Biochemistry 1997;36:7464‐7473. 
  (76)   Trougakos IP, Poulakou M, Stathatos M, Chalikia A, 
Melidonis A, Gonos ES. Serum levels of the senescence biomarker 
clusterin/apolipoprotein J increase significantly in diabetes type II and 
during development of coronary heart disease or at myocardial 
infarction Exp Gerontol 2002;37:1175‐1187. 
  (77)   Swertfeger DK, Witte DP, Stuart WD, Rockman HA, 
Harmony JA. Apolipoprotein J/clusterin induction in myocarditis: A 
localized response gene to myocardial injury Am J Pathol 
1996;148:1971‐1983. 
  (78)   Jones SE, Jomary C. Clusterin Int J Biochem Cell Biol 
2002;34:427‐431. 
  (79)   Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in 
human aging and cancer Int J Biochem Cell Biol 2002;34:1430‐1448. 
  (80)   Calero M, Tokuda T, Rostagno A et al. Functional and 
structural properties of lipid‐associated apolipoprotein J (clusterin) 
Biochem J 1999;344 Pt 2:375‐383. 
  (81)   Ammar H, Closset JL. Clusterin activates survival through 
PI‐3 kinase/AKT pathway J Biol Chem 2008. 
  (82)   Li Y, Sagar MB, Wassler M, Shelat H, Geng YJ. 
Apolipoprotein‐J prevention of fetal cardiac myoblast apoptosis 
induced by ethanol Biochem Biophys Res Commun 2007;357:157‐161. 
  (83)   Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch‐
Brandt C. Multiple receptors mediate apoJ‐dependent clearance of 
cellular debris into nonprofessional phagocytes Exp Cell Res 
2001;271:130‐141. 
  (84)   Singla DK, McDonald DE. Factors released from embryonic 
stem cells inhibit apoptosis of H9c2 cells Am J Physiol Heart Circ 
Physiol 2007;293:H1590‐H1595. 
  (85)   Krijnen PA, Niessen HW. The antiapoptotic protein 
clusterin protects cardiomyocytes against ischemia‐induced cell death 
Am J Physiol Heart Circ Physiol 2007;293:H3223. 
 
 
 
  
157
 158
Summary 
 
159
Inflammation and the induction of acute myocardial infarction (AMI) 
It is well known that the inflammatory protein type IIA secretory Phospholipase A2 (sPLA2-IIA) is 
involved in the pathogenesis of atherosclerosis. sPLA2-IIA releases fatty acids from membrane 
phospholipids that form precursors for inflammation inducing eicosanoids. Membrane phospholipids 
from which sPLA2-IIA has freed a fatty acid are lysophospholipids. These lysophospholipids act as 
binding sites for another inflammatory protein C-reactive protein (CRP), which in turn can activate 
complement. Furthermore, sPLA2-IIA can also kill cells by itself. In chapter 2 we show that sPLA2-IIA is 
significantly more expressed in culprit coronary atherosclerotic plaques that caused AMI than in 
coronary plaques that caused angina pectoris. This sPLA2-IIA may be involved in the death of smooth 
muscle cells in the plaque, which contributes to plaque instability. This implies that sPLA2-IIA is 
involved in the induction of plaque complications and therefore also AMI. 
Branched off from the coronary arteries that lie on the heart (epicardial) are the arteries that lie 
embedded in the heart muscle; the so-called intramyocardial arteries. In chapter 3 we investigated the 
accumulation of advanced glycation end products (AGEs), in this case εN-carboxymethyllysine (CML), 
in these intramyocardial arteries. AGEs are the product of non-enzymatic glycation of proteins which 
disrupts the functioning of these proteins. AGEs accumulate during aging and at an accelerated rate in 
diabetes. We found significantly more accumulation of CML in the intramyocardial arteries of the left 
ventricle in AMI patients than in control patients. These patients did not have diabetes.  CML was found 
in intramyocardial arteries throughout the left ventricle, not just the infarction area, and was found 
shortly after the onset of infarction. Furthermore, we found in vitro and in a rat AMI model that CML 
was likely not formed as a result of AMI, but accumulated prior to the onset of AMI. The CML in the 
intramyocardial arteries did not correlate with CML in the epicardial arteries. It has been shown before 
that CML, via the receptor for AGEs (RAGE), can upregulate adhesion molecules (E-selectin, ICAM-1) 
on endothelial cells, thereby inducing a pro-inflammatory state of these cells. This implicates a possible 
role for intramyocardial arteries and CML-induced inflammation herein, in the pathophysiology of AMI 
and perhaps in the induction of AMI.  
These two studies, sPLA2-IIA in the epicardial coronary arteries and CML in the intramyocardial arteries 
endorse the role of inflammation in aberrations of cardiac blood vessels that may lead to infarction.  
 
Inflammation after acute myocardial infarction 
Death of cardiomyocytes 
As a result of AMI cardiomyocytes die. Cell death can be executed roughly via two processes: apoptosis 
and necrosis. Apoptose is the regulated form of cell death; self-termination occurs in a regulated manner 
via different signaling routes that ultimately lead to the activation of caspases. A cell needs energy to 
complete apoptosis. With necrosis the self-termination is less well regulated (through lack of energy), 
which leads to the disintegration of the cell. In the infarcted heart both processes take place. In areas 
where intense ischemia leads to complete depletion of cellular energy, cardiomyocytes will become 
necrotic. In areas where (sufficient) energy remains, supposedly in the border zones of infarction or after 
reperfusion, cardiomyocytes will become apoptotic.  
It has been shown before that reactive oxygen species (ROS) play a role in apoptosis. In chapter 7 we 
show for the first time that the ROS-producing protein Nox2 is expressed in human cardiomyocytes and 
that this expression is upregulated in the infarction area in AMI patients. In chapter 8 we show in 
cardiomyocytes in vitro that as a result of ischemia this Nox2 translocated to the nucleus and produced 
ROS there. The Nox2 produced ROS in the cardiomyocyte nucleus play an important role in the process 
of apoptosis, as these cells did not become apoptotic when Nox2 related ROS were inhibited.  
 
Membrane flip-flop and reversibly damaged cells 
In the border zones of infarction also reversibly damaged cardiomyocytes exist. Reperfusion of the heart 
after AMI can cause additional damage in which the sPLA2-IIA – CRP – complement inflammatory 
cascade plays a key role. The binding of sPLA2-IIA to reversibly damaged cardiomyocytes is an 
important initial step herein. sPLA2-IIA does bind to (reversibly) damaged cells but not to healthy cells 
and can thus discriminate between the two. We have shown earlier that cardiomyocytes that bind 
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sPLA2-IIA had membrane alterations. These cells exposed the membrane phospholipid 
phosphatidylserine (PS) in the outer layer of the plasma membrane, which in healthy cells is kept 
actively within the inner plasma membrane leaflet by a trans-membranous protein called flippase. This 
process is also called membrane flip-flop. Membrane flip-flip is a hallmark of apoptotic and thus dying 
cells. However, membrane flip-flip also occurs in reversibly damaged cells, as we show in 
cardiomyocytes in chapter 13. Membrane flip-flop in reversibly damaged cells therefore is an important 
characteristic that is utilized by inflammation to cause extra damage in the infarcted heart. In chapter 6 
we analyzed whether RhoA – ROCK signaling is involved in the process of membrane flip-flop. We 
found that inhibition of RhoA – ROCK activity led to membrane flip-flop in cardiomyocytes. This 
coincided with decreased flippase activity, which can explain why these cells exposed PS. These data 
show that in cardiomyocytes RhoA – ROCK signaling is necessary to prevent membrane flip-flop. 
Whether this plays a role in the heart after infarction is subject of further study.  
Thus cardiomyocytes die after AMI, both through apoptosis, with a probable role herein for Nox2 
produced ROS, and necrosis. Also reversibly damaged cardiomyocytes exist. Membrane flip-flop occurs 
in all these cells. sPLA2-IIA binds to and disposes of these cells, either directly or through CRP – 
complement activation. This results in the disposal of already dead cells, but also in additional damage 
through the disposal of reversibly damaged cells. 
 
Complement activation in the infarcted heart 
After reperfusion of the infarcted heart an inflammatory reaction is induced, wherein sPLA2-IIA, CRP 
and complement thus play an important role. Complement induces cell lysis and the influx of 
neutrophilic granulocytes. In chapter 10 we show that in AMI patients that received reperfusion therapy, 
either the thrombolytic streptokinase or coronary artery bypass grafting (CABG), had significantly more 
depositions of CRP and complement in the heart than AMI patients who did not receive reperfusion 
therapy. This was however not the case in AMI patients who received percutaneous transluminal 
coronary angioplasty (PTCA). Also patients who suffered from reinfarction within two weeks of the first 
infarction had more extensive CRP and complement depositions.  More extensive depositions of CRP 
and complement implicate more damage in the heart after AMI. These data show that the method of 
reperfusion can influence the ultimate damage in the infarcted heart. Furthermore, a second infarction 
relatively soon after a first infarction leads to an increased inflammatory response, leads to more 
extensive damage in the infarcted heart. 
It is known that CRP can activate complement on cells. We have shown before that this occurs in the 
infarcted heart. Another known complement activator is the immunoglobuline IgM, which for instance 
can activate complement on bacteria. In chapter 11 we show colocalization of IgM with CRP and 
complement in the infarcted heart. These data imply that within the infarcted heart complement can also 
be activated by IgM. 
 
Acute myocardial infarction and therapy 
The activation of the sPLA2-IIA – CRP – complement inflammatory cascade contributes to the 
additional damage in the heart after AMI. Inhibition of this cascade therefore may limit this damage. It is 
however of crucial importance that the clearance of dead tissue is not inhibited, because this leads to a 
disturbed wound healing. This may lead to a weakened ventricle wall which may lead to rupture and 
resulting death. Therefore, intervening in the post-AMI inflammation should never be done at the 
expense of successful wound healing (see also chapter 9). 
In chapter 12 we show that an inhibitor of sPLA2-IIA, named PX18, can indeed reduce infarction size in a 
rat AMI model. Furthermore, we show that PX18, in addition to sPLA2-IIA, can inhibit the extent of 
membrane flip-flop in cardiomyocytes. In this way PX18 can have a double effect in the infarcted heart: 
it inhibits sPLA2-IIA and inhibits binding sites for sPLA2-IIA on cardiomyocytes. PX18 did not disrupt 
normal wound healing, probably because inhibition of sPLA2-IIA does not prevent binding of CRP and 
complement to dead cells; these cells are still cleared. This study shows that specific inhibition of 
inflammatory mediators can limit reperfusion damage after AMI, leading to less damage in the heart, 
lessening the chance of developing heart failure.  
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In chapter 13 we studied clusterin in myocardial infarction. Clusterin as a multi-potent protein that is 
widespread expressed in the body and is involved in many different processes. It was found before that 
clusterin can be cytoprotective through the inhibition of complement. It was also shown that clusterin 
colocalized with complement in the infarcted heart. This shows that also anti-inflammatory mediators 
deposit in the infarcted heart, presumably to control the inflammatory response. We have now shown 
that clusterin is also found in cardiomyocytes of the border zones of infarction, without complement. 
Furthermore, we show in vitro that clusterin protects cardiomyocytes from ischemia induced cell death, 
independent of complement. Elevating clusterin levels after AMI might therefore be useful to limit 
reperfusion damage. Meanwhile we have analyzed the effect of elevated clusterin levels in the blood on 
infarct size in the AMI rat model. Elevated levels of clusterin indeed led to decreased infarction size, 
without disrupting normal wound healing. 
 
Conclusions 
The studies in this thesis support the notion that inflammation is important in the pathophysiology of 
acute myocardial infarction. We show that inflammation in blood vessels in and on the heart can play a 
role in the development of AMI. In addition, we show the existence of reversibly damaged 
cardiomyocytes and that certain inflammatory mediators can bind to and kill these cells, because they 
signal their a staite of stress through membrane flip-flop. We also show that inhibition of these 
inflammatory mediators in vivo can lead to lessened myocardial damage after AMI and a better 
prognosis. 
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Het acute myocard infarct 
Een hartinfarct of myocardinfarct ontstaat doordat een bloedvat dat een gedeelte van het hart van 
zuurstofrijk bloed voorziet verstopt raakt, bijvoorbeeld door een bloedprop (thrombus), met als gevolg 
dat dit deel van het hart onvoldoende zuurstof en metabolieten ontvangt. In dit gebied van het hart 
ontstaat dan een toestand van ischemie (een tekort aan zuurstof en metabolieten). Als gevolg hiervan 
sterven hartspiercellen (cardiomyocyten) af of raken beschadigd. Een gedeelte van de mensen die een 
hartinfarct krijgt overlijdt hieraan. Bij mensen die een hartinfarct overleven is wel blijvende schade 
ontstaan in het hart. Dit kan leiden tot verlies van hartfunctie; door het infarct gaat namelijk 
hartspierweefsel verloren waardoor bijvoorbeeld de pompcapaciteit van het hart verminderd. Dit kan 
resulteren in hartfalen. Hoe meer schade is ontstaan door het hartinfarct, hoe groter de kans op hartfalen 
is.  
Bij mensen die een hartinfarct doormaken is het eerste klinische ingrijpen erop gericht de bloedtoevoer 
naar het hart weer op gang te krijgen, de reperfusie therapie. Dit kan op verschillende manieren. Een 
veel voorkomende behandeling is de percutane transluminale coronair angioplastiek (PTCA; dotter) 
behandeling, waarbij d.m.v. een ballonnetje het vat mechanisch wordt verwijdt. Eventueel kan hierbij 
ook een stent (gazen kokertje) in het bloedvat worden geplaatst om het bloedvat open te houden. Ook 
CABG (coronary artery bypass grafting) is een optie, waarbij chirurgisch nieuwe bloedvaten op het hart 
worden geplaatst. Er worden ook medicamenten gebruikt om de bloedtoevoer te bevorderen zoals 
bloedverdunners (b.v. heparine) en antistolling d.m.v. de zogenaamde thrombolytica (b.v. 
streptokinase). Echter, reperfusie therapie heeft ook een keerzijde. Reperfusie van het ischemisch 
myocardium kan namelijk additionele schade veroorzaken. We spreken dan van reperfusieschade, 
waarin ontsteking een belangrijke rol speelt. 
 
Ontsteking 
Ontsteking (inflammatie) in de breedste zin van het woord is de (immunologische) reactie van het 
lichaam op prikkels van binnen (bv. weefselschade) of prikkels van buiten (bv. infectie), met als doel het 
herstellen van de schade of verwijderen van een infectueuze agens. Bij ontsteking kunnen tal van 
verschillende componenten betrokken zijn: ontstekingscellen (zoals neutrofiele granulocyten en 
macrofagen) en ook ontstekingsmediatoren (zowel pro- als anti-inflammatoire eiwitten/peptiden en 
andere verbindingen). In de meeste gevallen heeft de ontsteking een effect dat als nuttig voor het 
lichaam mag worden beschouwd, zoals het opruimen en herstellen van weefselschade na een wond. 
Echter het wordt steeds meer duidelijk dat ontsteking tevens kan bijdragen aan het veroorzaken van 
additionele schade in verschillende ziektebeelden, waaronder reuma en de cardiovasculaire 
aandoeningen atherosclerose en het acute myocardinfarct.  
 
Atherosclerose en ontsteking  
Atherosclerose is een aandoening waarbij vaatvernauwing optreed (eigenlijk alleen in arteriën) door het 
ontstaan van atherosclerotische plaques in de vaatwand. Atherosclerotische plaques ontstaan door de 
opeenhoping van vetachtige structuren als lipoproteïnen (LDL) en extracellulaire matrix componenten 
tussen het endotheel (de binnenbekleding van een bloedvat) en de gladde spiercellen. Het wordt steeds 
meer duidelijk dat ontsteking, zowel ontstekingscellen als ontstekingsmediatoren, een belangrijke rol 
speelt bij de pathophysiologie van atheroslerose. In hoofdstuk 1 staat een en ander beschreven over het 
proces van atherosclerose en de rol hierin van o.a. het ontstekingseiwit type IIA secretoir Phospholipase 
A2 (sPLA2-IIA) en macrofagen.  
Er wordt bij atherosclerotische plaques een onderscheid gemaakt tussen stabiele en instabiele plaques. 
Stabiele plaques bestaan uit een relatief kleine vetkern en een relatief dik bedekkend bindweefsel kapsel. 
Instabiele plaques worden gekenmerkt door een relatief grote vetkern en een dun bedekkend 
bindweefsel kapsel. Dit laatste type plaques is vooral gevaarlijk omdat plaque instabiliteit kan leiden tot 
plaque complicaties zoals een plaqueruptuur met als mogelijk gevolg het ontstaan van een stolsel of 
thrombus op de plaque. Dit kan leiden tot het afsluiten van het bloedvat en tot infarcering. Op deze 
manier kan ontsteking dus bijdragen aan het ontstaan van een hartinfarct. 
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Acuut myocardinfarct en ontsteking 
Zoals eerder vermeld sterven er als gevolg van de ischemie hartspiercellen af, met name op die plekken 
waar de belemmering van de zuurstof/bloedvoorziening het sterkst is. Daaromheen is de ischemie 
minder absoluut door een gedeeltelijke bloedtoevoer uit aangrenzende bloedvaten die niet afgesloten 
zijn. Op deze plekken, die we border zones noemen, worden hartspiercellen in meer of mindere mate 
beschadigd, maar zijn niet dood op het moment dat de bloedtoevoer na een infarct weer tot stand is 
gebracht (reperfusie). Een gedeelte van deze beschadigde cellen is reversibel (omkeerbaar) beschadigd 
en dus nog levensvatbaar. Na reperfusie komt een ontstekingsreactie op gang, met als doel het 
opruimen van dood hartweefsel (opruimfase) en in een daaropvolgende fase ervoor te zorgen dat 
verbindweefseling op de plaats waar hartspierweefsel is afgestorven optreedt (helingfase). Dit is van 
eminent belang omdat anders een zwakke hartwand zou ontstaan die zou kunnen scheuren 
(hartruptuur). Tijdens de opruimfase infiltreren grote hoeveelheden ontstekingsmediatoren, waaronder 
sPLA2-IIA, C-reactive protein (CRP) en complement, en ontstekingscellen, waaronder neutrofiele 
granulocyten, het infarctgebied. 
Eerder hebben we al laten zien dat sPLA2-IIA aan deze reversibel  beschadigde cellen bindt en of zelf, of 
met behulp van CRP en complement, kan zorgen dat deze reversibel beschadigde cellen alsnog 
afsterven. Deze sPLA2-IIA – CRP – complement ontstekingscascade is een belangrijke initiator van extra 
ontstekingsschade in het geïnfarceerde hart.  
 
Ontsteking bij het ontstaan van een acuut myocardinfarct 
Zoals vermeld is het bekend dat het ontstekingseiwit sPLA2-IIA betrokken is bij de pathogenese van 
atherosclerose. sPLA2-IIA  knipt vetzuren vrij uit membraanfosfolipiden die precursors vormen voor 
ontstekingsbevorderende eicosanoiden. Membraanfosfolipiden waaruit door sPLA2-IIA een vetzuur is 
vrij geknipt is zijn lysofosfolipiden. Deze lysofosfolipiden vormen bindingsplaatsen voor CRP dat op 
zijn beurt weer complement kan activeren. Bovendien is sPLA2-IIA zelf in staat cellen te doden. In 
hoofdstuk 2 laten we zien dat sPLA2-IIA significant meer tot expressie komt in coronaire plaques die een 
hartinfarct hebben veroorzaakt dan in coronaire plaques van patiënten met angina pectoris. Dit sPLA2-
IIA zou betrokken kunnen zijn bij de sterfte van gladde spiercellen in de plaque wat bijdraagt tot plaque 
instabiliteit. Dit impliceert dat sPLA2-IIA betrokken is bij het ontstaan van plaque complicaties en dus 
ook het hartinfarct.  
Aftakkingen van de op het hart liggende (epicardiale) coronair arteriën gaan de hartwand in en liggen 
dus ingebed in het hartspierweefsel. We spreken dan van intramyocardiale arteriën. In hoofdstuk 3 
hebben we de accumulatie van advanced glycation end-products (AGEs) onderzocht in deze 
intramyocardiale arteriën, meer specifiek de AGE εN-carboxymethyllysine (CML). AGEs zijn het 
product van non-enzymatische versuikering van eiwitten, wat de functie van deze eiwitten verstoord. 
AGEs ontstaan bij het ouder worden en in een versneld tempo in mensen met diabetes. Wij vonden 
significant meer accumulatie van CML in de intramyocardiale arteriën van het linker ventrikel in 
hartinfarct patiënten dan in controle patiënten. Deze patiënten hadden geen diabetes. Het CML werd 
verhoogd gevonden in de intramyocardiale arteriën van de gehele linker ventrikel, niet alleen in het 
infarctgebied, en werd al kort na het ontstaan van het infarct gevonden. Bovendien hebben we in vitro 
en in een rat hartinfarct model laten zien dat CML waarschijnlijk niet als gevolg van een infarct is 
ontstaan maar al voor het infarct is geaccumuleerd. Tevens correleerde de accumulatie van CML in de 
intramyocardiale arteriën niet met de afwijkingen van de epicardiale coronair arteriën. Al eerder is 
aangetoond dat CML, via de receptor voor AGEs (RAGE), adhesie moleculen (E-selectin, ICAM-1) op 
het endotheel kan opreguleren waardoor dit endotheel pro-inflammatoir wordt. Dit impliceert een 
mogelijke rol voor intramyocardiale arteriën en CML geïnduceerde ontsteking hierin, in de 
pathofysiologie van het hartinfarct en wellicht in het ontstaan van een infarct.  
Deze twee studies, sPLA2-IIA in epicardiale coronair arteriën en CML in de intramyocardiale arteriën, 
onderschrijven de rol van ontsteking in afwijkingen van cardiale bloedvaten die kunnen leiden tot 
infarcering. 
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Ontsteking na een acuut myocardinfarct 
Dood van hartspiercellen 
Als gevolg van een hartinfarct gaan dus hartspiercellen dood. Celdood kan grofweg via twee processen 
plaatsvinden: apoptose en necrose. Apoptose is de gereguleerde vorm van celdood; het zichzelf 
termineren en afbreken van de cel vindt plaats op een gereguleerde wijze via verschillende 
signaleringsroutes die uiteindelijk leiden tot de activatie van caspases oftewel ‘eiwit afbrekers’. Voor het 
uitvoeren van apoptose heeft een cel energie nodig. Bij necrose is het zichzelf termineren en afbreken 
van de cel minder gereguleerd (door gebrek aan energie), wat leidt tot het uiteenvallen van de cel. In het 
infarct hart vinden beide processen plaats. In gebieden waar door intense ischemie de cellulaire energie 
geheel gereduceerd is, zullen cellen in necrose gaan. In gebieden waar nog cellulaire energie is, 
vermoedelijk in border zones tijdens het infarct of na reperfusie, zullen hartspiercellen in apoptose gaan. 
Eerder is al aangetoond dat zuurstofradicalen of ROS (reactive oxygen species) bij het proces van 
apoptose een rol spelen. In hoofdstuk 7 laten we voor het eerst zien dat het ROS producerende eiwit 
Nox2 tot expressie wordt gebracht in humane hartspiercellen en dat de expressie hiervan wordt 
opgereguleerd in hartspiercellen in het infarctgebied in patiënten met een hartinfarct. In hoofdstuk 8 
laten we vervolgens in vitro zien dat dit Nox2 zich in hartspiercellen als gevolg van ischemie naar de 
celkern verplaatst en daar ROS produceert. Deze Nox2 geproduceerde ROS in de celkern spelen een 
belangrijke rol bij het proces van apoptose in deze hartspiercellen, aangezien deze cellen niet in apoptose 
gaan als we deze Nox2 gerelateerde ROS productie remmen.  
 
Membraan flip-flop en reversibel beschadigde cellen 
In de border zones bevinden zich ook hartspiercellen die reversibel beschadigd zijn. Zoals eerder 
vermeld kan reperfusie van het hart na een infarct additionele schade veroorzaken en de sPLA2-IIA – 
CRP – complement ontstekingscascade speelt hierin een belangrijke rol. Hierbij is de binding van sPLA2-
IIA aan reversibel beschadigde hartspiercellen een belangrijke initiële stap. sPLA2-IIA bindt wel aan 
(reversibel) beschadigde cellen, maar niet aan gezonde cellen en kan dus tussen de twee discrimineren. 
Eerder hebben we laten zien dat de hartspiercellen waaraan sPLA2-IIA bindt een membraanverandering 
hebben ondergaan. Deze cellen exposeren het membraan fosfolipid phosphatidylserine (PS), wat in 
gezonde cellen actief in de binnenlaag van de celmembraan wordt gehouden door een transmembraan 
eiwit genaamd flippase, in de buitenlaag van de celmembraan. Dit proces heet ook wel membraan flip-
flop. Membraan flip-flop is een kenmerk van cellen die in apoptose zijn en dus dood gaan. Daarnaast 
echter komt membraan flip-flop voor in cellen die reversibel beschadigd zijn, zoals we laten zien in 
hartspiercellen in hoofdstuk 13. Membraan flip-flop in reversibel beschadigde hartspiercellen is dus een 
belangrijk kenmerk waarop de ontsteking kan aangrijpen en zo zorgen voor extra schade in het hart na 
een infarct.  
In hoofdstuk 6 hebben we geanalyseerd of RhoA – ROCK signalering is betrokken bij dit proces van 
membraan flip-flop. We vonden dat remming van RhoA – ROCK activiteit leidt tot membraan flip-flop 
in hartspiercellen en tevens tot een verlaging van flippase activiteit, wat kan verklaren waarom deze 
cellen membraan flip-flop vertonen. Deze data laat zien dat in hartspiercellen RhoA – ROCK signalering 
nodig is om membraan flip-flop te voorkomen. Of dit een rol speelt in het hart na een infarct moet nog 
verder worden onderzocht.  
We zien dus dat in het hart na een infarct hartspiercellen sterven, zowel door apoptose, met hierin 
waarschijnlijk een rol voor Nox2 geproduceerde ROS, en ook necrose. Bovendien ontstaan reversibel 
beschadigde hartspiercellen. Membraan flip-flop vindt in al deze cellen plaats. sPLA2-IIA grijpt aan op 
cellen met membraan flip-flop en doodt deze cellen, of rechtstreeks of via CRP – complement activatie. 
Dit zorgt voor de opruiming van reeds dode cellen, maar resulteert ook in extra schade door het doden 
van reversibel beschadigde hartspiercellen. 
 
Activatie van complement in het infarct hart  
Er komt na reperfusie in het hart dus een ontstekingsreactie op gang, waarin sPLA2-IIA, CRP en 
uiteindelijk de activatie van het complement systeem een belangrijke rol spelen. Complement zorgt voor 
cellysis en voor het aantrekken van neutrofiele granulocyten. In hoofdstuk 10 laten we zien dat in 
patiënten die na een hartinfarct reperfusie therapie hebben ontvangen, te weten streptokinase of CABG, 
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significant meer deposities hebben van CRP en complement in het hart, dan patiënten die geen 
reperfusie therapie hebben ontvangen. Dit geldt overigens niet voor patiënten die PTCA als reperfusie 
therapie hebben ondergaan. Ook patiënten die een reinfarct ondergaan, d.w.z. deze mensen ondergaan 
een tweede infarct binnen twee weken na het eerste infarct hebben meer deposities van CRP en 
complement. Extensievere deposities van CRP en complement impliceert meer schade in het hart. Deze 
data toont aan dat de methode van reperfusie therapie invloed kan hebben op de uiteindelijke schade in 
het hart na een hartinfarct. Bovendien zorgt een tweede infarct relatief kort na het eerste infarct voor een 
vergrootte ontstekingsrespons, wat leidt tot meer schade in het hart na een hartinfarct. 
Dat CRP complement kan activeren op cellen was al langer bekend. We hebben eerder al aangetoond dat 
dit ook gebeurd in het infarct hart. Een andere bekende activator van complement is de 
immunoglobuline IgM. Dit IgM activeert complement b.v. op infectueuze bacteriën. In hoofdstuk 11 
laten we zien dat IgM in het infarct hart colocaliseert met CRP en complement. Deze data impliceert dat 
complement in het hart na een hartinfarct ook geactiveerd kan worden door IgM. 
 
Therapie en het hartinfarct 
De activatie van de sPLA2-IIA – CRP – complement ontstekingscascade draagt dus bij aan de extra 
schade in het hart na een hart infarct. Remming van deze cascade zou deze schade in het kunnen 
beperken. Het is echter wel van cruciaal belang dat de opruiming van dood weefsel niet wordt geremd, 
omdat dan de helingfase, en dus de verbindweefseling, wordt verstoord. Zoals vermeld leidt dit tot een 
verzwakte hartwand en mogelijk een hartruptuur, wat de dood tot gevolg heeft. Het interveniëren in 
post-infarct ontsteking mag dus nooit ten koste gaan van de wondheling (zie ook hoofdstuk 9). 
In hoofdstuk 12 laten we zien dat een remmer van sPLA2-IIA, PX18 genaamd, de infarctgrootte 
inderdaad kan verkleinen in een hartinfarct model in de rat. Bovendien laten we zien in vitro dat PX18, 
naast het remmen van sPLA2-IIA, de mate van membraan flip-flop kan remmen in hartspiercellen. Op 
deze manier kan PX18 een dubbel effect hebben in het hart na een infarct: het remt sPLA2-IIA en remt de 
beschikbaarheid van bindingsplaatsen voor sPLA2-IIA op hartspiercellen. Het gebruik van PX18 had 
geen effect op succesvolle wondgenezing. Dit komt vermoedelijk omdat remming van sPLA2-IIA geen 
invloed heeft op de bindingscapaciteit van CRP en complement op dode cellen; deze worden nog steeds 
opgeruimd. Deze studie toont in vivo aan dat specifieke remming van ontstekingseiwitten extra schade 
in het hart na een infarct kan beperken, waardoor uiteindelijk dus minder hartschade ontstaat en dus 
ook minder kans op hartfalen. 
In hoofdstuk 13 hebben we clusterine bestudeerd in het hartinfarct. Clusterine is een veelzijdig eiwit dat 
uitgebreid in het lichaam voor komt en betrokken is bij veel verschillende processen. Eerder werd al 
bekend dat clusterine celbeschermend kan werken vanwege zijn remmend effect op complement 
activatie. Ook was aangetoond dat clusterine colocaliseert met complement in het infarct hart. Dit wijst 
erop dat ook anti-inflammatoire componenten in het infarct hart komen, vermoedelijk om de ontsteking 
in te tomen. Wij tonen nu aan dat clusterine ook in de border zones op hartspiercellen wordt gevonden, 
dus zonder complement. Bovendien tonen we in vitro aan dat clusterine hartspiercellen beschermt tegen 
ischemie geïnduceerde celdood, onafhankelijk van complement. Ook het verhogen van clusterine levels 
zou dus een mogelijk therapeuticum kunnen zijn om extra schade in het hart na een infarct te beperken. 
Intussen hebben we het verhogen van clusterine bloed levels getest op de infarctgrootte in het 
hartinfarct model in de rat. Het verhogen van de clusterine bloed levels leidde inderdaad tot kleinere 
infarctgrootte, terwijl het geen effect had op succesvolle wondgenezing. 
 
Conclusie 
De studies in dit proefschrift hebben de notie dat ontsteking een belangrijke speler is in de 
pathofysiologie van het hartinfarct versterkt. We hebben laten zien dat ontsteking in bloedvaten in en op 
het hart een rol kunnen spelen in het ontstaan van een hartinfarct. Bovendien hebben we het bestaan 
laten zien van reversibel beschadigde hartspiercellen en dat bepaalde ontstekingsmediatoren aan deze 
cellen gaan binden en ze doden omdat ze d.m.v. membraan flip-flop signaleren dat ze gestrest zijn. Ook 
laten we zien dat remming van deze bepaalde ontstekingsmediatoren in vivo kan leiden tot het 
verminderen van hartschade na een infarct en dus een betere prognose. 
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